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1. INTRODUCTION 
 
A central goal in biology is to unravel the complex molecular mechanisms by 
which a cell coordinates its many functions as part of a multicellular organism. The 
discovery and use of naturally occurring pharmacological agents to inhibit the 
function of intracellular signaling molecules has been of great importance in this 
process. Such compounds also provide starting points for development of many 
therapeutically important drugs. One major methodology of drug development 
focuses on screening of vast libraries of molecules for biological activity from 
which variants are produced to maximize beneficial medical characteristics. An 
alternative method, rational drug design, uses protein sequence and three-
dimensional structure information to obtain insight in to protein functions. These 
informations suggest that the mechanisms by which molecules interact, and thus 
mediate signals, may be predictable, allowing the rational design of inhibitors of 
such interaction. 
Many of the diverse signaling molecules found in a cell use similar mechanisms to 
interact, and thus mediate the propagation of a signal. Of particular importance to 
influence such interactions is the principle that short peptide sequences mediate 
both affinity and specificity for the interaction of the molecules. In many cases 
these short target peptides contain an amino acid sequence that allows their 
identification and prediction of their function by a combination of bioinformatic and 
biochemical methodology. This class of peptide-protein or protein-protein 
interaction is an ideal subject for the rational design of inhibitors. Such inhibitors 
have the dual benefits that they allow elucidating the roles of their target molecules 
in cellular function and evaluating their potential as targets of therapeutic 
intervention. One approach involves the identification of a possible interaction by 
analysis of the sequence of candidate interacting molecules, and by designing 
short peptides based on the target sequence. Consequently agents that can 
competitively and specifically inhibit the interaction may be generated. In practice, 
design of peptide inhibitors proved very difficult for several reasons. Firstly, 
peptides in general are very flexible. This flexibility makes all structural studies 
extremely difficult. Moreover, the relationship between the primary structure 
(constitution) and the so-called “bioactive conformation” is far from being obvious. 
The structural contribution to selectivity and activity of the peptides can be 
attributed to different backbone conformations or different side chain 
conformations. Secondly, peptides are prone to hydrolysis by different proteases 
present in living systems. Third, the cell membrane is a barrier for passing of large 
hydrophilic molecules such as peptides into cells. To overcome these problems 
different approaches are used. The transport problem may be overcome by the 
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recently developed “Trojan horse” approach. This method involves the association 
of the peptide (or other bioactive molecule) to one of an emerging class of  
cell-permeable peptide vectors, which can translocate with ease across plasma 
membranes and enter the cytoplasm with high efficiency without compromising 
normal cellular function.1  
Both of the first two disadvantages can be diminished by introducing 
“nonstandard” amino acids, like D- or β-amino acids, in a peptide chain. These 
amino acids are often not recognized by different peptidases. Because of this the 
rate of peptide hydrolysis by a peptidase can be lower. Peptides composed of only 
D-amino acids exhibit resistance toward enzymatic proteolysis.2 Recently, 
protease-resistant antimicrobial peptides composed of β-amino acids have also 
been constructed.3 To reduce the number of possible conformations of an active 
sequence often cyclic constrained peptides are used with tailor made amino acids 
at a specific position in the peptide chain that could fix the peptide in an active 
conformation. As these tailor-made amino acids D-amino acids are used but β-
amino acids have also served as important building blocks in natural and 
pharmaceutical candidates such us RGD (Arg-Gly-Asp) mimetics.4 β-Amino acids 
may provide a convenient molecular tool to force a peptide segment to adopt a 
well determined folded conformation and incorporation of a distinct β-amino acid in 
cyclic peptides results in the stabilization of the overall secondary structure. The 
controlled employment of β-amino acids together with their structural preferences, 
and another structural bias, could allow the fine-tuning of biologically active cyclic 
peptide conformations.  
In this work the influence of β-amino acids on conformations of cyclic peptides in 
different solutions has been examined with different techniques (CD, FTIR, NMR). 
The findings of these studies are used for the synthesis of cyclic constrained 
peptides with different recognition sequences as selective and effective inhibitors 
of the integrin family of heterodimeric cell surface receptors and their extracellular 
matrix protein ligands. Several different integrins have been implicated in disease 
processes and potent inhibitors of their interaction with protein ligands have 
aroused widespread interest as potential targets for drug discovery.  
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2. THEORETICAL PART 
 
2.1.
 β-AMINO ACIDS 
 
 
β-Amino acids are emerging as an interesting class of compounds for the 
medicinal chemist. They are naturally produced in humans, animals, 
microorganisms, marine organisms and plants either in free form or as a part of a 
peptide or depsipeptide. They are 
found as components of peptidic 
natural products with antibiotic, 
antifungal, cytotoxic, and other 
pharmacological properties.5 The 
most well-known medicinally 
important class of nonpeptidic  
β-amino acids are found in  
β-lactams.  
Figure 1: Nomenclature example for β-amino acids. 
 
These include antibiotics, β-lactamase inhibitors, human leukocyte elastase 
inhibitors, and cholesterol uptake inhibitors.5 β-Amino acids are analogs of  
α-amino acids in which the carboxy and amino group are separated by two carbon 
atoms. Trivial names for β-amino acids are used very often. The extension of the 
amino acid skeleton by one carbon atom is designated in nomenclature by the 
prefix homo.6  
Consequently, β-homoamino acids are analogs of α-amino acids in which a  
CH2- group has been inserted between the α-carbon and carboxy or amino group 
of the parent α-amino acid. Depending on the position of the side chain, β-amino 
acids can be β2-amino acids (Figure 1 right), β3-amino acids (Figure 1 left) or β2, 3 
amino acids.  
There are significant chemical differences between β-amino acids and their  
α-analogs. For example β-amino acids are stronger bases and weaker acids than 
their α-analogs. It is also known that peptidic molecules containing β-amino acids 
are generally more stable to enzymatic hydrolysis due to the inability of peptidases 
to cleave the amide bonds adjacent to the β-amino acid.  
There are a variety of approaches to the synthesis of β-amino acids.5,7,8  
β3-substituted derivatives (III) may be conveniently prepared using Arndt Eistert 
β2
β3-Leucine
β3-Homovaline -Homovaline
1
3
2 O
OHNH2
2 1
3
O
OHNH2
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homologation of α-amino acids, which is compatible with a variety of protecting 
groups including Boc and Fmoc. The overall yields for the generation of the  
β3-amino acid (III) from the corresponding α-amino acid range from 33 % to 58 % 
depending on amino acid and protecting groups.9 This method is used in this work 
and it is in detail described in chapter 4.1, P. 25. Another important method for the 
synthesis of β3-amino acids (III), with broad applicability, relies on the addition of 
metal enolates derived from acetic acid esters to chiral sulfinimines (I) in an aldol 
type reaction.10 The reaction (Scheme 1) proceeds with high diasteroselectivity 
and good overall yield. Given the variety of effective methods available for the 
preparation of chiral sulfinimines (I), this route to β3-amino acids (III) should become 
increasingly attractive. 
 
S
N R
HO
R
ONH
OMe
S
O
R
ONH
OMe
:
p-Tolyl:
p-Tolyl
Boc
1. TFA/MeOH
2. (Boc)2O
(I) (II) (III)
CH3CO2CH3
NaHMDS/Et2O
- 78 oC
 
Scheme 1: Synthesis of β3-amino acids via chiral sulfinimines. 
 
β2-substituted amino acids (V) may be readily synthesized in enantiomerically pure 
form by aminomethylation of acyl derivatives of Evans’ chiral auxiliary (IV) (Scheme 
2).11 Aminomethylation of the titanium-enolates proceeds with high 
diastereoselctivities and very good yields.9b  
 
N O
OO
R
Ph
R
OH
O
NH2
1. TiCl4, Et3N, 
    PhCONHCH2Cl
2. LiOH, H2O2
3. HCl, AcOH, H2O
(V)(IV)  
Scheme 2: Synthesis of β2-amino acids by aminomethylation of Evans’ chiral auxiliary (IV). 
 
β2,3-disubstituted amino acids (VI) or (VII) may be synthesized by α-alkylation of the 
urethane protected β3-amino acid methyl esters (III) via doubly lithiated 
intermediates (Scheme 3). Procedures for obtaining either diastereomer with good 
stereochemical control are known.12 
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R O
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(III)
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(VII)
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2. CH3I
 
Scheme 3: Synthesis of β2,3-amino acids via α-alkylation of β3-amino acids. 
 
 
2.2. PEPTIDES 
 
Proteins play a crucial role in almost all fundamental processes in the living cell. 
Although they carry out an almost bewildering range of functions in living things, all 
proteins are composed of the same basic building blocks, being biopolymers of the 
21 DNA-encoded amino acids. They are not just unstructured chains of their 
constituent monomers, but rather adopt characteristic, highly organized three-
dimensional arrangements in solution that are intimately related to their biological 
function. 
Peptides are simply smaller versions of proteins. While there is no clear borderline 
between peptides and proteins, an acceptable working distinction is that proteins 
are large peptides, where large is a relative term and may mean anything from 
perhaps 50 to several hundred amino acid residues.  
All of the 21 DNA-encoded or proteinogenic amino acid building blocks have the 
same basic structure that incorporates an amino and a carboxy group and differs 
only in the nature of the side chains. Proline is unique in having a cyclic structure 
with a secondary amine. With the exception of glycine, all are chiral, due to the 
presence of at least one stereogenic carbon atom, and belong to the L-
stereochemical series. Consequently, the chiral α-amino acids all have the S 
configuration, except cysteine in which it is R as a consequence of the Cahn-
Ingold-Prelog convention.13 Two amino acids, threonine and isoleucine, have a 
second stereogenic centre at the β-carbon atom.  
Since the difference between peptides and proteins is essentially one of size or 
length of the amide backbone, the problems involved in the chemical synthesis of 
proteins are basically those of the synthesis of peptides. 
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2.2.1.Peptide Synthesis 
 
Generally peptides are formed by the connection of α-amino acids involving amide 
bonds. It is necessary to activate the carboxy group of one amino acid so that 
nucleophilic attack by the amino group of the second amino acid can take place 
forming the desired amide bond. This process of amide bond formation is called 
coupling. Using a coupling reagent is today the most common general coupling 
method in peptide synthesis. The coupling reagent reacts with the free carboxy 
group of an amino acid, generating a reactive species, which is not isolated and 
which is sufficiently reactive to allow amide bond formation to occur at room 
temperature or below. 
The most common coupling reagents are the carbodiimides (IX) of which the most 
popular one is dicyclohexylcarbodiimide (DCC).14  
 
O
R
OH
N C N R1R1 N C N
H
+
R1R1
O
R
O
N CR1 N
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R
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R2 NH2
O
R
N
H
R2
R2 NH2
R2 NH2
R
O
O
O
R
X N
N
N
OH
(XIII)  x=CH: HOBt
(XIV) x=N: HOAt
peptide 
(VIII) (IX) (X)
(VIII)
(XI)
(XV)
(XVI)
(XVIII)(XVI) (XVI)
(XVII)
(XII)
+
+ +
+
+ +
 
Scheme 4: Peptide bond formation via carbodiimide activation. 
 
This activation process is often employed in the presence of a hydroxylamine 
derivate (HOBt (XIII) or HOAt (XIV)) that suppresses racemization and excludes 
dehydration of carboxamide residues like Asn and Gln. Reaction of a N-protected 
2. Theoretical part 7 
amino acid (VIII) with a carbodiimide (IX) is believed to involve a labile  
O-acylisourea (XII), which reacts with the amino component (XVI) to give the 
corresponding amide (Scheme 4).15 If two equivalents of protected amino acids 
(XII) are employed the intermediate O-acylisourea (XII) reacts with the second 
equivalent of acid (XII) to give the corresponding symmetrical anhydride (XV). In the 
presence of HOBt (XIII) or HOAt (XIV) as additives, O-acylisourea (XII) reacts with 
them to give active esters (XVII). 
In the last few years, O-acyl uranium/guanidinium and O-acyl-phosphonium type 
coupling reagents (Figure 23, P. 53) enabling in situ generation of active esters in 
the presence of a tertiary nitrogen base have become more and more popular. 
Facile handling, very short coupling time and hardly any loss of configuration 
during coupling makes them highly suitable for automated solid phase peptide 
synthesis. The most commonly used coupling reagents are HBTU,16 TBTU17 and 
HATU.18 A tertiary amine is used as a base to form the carboxylate ion (XIX) of the 
carboxy component. Initial attack of this on the uronium salt (XX) leads to an 
acyloxyuronium salt (XXI). This is extremely reactive and is attacked by the 
oxyanion (XXII) of 1-hydroxy-benzotriazole, forming the benzotriazolyl ester (XXIII), 
thought to be the predominant species suffering aminolysis (Scheme 5).19 
 
R
O
O
R
O
O
R1
NH2 R
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CH3
CH3
CH3
CH3
R
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R1
CH3
CH3
CH3
CH3
+
H+-base X-
+
(XIX)
(XXIII) (XXIV) (XXV)
X-
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Scheme 5: Peptide bond formation via uronium activation. 
 
For the synthesis of even the smallest peptide in a controlled manner it becomes 
obvious that certain functional groups must be protected. In order to couple amino 
acids in a way that is useful for the synthesis of complete peptides, the functional 
groups that are not directly involved in the amide bond-forming reaction must also 
be protected or blocked. For peptide synthesis the Nα-protecting group is almost 
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always a urethane derivative, and there are several reasons for this. Urethane 
groups are easily introduced and, depending upon their structure, can be easily 
removed. This leads in the first instance to carbamic acids, which spontaneously 
decarboxylate generating the free amine of the N-terminal amino acid. In addition, 
the activation and coupling of amino acids with urethane Nα-protecting groups can 
be accomplished with minimal racemization of the α-stereogenic centre. The  
Nα-amino group of one of the amino acids and C-terminal carboxy group of the 
other are both blocked with suitable protecting groups. Formation of the desired 
amide bond can now occur upon activation of the free carboxy group. After 
coupling, peptide synthesis may continue by deprotection of the Nα-amino group of 
the dipeptide and coupling with the free C-terminus of another protected amino 
acid or of a suitably protected peptide. 
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Scheme 6: Solid phase peptide synthesis. 
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Protecting groups are classified as either “permanent” or “temporary”. Permanent 
protecting groups are retained until assembly of the peptide chain is complete, 
while temporary protecting groups are removed at intermediate stages. 
In the solid phase peptide synthesis (Scheme 6), introduced by Merrifield,20 a 
C-terminal amino acid of the target peptide is anchored on the insoluble polymeric 
support that serves as permanent protection group, via its carboxy group. Any 
functional group in amino acid side chains must be masked with permanent 
protecting groups that are not affected by the reaction conditions employed during 
peptide chain assembly. The temporary protecting group masking the α-amino 
group during the initial resin loading is then removed. An excess of the second 
amino acid is added, with the carboxy group of this amino acid being activated for 
amide bond formation. After coupling, excess reagents are removed by washing 
and the protecting group is removed from the N-terminus of the dipeptide, prior to 
addition of the next amino acid residue. This process is repeated until the desired 
peptide sequence is assembled. In a final step, the peptide is released from the 
support and the side-chain protecting groups are removed. Generally, side-chain 
protecting groups and resin linkage are chosen such that protecting groups are 
removed and the assembled peptide released under the same conditions. 
In this way, the desired peptide chain is assembled on the support in a linear 
fashion, almost always from the C-terminus to the N-terminus (the C→N strategy). 
This is the reverse of the ribosomal peptide synthesis in nature, where chain 
elongation takes place from the N-terminus. The main problem in the N→C solid 
phase peptide synthesis is racemization. Nevertheless, there are a few reports 
where racemization can be efficiently suppressed and the peptides are 
synthesized in N→C direction on solid support.21 The two most extensively used 
protecting group schemes in solid phase peptide synthesis (SPPS) are Boc/Bzl, 
and Fmoc/t-Bu- approaches.  
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Scheme 7: Acidolytic removal of the Boc group. 
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In Boc/Bzl synthesis, all protecting groups are removed by acidolysis. The side 
chain-protecting groups are, however, stable to the repeated treatments with 
moderately strong acid solutions, such as 33% TFA in DCM, required for removing 
the temporary Boc group (Scheme 7). Once the peptide has been synthesized, the 
side chain-protecting groups are removed by treatment with strong acid, often 
liquid hydrogen fluoride or, less commonly, trifluoromethanesulfonic acid. This 
detaches the completed peptide chain from the solid support at the same time.  
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Scheme 8: Removal of the Fmoc protective group with piperidine. 
 
In Fmoc/t-Bu synthesis, the temporary Fmoc protective group is labile to a solution 
of a secondary amine, normally 20% piperidine in dimethylformamide. The 
mechanism of cleavage (Scheme 8) proceeds by initial proton abstraction to give 
the stabilized dibenzocyclopentadienide ion (XXXIV), which on elimination gives rise 
to dibenzofulvene (XXXV). The latter is then trapped by reaction with an excess of 
piperidine (XXXIII).22 This leads to carbamic acid (XXXVI), which spontaneously 
decarboxylates generating the free amine of the N-terminal amino acid (XXXI). 
Other reagents, such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)23 or fluoride 
ion,24 are also effective for Fmoc group removal. The side chain-protecting groups 
and the peptide-resin anchorage are also labile to acid in the Fmoc/t-Bu approach. 
However, the use of strong acids such as liquid hydrogen fluoride is not 
necessary. In the majority of cases treatment with TFA is sufficient to cleave the 
peptide from the solid support and to remove all protecting groups. 
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2.2.2. Peptide Secondary Structures  
 
The properties of peptides and proteins, which form the molecular machinery of 
living systems, are largely determined by their three-dimensional structure. 
Proteins fold into well-defined three-dimensional structures in physiological 
solution, while peptides often adopt unique structures only while bound to their 
appropriate receptors. 
A polymer’s secondary structure (2˚ structure) is defined as the local conformation 
of its backbone. For proteins and peptides, this means the specification of regular 
polypeptide backbone folding patterns: helices, pleated sheets and turns. 
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Figure 2: Torsion angles of α-amino acids (A) and β-amino acids (B) in a peptide bond. 
 
The backbone of peptides is a linked sequence of rigid planar amide groups, and 
their conformation can be specified by the torsion angles about the Cα-N bond (φ) 
and the Cα-C bond (ψ) of each of its amino acid residues (Figure 2 A). 
For β-amino acids an additional torsion angle θ around the central Cα-Cβ bond is 
present (Figure 2 B). Because of the additional methylene group higher flexibility 
and greater structural variability is possible for β-amino acids. However, the 
conformational space and the flexibility might be restricted by the side chains R 
and R’ at the Cα- and Cβ-atoms. Folded helical or turn-like conformations of 
peptides, which contain β-amino acids, require a gauche conformation about the 
torsion angle θ.25 The torsion angles φ and ψ of several naturally abundant 
periodic secondary structures are shown in Table 1.  
Helices are the most striking elements of protein 2˚ structure. If a polypeptide 
chain is twisted by the same amount about each of its Cα-atoms, it assumes a 
helical conformation. As an alternative to specifying its φ and ψ angles, a helix may 
be characterized by the number, n, of peptide units per helical turn, and its pitch, 
p, the distance the helix raises along its axis per turn. A helix has also chirality, it 
may be either right-handed, P, or left handed, M. A right-handed helix turns in the 
direction that the fingers of a right hand curl when its thumb points along the helix 
axis in the direction that the helix raises. Additional stabilization of helix and other 
2˚ structures is hydrogen bonding. 
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Table 1: The torsion angles φ and ψ of several secondary structures. 
 
Secondary structure φ/deg. ψ/deg. 
Right-handed α-helix -57 -47 
Parallel β-pleated sheet -119 113 
Antiparallel β-pleated sheet -139 135 
Right-handed 310 helix -60 -30 
Right-handed π helix -57 -70 
2.27 ribbon -78 59 
Left-handed polyglycine II and poly-L-proline II helices -79 150 
Collagen -51 153 
Left-handed α -helix 57 47 
 
Very often the helices are described by the notation nm where n is the number of 
residues per helical turn, and m is the number of atoms, including H, in the ring 
that is closed by the hydrogen bond (Figure 3). The most common secondary 
structure element of both fibrous and globular proteins, the α-helix, is described as 
3.613 according to this notation. Hydrogen bonded rings are formed from the C- to 
the N-terminus (backward direction), between the NH group of amino acids i and 
the CO group of amino acid i-n. Opposite orientations of the helix dipoles, as the 
consequence of the structural difference, are observed for the helices formed by  
β-amino acids (β-peptides).26 In these helices hydrogen bonds may also be formed 
in the N- to C-terminal direction (forward direction) between the NH groups of 
amino acids i and the CO groups of amino acids i+n.  
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Figure 3: The hydrogen-bonding pattern of several polypeptide helices. 
 
In β-pleated sheets hydrogen bonding occurs between neighboring polypeptide 
chains rather than within one as in α-helices. There are two kinds of β-pleated 
sheets: 
a) The antiparallel β-pleated sheet, in which neighboring hydrogen bonded 
polypeptide chains run in opposite directions (Figure 4). 
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b) The parallel β pleated sheet, in which neighboring hydrogen bonded 
polypeptide chains extend in the same direction (Figure 4). 
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Figure 4: Antiparallel (above) and parallel (below) β pleated sheets. 
 
The conformations in which these β structures are optimally hydrogen bonded vary 
somewhat from that of a fully extended polypeptide (φ=ψ=±180°). They therefore 
have a rippled or pleated edge-on appearance, which accounts for the appellation 
“pleated sheet”. 
While the α-helix and β-sheet are periodically ordered conformations having on 
average the same φ, ψ angles, turns are aperiodic ordered secondary structures 
(their residues have different φ, ψ torsions angles). The X-ray structural analysis of 
an increasing number of proteins has revealed that turns are common in proteins, 
accounting for 25-30 % of the residues to the total molecule. It is also found that 
about one-fourth of turns does not possess hydrogen bonding. Turns have been 
recognized as sites where the polypeptide chain reverses its overall direction and 
they alone, or as a part of the larger loops, are very often located on the protein 
surface. As a consequence of the folded geometry of the peptide backbone, the 
polar side-chain groups in corner positions (i+1 and i+2) point outward and may 
serve as a site for molecular recognition. Indeed, turns frequently have been 
suggested as the bioactive conformation involved in receptor binding, immune 
recognition, posttranslational modifications, and other recognition processes. 
Depending on the number of amino acids, three types of turns can be classified,  
α- (five amino acids), β- (four amino acids) and γ-turn (three amino acids). These 
aperiodically folded structures may or may not be stabilized by intramolecular 
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hydrogen bonds: NHi+4 to COi for α-turn, NHi+3 to COi for β-turn and NHi+2 to COi 
for γ-turn (Figure 5). 
 
 
 
Figure 5: γ− (left) and β− (right) turn. 
 
Like other 2˚ structures, turns are defined by torsion angles about the Cα-N (φ) and 
the Cα-C bond (ψ) of each of its amino acid residues. These torsion angles for 
different turns are shown in Table 2. An additional turn criterion is that the  
Cα(i)- Cα(i+3) distance is less than 7 Å for a β-turn.27 
 
 
Table 2: Characteristic turn torsion angles. 
 
Turn φi+1/Deg ψi+1/Deg φi+2/Deg ψi+2/Deg φi+3/Deg ψi+3/Deg 
I-αRS -60 -29 -72 -29 -96 -20 
II-αRS -59 129 88 -16 -91 -32 
I-αRU 59 -157 -67 -29 -68 -39 
I-αLU -61 158 64 37 62 39 
βI -60 -30 -90 0 - - 
βI’ 60 30 90 0 - - 
βII -60 120 80 0 - - 
βII’ 60 -120 -80 0 - - 
βIII -60 -30 -60 -30 - - 
βIII’ 60 30 60 30 - - 
βVIa -60 120 -90 0 - - 
βVIb -120 120 -60 150 - - 
γ 75 -64 - - - - 
γi -79 69 - - - - 
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2.3. INTEGRINS 
 
In order to understand how the extracellular matrix interacts with cells, one has to 
identify the cell-surface molecules (matrix receptors) that bind the matrix 
components as well as the extracellular matrix components themselves. Integrins 
are the principal receptors on animal cells responsible for binding most 
extracellular matrix proteins, including collagen, fibronectin and laminin. The 
integrins constitute a large family of homologous transmembrane linker proteins. 
The name of these receptors emphasizes their role in integrating the intracellular 
cytoskeleton with the external environment. Integrins differ from cell-surface 
receptors for hormones and for other soluble signaling molecules in that they bind 
their ligands with relatively high affinity (Ka=106-109 M-1) and are usually present in 
about ten- to hundredfold higher concentration on the cell surface. This 
arrangement makes sense, as binding simultaneously to a large number of matrix 
molecules allows cells to explore their environment without losing all attachment to 
it. Integrins are crucially important receptor proteins because they are the main 
way that cells both bind to and respond to the extracellular matrix. These receptors 
are involved in fundamental cellular processes such as attachment, migration, 
proliferation, differentiation, and survival. Integrins also contribute to the initiation 
and/or progression of many common diseases including neoplasia, tumor 
metastasis, immune dysfunction, ischemia-reperfusion injury, viral infections, 
osteoporosis and coagulopathies.28,100a They are ~280 Å long heterodimeric 
membrane glycoproteins, composed of an α- (150 to 180 kD) and a β- (~90 kD) 
subunit, both of which are type I membrane proteins. Eighteen α and eight β 
mammalian subunits are known, which assemble noncovalently to give 24 
different heterodimers. Although these subunits could in theory associate to give 
more than 100 integrin heterodimers, the actual diversity appears to be much 
more restricted. Contacts between the α and β subunits primarily involve their  
N-terminal halves, which together form a globular head, the remaining portions 
form two rod-shaped tails that also span the plasma membrane. Each integrin 
subunit has a large extracellular domain, a single membrane spanning domain and 
usually a short cytoplasmic domain (40-60 amino acids).29 These short 
cytoplasmic domains of the α and β integrin subunits do not have intrinsic 
enzymatic activities, but can interact with a variety of cytoplasmic proteins, 
including cytoskeletal and signaling molecules. The α cytoplasmic domains are 
highly diverse, whereas the β cytoplasmic domains are somewhat conserved but 
they are necessary and sufficient for integrin-dependent signaling.29 Association of 
α and β subunits defines distinct, although largely overlapping ligand specificity. 
Integrin binding to extracellular matrices can be classified as either  
 2. Theoretical part 16 
RGD-dependent (binding e.g. fibronectin, vitronectin and fibrinogen) or  
RGD-independent (binding e.g. collagen and invasin). In addition, some integrins 
can bind to counterreceptors (such as intercellular adhesion molecules ICAMs) on 
adjacent cells leadings to homotypic and heterotypic cell-cell interaction. Like other 
receptors, integrins transmit signals to the cell interior (“outside-in” signaling), 
which regulates organization of the 
cytoskeleton, activates kinase-signaling 
cascades, and modulates the cell cycle and 
gene expression.30 Unlike other receptors, 
ligand binding to integrins is not generally 
constitutive but is regulated to reflect the 
activation state of the cell. This “inside-out” 
regulation of integrins protects the host from 
pathological integrin–mediated adhesion.28  
Inside-out and outside-in signaling are 
associated with distinct conformational 
changes in the integrin extracellular 
segment.  
 
Figure 6: The domain structure of the  
 αvβ3 integrin. 
 
These changes vary with cell type and the state and nature of the ligand, and are 
modulated by divalent cations that are also required for integrin-ligand 
interaction.31 Despite extensive investigation, it is not exactly clear how integrins 
interact with their ligands, how ligand occupancy affects integrin conformation, and 
how receptor activation is coupled to bi-directional signal propagation. Xiong et. 
al.32 reported crystal structures of the extracellular segment of αvβ3 integrin with a 
cyclic RGD peptide ligand and without it and thus advanced the field an enormous 
stride toward achieving these goals. The extracellular segment of the αA-lacking 
αvβ3 integrin has been crystallized in the presence of Ca2+ and Mn2+ ions.  
The overall shape of the crystallized conformer (resolved to 3.1 Å) is that of a large 
“head” on two “legs” (Figure 6),33 similar to the images seen using electron 
microscopy.34 The head has dimensions of ~ 90 Å by 60 Å by 45 Å and contains a 
seven-bladed β-propeller structure. The β-propeller (a toroidal arrangement of 
seven β-sheets) is found in many other proteins, including the β-subunit of 
heterotrimeric GTP-binding proteins (G proteins). Six Ca2+ binding sites (black 
dots), which are essential for binding of an integrin to its ligand, are seen in the 
structure. Four solvent-exposed Ca2+ binding sites are found in the A-B-β hairpin 
loops of blades 4-7 at the β propeller’s bottom, and another site is in the knee 
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region of the α subunit. The top face of the βA domain contains two potential 
cation-binding sites. The first one is known as a metal ion-dependent adhesion 
site, or MIDAS,35 although this is unoccupied in the crystal structure, the second 
has been named ADMIDAS by the authors.  
The crystal structure of the extracellular part of the αvβ3 integrin in complex with 
cyclic pentapeptide ligand c-(Arg-Gly-Asp-D-Phe-Val(NMet)-) and eight Mn2+ ions 
is also resolved. In this crystal structure six of the Mn2+ ions occupied the same 
position like Ca2+ ions in previous crystal structure. Again is no metal ion visible at 
MIDAS. The cyclic pentapeptide inserts into a crevice between the propeller and 
βA domains on the integrin head. As predicted the RGD sequence makes the main 
contact area with the integrin. The Arg and Asp side chains point in opposite 
directions, exclusively contacting the propeller and βA domains, respectively. 
The signaling pathways activated by integrins have been identified through the 
analysis of biochemical events that are triggered by integrin engagement, and by 
the identification of proteins that associate with focal adhesion complexes. These 
signaling pathways control activation of both protein tyrosine kinase and members 
of the Rho family of small GTP-binding proteins. Protein phosphorylation is one of 
the earliest events detected upon integrin stimulation. Increased tyrosine 
phosphorylation has been shown to be a common response to integrin 
engagement in many cell types including platelets, fibroblasts, carcinoma cells and 
leukocytes.  
Individual cells can and do vary their adhesive properties by selective expression 
of integrins. Further versatility is introduced by the ability of cells to modulate the 
binding properties of integrins so that specificity and affinity of a given integrin 
receptor on a given cell are not always constant. There are numerous examples of 
modulation of integrin function. A particular important feature of integrins is that 
they undergo activation. It is commonly the case in an adhesion process that 
integrins provide strong adhesion only after activation by other stimuli, which can 
include soluble mediators (hormones, cytokine, etc.) and/or insoluble reactants 
(extracellular matrix or other cells). The specificity of the overall adhesion event 
lies in the coupling of activation of the final adhesion receptor, often an integrin 
that is not intrinsically highly specific, to a cascade of signals triggered by specific 
and /or local events. Usually an integrin is activated at the appropriate time and 
place by input of several specific signals. Of equal importance as activation of 
integrins is their inactivation. It is crucially important that cells should not attach at 
the wrong times and places. Platelets and leukocytes offer two prime examples in 
which inappropriate adhesion leads to thrombosis and inflammation, respectively. 
The integrins are a fascinating recognition system that has the potential of 
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becoming one of the best understood protein-protein interaction system with 
profound biological and medical significance. 
 
 
2.3.1. RGD Recognition Sequence 
 
Proteins containing an arginine-glycine-aspartic acid (RGD) attachment site, 
together with the integrins that serve as receptors for them, constitute a major 
recognition system for cell adhesion. At least eight, and possibly as many as 
twelve, of the currently known 24 integrins recognize the RGD sequence in their 
adhesion protein ligands. A partial list of adhesion proteins with RGD sites include 
fibronectin, vitronectin, fibrinogen, von Willebrand factor, thrombospondin, laminin, 
enactin, tenascin, osteopontin, bone sialoprotein, and, under some conditions, 
collagens.36 Also many RGD-containing microbial proteins, such as the penton 
protein of adenovirus,37 the foot and mouth virus coat protein,38 the Coxsackie 
type virus,39 and a surface protein of Bordetella pertussis40 serve as ligands 
through which these microbes bind to integrins on the cell surface and gain entry 
into the cell. Also the Tat protein of the human immunodeficiency virus (HIV) is an 
RGD-containing protein with cell attachment activity. The interaction of Tat with 
cells is important because Tat can be internalized by cells, thus allowing Tat 
produced by one cell to enter another cell and turn on the production of latent 
HIV.41 The role of the RGD sequence in the interactions of Tat with cell surfaces is 
still not obvious. Two groups42 have found the RGD site on Tat to be active, 
whereas two others43 find that the cell attachment activity of the Tat protein is 
linked to a highly basic sequence (RQR) in Tat. The attachment mediated by the 
basic sequence is found to be dependent on a αvβ5 integrin, which has both an 
RGD-directed binding site and a site for a basic sequence. Nevertheless, this 
integrin despite its ability to bind Tat does not appear to play any significant role in 
the internalization of Tat by cells.  
Not all RGD-containing proteins mediate cell attachment. This is so because the 
RGD sequence may not always be available at the surface of the protein or may 
be presented in a context that is not compatible with integrin binding. 
The presentation of the RGD sequence in the RGD proteins is important for their 
recognition by integrins. For example, the RGD site in fibronectin exists in a loop 
flanked by β-strands. A similar situation has been encountered with disintegrins, 
small RGD-containing snake venom proteins that bind to different integrins and 
inhibit their function.44 The dependence of the integrin specificity for RGD on the 
conformation of the RGD site and the nature of the surrounding amino acids has 
been successfully utilized in the design of integrin-selective peptides. Peptides that 
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bind selectively to an integrin with affinities 10,000 to 50,000 fold higher than those 
of the original RGD peptides have been designed.45 The peptides are cyclized to 
provide conformational restraint and the sequences flanking the RGD are selected 
to give the best possible affinity and selectivity. 
Short peptides containing the RGD sequence can mimic cell adhesion proteins in 
two ways: When coated onto a surface, they promote cell adhesion, whereas in 
solution they act as decoys, preventing adhesion. Both modes of using RGD 
peptides have found applications: Surface-coated RGD peptides are being 
investigated for improvement of tissue compatibility of various implanted devices, 
and soluble peptides targeted towards individual integrins show promise as 
potential drugs for treatment of a number of diseases. 
RGD peptides, or compounds that mimic the pharmacophoric guanidine and 
carboxy groups, inhibit the function of the αIIbβ3 integrin and are already in late-
stage clinical trials as anti-thrombotics. Other applications being explored include 
the targeting of the αvβ3 integrin in osteoporosis. Osteoclasts attach to the bone 
through this integrin and inhibition of their attachment prevents bone 
degradation.46 The RGD peptides can also prevent tumor growth in vivo by 
interfering with the angiogenic process that the growing tumor would need to 
maintain its blood supply.47 Better understanding of the antitumor effects of the 
RGD peptides could lead to the development of promising new anticancer 
compounds. 
Finally, protein engineering with RGD can have applications in protein targeting 
and gene therapy with viruses. Advances in the application of RGD and related 
sequences to various purposes will depend on detailed understanding of  
integrin-ligand recognition. 
 
2.3.2. Vascular Cell-Adhesion Molecule 
 
The cell-surface glycoprotein vascular cell adhesion molecule-1 (VCAM-1) is 
induced on the surface of vascular endothelial cells. Together with the intercellular 
adhesion molecules ICAM-1, ICAM-2, ICAM-3 and the mucosal vascular 
addressin MAdCAM-1 it forms an integrin-binding subgroup of the immunoglobulin 
superfamily. This protein mediates intercellular adhesion by specific binding to the 
α4β1 integrin, also known as very-late antigen-4 (VLA-4).48 This integrin is a key 
cell-surface receptor that is expressed on leukocytes such as lymphocytes, 
monocytes, mast cells, macrophages, basophils and eosinophils, but not 
neutrophils. It mediates cellular adhesion and activation through a variety of cell-
cell and cell-matrix interactions that regulate leukocyte migration into tissues 
during inflammatory responses and lymphocyte trafficking.49 Blocking of these 
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interactions has the potential to inhibit several processes that play important roles 
in inflammation and thus may be especially useful in the treatment of inflammatory 
diseases. The binding of the α4β1 receptor to cytokine-induced VCAM-1 at sites of 
inflammation results in firm adhesion of the leukocyte to the vascular endothelium 
followed by extravasation into the inflamed tissue.50 Binding of α4β1 integrin to 
VCAM-1 also plays a key role in stem cell adhesion to bone marrow stroma cells51 
and may also be involved in tumor cell metastasis.52 Monoclonal antibodies 
directed against α4β1 integrin or VCAM-1 have been shown to be effective 
modulators in animal models of chronic inflammatory diseases such as asthma, 
rheumatoid arthritis and inflammatory bowel disease.50 In addition to their clinical 
relevance in inflammation, these molecules act as cellular receptors for viral and 
parasitic agents.53 The predominant form of VCAM-1 in vivo has an amino-terminal 
extracellular region comprising seven immunoglobulin-like domains. 
Structure/function studies indicate that domain 1 (or the homologous domain 4) is 
most important for binding, with the contiguous domain 2 (or domain 5) required at 
least for stabilization of structure. The X-ray crystal structure for the binding region 
of VCAM-1 (Figure 20, P. 45) indicates the existence of a loop that protrudes from 
the surface of the molecule.54 This region is a good target for synthetic peptides 
and peptide-like substances (i.e. peptidomimetics) that could inhibit the interaction 
of VCAM-1 with α4β1 integrin and on this way have numerous medicinal 
applications. 
 
 
2.3.3. Invasin 
 
A number of bacterial pathogens is able to enter normally nonphagocytic cultured 
cells. There are numerous potential roles that cellular entry plays in establishing 
diseases. Organisms, such as the enteropathogens Yersinia and Salmonella 
appear to utilize cellular entry to gain access to subepithelial regions. Once 
microorganisms translocate across the epithelium, the routes that different 
organisms take to promote disease may diverge significantly from one to another. 
Efficient entry of enteropathogenic Yersinia into both cultured mammalian cells 
and M cells requires the bacterial protein invasin, which binds multiple members of 
the integrin receptor superfamiliy.55 The protein is part of a family of adhesins 
encoded by enteropathogenic bacteria that includes the intimins, which are 
involved in promoting attachment and effacing lesions by enteropathogenic 
Escherichia coli, as well as Citrobacter freundii. All members of this family appear 
to be involved in binding to receptors present on the mammalian cell plasma 
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membrane that signal to the host cytoskeleton.56 The most significant region of 
similarity between these family members is found in the 500 amino acids of the Y. 
pseudotuberculosis invasin, which is required for outer membrane localization and 
export of carboxy termini of these peptides.57  
The integrin binding region of invasin consists of 
five domains in tandem (D1-D5, with D1 being at 
the amino terminus) of which D1-D4 display the 
folding pattern of the immunoglobulin superfamily. 
D5 has a topology similar to C-type lectin like 
domains. D5 + D4 is the cell adhesion module of 
the protein and the large interface between D4 and 
D5 gives the appearance of a single superdomain 
(Figure 7). 
Invasin does not contain an RGD sequence. Three 
sites are involved in binding to integrin receptors. 
The first region is located in a disulfide loop and 
centered around the residue Asp911. Even a 
conservative change of this residue to a Glu 
residue results in total loss of bacterial uptake in 
host cells.58,59 
Figure 7: Crystal structure of invasin. 
 
The second region is centered around residue Asp811, although residue changes 
in this region have weaker effects than seen with Asp911. This region that appears 
to play a role in supporting integrin binding is called synergy region. The third 
Arg883 residue, also in the synergy region, is located about 30 Å apart from 
Asp911. The five integrins that bind invasin (α3β1, α4β1, α5β1, α6β1, αvβ1) are either 
receptors for extracellular matrix proteins or are involved in cell-cell interactions. 
The best characterized representative of this group is α5β1, which is also known as 
the fibronectin (Fn) receptor. Although there is no detectable similarity between 
invasin and fibronectin, the crystal structure suggests striking similarities in the 
receptor recognition properties of fibronectin and invasin. In fact, the two 
substrates appear to bind to the same site on the α5β1 receptor based on 
competitive inhibition studies, mutational analysis and monoclonal antibody 
inhibition results.60 Nevertheless, invasin binds much more efficient than 
fibronectin, particularly under conditions in which the amount of receptor on the 
target cell is relatively low. The much higher receptor binding affinity of invasin 
appears to be the reason for this difference.61 There are two explanations on the 
structural basis for higher activity of invasin. First, the rigidity of the D4-D5 
adhesion module may lock the protein in an optimal conformation for binding that 
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stabilizes ligand-receptor interaction. Fibronectin, in contrast appears to have 
great flexibility between the two domains involved binding integrins, and it may 
assume several conformations that are not optimal for binding. Secondly, in 
invasin there exists a patch of five aromatic amino acids in the region between 
Asp911 and Asp811 residues that forms a protrusion of the surface of D4. This 
region could facilitate either hydrophobic interactions or hydrogen bonding with the 
receptor and might contribute greatly to the binding energy. Fibronectin has a 
deep cleft in the corresponding region that may not contribute significantly to 
binding.  
These invasin binding regions are good targets for design of powerful integrin 
inhibitors, which could have numerous medicinal and biological implementations. 
 
 
2.4. TYROCIDINE A 
 
Tyrocidine A (Figure 8) belongs to the group of peptides produced naturally by 
microorganisms living in different habitats, spread from aquatic to terrestrial 
environments. They are not genetically encoded but are synthesized non-
ribosomally on large multifunctional enzymes called peptide synthetases.62  
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Figure 8: Tyrocidine A. 
 
In this non-ribosomal mechanism of peptide synthesis, compounds such as 
lipopeptides, depsipeptides, and peptidolactones are assembled from an 
exceedingly diverse group of precursors (more than 300 are known63) including 
pseudo amino acids, nonproteinogenic amino acids, hydroxyl acids, N-methylated 
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amino acids, D- and β-amino acids. This non-ribosomal protein template directed 
synthesis of peptides is limited only by the length of the peptide chain formed, 
which has been found to range from 2 to 48 residues.64 The peptide backbone of 
these short bioactive peptides can be composed of linear, cyclic, or cyclic 
branched structures that may be further modified by acylation, glycosylation or 
heterocyclic ring formation.  
These structurally diverse compounds are endowed with a broad spectrum of 
biological properties, including antimicrobial, antiviral and antitumor activity and 
could be interesting targets for drug discovery. 
Although diverse in structure, most of the non-ribosomally synthesized peptides 
share a common mode of synthesis by enzymes that employ a multiple-carrier 
thiotemplate mechanism. The peptide synthetases have a unique modular 
structure in which each module is responsible for the recognition, activation and in 
some cases modification (epimerization, N-methylation etc.) of a single substrate 
residue of the final peptide product. The modules are aligned in a sequence that is 
collinear with the sequence of the peptide product. With this template arrangement 
in peptide synthetases, the modules seem to operate independently of one 
another, but they act in concert to catalyze the formation of successive peptide 
bonds.65  
SH SH SH SH SH SH SH OHSH SH SH
TycA
(123 K)
TycB
405 K 
TycC
(724K)
A PCP E
module 1
E
module 2 module 3 module 4
TE
module 5 module 6 module 7 module 8 module 9 module 10
C A A AC C C A A AC C C A A AC CPCP PCP PCP PCP PCP PCP PCP PCP PCP
Figure 9: The tyrocidine non-ribosomal peptide synthetase. 
 
Synthetase subunits TycA, TycB, and TycC are represented by a series of boxes. 
Each box represents a functional domain: A, adenylation (catalyzes amino acid 
activation); PCP, peptidyl carrier protein; C, condensation (catalyzes peptide bond 
formation); E, epimerization; TE, thioesterase. 
The modular structure of peptide synthetases gives them the advantage of being 
suitable candidates for the combinatorial biosynthesis of non-ribosomal peptides 
by rearranging or substituting the modules such that a new substrate amino acid 
or modification is placed within the final product.66 This technology has already 
been successful in the engineering of modular polyketide synthases for the 
rational design of altered polyketides.67 Recently it has been shown that a carboxy 
terminal thioesterase domain of peptide synthetase, that is involved in cyclization 
and product release can also catalyze macrocyclization, and elongation in the 
case of symmetric cyclic peptides, independently of upstream domains.68 
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3. AIMS 
 
Several goals were to be achieved in this work: 
-Because of the growing number of evidence69 that β-amino acids exert 
characteristic and predictable influence on the conformation of cyclic peptides 
in solution, cyclic model peptides are required. Cyclic tetra-, penta- and hexa- 
peptides and their analogs in which one α-amino acid is replaced with β-amino 
acid are ideal models for such studies. The conformation in solution of these 
cyclic peptides and influence of cations on conformations should be studied 
using different spectroscopic techniques (CD, FTIR, NMR).  
-The second aim is the synthesis of cyclic penta- and hexapeptides based on 
the binding epitope of VCAM-1 (TQIDSPLN). In these peptides D-amino acids 
and β-amino acids should be incorporated to induce regular turns and to 
improve the stability of these peptides toward enzymatic hydrolysis. Such 
peptides could be strong and selective inhibitors of VCAM-1 interactions with 
the α4β1 integrin and could find numerous medicinal and scientific applications. 
Conformational analysis in solution of these peptides together with the 
determination of their inhibitor activity should provide more insight in the 
relative orientation of the pharmacophoric groups (structure-activity 
relationship) and could lead to the development of even stronger nonpeptidic 
inhibitors. 
-The third aim is the synthesis of the cyclic peptides based on the invasin 
binding epitope (SDMS). This sequence has to be positioned in a β-turn for 
optimal activity of the peptides. Also the influence of an Arg residue, which is 
about 30 Å distant from the SDMS loop in invasin, should be investigated and 
peptides that mimic these two recognition sites should be synthesized. These 
peptides will be tested as inhibitors of the laminin interaction with the integrin 
α3β1. 
-The fourth goal of this work is to synthesize linear precursors of tyrocidine A 
and their analogs (α-amino acids replaced by β-amino acids) using the recently 
developed “safety catch” linker strategy for the introduction of a thioester at the 
C-terminus of the linear precursor. Cyclization of these linear precursors to the 
Tyrocidine A analog will be performed using overexpressed and purified TycC 
TE domain of the large multifunctional enzymes called peptide synthetases. 
-The last objective is the synthesis of different cyclic RGD peptides in which  
β-amino acids are incorporated. Also the influence of the hydrophobicity of the 
residue following the RGD sequence on the inhibitor activity toward integrins 
binding should be studied. 
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4. RESULTS AND DISCUSSION 
 
4.1.
 β-HOMOAMINO ACIDS 
 
In the course of this study aimed at obtaining modified biological molecules with 
potential pharmacological activity, a useful approach to β-homoamino acids was 
needed. Among others, the homologation of α-amino acids is an important 
strategy for the asymmetric synthesis of β-homoamino acids.5,7,8 
The Arndt-Eistert approach towards β-homoamino acids via Wolff rearrangement 
of diazo ketones derived from protected α-amino acids has been utilized since the 
early 1950s.70 This protocol was reinvestigated thoroughly with respect to possible 
epimerization of the chiral centre.71 The Wolff rearrangement of α-diazo ketones 
can be accomplished thermally, photochemically, or by metal ion (Ag+) catalysis 
and has been shown to proceed in most cases with complete retention of 
configuration.71,72 It has been shown that epimerization occurs only in the case of 
urethane protected phenyl glycine, presumably during carboxy group 
activation.71,73 Recently it has been also described that base-free, Ag+ catalyzed 
Wolff rearrangement of Fmoc protected α-diazo ketones proceeds smoothly within 
minutes at room temperature and without epimerization (except for phenylglycine) 
on sonication using an ultrasound-cleaning bath.74 This method is compatible with 
base labile protective groups and is chosen for the synthesis of Fmoc-protected  
β-amino acids used later in solid phase peptide synthesis. 
The instability of the acyl chloride intermediates, their pronounced tendency to 
undergo racemization at the α-carbon and incompatibility with acid labile protective 
groups prevents the application of acyl chlorides as preactivated α-amino acids. It 
is also possible to use acyl fluorides75 as preactivated α-amino acids or to use 
DCC76 as activating reagent. The Fmoc-protected α-amino acids (1) are activated 
as mixed anhydrides (2) using ethyl chloroformate.71,77 Reaction with a sufficiently 
high excess of diazomethane secures complete conversion into diazo ketone (3). 
It has been reported that application of this protocol to the Fmoc protected 
substrates often gives poor yields, racemic starting materials and their methyl 
esters as by-products.78 
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Scheme 9: Synthesis of diazo ketones (3). 
 
Although methyl esters of α-amino acids (1) are observed in the reaction mixtures, 
this has no influence on the next synthetic step, and the diazo ketones (3) can be 
used without further purification. Nevertheless, some diazo ketones  
(Fmoc-L-isoleucyldiazomethane (10), Fmoc-L-phenylalanyl-diazomethane (13),  
Fmoc-L-prolyldiazomethane (17), Fmoc-L-valyldiazomethane (20)) have been 
isolated and purified. The corresponding β-amino acids are obtained from such 
intermediates with good yields and purity but overall yields are almost the same as 
observed in reactions without isolation of intermediary diazo ketones. 
Wolff rearrangement by sonication of the diazo ketone (3) in 1,4-dioxane in the 
presence of silver benzoate and a suitable hetero nucleophile (water) results in a 
clean formation of the β-amino acid derivative (4). 
 
R
NH
O
H
N2
Fmoc
R
NH O
OH
Fmoc
C6H5COO-Ag+
dioxane/H2O
 
 (3) (4) 
Scheme 10: Wolff rearrangement of the diazo ketones (3). 
 
The β-homoamino acids obtained by this method can be used in peptide synthesis 
without further purification. 
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Table 3: Synthesized β-homoamino acids. 
 
β-homoamino acids D/L nomenclature Yielda /% 
Fmoc-(R)-β3-hAla-OH (5) D 50 
Fmoc-(S)-β3-hAsn(Trt)-OH (6) L 75 
Fmoc-(R)-β3-hAsp(Ot-Bu)-OH (7) L 39 
Fmoc-(S)-β3-hGln-OH (8) L 53 
Fmoc-(R)-β3-hGln-OH (9) D 42 
Fmoc-(3R,4S)-β3-hIle-OH (11) L 50 
Fmoc-(S)-2-β3-hNal-OH (12) L 67 
Fmoc-(S)-β3-hPhe-OH (14) L 60 
Fmoc-(R)-β3-hPhg-OH (15) L 52 
Fmoc-(S)-β3-hPhg-OH (16) D 57 
Fmoc-(S)-β3-hPro-OH (18) L 64 
Fmoc-(R)-β3-hSer(t-Bu)-OH (19) L 80 
Fmoc-(R)-β3-hVal-OH (21) L 62 
Fmoc-(S)-β3-hVal-OH (22) D 62 
a Yields are calculated from the starting Fmoc protected α-amino acids. 
 
 
4.2. MODEL PEPTIDES 
 
Cyclic peptides are appealing targets for combinatorial library development.79 They 
are excellent tools for examination of the conformational requirements of peptide 
or protein recognition and serve as models for the design of bioavailable drugs. 
Some cyclic peptides are drugs in their own right, examples include octreotide80 
and cyclosporin A.81 The continuously growing interest in the rational design of 
biologically active peptides led to the development of molecular tools that should 
be capable to force conformationally flexible peptides to preferentially adopt a 
required bioactive three-dimensional structure. One excellent example of rational 
drug design using molecular modeling techniques has been contributed by Kessler 
et al.45 They incorporated the triad Arg-Gly-Asp (RGD), which is known to be a 
universal cell recognition sequence binding to cell surface-exposed integrins, in 
conformationally restricted penta- and hexapeptides. The hexapeptide (23), a 
product of this rational design, efficiently inhibits binding of fibrinogen to the 
integrin αΙΙbβ3  involved in thrombocyte aggregation, while the cyclic pentapeptide 
(24) prevents binding of vitronectin to the integrin αVβ3 playing a role in tumor cell 
adhesion, angiogenesis and osteoporosis. The selectivity profile of these 
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cyclopeptides is rationalized by a mutually different presentation of the 
pharmacophoric group (RGD).  
 
c-(-Arg-Gly-Asp-D-Phe-Val-Gly-) (23) c-(-Arg-Gly-Asp-D-Phe-Val-) (24) 
 
Figure 10: Cyclic RGD peptides (23) and (24) as integrin antagonists. 
 
The RGD motif is found to occupy positions i+1 to i+3 of a β-turn in the αΙΙbβ3  
selective hexapeptide (23) while it resides in positions i to i+1 of a regular γ-turn in 
the αVβ3 selective pentapeptide (24). One D-amino acid is used to achieve this 
strong conformational bias. It is known82 that D-amino acids are inducing β-turns in 
which they occupy i+1 position. 
Peptides containing β-amino acids are characterized by a different skeleton atom 
pattern. The peptide backbone is extended by a C1 unit for each β-amino acid 
present. Replacement of one α- by a β-amino acid in cyclic peptides induces 
conformational changes in such peptides. 
It has been shown that by incorporation of β-amino acids the active RGD 
sequence can be placed in a proper conformation and that β-amino acids may 
posses a higher conformational bias than D-amino acids.69 By replacing the D-Phe 
residue in the cyclopentapeptide (24), a strong αVβ3 integrin antagonist, with D-β-
Phe, the cyclo-pentapeptide c-(-Arg-Gly-Asp-D-β-Phe-Val-) (25) obtained (Figure 
11) has inhibitory activity toward αIIbβ3 integrin. This is again explained with 
different conformational preferences of these two amino acids. The β-amino acid 
in (25) occupies the central position of an extended γ-turn, while the D-amino acid 
in (24) occupies i+1 position of a βII’-turn. This γ-turn forces the RGD sequence to 
adopt a β-turn, which is responsible for selective inhibitory activity toward αIIbβ3 
integrin of this peptide. 
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 c-(-Arg-Gly-Asp-D-β-Phe-Val-) (25)  c-(-Arg-Gly-Asp-D-β-hPhe-) (26) 
 
Figure 11: Cyclic RGD peptides (25) and (26) as integrins antagonists. 
 
The tetrapeptide (26), which is obtained by replacing the dipeptide sequence  
D-Phe-Val in (24) by the β-homoamino acid D-β-hPhe, is a strong and selective 
antagonist of αvβ3 integrin. Presentation of the RGD sequence in a γ-turn seems to 
be a prerequisite of selective αvβ3 antagonism. 
 
 
4.2.1. Synthesis of Model Peptides for CD and FTIR Studies 
 
Cyclic model peptides in which one α-amino acid is replaced by a β-amino acid 
analog are required for the conformational investigation of turn structures induced 
by β-amino acids in cyclic peptides. The cyclic peptides should have different ring 
sizes. Cyclic tetra-, penta- and hexa- peptides are ideal models for such studies. 
The amino acids are chosen so that some conditions are fulfilled: 
a) Amino acids without side-chain functionality that could interfere with 
spectroscopic techniques (Leu, Ala, Val, Gly, Pro) should be used. 
b) Because conformational changes depending on the solvent are also part of 
the study, amino acids with hydrophobic side chains that can improve 
solubility of the corresponding cyclic peptides in organic solvents should be 
used. 
c) A Gly residue should be present in all synthesized peptides at the  
C-terminus of the linear precursor to avoid epimerization during cyclization.  
d) A Pro residue, which exerts strong conformational bias should also be 
present in all synthesized cyclic peptides to improve the cyclization rate 
over dimerization. Moreover, for studying the conformational preferences of 
β-amino acid this amino acid is chosen to be replaced by the β-homo 
analog (Table 4). 
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Table 4: Model peptides. 
 
 All α-amino acid Analogs 
Tetrapeptide c-(-Ala-Pro-Phe-Gly-) 
(37) 
c-(-Ala-β-hPro-Phe-Gly-) 
(38) 
Pentapeptide c-(-Ala-Val-Pro-Phe-Gly-) 
(35) 
c-(-Ala-Val-β-hPro-Phe-Gly-) 
(36) 
Hexapeptide c-(-Leu-Ala-Val-Pro-Phe-Gly-) 
(33) 
c-(-Leu-Ala-Val-β-hPro-Phe-Gly-) 
(34) 
 
The corresponding linear peptides are synthesized on Wang resin and Sasrin, 
resp., in the automated peptide synthesizer. For the synthesis Fmoc chemistry 
is used with a solution of 2 % DBU, 2 % piperidine in DMF as the deprotection 
agent, TBTU as coupling reagent and DIPEA as base (Table 30, P. 114). 
Linear peptides are cleaved from the resin with an adequate cleavage cocktail 
(protocol 9, P. 118 for Sasrin and protocol 10, P. 118 for Wang resin) and 
purified by reverse phase preparative HPLC. Results are represented in Table 
5. 
 
Table 5: Synthesis of linear precursors of the model peptides (33) – (38). 
 
Yield 
Linear peptide Resin µmol 
mg µmol % 
H-Leu-Ala-Val-Pro-Phe-Gly-OH (27). Sasrin 100 50 80 80 
H-Leu-Ala-Val-β-hPro-Phe-Gly-OH (28). Wang 150 65 89 59 
H-Ala-Val-Pro-Phe-Gly-OH (29). Sasrin 200 60 123 62 
H-Ala-Val-β-hPro-Phe-Gly-OH (30). Sasrin 200 68 135 68 
H-Ala-Pro-Phe-Gly-OH (31). Sasrin 200 47 120 60 
H-Ala-β-hPro-Phe-Gly-OH (32) Wang 150 36 89 59 
 
 
Two main reasons influenced the yields of linear peptides. Some quantities of 
peptides are lost during the purification of the peptides by reverse phase 
preparative HPLC. Diketopiperazine formation during deprotection of the second 
amino acid in the peptide, which is known83 to be the main side reaction in peptide 
synthesis, also lowers the yields of the linear peptides. This reaction is kinetically 
and thermodynamically favored if one of the first two amino acids can easily adopt 
an amide bond having the cis-configuration, like proline or glycine. 
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These linear peptides are cyclized in solution under high dilution condition using a 
large amount of solvent (protocol 7, method A, P. 116) or two injection pumps 
(protocol 7, method B, P. 116). HATU is used as the coupling reagent with DIPEA 
as the base. The results are given in Table 6. 
As it was expected the best yields of cyclic peptides are achieved with 
hexapeptides (33) and (34). Comparing these two peptides, a higher yield is 
obtained for the analog with the β-homoamino acid (34). This can be caused by two 
reasons: 
a) Smaller ring strain due to an additional methylene group from the β-homoamino 
acid, and/or formation of a pseudo-γ-turn, which brings the peptide in a 
conformation that favors cyclization. 
b) The method of cyclization with two injection pumps has great advantage, 
dimerization can be completely suppressed by fine regulation of the peptide 
addition rate. 
 
Table 6: Cyclization in solution of model peptides. 
 
Yield 
Cyclic peptide Met. Coupling reagents 
mg µmol % 
c-(-Leu-Ala-Val-Pro-Phe-Gly-) 
(33) 
A 
1.1 equiv HATU 
3.0 equiv DIPEA 
20 34 41 
c-(-Leu-Ala-Val-β-hPro-Phe-Gly-) 
(34) 
B 
1.5 equiv HATU 
3.0 equiv DIPEA 
45 75 76 
c-(-Ala-Val-Pro-Phe-Gly-) 
(35) 
A 
1.1 equiv HATU 
3.0 equiv DIPEA 
25 53 43 
c-(-Ala-Val-β-hPro-Phe-Gly-) 
(36) 
A 
1.1 equiv HATU 
3.0 equiv DIPEA 
18 37 28 
c-(-Ala-Pro-Phe-Gly-) 
(37) 
A 
1.1 equiv HATU 
3.0 equiv DIPEA 
1 2 2 
c-(-Ala-β-hPro-Phe-Gly-) 
(38) 
B 
1.5 equiv HATU 
3.0 equiv DIPEA 
15 37 41 
 
As expected pentapeptides (35) and (36) are obtained in lower yield than 
hexapeptides (33) and (34). An unexpected low yield is obtained for the 
pentapeptide with β-homoamino acid (36), caused by dimerization. The final 
concentration of this peptide was approximately 0.19 mmol/l, which is much higher 
compared to the cyclo-pentapeptide (35) (about 0.1 mmol/l). The latter is 
synthesized with relatively good yield.  
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Again in good agreement with theory tetrapeptide (37) is synthesized with very low 
yield. In most cases the product of the reaction was the linear dimer and the cyclic 
dimer of the corresponding linear peptide (31). An additional experiment, 
cyclization with two injection pumps did not give better yield. Tetrapeptides always 
represent a problem for cyclization because their ring is too strained and the 
intermolecular dimerization reaction is much faster than intramolecular cyclization 
despite the high dilution conditions. The additional methylene group of the  
β-homoamino acids in the peptide backbone proved to be beneficial for cyclization 
because this provides more conformational flexibility and probably arranges the 
peptide in a conformation that favors the intramolecular cyclization over 
intermolecular dimerization. The analog tetrapeptide (38) with β-homoamino acids 
is obtained in relatively high yield. 
 
 
4.2.2. Spectroscopic Studies 
 
Because the crystallization of the cyclic model peptides remained unsuccessful so 
far, x-ray crystallography could not be employed. Moreover, solid-state structures 
of flexible molecules may not reflect the conformational tendencies of isolated 
molecules since lattice forces are not negligible. In fact, they are sometimes the 
prevailing forces. The biological significance of solid-state structures is difficult to 
assess, not only because of the above-mentioned influence of crystal packing on 
conformation but also because the lattice is certainly different from any of 
biological environments in which the peptide can be found. Despite these 
limitations, solid-state structures are very valuable. They are actual low-energy 
conformations that represent reference structures to which conformers predicted 
by computational methods and found in solution can be compared.84 
Three other techniques are frequently used. NMR is the most powerful method for 
conformational studies of peptides and proteins in solution. From the wealth of 
data provided by NMR, coupling constants (J) and nuclear Overhauser effects 
(NOE) may be converted into structural information. However, the interpretation of 
NMR data for flexible small and midsize peptides must be carried out with caution. 
NMR is a slow method with a time scale of second to hundreds of seconds. 
Hence, conformational interconversions not requiring peptide bond rotations will 
result in averaged NMR parameters. The interpretation of these averaged 
parameters is of little value for conformation analysis.85 Despite this, 
multidimensional NMR experiments in combination with energy calculations and 
molecular modeling by means of molecular mechanics (MM) and molecular 
dynamics (MD) methods are prevalent in the cyclic peptide field. 
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The time scale of chiroptical and vibrational spectroscopic methods is much 
shorter than that of NMR. Circular dichroism (CD) spectroscopy, one of several 
chiroptical methods, has been established as a simple but sensitive tool for 
detecting protein and peptide secondary structure. CD reflects for instance the 
relative spatial orientation of consecutive amide groups. By the end of the 1980s it 
became evident that the information inferred from the CD spectra gave only a “low 
resolution” picture of the steric structure.  
Fourier transform infrared (FTIR) spectroscopy is the simplest method for 
characterizing H-bonded folded secondary structures.86 Amide vibrations are 
highly sensitive to H-bonding. Thus, vibrational techniques are of great help not 
only in detecting turns but also quantitating their distortions. The most important 
region for studying of peptides turns is the amide I spectral region (1620-
1700 cm-1). Using the mathematical procedure of band narrowing-Fourier self 
deconvolution (FSD) and Fourier derivation (FD), individual amide I components 
representing different secondary structures are visually separated.87 CD and FTIR 
spectroscopy reflect weight-dependent spectral contribution of all components of a 
pool of conformers. The combined application of these simple and inexpensive 
methods is advantageous in preliminary conformational studies (conformational 
screening) because measurements performed under the same conditions provide 
complementary data on the three-dimensional structure. 
 
 
4.2.2.1. Circular Dichroism (CD) Spectroscopy 
 
The CD spectra of proteins are determined by the relative spatial arrangement of 
the amide chromophores repeated periodically along the polypeptide chain. The 
relative orientation of the consecutive amide groups depends on the geometry 
(type) of the turn. The CD spectrum reflects this relative spatial orientation of the 
amide groups, which in regular ordered conformations are linked together by  
H-bonds of different strength. CD spectroscopy is used very often for fast 
screening of regular ordered secondary structures in proteins. The CD curves of 
different helices and β-sheets are well documented. The CD curve of an α-helix 
has a negative band at 222 nm associated with the nπ∗ transition and a ππ∗ couplet 
located at 208 nm (negative band) and 192 nm (positive band).88 The β-pleated 
sheet has a CD spectrum composed typically of a negative band near 215 nm, 
which is assigned to the nπ∗ transition, and a positive band near 198 nm, which is 
assigned to ππ∗ excitation components.89 Different types of turns have 
characteristic chiral contributions, which permit their detection and discrimination 
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from other conformations. The CD spectra of different β-turns are also known in 
the literature. The spectrum of a type I β-turn qualitatively resembles that of the  
α-helix in the long-wavelength region, but the positive band at short wavelengths is 
weaker in the turn spectrum. Type II β-turns give rise to a spectrum that resembles 
the β-sheet spectrum but the bands are shifted to the red by 5-10 nm. The γ-turn 
represents the other main type of folded secondary structures, but contributions of 
γ-turns to CD-spectra are not clearly described in the literature. There are 
suggestions that an inverse γ-turn has a negative nπ∗ CD band near 230 nm but 
the ππ∗ region of their CD spectra has not been sufficiently characterized.86, 90 
Due to geometric factors, cyclic pentapeptides often form one β- and one 
complementary γ-turn, while cyclic hexapeptides have a ring size, which allows the 
adoption of even two β-turns. Also structures with one β- and one γ-or with two or 
more γ-turns have been found.91 Because of simple geometric reasons, cyclic 
tetrapeptides and tripeptides cannot adopt a β-turn backbone conformation and 
only γ-turn formation is possible. Tetrapeptides are ideal models for studying the 
contribution of the γ-turn in CD spectra. For fast screening of conformational 
changes that occur by replacing one α-amino acid by its β-analog in a cyclic 
peptide, the CD spectra of all model peptides (Table 4, P. 30), except for c-(-Ala-
Pro-Phe-Gly-) (37) because of its low solubility, in different solvents have been 
recorded.  
CD spectra of these cyclic peptides in ACN are shown in Figure 12. These spectra 
are results of different peptide conformations, turn contributions and the aromatic 
contribution by phenylalanine. In the majority of cases CD spectroscopy is applied 
for monitoring the conformational flexibility rather than characterizing the 
conformation of the cyclic molecule. Nevertheless, some similarities are to be 
observed. The CD curve of two peptides containing a β-homoamino acid, c-(-Leu- 
-Ala-Val-β-hPro-Phe-Gly-) (34) (blue), and c-(-Ala-Val-β-hPro-Phe-Gly-) (36) 
(brown) are very similar with a negative band near 202 nm and a shoulder near 
195 nm. In the NMR and molecular modeling studies (chapter 4.2.2.3, P. 40) it has 
been shown that the cyclic pentapeptide (36) is present in two conformations in 
DMSO (Figure 14 and Figure 15, P. 41). The major conformation, about 70 % of 
the population, contains one pseudo-γ-turn with β-homoproline in the central 
position and one β-turn with glycine in i+1 position. The minor conformation 
consists of one γ-turn with alanine in the central position and one pseudo-β-turn 
with β-homoproline in i+1 position. From the similarity of the CD spectra of these 
two peptides, (34) (blue) and (36) (brown), similar conformations might be expected 
for cyclic hexapeptide (34). The CD spectra of the third peptide with β-homoamino 
acid, c-(-Ala-β-hPro-Phe-Gly-) (38) (violet), is also characterized by a negative 
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minimum, but shifted near 207 nm, and with much lower intensities than in the 
case of two previous peptides (34) (blue) and (36) (brown). Also instead of the 
negative shoulder near 195 nm a positive band is present. The third band of this 
peptide (38) (violet) is very broad with low intensity between 220 and 240 nm. 
Obviously this curve has a completely different profile than the CD spectra of 
peptides (34) (blue) and (36) (brown). 
 
 
Figure 12: CD spectra of model peptides in acetonitrile. 
 
The CD spectra of the cyclic peptide c-(-Leu-Ala-Val-Pro-Phe-Gly-) (33) (red), 
which does not contain any β-amino acids has a different curve profile, which is 
characterized by a negative band near 195 nm, and a negative band near 220 nm 
with a shoulder near 225 nm. The CD spectrum of the cyclopentapeptide without 
any β-amino acid c-(-Ala-Val-Pro-Phe-Gly-) (35) (green) shows the same profile but 
with much lower band intensity near 192 nm. 
The influence of the solvent on the conformation of the peptides (34) and (36) has 
been examined for the peptides containing a β-homoamino acid by changing the 
solvent to more polar TFE or TFE/H2O. A representative example is presented in  
Figure 13. The CD spectrum of cyclopentapeptide (36) in the strong proton 
donating solvent TFE (red or green in Figure 13) completely changes the profile of 
the curve. Instead of the negative shoulder near 195 nm, a positive band at the 
same wavelength is observed. A negative band near 202 nm is present, but with 
lower intensity. A third very broad band of low intensity between 220 and 230 nm 
is also present. This curve is now similar to the curve of the tetrapeptide (38) in 
ACN (violet, Figure 12). The NMR and molecular modeling studies (chapter 
4.2.2.3, P. 40) show that the cyclic pentapeptide (36) is present in only one 
 4. Results and Discussion 36 
conformation in TFE (Figure 16, P. 41) and that this conformation is similar to the 
major conformation of the cyclic pentapeptide (36) in DMSO. In this conformation 
the cyclic peptide (36) contains one pseudo-γ-turn with a β-homoproline residue in 
central position of the turn, but the β-turn is not present.  
 
Figure 13: CD spectra of c-(Ala-Val-β-hPro-Phe-Gly-) (36) in different solvents. 
 
Because of the similarity between the CD spectra of the cyclic tetrapeptide (38) 
(that do not change with the solvent) and cyclic pentapeptide (36) in TFE it is to be 
concluded that cyclic tetrapeptide (38) adopts predominantly one conformation. 
Also this conformation should accomplish one pseudo-γ-turn probably with  
β-homoproline in the central position. There are only few literature data86, 90 about 
the influence of the γ-turn on the CD spectra of cyclic peptides and no data about 
pseudo-γ-turn but it seems that the positive band near 195 nm and the positive 
broad band near 230 nm could be connected with γ- and pseudo-γ-turn while the 
negative band near 207 nm is more likely to be influenced by phenylalanine and/or 
other irregular structures. A significant change of the CD spectra with the solvent 
is neither observed for the cyclic penta- and hexapeptides (33) and (35) that do not 
contain β-homoamino acids nor for tetrapeptide (38). 
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4.2.2.2. FTIR Spectroscopy 
 
The amide group gives rise to several strong FTIR bands, the fine structure of 
which depends on the various types of secondary structures and their relative 
amounts. However, the majority of amide bands reflecting H-bond strength and 
skeletal conformations are usually hidden because of the complexity of IR spectra. 
Among the vibrations of the amide function, it is amide I band (1620-1700 cm-1) 
that has attracted most attention. The major factors responsible for the 
conformational sensitivity of the amide I band are H-bonding and the coupling of 
transition dipoles.92 The band shifts caused by H-bonding and/or transition dipole 
coupling depend on the orientation and distance of interacting amide dipoles and 
thus provide information about the relative steric position of amide groups. Among 
the various vibrational techniques, Fourier-transform infrared (FTIR) spectroscopy, 
coupled with mathematical procedures for visual separation of individual 
component bands in the broad amide I band contour, is most widely used in the 
field of protein and peptide secondary structure analysis. Generally, FTIR bands 
appearing between 1660 and 1690 cm-1 have been assigned to β-turns.93 This 
spectral region corresponds to weakly solvated or shielded amide carbonyls, 
which are not involved in H-bonds matching the strength of the H-bonds of α-helix 
(1650-1657 cm-1), or β-sheet (1620-1640 cm-1). The turns (type I or II) are fixed by 
1←4 (C10) intramolecular H-bonds. FTIR spectroscopic studies on many cyclic and 
linear peptides have given support to the proposal that characteristic acceptor 
amide I band of H-bonded type I and II β-turns appears near 1640 cm-1 in D2O, 
CHCl3 and ACN.87b In halogenated alcohols (e. g. TFE) this band may be shifted 
down to 1634 cm-1.  
There are only few literature data about FTIR of a γ-turn.86,94 Nevertheless, bands 
found around 1620 cm-1 are assigned to the hydrogen bonding in a γ-turn.  
There are no literature data about FTIR of a pseudo-γ-turn, but it should not 
essentially differ from the γ-turn. 
The FTIR spectra of all model peptides have been recorded in acetonitrile and 
TFE, resp.. Data for the amide I region are summarized in Table 7. These data are 
in good correlation with data obtained from CD and NMR/molecular modeling 
studies. For all cyclopeptides different spectra are obtained in TFE and 
acetonitrlile. 
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Table 7: Assignment of Amide I component bands in the FTIR spectra of cyclic peptides. 
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* Higher values (1690-1700 cm-1) result from distorted (non-planar) amides. 
** Lower values are assigned to strongly H-bonded γ-turns (C7). 
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Cyclo-pentapeptide c-(-Ala-Val-β-hPro-Phe-Gly-) (36) in TFE gives rise to two 
bands, which could be correlated with β-turn (1643 cm-1) and pseudo-γ-turn (1628 
cm-1), which is in good correlation with data obtained with CD spectroscopy and 
NMR/molecular modeling experiments. 
The same peptide (36) in acetonitrile has different spectra in the turn-region. Only 
one band is observed at 1634 cm-1 that may be the result of two conformations 
and overlapping of different bands. Cyclotetrapeptide c-(-Ala-β-hPro-Phe-Gly-) 
(38), because of the similarity of CD spectra of this peptide and pentapeptide (36), 
should have only one pseudo-γ-turn probably with β-homoproline residue in the 
central position of the turn. The FTIR spectra of this peptide in TFE and in ACN 
show only one band, in TFE at 1622 and in ACN at 1636 cm-1. This is in good 
correlation with theoretical observations that bands are shifted to lower 
wavenumbers in TFE than in ACN, although these shifts in acetonitrile are smaller 
than expected. The FTIR spectra of cyclopentapeptide c-(-Ala-Val-Pro-Phe-Gly-) 
(35), which should have one γ- and one β-turn, are again in good correlation with 
CD spectra of the same peptide and with theory. Using both spectroscopic 
methods no changes with different solvents are observed. For both solvent 
systems two bands are present at 1641 cm-1 (1636 cm-1) for one β-turn and 1622 
cm-1 (1619 cm-1) for one γ-turn. Surprisingly bands are shifted more in acetonitrile 
than in TFE. Hence, it might be concluded that turns probably are formed by 
different amino acid residues. 
The situation is more complicated for the two cyclohexapeptides (33) and (34). 
Cyclo-hexapeptide c-(-Leu-Ala-Val-Pro-Phe-Gly-) (33) that does not contain a  
β-amino acid residue adopts two β-turns. The FTIR spectrum of this peptide in 
acetonitrile has only one band at 1630 cm-1, which could be connected to two  
β-turns although this value is shifted to smaller wavenumbers than would be 
expected for one β-turn. In TFE not only a band at 1636 cm-1, connected to  
β-turns, but also an additional small band on 1626 cm-1 is present. In this case 
larger shifts are again observed in acetonitrile than in TFE.  
Cyclohexapeptide c-(-Leu-Ala-Val-β-hPro-Phe-Gly-) (34), because of the 
additional methylene group in the peptide backbone, has even more 
conformational flexibility than cyclohexapeptide (33). Nevertheless, FTIR spectra 
of this peptide in acetonitrile shows one strong band on 1633 cm-1 and one weak 
on 1619 cm-1. That suggest that the major conformations of peptide is 
accomplished of two β-turns, but conformations with γ-turns are also present. In 
TFE solution of this peptide (34) only one band is present but strongly shifted to 
1626 cm-1. 
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4.2.2.3. NMR/Molecular Modeling Studies 
 
The results of the NMR/molecular modeling studies are in good agreement with 
the results obtained from FTIR and CD measurements. 
Until now molecular modeling/NMR experiments have been performed only for 
one peptide (36) in two solvents by Dr. Frank Schumann and Ulf Strijowski. 
The structures have been simulated using GROMACS software95 in DMSO and 
TFE boxes, using parameters obtained from ROESY and NOESY NMR 
experiments for interproton distances as boundary conditions. 
 
Figure 14: Conformer I c-(-Ala-Val-β-hPro-Phe-Gly-) (36) in DMSO. 
 
 
Figure 15 Conformer II c-(-Ala-Val-β-hPro-Phe-Gly-) (36) in DMSO. 
 
Both conformations of peptide (36) found in the DMSO box are in agreement with 
the results obtained using CD and FTIR. The major conformation (~ 70 % of the 
population) adopts two turns, a pseudo-γ-turn with β-homoproline in the central 
position of the turn and a corresponding β II' turn with glycine in i+1 position 
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(Figure 14). The minor conformation (~ 30 % of the population) adopts a pseudo-
β-turn with β-homoproline in i+1 position and a γ-turn with alanine in the central 
position of the turn (Figure 15). 
Because the CD curve of this peptide (36) in TFE is significantly different from that 
in ACN (Figure 13, P. 36), NMR spectra of this peptide (36) have been recorded in 
CF3CD2OH as the solvent and these data have been used for molecular modeling 
in TFE box. In this solvent the cyclic pentapeptide (36) is found in only one 
conformation that is similar to the major conformation found in DMSO. This 
conformation has also the pseudo-γ-turn with β-homoproline in the central position 
of the turn and but the corresponding β- turn with glycine in i+1 position is missing 
(Figure 16).  
 
Figure 16: c-(-Ala-Val-β-hPro-Phe-Gly-) (36) in TFE. 
 
In this case the pseudo γ-turn is stabilized by a hydrogen bonding between the 
valine oxygen and the phenylalanine amid bond hydrogen (distance between 
these two atoms is 2.5 Å). Hydrogen bonding between the same oxygen and the 
glycine amide bond hydrogen is also present (distance is 2.6 Å) that can stabilize 
a pseudo-β-turn. The φ, ω and ψ torsion angles of all amino acids in this 
conformation are given in Table 8. 
 
Table 8: Torsion angles for c-(-Ala-Val-β-hPro-Phe-Gly-) (36) in TFE. 
 
 ψ φ ω 
Phe -50.2 -63.3 172.2 
Gly -97.3 -130.7 176.8 
Ala -44.9 -79.8 160.2 
Val 112.6 -85.8 -133.6 
β-hPro -98.5 -86.7 169.5 
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4.2.3. Cation Binding Studies 
 
Cations, especially Ca2+, are involved in a number of biological processes.96 On 
cation binding, peptides or even proteins may undergo structural changes. These 
changes are often important for the biological activity of the peptides.97 For 
example, cycloss-KYGCRGDWPC is a much stronger inhibitor of fibrinogen binding 
to the αIIbβ3 integrin in presence of Mn2+ than in presence of Ca2+ ions. The IC50 
value is 100 nM in presence of Ca2+ ions and 1 nM in the presence of Mn2+ ions.98  
 
 
Figure 17: CD spectra of c-(-Ala-Val-β-hPro-Phe-Gly-) (36) in the presence of different 
cations in TFE. 
 
CD spectroscopy has also been applied in this field of cation-binding studies. 
Cyclic peptides are excellent models of CD-monitored cation-binding studies.99 
CD spectra of model cyclic peptides (33) - (38) (Table 4, P. 30) in TFE c≅1mM with 
different cations have been recorded. Again as a representative example, the CD 
spectra of pentapeptide c-(-Ala-Val-β-hPro-Phe-Gly-) (36) in complex with different 
cations are shown in Figure 17. Calcium ions in a molar ratio peptide : Ca2+ = 1 : 1 
or peptide : Ca2+ = 1 : 2 have the strongest influence on conformation of the 
peptide according to the CD spectra. 
Complexation with Mg2+(brown curve) results in small changes of the CD curve. 
The small and broad positive band near 220 nm is shifted to 215 nm, but there are 
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no changes in the positive band near 195 nm. This becomes more prominent with 
Ca2+ ions. Both spectra show a broad positive band near 213 nm (red and green 
curves), with much higher intensity than for pentapeptide alone (36) (blue curve) in 
the same solvent. The similarity of the spectra with peptide : Ca2+ ration of 1:1 and 
1:2 lead to the conclusion that a 1:1 complex is formed. Sodium has not very much 
influence on the CD curve of this cyclic peptide. 
Very similar results are obtained in the cation binding studies of cyclic hexapeptide 
 (34) (Figure 18). 
 
 
Figure 18: CD spectra of c-(-Leu-Ala-Val-β-hPro-Phe-Gly-) (34) in the presence of different 
cations in TFE. 
 
Again the biggest influence on peptide conformation is observed in the experiment 
with Ca2+, (red curve). Cation binding has no or relatively small influence on the 
band near 195 nm, which is shifted a little and has stronger intensity, but a new 
broad positive band between 210 and 220 nm is observed again. The negative 
band near 205 nm with shoulder near 213 nm in peptide (34) (blue curve) 
completely disappears or is covered by this new positive band. The same 
changes, but with smaller intensities are observed for all cations tested except 
Al3+. CD spectra of complex of peptide (34) with this cation has same curve shape 
like hexapeptide (34) without cation but stronger intensity.  
Analogs cation binding studies have been performed with the cyclic hexa- and 
pentapeptides (33) and (35), giving very similar results that are shown in Figure 19 
for c-(-Leu-Ala-Val-Pro-Phe-Gly-) (36). Like before cation binding has no influence 
or has influence only on the band intensities for the negative band near 200 nm, 
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but the negative band near 220 nm completely disappears, or is covered with 
positive band on approximately same place. The similarity of the spectra with 
peptide : Ca2+ ration of 1:1 (red curve) and 1:2 (green curve) lead to the 
conclusion that a 1:1 complex is formed. The 1:1 complex is also formed with Mg2+ 
ions. Contrary with Zn2+ ions 1:2 complex is formed.  
 
Figure 19: CD spectra of c-(-Leu-Ala-Val-Pro-Phe-Gly-) (33) in the presence of different  
cations in TFE. 
 
Similar results have been obtained for all peptides examined but conclusions on 
the conformational properties of the cyclic peptides in complex with Ca2+ or other 
cations have to rely on NMR experiments. Nevertheless, some general 
observations have been also obtained with CD. Using this technique it has been 
shown that cation binding, especially of Ca2+, has influence on conformation of the 
peptide in solution. Changes in conformation for all of these peptides are similar 
although these peptides have different conformations without cations.  
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4.3. CYCLIC ANALOGS OF VCAM-1 BINDING EPITOPE 
 
The interaction between an integrin (family of heterodimeric cell surface receptors) 
and their protein ligands are fundamental for maintaining cell function, for example 
by tethering cells to a particular location, facilitating cell migration or by providing 
survival signals to cells from their environment.100 Several different integrins have 
been implicated in disease processes and have attracted widespread interest as 
potential targets for drug discovery.  
The integrin α4β1 is expressed primarily on human monocytes, lymphocytes, 
eosinophils, basophils and macrophages.48 The primary ligands for the α4β1 
integrin are the endothelial surface protein vascular cell adhesion molecule-1 
(VCAM-1), and an alternatively spliced form of the extracellular matrix protein 
fibronectin containing the type III connecting segment (CS-1 fibronectin).101 
Binding of α4β1 to VCAM-1 plays a key role in extravasations of the leukocyte into 
the inflamed tissue, stem cell adhesion to bone marrow stromal cells and may also 
be involved in tumor cell metastasis.51,52 Monoclonal antibodies directed against 
α4β1 or VCAM-1 have been shown in animal models to be effective modulators of 
chronic inflammatory diseases such as asthma, rheumatoid arthritis, and 
inflammatory bowel disease.102 Antagonists of α4β1 might therefore be useful for 
treatment of a number of 
inflammatory and autoimmune 
diseases, for mobilization of bone 
marrow stem cells, or even find 
application as antitumor agents.103  
Cyclic peptide inhibitors containing 
RGD or LDV sequences were 
shown to block binding of 
fibronectin to α4β1 and α5β1, 
respectively, at low micromolar 
concentrations. 104,105 Indeed, 
many integrin ligands including 
fibrinogen, vitronectin, and 
collagen display similar sequences 
in their binding sites. 
 
Figure 20: Recognition motif of VCAM-1.54a  
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Compounds containing such motifs will probably become useful therapeutic 
agents.  
The integrin binding sites of VCAM-1 are thought to reside in the first and fourth 
domains of the seven-domain protein.106 The crystal structure of domains 1 and 2 
of VCAM, solved by two independent groups,54 propose the sequence 
RTQIDSPLN in a surface-exposed loop connecting two β-strands (the CD-loop) as 
integrin binding-epitope of VCAM-1 (Figure 20). By utilizing functional groups 
similar to those found in the binding epitope of VCAM-1, it has been found that 
simple replacement of arginine by tyrosine in the parent cyclic peptide c-(-Arg-Cys- 
-Asp-Pro-Cys-) leads to nearly a 1000-fold enhancement in binding affinity for 
α4β1.107  
Head to tail cyclic peptides, important targets in peptide synthesis over decades, 
have attracted considerable interest in recent years.108 Constraining highly flexible 
linear peptides by cyclization induces or stabilizes the conformation of the peptide 
and at the same time increases their resistance to enzymatic degradation.109  
The aim of this work was to synthesize constrained cyclic peptides (Table 9) as 
mimics of the binding epitope of VCAM-1, which could bind to the integrin with 
higher affinity and selectivity and at the same time be resistant to enzymatic 
degradation. For that reasons D-and β-homoamino acids as a strong 
conformational inducers have also been incorporated in the cyclic peptides.69,82 
 
 
Figure 21: Design principle for the C-terminal analogs of VCAM-1 binding epitope. 
 
Both proline and D-amino acids induce a β-turn in cyclic peptides and have the 
strong conformational preference to i+1 position in the β-turn. Contrary β-amino 
acids induce a pseudo-γ-turn and occupy the central position of the turn (see 
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chapter 4.2.2, P. 32). Using different combinations of these amino acids various 
spatial orientation of the pharmacophoric group could be achieved. An example of 
such spatial screening is schematic presented in Figure 21 for C-terminal analogs 
of the VCAM-1 binding epitope. 
 
Table 9: Cyclic analogs of VCAM-1 binding epitope. 
 
Analogs of the C-terminal 
region 
Analogs of the N-terminal 
region 
Analogs of the central 
part 
c-(-Ile-Asp-Ser-Pro-Leu-Asn-) 
(39) 
c-(-Thr-Gln-Ile-Asp-Ser-Pro-) 
(49) 
c-(-Gln-Ile-Asp-Ser-Pro-) 
(55) 
c-(-Ile-Asp-Ser-β-hPro-Leu-Asn-) 
(40) 
c-(-Thr-Gln-Ile-Asp-Ser-β-hPro-) 
(50) 
c-(-Gln-Ile-Asp-Ser-β-hPro-) 
(56) 
c-(-Ile-Asp-β-hSer-Pro-Leu-β-hAsn-) 
(41) 
c-(-Thr-β-hGln-Ile-Asp-β-hSer-Pro-) 
(51) 
c-(-Gln-Leu-Asp-Ser-Pro-) 
(57) 
c-(-Val-Asp-Ser-Pro-Leu-Asn-) 
(42) 
c-(-Thr-Gln-Val-Asp-Ser-Pro-) 
(52) 
c-(-Ile-Asp-Ser-β-hPro-Leu-) 
(58) 
c-(-D-Val-Asp-Ser-Pro-Leu-Asn-) 
(43) 
c-(-Thr-Gln-Val-Asp-Ser-β-hPro-) 
(53)  
c-(-Val-Asp-Ser-β-hPro-Leu-Asn-) 
(44) 
c-(-Thr-Gln-D-Val-Asp-Ser-Pro-) 
(54)  
c-(-D-Val-Asp-Ser-β-hPro-Leu-Asn-) 
(45) 
  
c(-Asp-Ser-Pro-Leu-Asn-) 
(46)   
c-(-Asp-Ser-Pro-Leu-β-hAsn-) 
(47) 
  
c-(-β-hAsp-Pro-Leu-Asn-) 
(48) 
  
 
Among many other methods,108 on-resin cyclization is a promising method for 
cyclization of linear peptides. As compared with solution phase procedures,  
on-resin cyclization has the following advantages: 
a) Coupling reagents can be separated from the resin-bound peptide by simple 
filtration.  
b) Excess of coupling reagents can be used to ensure faster ring closure, which 
minimizes epimerization. 
c) Pseudo–dilution minimizes dimerization110. 
Among the three strategies for on-resin cyclization, side chain-to side-chain, side-
chain to backbone, and head-to tail, the latter has been investigated extensively. 
Two distinct protocols are employed in the solid phase synthesis. One extensive 
studied approach is the on-resin cyclization of a peptide anchored via a side chain 
functional group such as imidazole,111 carboxylic acid,112 amine113 or alcohol114 
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which commonly is distinguished from the cyclization-cleavage approach, in which 
the peptide is cyclized with simultaneous cleavage from the resin.115 One major 
advantage of the latter method is that the side chain does not need to be 
anchored, making the approach more general than the first one. The published 
methods used in the latter approach employ either the Kaiser oxime resin115a-c with 
a Boc/benzyl-based protocol or thioester resin115d, 116 employing both Fmoc- and 
Boc/benzyl-based protocols for the synthesis of the linear peptides. The first 
approach for on-resin synthesis of head to tail cyclic peptides comprises (I) 
attachment of orthogonally protected amino acid on resin, (II) stepwise solid phase 
synthesis of the linear peptide, (III) orthogonal deprotection to liberate selectively 
the C-terminal carboxy function, (IV) activation of the C-terminal carboxy group 
and its condensation with the free amino group at the N-terminus and finally (V) 
deprotection and cleavage to release the required free cyclic peptide into 
solution.117 
Depending on the synthetic goal, the anchoring bond should be compatible to 
most common peptide synthesis tactics, (e.g. Fmoc) and orthogonal to the C-
terminal protecting group. The latter is to be cleaved selectively under mild 
conditions at the end of the peptide chain assembly prior to the cyclization step. 
The anchoring bond, e.g. for trifunctional amino acids present in binding epitope of 
VCAM-1 can be an ester (Asp, Glu, Ser, Thr), amide (Asn, Gln) or mixed 
carbonate (Ser, Thr).  
These requirements in turn suggest that a trifunctional amino acid can be attached 
directly to a polystyrene resin (hydroxymethyl resin, aminomethyl resin) or to a 
modified or activated polystyrene resin. 
 
 
4.3.1. Orthogonally Protected Aspartic and Glutamic Acid 
 
It is obvious that orthogonally protected aspartic or glutamic acids are essential for 
this kind of head to tail cyclization on resin. There are several possibilities for 
orthogonal protection of the Cα carboxy function of aspartic or glutamic acid. The 
most widely used protective groups for the α-carboxy function of these amino 
acids are presented in Figure 22.  
a) Allyl ester (Figure 22a), cleaved with [Pd(PPh3)4] in different mixtures of solvents 
and in the presence of a nucleophile (morpholine, dimedone, N-methyl aniline), 
the role of which is to scavenge the allyl group released during deprotection.118 
b) Dmab ester (Figure 22b), cleaved with 2 % hydrazine in DMF.119 
c) Dmb ester (Figure 22c), cleaved with 1 % TFA in DCM.112 
d) Trimethylsilylethyl ester, (Figure 22d) cleaved with fluoride ion.120 
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Figure 22: Orthogonal protective groups for α-carboxy function. 
 
There are also other examples of orthogonal protection for these and other amino 
acids.121 Allyl protection is an excellent approach but often yields significant 
amounts of by-products and/or low yields. Side reactions and low yield is also 
reported for the Dmab protection strategy.122 For these reasons Dmb esters of 
aspartic and glutamic acid have been chosen as protection tactics for cyclization 
on resin. 
In the first step of the synthesis Fmoc protected aspartic (59) or glutamic (60) acid is 
converted to the corresponding acid anhydride (61) and (62).123 
 
NH
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OH
O O
X
NH
O
O
ClCOOR
NMM
+ ROH + CO2
Fmoc Fmoc  
 (59) X = CH2 (61) X = CH2 
 (60) X = (CH2)2 (62) X = (CH2)2 
 
Scheme 11: Synthesis of anhydrides. 
 
By this method both anhydrides (61) and (62) are synthesized with good yields (87 
% starting from Fmoc-Asp-OH (61) and 94 % starting from Fmoc-Glu-OH (62)). In 
this process the main by-product is an ester formed by nuclephilic attack of the 
alcohol, which is the chloroformate hydrolysis product, on cyclic anhydride. This 
can be suppressed by using isopropenyl chloroformate as activating reagent, 
which upon hydrolysis produces acetone.124 
Fmoc-Asp-ODmb (64) is prepared by addition of an etheral solution of DCHA to a 
solution of Fmoc-aspartic acid anhydride (61) and 2,4-dimethoxybenzyl alcohol (63) 
in DCM.125 
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Scheme 12: Synthesis of Fmoc-Asp-ODmb. 
 
The α-carboxy group is rendered more electrophilic by the electron-withdrawing 
amino group, allowing its selective esterification. A mixture of α- (64) and β- (65) 
isomers is obtained, which can be separated by flash chromatography. The α/β 
ratio depends on the solvent and the substrate used. The best results (α/β ratio 25 
according to HPLC) for Fmoc protected aspartic acid (59) are obtained with a 
mixture of THF and diethyl ether. Because of the acid sensitivity of the Dmb group, 
the conditions for liberating the carboxylic acid from the dicyclohexyl ammonium 
salt may be the reason for the lower yield (33 %). 
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Scheme 13: Synthesis of Fmoc-Glu-ODmb. 
 
The synthesis of Fmoc-Glu-ODmb (66) by this protocol proceeds with low yield and 
bad regioselectivity. Fmoc-Glu-ODmb (66) is synthesized in situ mixing Fmoc 
protected glutamic acid (60) with one equivavelnt of phosgene, one equvivalent of 
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2,4-dimethoxybenzyl alcohol (63) and two equivalents of a base  
(N-methylmorpholine). Two isomers, α (66) and γ (67), can be separated with flash 
chromatography. The best α/γ isomeric ratio (α/γ ratio is 14) for this reaction is 
obtained in DCM as solvent. The structure of the isomers has been elucidated by 
1H-NMR spectroscopy. According to the literature, benzyl protons of α isomers 
should be shifted downfield compared to the corresponding γ isomer.123 The 
benzyl protons of the α isomer (66) are found as two doublets at 5.09 ppm and 
5.19 ppm with coupling constants of 11.9 Hz while the benzyl protons of the γ 
isomer (67) are found as a singlet at 4.99 ppm.  
 
 
4.3.2. On Resin Cyclization  
 
 
Scheme 14: On resin cyclization according to McMurray. 
 
Asp and Ser residues are essential for the binding affinity of the peptides and are 
both present in all planned peptides (Table 9, P. 47). It is also known that bonds 
between Asp and Ser residues are very often prone to base or acid catalyzed 
hydrolysis and other side reactions. For these reasons it was decided to use the 
McMurray approach for the synthesis of cyclic constrained analogs of the binding 
epitope of VCAM-1, peptides (39) - (58). In this approach aspartic acid, with the  
α-carboxy function being orthogonally protected by the Dmb group, is attached to 
the resin using the β-carboxy group. The linear peptides are assembled using 
Fmoc chemistry. The last amino acid residue to be connected is serine in the 
TQIDSP series. The α-carboxy function of aspartic acid is deblocked with 1 % TFA 
in DCM and peptides are cyclized on the resin. Although the original procedure 
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suggests that yields and purity of the product are better if the amino function is 
deprotected after α-carboxy function, no difference has been observed in this 
work. Finally the cyclic peptides are completely deprotected and simultaneously 
cleaved from the resin. 
 
 
Anchoring of the first amino acid on Wang resin: 
 
Orthogonally protected Asp is attached with its β-carboxy group on Wang resin 
using DMAP-catalyzed coupling with carbodiimide. To achieve optimal conditions 
for cyclization the loading of the resin should range between 0.5 and 0.7 mmol/g 
resin. Alternatively this amino acid could be attached to the Rink amide resin, 
which, after cleavage with concentrated TFA, gives an amide functionality (Asn, 
Gln).126 
 
 
Assembly of linear peptides: 
 
Linear peptides are assembled in an automated peptide synthesizer by a standard 
protocol (Table 30, P. 114).127 Fmoc is used as temporary protective group for the 
amino function. Permanent protective groups are used as follows: 
t-butyl ethers for the hydroxy function of serine and threonine, trityl for the amide 
function of asparagine and glutamine. These protective groups are stable to basic 
conditions used for Fmoc-deprotection and to acidic conditions (1 % TFA/DCM) 
used for Dmb deprotection, and they are easily cleaved under strongly acidic 
conditions used for cleavage of the peptides from the resin. All attempts to 
synthesize the target peptides without protection on the amide functional group of 
asparagine and glutamine failed.  
Onium salts based on 1-hydroxybenzotriazole (HOBt) and 1-hydroxy-7- 
-azabenzotriazole (HOAt), (Figure 23, P. 53) are widely used as coupling reagents 
in peptide synthesis because of their high efficiency and low racemization rate. 
Their aza derivates are even more reactive than the parent benzotriazole 
derivatives in both activation and coupling. 128  
TBTU in the presence of base (DIPEA) in DMF was used as a relatively cheap, 
commercially available and efficient coupling reagent. The solvent can enhance 
coupling efficiency and shorten coupling time.129 DMSO, NMP and DMF display 
best characteristics. Although DMSO very often is superior regarding acylation 
yield and reaction rate, DMF has been chosen because of the much lower price. 
Coupling and/or deprotection have been repeated twice or the coupling time was 
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prolonged if necessary. Fmoc deprotection is achieved with a mixture of 2 % DBU, 
2 % piperidine in DMF. Additional quantities (0.1 mmol/l) of HOBt are added to the 
deprotection mixture because this can suppress base or acid catalyzed side 
reactions like aspartimide formation for Asn and Asp residues,130 pyroglutamyl and 
glutarimide formation for Glu and Gln residues131 and asparagine or glutamine 
deamidation.132 Peptides are especially prone to base catalyzed aspartimide 
formation as a side reaction when an Asp residue follows Asn or Gly residues. The 
partial sequence -Asp-Ser- is susceptible to acid catalyzed aspartimide 
formation.130c  
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Figure 23: Highly efficient coupling reagents. 
 
Small samples of the peptides are cleaved from the resin, completely deprotected 
and analyzed with analytical HPLC and MALDI-ToF MS to monitor the reaction 
progress. Although, in MALDI-ToF MS the desired linear peptides are detected, 
HPLC chromatograms showed a mixture of compounds, which consists of desired 
peptides, by-products of synthesis, cleavage products of protective groups and 
scavengers. From these chromatograms it is not possible with certainty to 
determine the yield and purities of the linear peptides. For the cyclization in 
solution linear protected peptides with the same amino acid residues, but different 
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order of amino acids, are synthesized using the same protocol on the 2-ClTrt 
resin. After cleavage and purification linear peptides are isolated with varying 
yields of 50-90 % depending on amino acid sequence. 
 
 
Cyclization: 
 
The first series of on-resin cyclizations was done with 3.0 equiv of HATU (relative 
to resin loading) as a coupling reagent, and 6.0 equiv of DIPEA (relative to resin 
loading) as a base in DMF during 45 min at room temperature. After the reaction, 
small samples have been cleaved from resin and analyzed with MALDI-ToF MS 
and analytical HPLC. The cyclization was repeated until no more starting linear 
peptide is present in the mixture. The peptide was completely deprotected and 
cleaved from the resin with cleavage reagents TFA/TIS/H2O = 95 : 2.5 : 2.5.  
Analytical HPLC chromatograms of the crude products showed a mixture of 
compounds from which the isolation of the desired cyclic peptides by reverse 
phase preparative HPLC was a laborious task. Results are given in Table 10.  
Overall yields are calculated for isolated pure cyclic peptides referring to the first 
amino acid anchored on the resin. Because the complete peptide synthesis, 
cyclization and cleavage consist of 14 chemical synthesis steps (for hexapeptides) 
or 12 steps (for pentapeptides) high overall yields are not to be expected (if every 
step for a cyclic hexapeptide proceeds with a yield of 90 % the calculated overall 
yield is 0.914x100 = 23 %). The critical step in cyclic peptide synthesis is the 
cyclization of the linear precursor. Although ring closure of hexa- and 
pentapeptides sometimes is hampered, the ease of cyclization is often enhanced 
by the presence of turn structure-inducing amino acids such as glycine, proline, or 
D-amino acids.133 Obviously, the success in cyclization depends on the propensity 
of the linear precursor to adopt a conformation similar to the transition state 
required for cyclization.134 For the linear peptides, which do not contain amino acid 
residues that stabilize turn structures, the cyclization reaction may be an inherently 
improbable or slow process, and side reactions, such as dimerization, may 
dominate even at high dilutions. For such slow cyclizations the increased lifetime 
of the intermediate activated linear peptide provides an opportunity for increased 
epimerization at the C-terminal residue. Some amino acids are prone to side 
reactions (Asp, Asn, Gln) and coupling and deprotection of sterically hindered 
(Thr, Ile, Val) proceeds with lower efficiency. Also amide bond hydrolysis of some 
combinations of amino acids (-Asp-Ser-) represents an additional problem.  
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Table 10: Overall yields for the on-resin cyclization. 
 
Resin Yielda 
 mg mmol 
Peptide 
mg µmol % 
Wang 400 0.20 6 9 4 
Rink 
amide 
100 0.06 
c-(-Ile-Asp-Ser-Pro-Leu-Asn-) 
(39) - - - 
Wang 300 0.20 1 2 1 
Rink 
amide 
170 0.10 
c-(-Ile-Asp-Ser-β-hPro-Leu-Asn-) 
(40) - - - 
Wang 170 0.09 c-(-Ile-Asp-β-hSer-Pro-Leu-β-hAsn-) 
(41) 
3 4 4 
Wang 400 0.20 c-(-D-Val-Asp-Ser-Pro-Leu-Asn-) 
(43) 
9 14 7 
Wang 330 0.20 c-(-D-Val-Asp-Ser-β-hPro-Leu-Asn-) 
(45) 
13 30 15 
Wang 400 0.20 c-(-Val-Asp-Ser-β-hPro-Leu-Asn-) 
(44) 
10 16 8 
Wang 500 0.20 c-(-Thr-Gln-Ile-Asp-Ser-Pro-) 
(49) 
10 15 8 
Wang 400 0.20 c-(-Thr-Gln-Ile-Asp-Ser-β-hPro-) 
(50) 
6 8 4 
Wang 200 0.09 c-(-Thr-β-hGln-Ile-Asp-β-hSer-Pro-) 
(51) 
3 5 5 
Wang 330 0.20 c-(-Thr-Gln-Val-Asp-Ser-β-hPro-) 
(53) 
10 16 8 
Wang 330 0.20 c-(-Thr-Gln-Val-Asp-Ser-Pro-) 
(52) 
6 10 5 
Wang 400 0.20 c-(-Thr-Gln-D-Val-Asp-Ser-Pro-) 
(54) 
9 14 7 
Wang 130 0.10 c-(-Gln-Ile-Asp-Ser-Pro-) 
(55) 
3 6 6 
Wang 125 0.05 c-(-Gln-Ile-Asp-Ser-β-hPro-) 
(56) 
4 7 14 
Wang 130 0.10 c-(-Asp-Ser-Pro-Leu-Asn-) 
(46) 
12 23 23 
a Overall yields are calculated on isolated pure products for all synthesis from 
loading of the first amino acid (Fmoc-Asp-ODmb) on the resin. 
 
The largest problem is the profile of by-products, mismatch sequences, and core 
sequences accumulated during synthesis. These by-products have very similar 
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retention times in reverse phase HPLC like the desired cyclic peptides, which 
represents an additional problem and lowers the overall yields. 
Efforts are made to identify the by-products and to improve of the cyclization 
efficiency. Analysis of mass spectra obtained from MALDI-ToF MS of reaction 
mixtures gave some insight into by-products formed during the synthesis. In 
almost all cases dimeric and cyclic dimeric products were found in the mixture 
despite the high dilution effects of the low resin loading. This can be explained by 
a too high local concentration of the amino acid on the resin because of unequal 
distribution of the linker on the resin, different size of the resin pores and bad 
mixing conditions during anchoring of the first amino acid on the resin. Using such 
an inappropriate resin, formation of dimers and cyclodimers cannot be avoided 
during peptide synthesis. 
One more by-product very often identified in mass spectra of the reaction mixtures 
is characterized by a mass difference of +116 compared to the cyclic peptide (and 
+ 98 compared to the linear peptide). This by-product (68) occurs because of 
guanylation of the free N-terminus of the linear peptide (Scheme 15).135 Such side 
reactions are not prevalent during the solid-phase coupling of single amino acids, 
since the activation step is fast and the coupling reagent is rapidly consumed by 
reaction with the carboxy group of the amino acid. 
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Scheme 15: N-terminal guanylation. 
 
However, because of the much slower activation of hindered amino acids and the 
slower cyclization, protected peptide segments or carboxylic acids involved in 
cyclization steps, the coupling reagent may undergo reaction with the amino 
component. Coupling reagents used in cyclization are in large excess to the linear 
peptide (3.0 equiv relative to the resin loading, and 4.0 equiv assuming that the 
linear peptide is synthesized with an approximate yield of 70 %). Therefore, it is 
not completely consumed by activation of the carboxy function of the linear 
peptide. Additives such as HOAt and HOBt can suppress side reactions, improve 
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cyclization yields and suppress racemization forming ring transition states (69) and 
(70) (Figure 24).136 The better effects of HOAt over HOBt are explained with the 
electron withdrawing properties of the pyridine nitrogen atom, than provide for a 
better leaving group and thus increased reactivity for the derived O-acyl ester.  
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Figure 24: Proposed transition states of HOAt and HOBt esters with linear peptide. 
 
Indeed, cyclization of the linear peptide H-Ser(t-Bu)-Pro-Gln(Trt)-Ile-Asp(Wang)-
OH (116) with a smaller excess of HATU (1.1 equiv relative to resin loading), and 
additional HOAt (2.0 equiv relative to resin loading) gives a better overall yield  
(Table 37, P. 157). However, the guanidino by-product (68) is again detected in the 
reaction mixture.  
Newly developed coupling reagents like PyAOP137 (Figure 23, P. 53) have also 
been employed in cyclizations (Table 31, P. 127 and Table 36, P. 144), although 
side reactions with these coupling reagents have also been reported.138 
Nevertheless, in the cyclization with this reagent the guanidino by-product is not 
observed, but overall yields are not significantly improved. 
Another possible reason for this side reaction could be incomplete deprotection of 
the α-carboxy function of the linear peptide. This is also the most important 
disadvantage of this approach: there are no analytical methods to monitor the 
efficiency of Dmb-protective group hydrolysis. Nevertheless, experiments with 
prolonged reaction times or repeated deprotection of the α-carboxy function with 1 
% TFA/DCM did not give better results.  
The mechanism of the amino acid acylation with the phosphonium and uronium 
compounds (Scheme 5, P. 7) suggests that the role of the base is only an 
abstraction of a proton from the carboxy group of the amino acid. However, the 
nature of the base has an important influence on the reaction rate, yield and level 
of racemization. A lot of work have been done to find the best base,139 but it 
seems to depend on the case and should be optimized for every peptide 
individually. However, the best results are obtained with DIPEA and/or collidine. 
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Finally cleavage of the cyclic peptides from the resin and deprotection presents 
also a source of different side reactions and by-products especially for peptides 
that contain the -Asp-Ser- sequence which undergoes acid catalyzed side 
reactions as has been mentioned before. 
Several cleavage mixtures have been employed: 
95 % TFA, 2.5 % H2O, 2.5 % TIS, 
(47-49) % TFA, (47-49) % DCM, (3-6)% TIS,  
82.5 TFA, 5 % Phenol, 5 % H2O, 5 % Thioanisol, 2.5 % EDT (reagent K), 
88 % TFA, 5 % Phenol, 2 % TIS, 5 % H2O (reagent B) 
The appropriate cleavage reagent should also be chosen individually for every 
peptide.140 Anyway, these cleavage mixtures are a good starting point for the 
optimization of cleavage and deprotection conditions. 
Several cases have been reported in the literature in which cyclization yields 
depend strongly on the sequence of the linear peptide precursor.137,141 Moreover, 
several linear precursors, all leading to the same cyclic product, often showed 
highly variable yields in the cyclization.141b-e 
For taking advantages from this conformational effect two more strategies have 
been employed: on-resin cyclization-cleavage approach and cyclization in solution. 
 
 
On-resin cyclization-cleavage approach: 
 
In this approach (Scheme 16) the first amino acid is anchored on Kenner’s “safety 
catch” sulfonamide linker, which is stable to nucleophilic attack, is compatible with 
Fmoc chemistry, but can be activated when required.142  
The peptide sequence is synthesized following Fmoc chemistry. The last amino 
acid should not be Fmoc protected at the N-terminus before activation of the 
sulfonamide linker by cyanomethylation because the Fmoc protective group is 
unstable under this condition. In this work the trityl group is used for the protection 
of the last amino acid. This can be achieved by using a trityl-protected amino acid 
in the last step of the peptide synthesis or with two additional steps in the 
synthesis: Fmoc deprotection and introduction of trityl protection on the peptide  
N-terminus. After activation by cyanomethylation, the resin is treated with a 
solution of 3 % TFA and 5 % TIS in DCM to remove the trityl protecting group. 
Cyclization and cleavage by nucleophilic attack of the N-terminal amino group are 
accomplished by treatment with DIPEA in THF at room temperature. If necessary 
the cyclic fully protected peptide can be purified by reverse phase preparative 
HPLC. After that, the cyclic peptide is completely deprotected by treatment with an 
appropriate cleavage cocktail. 
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The anchoring of the first amino acid on 
the alkanesulfonamide “safety catch” 
linker proceeds smoothly and without 
racemization According to an optimized 
method143 using PyBOP and DIPEA as 
coupling reagents in CHCl3 at -20 ºC 
during 8 h. Nevertheless, the maximum 
loading with this method was 0.7 
mmol/g and a repeated procedure did 
not give better loading. The rate of 
loading and racemization are strongly 
dependent on the temperature and time 
of the reaction. Only few syntheses 
have been tried with this strategy. 
Nevertheless, in all cases almost only 
dimeric and cyclodimeric products have 
been obtained, the wanted cyclic 
product was formed only in traces. 
The disadvantage of this strategy is the 
relatively long procedure for cleavage 
of the product from the resin, so that 
analytical monitoring during the 
synthesis is time-consuming. 
For these reasons it is decided to try 
the synthesis with more traditional 
cyclization in solution. 
 
 
 
Scheme 16: On-resin cyclization-cleavage  
  approach. 
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4.3.3. Cyclization in Solution 
 
In this approach, the linear peptide is synthesized on 2-ClTrt resin or Sasrin and 
cleaved from the resin with 1 % TFA/DCM so that all side chain functional groups 
are still protected. The linear peptide is then cyclized in solution under high dilution 
conditions to minimize dimerization and finally completely deprotected (Scheme 
17). 
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Scheme 17: Cyclization in solution. 
 
For this strategy it is essential that the peptide is cleaved from the resin without 
concomitant cleavage of the protective groups from the amino acid side chain 
functional groups. 2-Cl trityl resin or Sasrin is chosen, because it is possible to 
cleave the peptide from these resins with 1 % TFA/DCM while under this condition 
all protective groups used (t-butyl for serine and threonine144, t-butoxy for aspartic 
acid145, trityl for asparagine and glutamine146) are stable.147 The chloro trityl resin 
has the advantage over Sasrin that it, because of its bulkiness, can suppress 
diketopiperazine formation during assembly of the first three amino acid residues. 
Moreover, relatively fast esterification of the first Fmoc-protected amino acid 
residue on this resin proceeds without enantiomerization and dipeptide 
formation.148  
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4.3.3.1. Cyclic Analogs of the C-terminal VCAM-1 Binding Epitope 
 
c-(-Ile-Asp-Ser-Pro-Leu-Asn-) (39) was used as a test peptide for the synthesis of 
this group of cyclic peptides. The linear protected precursor H-Asn(Trt)-Ile-Asp(Ot- 
-Bu)-Ser(t-Bu)-Pro-Leu-OH (72) of this peptide is synthesized on Sasrin so that Leu 
is the first amino acid anchored on the resin and the C-terminal residue of the 
linear peptide for the following reasons: 
a) Isoleucine should be avoided at the C- or N- terminus of the peptide chain, 
because this amino acid is sterically hindered and represents a problem for 
cyclization. 
b) Proline is in a position in the peptide chain where, by cis-trans isomerization, it 
can introduce a proper conformation for cyclization.149 
c) The number of basic Fmoc deprotection steps for the peptide, once aspartic 
acid and asparagine residues have been incorporated should be minimal, 
because that undergo different base catalyzed side reactions. 
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Figure 25: The influence of cis-trans isomerization of the -Xaa-Pro- amide bond on the  
   cyclization. 
 
After the synthesis of the linear protected peptide H-Asn(Trt)-Ile-Asp(Ot-Bu)-Ser- 
(t-Bu)-Pro-Leu-OH (72) it is cleaved from the resin with 1 % TFA in DCM, and the 
mixture is immediately neutralized with pyridine. For removal of the pyridinium salt 
of trifluoracetic acid from the linear protected peptide (72) a recently developed 
precipitation-extraction process is used.150 The technique uses normal approaches 
of chromatography and solid-phase extraction sorbents with a precipitation or 
drying procedure so that the sorbent becomes a support matrix for thin-film 
deposition of the compounds of interest. Reverse phase C18 material is used. The 
purity of the linear peptide thus obtained was approximately 70 %, and the linear 
peptide is cyclized without further purification. Alternatively, the linear peptide 
could be purified by reverse phase preparative HPLC, but this is a time and 
solvent consuming process, that is not necessary at this stage of the synthesis. 
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The linear protected peptide (72) is cyclized under high dilution conditions using 
three different coupling reagents (Table 32, P. 128). 
The best results are obtained with PyAOP and DIPEA as a coupling reagent, but 
the reaction was relatively slow. The reaction is monitored by MALDI-ToF MS 
every ½ h. Because the reaction was not completed after ½ h additional quantities 
of PyAOP are added to the reaction (PyAOP is stable in basic solution for approx. 
30 min128). After evaporation of DMF, the cyclic fully protected peptide is purified 
by reverse phase preparative HPLC. The cyclic dimer and the unreacted linear 
peptide are isolated as by-products in this reaction. With DIC and HOAt as 
coupling reagents151 only traces of product are detected after 24 h. HATU and 
DIPEA lead to lower yield than with PyAOP, but the reaction is faster. After ½ h no 
more starting compound is detected by MALDI-ToF MS (Table 32, P. 128). The 
cyclic dimer was present as a by-product but no epimerization or guanylation by-
product is detected with analytical HPLC and MALDI-ToF MS. The full amount of 
the protected cyclic peptide (73) is completely deprotected using the cleavage 
mixture TFA/H2O/TIS = 95 : 2.5 : 2.5 during 3 h and finally purified by reverse 
phase preparative HPLC. The yield of this final deprotection was only 74 %. 
Sufficient quantities of high purity peptide needed for biological tests and 
conformational analysis are obtained with this methodology. The overall yield was 
again low (18 %), but much better compared to on-resin cyclization. Moreover, this 
methodology allows analysis and additional purification after every step. The linear 
protected peptide (72) was synthesized with a yield of 70 % and purity (HPLC) of 
70 %. It is possible to purify the linear protected peptides before cyclization. The 
cyclization proceeds with moderate yield as expected, accompanied by 
dimerization despite the low peptide concentration. However, no epimerization has 
been noted. Surprisingly low yield (~70 %) is obtained in the final cleavage of all 
protective groups, which can be due to the low stability of these peptide under 
acidic conditions, and especially of the -Asp-Ser- amide bond. 
The synthesis of the C-terminal analogs of the binding epitope of VCAM-1 (Table 
9, P. 46) was performed an Sasrin or 2-ClTrt resin. In most cases Fmoc-protected 
leucine was used as the first amino acid anchored on the resin, but proline have 
also been used. Eight new linear peptides have been synthesized via this route. 
The results are presented in Table 11. From these results it is obvious that Sasrin 
has better characteristics for the synthesis of these linear peptides compared to  
2-ClTrt resin. Peptides are obtained from Sasrin with yield of 60-75 % and good 
purity. With 2-ClTrt resin yields are much lower, but the purity of the peptides was 
also satisfactory. Only in one case (H-Asn(Trt)-Val-Asp(Ot-Bu)-Ser-(t-Bu)-Pro-Leu- 
-OH (80)) the linear peptide had to be purified by reverse phase preparative HPLC 
before cyclization. Also by-products (mismatch sequences) have not been 
detected upon purification of the peptides (MALDI-ToF MS). 
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The problem is probably the instability of the 2-ClTrt resin after anchoring the first 
amino acid on the resin. Normally, resin is stored on 4 °C until peptide synthesis, 
after the loading the resin with the first amino acid, estimation of the level of 
loading and removing the Fmoc protective group.  
 
Table 11: Synthesis of linear C-terminus analogs of the binding epitope of VCAM-1. 
 
Yield 
Linear peptide 
Resin/ 
µmol mg µmol % 
Sasrin 
100 95 65 65 H-Asn(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Leu-OH 
(72) 2-ClTrt 
200 
213 173 86 
H-Asn(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-β-hPro-Leu-OH 
(75) 
Sasrin 
200 
134 120 60 
H-β-hAsn(Trt)-Ile-Asp(Ot-Bu)-β-hSer(t-Bu)-Pro-Leu-OH 
(78) 
Sasrin 
200 
180 140 70 
H-Asn(Trt)-Val-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Leu-OH 
(80) 
2-ClTrt 
200 
90 72 36 
H-Leu-Asn(Trt)-D-Val-Asp(Ot-Bu)-Ser(t-Bu)-Pro-OH 
(83) 
2-ClTrt 
200 
133 99 50 
H-Leu-Asn(Trt)-Asp(Ot-Bu)-Ser(t-Bu)-Pro-OH 
(88) 
2-ClTrt 
200 
101 90 45 
H-β-hAsn Trt)-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Leu-OH 
(90) 
Sasrin 
200 
167 150 75 
H-Asn(Trt)-β-hAsp(Ot-Bu)-Pro-Leu-OH 
(92) 
2-ClTrt 
200 
129 137 69 
a After purification by reverse phase preparative HPLC 
 
In this series also peptides with proline at the C-terminus have been synthesized. 
Proline at the C-terminus is very important because cyclization of such peptides 
can be achieved without epimerization152. 
For the cyclization of these linear peptides an apparatus with two injection pumps 
was used. The linear peptide and the coupling reagent are separately slowly 
added to the solution of the base in DMF. The low rate of addition of the peptide 
and coupling reagent in solution is necessary to minimize intermolecular 
condensation that results in dimer and cyclic dimmer formation. The rate of 
addition of peptide and HATU in solution is calculated from Equation 1. 
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Equation 1. 
 
 
 
mv  = rate of addition of peptide in solution in µmol/h 
av  = rate of addition of peptide solution to reaction mixture in ml/min. 
n = molarity of the peptide in µmol 
V = volume of peptide solution in ml 
 
Dimerization can thus be completely suppressed and quantities of the solvent may 
be drastically reduced, but the reaction time is relatively long. Because of the 
previous results obtained in the cyclization of the test peptide c-(-Ile-Asp-Ser-Pro- 
-Leu-Asn-) (39), HATU was chosen as a coupling reagent and DIPEA as base. 
With HATU the reaction was faster than with PyAOP what is essential for using 
pumps for cyclization. HATU is also not stable in basic solution and must be 
separately added to the reaction mixture. In some cases, HOAt has been added to 
the reaction mixture because this substance makes the reaction faster and 
suppresses on this way epimerization and dimerization. This method for 
cyclization is new and should be optimized with regard to quantities of HATU, 
base, rate of addition and additives. 
The results of cyclizations are presented in Table 12. 
After the cyclization, the peptides have been purified by reverse phase preparative 
HPLC or by filtration through a C18 plug and all yields are calculated on pure 
isolated peptide. The rate of dimerization is inverse proportional to the addition 
rate of peptide to the reaction mixture, but for some peptides, like tetrapeptide  
c-(-β-hAsp-Pro-Leu-Asn-) (92), it is not possible to avoid this side reaction. DMSO 
and NMP have not been used before as solvents for cyclization in solution 
because of the high boiling points of these solvents and the impossibility to isolate 
the cyclic peptide from large quantities of solvent. Using the advantageous method 
of cyclization with a dual pump (smaller solvent volumes) and purification by 
precipitation extraction method it is possible to use any solvent for cyclization. 
After the reaction, water is added to the mixture to precipitate the product. The 
mixture is then filtered through a small plug filled with C18 reverse phase material. 
The product on the plug is additionally washed with water and diethyl ether. After 
that, the product is eluted from the plug with acetonitrile, DCM or any other 
adequate solvent (powerful solvent mixtures TFE/DCM or HFIP/CHL, which 
proved to be useful for dissolving of sparingly-soluble protected peptides,153 can 
also be used), which is subsequently evaporated and the product is additionally 
purified by reverse phase preparative HPLC if necessary. 
V
nvv am
∗∗
=
60
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The best yield (85 %) for cyclization of the linear peptide H-Asn(Trt)-Val-Asp- 
(Ot-Bu)-Ser(t-Bu)-Pro-Leu-OH (80) is obtained with this method, but epimerization 
has been observed. 
 
Table 12: Cyclization of C-terminus analogs of the binding epitope of VCAM-1. 
 
Yield Linear 
peptide 
n/ 
µmol 
Coupl. 
reagent 
Solvent 
v/ 
µmol/h 
Cyclic 
peptide mg µmol % 
(75) 120 HATU 3.0 equiv 
DIPEA 6.0 equiv 
DMF 29 (76) 72 72 60 
(78) 140 HATU 1.6 equiv 
DIPEA 3.0 equiv 
DMF 11 (79) 78 76 54 
(80) 72 
HATU 1.0 equiv 
DIPEA 3.0 equiv 
HOAt 0.1 equiv 
DMSO 9 (81)a 75 61 85 
(83) 99 
HATU 2.0 equiv 
DIPEA 6.0 equiv 
HOAt 3.0 equiv 
DMF 4 (84) 59 60 61 
(88) 90 
HATU 1.5 equiv 
DIPEA 3.0 equiv 
HOAt 1.0 equiv 
DMF 5 (89) 90 60 68 
(90) 140 
HATU 1.5 equiv 
DIPEA 3.0 equiv 
HOAt 1.0 equiv 
DMF 19 (91)a 94 110 70 
(92) 137 HATU 4.0 equiv 
DIPEA 8.5 equiv 
DMF 8 (93) 51 48 35 
(72) 173 
HATU 1.2 equiv 
DIPEA 3.4 equiv 
HOAT 1.2 equiv 
DMF 5 (73) 205 126 73 
a Epimerization 
 
An influence of the proline on the C-terminus of the peptide and conformation of 
the linear peptide on racemization is observed with next two peptides. Val residue 
is replaced with D-Val in peptide H-Leu-Asn(Trt)-D-Val-Asp(Ot-Bu)-Ser(t-Bu)-Pro- 
-OH (83) and pentapeptide H-Leu-Asn(Trt)-Asp(Ot-Bu)-Ser(t-Bu)-Pro-OH (88) 
contains one amino acid less than analog (80). In both cases cyclization proceeds 
without epimerization.  
In the pentapeptide H-β-hAsn(Trt)-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Leu-OH (90), in which 
Asn is replaced by β-hAsn (β-hAsn is at the N-terminus of the peptide chain and 
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can not influence the conformation of the linear peptide), and Leu is on the  
C-terminus, epimerization is again observed. 
Surprisingly the tetrapeptide H-Asn(Trt)-β-hAsp(Ot-Bu)-Pro-Leu-OH (92) can be 
cyclized without epimerization, probably due to location of the β-homoamino acid 
in central position of the peptide chain, where it can induce a pseudo-γ-turn and 
bring the peptide in a proper conformation for cyclization. In summary, quite good 
yields are obtained using this cyclization method for all synthesized peptides. After 
the optimization had been done, the synthesis of the c-(-Ile-Asp-Ser-Pro-Leu-Asn-) 
(39) is repeated using new cyclization method. The linear precursor (72) is cyclized 
without epimerization or dimerization with very good yield (73 %). 
For the final deprotection of all protective groups, two different cocktails have been 
used. Results are presented in Table 13. 
 
Table 13: Deprotection of cyclic analogs of the binding epitope (C-terminal part) of  
   VCAM-1. 
 
Yield Cyclic 
protected 
peptide 
n/ 
µmol 
Cleavage 
cocktail 
Time/ 
h 
Cyclic 
deprotected 
peptide 
mg µmol % 
(73) 23 
TFA 95 % 
H2O 2.5 % 
TIS 2.5% 
3 (39) 10 17 70 
(73) 126 Reagent K 5 (39) 30 46 37 
(76) 72 Reagent K 4 (40) 47 71 99 
(79) 76 
TFA 95 % 
H2O 2.5 % 
TIS 2.5 % 
1 (41) 33 49 65 
(81) 61 Reagent K 5 (42) 29 47 77 
(84) 60 Reagent K 5 (43) 32 51 85 
(89) 60 Reagent K 5 (46) 79 60 100 
(91) 110 
TFA 95 % 
H2O 2.5 % 
TIS 2.5% 
2 (47) 25 46 44 
(93) 48 Reagent K 5 (48) 16 28 58 
 
Obviously some of these peptides are not stable in acidic medium, and the 
cleavage cocktail should be carefully chosen for every peptide individually.  
All epimeric mixtures are successfully separated using reverse phase preparative 
HPLC (method 3) under high flow (25 ml/min) with a small gradient. 
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4.3.3.2. Cyclic Analogs of the N-terminal VCAM-1 Binding Epitope 
 
Within this series of cyclic peptides, c-(-Thr-Gln-Ile-Asp-Ser-Pro-) (49) was taken 
as a model peptide for cyclization studies. This peptide contains two sterically 
hindered amino acids (Thr, Ile) that should be avoided as N- or C-terminal 
residues of the precursor linear peptide. This limits cyclization to the position 
between Ser and Pro or Asp and Ser. The latter combination is avoided because 
bad results have been obtained for on-resin cyclization of the same sequences.  
Nevertheless, some linear fully protected peptides are synthesized (Table 14). 
 
Table 14: Synthesis of linear precursors of c-(-Thr-Gln-Ile-Asp-Ser-Pro-) (49). 
 
Yield 
Linear peptide 
Resin/
µmol mg µmol % 
H-lle-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Thr(t-Bu)-Gln(Trt)-OH 
(95) 
200 209 119 58 
H-Thr(t-Bu)-Gln(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-Pro-OH 
(97) 
200 - - - 
H-Gln(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Thr(t-Bu)-OH 
(98) 
200 91 68 34 
H-Pro-Thr(t-Bu)-Gln(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-OH 
(99) 
200 - - - 
 
All peptides were synthesized on 2-ClTrt resin and cleaved with 1 % TFA/DCM 
with immediate neutralization of the mixture with pyridine. Two peptides,  
H-Thr(t-Bu)-Gln(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-Pro-OH (97) and H-Pro-Thr(t-Bu)- 
-Gln(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-OH (99) have not been separated from 
pyridinium trifluroacetate. Instead, cyclization was attempted with this mixture 
(Table 15). These cyclizations completely failed for peptide (99), or proceeded with 
low yield for peptide (97). Two others (linear protected peptides (95) and (98)) 
cyclized with improved but still relatively low yields (29 and 30 % respectively). 
Epimerization is also observed in both cases probably because the sterically 
hindered amino acids (Thr and Ile) are present on the N- or C-terminus of the 
linear precursors. Nevertheless, in both cases epimers can be separated by 
reverse phase preparative HPLC. 
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Table 15: Synthesis of c-(-Thr-Gln-Ile-Asp-Ser-Pro-) (49) 
 
Yield Linear 
peptide 
n/ 
µmol 
Coupling reagent 
v/ 
µmol/h mg µmol % 
(95) 120 4.5 equiv HATU 10 equiv DIPEA 7 37
 35 30 
(97) -c 
2.0 equiva HATU 
3.0 equiva DIPEA 
-c 16 b 15 8 
(98)  70 
1.5 equiv HATU 
3.0 equiv DIPEA 
10 21 20 29 
(99) -c 
2.0 equiva HATU 
3.0 equiva DIPEA 
-c 0 0 0 
a Relative to resin loading. b Calculated from resin loading. c Precursor was not 
purified  
 
Despite of these bad results, all peptides from this series are synthesized following 
the same methodology. 
The linear precursor peptides were synthesized on 2-ClTrt resin (Table 16). This 
time good yields were obtained for all peptides, probably because the resin was 
used immediately after loading with the first amino acid. Two linear protected 
peptides, (104) and (109), were not purified before cyclization.  
 
Table 16: Synthesis of linear analogs of the N-terminal binding epitope of VCAM-1. 
 
Yield 
Linear peptide µmol 
mg µmol % 
H-lle-Asp(Ot-Bu)-Ser(t-Bu)-β-hPro-Thr(t-Bu)-Gln(Trt)-OH 
(101) 
200 190 147 74 
H-β-hGln-Ile-Asp(Ot-Bu)-β-hSer(t-Bu)-Pro-Thr(t-Bu)-OH 
(104) 
100 - - - 
H-Thr(t-Bu)-β-hGln-Ile-Asp(Ot-Bu)-β-hSer(t-Bu)-Pro-OH 
(106) 
200 180 174 87 
H-Gln(Trt)-Val-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Thr(t-Bu)-OH 
(108) 
200 - - - 
H-Gln(Trt)-Val-Asp(Ot-Bu)-Ser(t-Bu)-β-hPro-Thr(t-Bu)-
OH (111) 
200 160 134 67 
H-D-Val-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Thr(t-Bu)-Gln(Trt)-OH 
(114) 
200 160 130 65 
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Cyclizations without isolation of the linear peptide from TFA/pyridinium salts have 
been tried because in a solid phase peptide synthesis using Boc chemistry it was 
found that in situ neutralization of peptide trifluoroacetates with bases such as 
DIPEA or collidine gives better results than separate neutralization, washing and 
than coupling.129a,154 In the cases tried, cyclization without removing the TFA salt 
gave bad results. For example, the linear protected peptide (104) was cyclized with 
only 18 % yield (calculated from resin loading). The same cyclic peptide (105) was 
obtained from a different precursor (106) that was previously purified by filtration 
through a C18 plug with much better, but still low yield (38 %) and without 
epimerization (Table 17). 
This peptide (106) is only one example in this series that cyclizes without 
epimerization. This is obviously due to the proline residue at the C-terminus of the 
peptide. One reason for the relatively low yields is that all of these peptides 
contain a β-hGln residue, where the side chain amide groups are not protected, 
which can lead to numerous by-products in every step of the synthesis. 
 
Table 17: Cyclization of the linear N-terminus analogs of the binding epitope of VCAM-1. 
 
Yield Linear 
peptide 
n/ 
µmol 
Coupl. 
reagent 
v/ 
µmol/h 
Cyclic 
peptide mg µmol % 
(101) 147 
1.8 equiv HATU 
6.0 equiv DIPEA 
1.0 equiv HOAt 
6 (102)a 114 107 73 
(104) -d 
1.1 equiv HATUc 
3.0 equiv DIPEAc 
-d (105)a 15 18 18b 
(106) 174 
2.3 equiv HATU 
4.5 equiv DIPEA 
2.3 equiv HOAt 
5 (105) 92 66 38 
(108) -d 
1.6 equiv HATUc 
3.0 equiv DIPEAc 
-d (109)a 16 15 8b 
(108) 155 3.0 equiv HATU 
6.0 equiv DIPEA 
26 (109)a 35 34 22 
(111) 134 3.0 equiv HATU 
6.0 equiv DIPEA 
32 (112)a 84 50 37 
(114) 130 
1.1 equiv HATU 
3.0 equiv DIPEA 
1.0 equiv HOAt 
5 (115)a 52 47 36 
a Epimerization is observed. b Yield is calculated on first amino acid loading on the 
resin. c Calculated on resin loading. d Precursor was not purified. 
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The linear protected peptide (108) is the first example in this methodology, where a 
large quantity (155 µmol from starting max 200 µmol) of starting linear peptide 
(108) was isolated after cyclization. This material was used for a second 
cyclization. In this reaction 22 % of cyclic peptide (109) and 16 % of linear peptide 
(108) was again isolated. Surprisingly not only cyclization but also dimerization is 
suppressed in this example. This can be due to strong sterical hindrance of the 
bulky t-butyl protective group in beta position of the threonine residue at the  
C-terminus of the linear peptide (108), although other peptides ((98), (104), (111)) 
have been synthesized with the same residue at the C-terminus without this effect 
but also with moderate yields. The linear protected peptide H-lle-Asp(Ot-Bu)-Ser(t- 
-Bu)-β-hPro-Thr(t-Bu)-Gln(Trt)-OH (101), with a β-homoamino acid in the central 
position of the peptide chain is cyclized again with high yield (73 %) but 
epimerization is not suppressed. Obviously epimerization is the main problem for 
cyclization of these peptides and can be suppressed only by using a proline 
residue at the C-terminus of the linear peptides. 
All these cyclic peptides are completely deprotected (Table 18) with two different 
cleavage cocktails and purified by reverse phase preparative HPLC. 
 
Table 18: Deprotection of the linear N-terminus analogs of the binding epitope of VCAM-1. 
 
Yield Cyclic 
protected 
peptide 
n/ 
µmol 
Cleavage 
cocktail 
Time/ 
h 
Cyclic 
deprotected 
peptide 
mg µmol % 
(96) 35 Reagent K 2 (49) 11 17 49 
(102) 107 Reagent K 5 (50) 36 55 51 
(105) 18 
TFA 95 
H2O 2.5 
TIS 2.5 
2 (51) 4 5.5 31 
(105) 66 Reagent K 5 (51) 14 21 32 
(109) 49 
TFA 95 
H2O 2.5 
TIS 2.5 
2 (52) 19 30 61 
(112) 50 Reagent K 2 (53) 27 42 84 
(115) 47 Reagent K 5 (54) 27 43 92 
 
Once again these peptides show instability during deprotection, and yields for the 
deprotection are lower as it was expected. Reagent K is better for deprotection of 
these peptides but it is also not always a good choice. For example, only a slightly 
better yield is obtained with reagent K than with another mixture for peptide (105).  
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Once again all epimeric mixtures are successfully separated using reverse phase 
preparative HPLC (method 3) under high flow (25 ml/min) with a small gradient. 
Following this methodology, some analogs of the binding epitope of VCAM-1 were 
synthesized, which mimics the central position of the epitope (Table 9, P. 47.) 
 
 
4.3.3.3. Cyclic Analogs of the Central Part of VCAM-1 Binding Epitope 
 
The linear peptides were synthesized on 2-ClTrt resin using Fmoc chemistry using 
an automated peptide synthesizer. Results are shown in Table 19. 
 
Table 19: Linear analogs of the central part of VCAM-1 binding epitope. 
 
Yield 
Linear peptide 
Resin/ 
µmol mg µmol % 
H-Ile-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Gln(Trt)-OH  
(117) 
200 150 89 45 
H-β-hPro-Gln(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-OH 
(120) 
200 74 72 36 
H-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Gln(Trt)-Leu-OHa 
(122) 
200 130 142 71 
H-Ile-Asp(Ot-Bu)-Ser(t-Bu)- β-hPro-Leu-OH 
(124) 
200 98 130 65 
a Purified by reverse phase preparative HPLC 
 
These four peptides are a good example of sensitivity to hydrolysis and other side 
reactions (already mentioned in chapter 4.3.2, P. 51) of -Asp-Ser- amide bond 
under basic conditions during Fmoc deprotection. The yield of the linear peptide is 
inverse proportional to the numbers of treatment with a base (Fmoc deprotection) 
for the -Asp-Ser- amide bond. For example, in the peptide H-β-hPro-Gln(Trt)-Ile- 
-Asp(Ot-Bu)-Ser(t-Bu)-OH (120), where the sequence -Asp-Ser- is attached to the 
resin, the yield of the linear protected peptide is very low (36 %). In the opposite 
case, when the sequence -Asp-Ser- is at the N-terminus of the linear peptide (122), 
the yield is much better (71 %).  
Results of cyclization of these linear protected peptides are shown in Table 20. 
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Table 20: Cyclization of linear analogs of the central part of VCAM-1 binding epitope. 
 
Yield Linear 
peptide 
n/ 
µmol 
Coupling 
reagent 
v/ 
µmol/h 
Cyclic 
peptide mg µmol % 
(117) 89 
HATU 6.0 equiv 
DIPEA 13.0 equiv 5 (118)
a 29 26 29 
(120) 72 
HATU 3.0 equiv 
DIPEA 6.0 equiv 
22 (121)a 40 26 36 
(122) 142 
HATU 1.1 equiv 
DIPEA 2.0 equiv 
HOAt 1.0 equiv 
4 (123) 120 101 71 
(124) 130 HATU 3.0 equiv 
DIPEA 6.0 equiv 
31 (125) 8 10 8 
a Epimerization is observed 
 
In this series of cyclic peptides epimerization was also observed but fully protected 
epimers are separated by reverse phase preparative HPLC. The rate of cyclization 
can be improved enormously with addition of HOAt and with slower addition rate of 
the peptide to the reaction solution. Using these conditions, peptide (122) is 
cyclized with a yield of 71 % and racemization is not observed. Other peptides 
((117), (120), and (121)), are cyclized without addition of HOAt with moderate yields. 
These cyclic peptides are completely deprotected with reagent K. The results are 
shown in Table 21. 
 
Table 21: Deprotection of cyclic analogs of the central part of VCAM-1 binding epitope. 
 
Yield Cyclic 
protected 
peptide 
n/ 
µmol 
Cleavage 
cocktail 
Time/ 
h 
Cyclic 
deprotected 
peptide 
mg µmol % 
(118) 26 Reagent K 5 (55) 15 24 92 
(121) 26 Reagent K 2 (56) 13 23 88 
(123) 101 Reagent K 5 (57) 32 44 44 
(125) 10 Reagent K 2 (58) 4 6 62 
 
The above mentioned problems with final deprotection could be avoided only by 
using a different protection scheme. A synthesis of the linear peptides with a 
benzyl type protective group instead of t-butyl type and without any protective 
groups on Gln and Asn residues, which could be deprotected by simple catalytic 
hydrogenation, failed. Analytical HPLC of the linear peptide after cleavage from 
the resin shows a mixture of compounds and in the MALDI-ToF MS only a product 
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with a mass of 108 less than expected is identified. The analytical HPLC in this 
case shows a mixture of compounds. 
All epimeric mixtures obtained during the cyclizations have been separated by 
preparative HPLC. After separation, some of these peptides are found by NMR to 
adopt at least two distinct conformations probably due to a cis-trans isomerization 
of a peptide bond. These species are characterized by the presence of two 
different sets of signals in the 1H NMR spectrum. The ratio of conformers differs 
from 10 : 90 to 50 : 50. Conformers with a ratio less than 20 % have not been 
further examined. For other cases the signals of both conformations were 
elucidated using two-dimensional 1H-1H COSY spectra.  
Although only one symmetric peak was observed in the analytical HPLC for all 
synthesized peptides, additional experiments were needed to prove that the two 
sets of signal are a result of two peptide conformations and not of two 
diastereomers: 
Peptide c-(-Ile-Asp-Ser-Pro-Leu-Asn-) (39) was chosen for additional NMR 
experiments. The changes of the ratio major/minor intensities of the several 
protons with temperature are given in the Table 22. The ratio between: 
a) Ile amide proton in the major conformation (8.73 ppm at 300 K) and Asn 
amide proton in the minor conformation (7.07 ppm at 300 K), 
b) Asx Hβ proton in the major conformation (2.88 ppm at 300 K) and Asx Hβ 
proton in the minor conformation (2.37 ppm at 300 K), 
c)  Asx Hβ proton in the major conformation (2.88 ppm at 300 K) and Asx Hα 
proton in the minor conformation (4.41 ppm at 300 K) are shown. 
 
Table 22: The ratio major/minor intensities of the several protons with temperature in 1H 
 NMR spectra of the peptide c-(-Ile-Asp-Ser-Pro-Leu-Asn-) (39). 
 
Temp./K 300 305 310 315 320 330 
Major Ile NH/minorAsn NH  2.4 2.5 2.7 2.8 2.9 3.2 
Major Asx Hβ/minor Asx Hβ 3.0 3.1 3.2 3.8 3.7 4.4 
Major Asx Hβ/minor Asx Hα 2.4 2.6 2.8 3.0 3.0a -a 
a The signal of the minor proton is partially covered with another signal.  
 
Because of the noise and overlapping of the signals the more accurate integration 
of the peaks was not possible. Nevertheless for all three cases the ratio 
major/minor signal intensity increase with increasing the temperature. This effect is 
not possible for the diastereomers. 
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4.4. CYCLIC ANALOGS OF INVASIN BINDING EPITOPE 
 
The protein invasin encoded by enteropathogenic Yersinia Sp. allows entry of 
bacteria into intestinal M cells by binding to multiple members of the integrin 
receptor superfamily. The five integrins that bind invasin (α3β1, α4β1, α5β1, α6β1, 
αvβ1) are either receptors for extracellular matrix proteins or are involved in  
cell-cell interactions.55,100a The best characterized member of this group is α5β1, 
which is also known as the fibronectin (Fn) receptor. Integrins are primarily 
localized on the basal surfaces of cells in the epithelium, and are normally not 
available for contact with bacteria in the lumen of the intestine. The exception to 
this rule is the M cell, which has at least two integrin invasin receptors uniformly 
distributed on its surface.59  
Because binding of the invasin to the integrins is very strong especially by low 
concentrations of the integrines on the cell surface it represents a good target for 
developing new integrine antagonists. Such antagonists could not only have 
medical application than also can be useful for studying ligand binding and signal 
transduction mediated by different integrins. 
The integrin binding motif consists of one loop region with conservative Asp911 
residue and two synergistic regions (see chapter 2.3.3, P. 20). 
 
 
Figure 26: Binding epitope of Invasin with the critical Asp residue in the β-turn.  
 
4. Results and Discussion 75 
The critical Asp911 residue is found in the i+1 position of the β-turn in the 
sequence -Ser-Asp-Met-Ser- (Figure 26).  
Two cyclic constrained peptides c-(-Ser-Asp-Met-Ser-D-Gln-Gly-) (126) and  
c-(-Ser-Asp-Met-Ser-D-Ala-Gly-) (127) were synthesized on Wang resin using the 
on-resin cyclization strategy already used for the synthesis of the cyclic analogs of  
VCAM-1 binding epitope (chapter 4.3.2, P. 51) Peptides present in the recognition 
sequence (-Ser-Asp-Met-Ser-) is locked in a suitable conformation for binding to 
the integrin by incorporation of a single D-amino acid (Figure 27). The D-amino 
acid induces usually a βII’ turn in a cyclic hexapeptide and leads to the formation 
of an additional complementary β-turn. 
 
 
c-(-Ser-Asp-Met-Ser-D-Gln-Gly-) (126)  c-(-Ser-Asp-Met-Ser-D-Ala-Gly-) (127) 
 
Figure 27: Proposed conformations for two cyclic SDMS peptides. 
 
These two peptides have been tested as inhibitors of the laminin-5 interaction with 
the integrin α3β1 by Dr. Johannes Eble, Universität Münster. 
The integrin α3β1/laminin-5 interaction is a target for modulation of tumor cell 
invasion and tissue remodeling.155 There are indications that elucidation of the 
mechanisms of the α3β1 /laminin-5 interaction is critical for understanding the roles 
of α3β1 in biological and pathological processes and for designing potential 
therapeutics.156 
The inhibitor activity of both peptides (126) and (127) is similar, which confirms that 
the sequence -Ser-Asp-Met-Ser- in the β-turn is responsible for binding activity 
(Figure 28) and that the two other amino acid residues are not important for 
binding activity. 
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Figure 28: Binding affinity of c-(-Ser-Asp-Met-Ser-D-Gln-Gly-) (126) and c-(-Ser-Asp-Met- 
  -Ser-D-Ala-Gly-) (127) and invasin on α3β1 integrin. 
 
Both peptides show same inhibitory activity with IC50 value in the mM range). The 
binding of the laminin-5 to α3β1 integrin is not completely inhibited. The inhibitory 
activity is much weaker than for invasin (IC50 in nM range). Obviously there are 
other contact points present in invasin that are also involved in binding of this 
protein to the integrin. Although there is no striking similarity between invasin and 
fibronectin, sequence determinants involved in receptor recognition appear to be 
similar. In fact, the two substrates appear to bind to the same site on the α5β1 
receptor.60 Nevertheless, invasin is much more efficient than fibronectin.61 
Comparing the invasin and fibronectin157 binding domains, two synergy regions in 
invasin are found (Figure 29). Invasin Asp811 is also involved in binding, but 
mutations on this place have 
much weaker effects than 
observed for Asp911.158 Both 
invasin and fibronectin synergy 
regions contain Arg residues 
that are located at identical 
distances (about 30 Å) from the 
critical Asp residues found in 
their respective carboxy 
terminal cell adhesion 
domains.159 
 
Figure 29: Cell adhesion domains of invasin (right)  
   and fibronectin (left).59  
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As a “second generation” α3β1 antagonist, a peptide c-(-Ser-Asp-Met-Ser-Lys(H- 
-Arg-(β-Ala)5-)-Gly-) (130) which contains both the cyclic constrained SDMS binding 
epitope present in a β-turn and an Arg residue in approximately 30 Å distance is 
synthesized by the following methodology.  
Two peptide segments, the fully protected cyclic peptide c-(-Ser(t-Bu)-Asp(O-tBu)- 
-Met-Ser(t-Bu)-D-Lys(Aloc)-Gly-) (134) and the linear peptide Fmoc-Arg(Pbf)-(β-
Ala)5-OH (131) are synthesized separately. 
The linear peptide Fmoc-Arg(Pbf)-(β-Ala)5-OH (131) is synthesized on 2-ClTrt resin, 
cleaved from the resin with 1 % TFA in DCM (protocol 9) and purified by reverse 
phase preparative HPLC. Protective groups are chosen so that additional 
purification of the partially protected peptide after segment condensation reaction 
and cleavage of the Fmoc protective group is possible if necessary. 
The linear peptide H-Ser(t-Bu)-Asp(Ot-Bu)-Met-Ser(t-Bu)-D-Lys(Aloc)-Gly-OH (133) 
is synthesized on 2-ClTrt resin and purified by reverse phase HPLC. The t-butyl 
group for serine, t-butoxy group for aspartic acid and Aloc for lysine are chosen for 
orthogonal protection of the linear peptide. These protective groups are stable 
under the basic conditions of Fmoc chemistry and Aloc can be selectively removed 
with Pd0 The fully protected cyclic peptide c-(-Ser(t-Bu)-Asp(O-tBu)-Met-Ser(t-Bu)- 
-D-Lys(Aloc)-Gly-) (134) is obtained by cyclization of this linear precursor (133) in 
DMF using a previously developed method (chapter 4.3.3, P. 60) with 1.5 equiv 
HATU as coupling reagent, 4.7 equiv DIPEA as base and 1.5 equiv HOAt as 
additive, which should improve the reaction rate and suppress dimerization and 
epimerization. 
All attempts made for selective deprotection of the Aloc protective group using 
[Pd(PPh3)4] and N-methylmorpholine, morpholine or N-methyl aniline as 
scavengers118 failed. The main product in the MALDI-ToF MS has a mass 16 
larger than the desired peptide, probably due to oxidation of methionine residue. 
Completely (100 % by analytical HPLC) and fast deprotection is achieved using 
phenylsilane160 as scavenger. The selectively deprotected peptide c-(-Ser(t-Bu)- 
-Asp(Ot-Bu)-Met-Ser(t-Bu)-D-Lys-Gly-) (132) is used in the next step without further 
purification. 
An excess of segment (131) is coupled to (132) in DMF using HATU as the coupling 
reagent and DIPEA as the base. The fully protected peptide (135) is deprotected 
first with a solution of 2 % DBU, 2 % piperidine in DMF to remove the Fmoc group 
and then with reagent K to cleave the t-Bu type protective groups. The fully 
deprotected peptide (130) is purified by reverse phase preparative HPLC. 
Peptide c-(-Ser-Asp-Met-Ser-Lys(H-Arg-(β-Ala)5-)-Gly-) (130) shows increased 
inhibitory activity (IC50 ~200 µmol). Although binding not as strongly as invasin, 
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this peptide (130) completely inhibits the binding of laminin-5 protein to the α3β1 
(Figure 30), which was not the case with previously tested peptides. 
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Figure 30: Binding affinity of (130) and invasin on α3β1 integrin. 
 
Still better inhibitory activity could be achieved by optimization of the length and 
the flexibility of the peptide chain between the Arg residue and the cyclic part of 
the peptide. Also incorporation of the second synergistic part of invasin (Asp811 
residue) should also improve the inhibitory activity of this compound. 
 
 
4.5. LINEAR PRECURSORS OF THE ANTIBIOTIC TYROCIDINE A AND 
THEIR ANALOGS 
 
Antibiotic tyrocidine A (Figure 8, P. 22) belongs to the group of the natural 
peptides synthesized non-ribosomally by large enzymes able to form peptide 
bonds from thiol-linked amino acids called peptide synthetases.66 Peptides 
synthesized in this manner are small in size and may acylated, glycosylated, 
methylated, heterocyclized or cyclized. This, non-ribosomal protein template 
directed synthesis of peptides is limited only by the length of the peptide chain 
formed, which has been found to range from 2 to 48 residues.64 The modular 
mechanism of action of these enzymes is shown on Figure 9, P. 23. Each module 
is responsible for the addition of a single amino acid. Modules activate and modify 
a specific amino acid and form the peptide bond between activated amino acids. 
Each module is made up of distinct domains. The adenylation domain (A-domain) 
is responsible for the recognition and activation as acyaladenylates of their 
substrate. In the next step activated amino acids are thioesterifed to the thiol group 
present in the thiolation domain, also called the peptidyl carrier protein (PCP). 
Peptide bond formation is catalyzed by condensation domain. During elongation, 
the intermediate peptides remain covalently attached to the peptide synthetase. 
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Release of the thioester-bound peptide is achieved via the action of a 
thioesterase. Recently it has been shown that a carboxy terminal thioesterase 
domain of peptide synthetase, that is involved in cyclization and product release 
can also catalyze macrocyclization, and elongation in the case of symmetric cyclic 
peptides, independent of upstream domains.161 The full length TycC (Mr 724K) is 
replaced with overexpressed and purified TycC TE domain (Mr 28K). This domain 
successfully catalyzes cyclization of synthetic peptide N-acetylcysteamine (NAC) 
thioesther. N-acetylcysteamine is structurally identical to the terminal portion of 
phosphopantetheine and thus a good mimic of the natural substrate decapeptide-
S-PCP.162 
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Scheme 18: Mechanism of TE-domain catalyzed macrocyclization and product release.161 
 
On the left side of Scheme 18 the proposed mechanism of thioesterase (TE)-
domain catalyzed macrocyclization and product release is shown, in which the 
peptide is transferred from peptidyl carrier protein (PCP) to peptide O-TE where it 
is cyclized and released from the enzyme. On the right side the mechanism is 
shown where the natural enzyme-substrate complex peptidylthio-PCP is replaced 
with a synthetic peptidyl N-acetylcysteamine thioester (peptidyl-SNAC) (136) and 
cyclized with overexpressed and purified TycC TE domain. Cyclization with 
synthetic peptide (136) proceeds smoothly and with negligible rate of hydrolysis. 
Mutation experiments with replacement of each residue in the linear precursor 
(136) by alanine show that the N-terminal residue D-Phe and C-terminal residue 
Orn are essential for cyclization. Recognition of both stereochemistry and the side 
chain of these residues is essential for cyclization. These results161 suggest that 
Tyr7, Val8, and Leu10 also contribute to substrate recognition, although their 
contribution is smaller than that of D-Phe1 and Orn9. 
The C-terminal peptidyl thioester is the key intermediate for this enzymatic 
macrocyclization. The C-terminal peptidyl thioester can be prepared by standard  
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solid-phase synthesis using t-butoxycarbonyl methodology but this requires final 
cleavage of the side chain protecting groups with liquid hydrogen fluoride in the 
last step of the synthesis.163 Some problems must be solved for using the Fmoc-
chemistry for synthesis of C-terminal thioesters. First of all, resin bound thioesters 
are unstable to repeated exposure to piperidine, which is used to remove the 
Fmoc protective group in Fmoc-based chemistry.  
Moreover, the susceptibility of thio esters to epimerization under basic conditions 
imposes an additional difficulty. 
Nevertheless, several strategies for 
solving these problems have been 
reported: 
In one approach164 a thioester-compatible 
Fmoc-cleavage cocktail (25 % 1-methyl- 
-pyrrolidine, 2 % hexamethylenimine, 2 % 
HOBt) has been used.  
Good results are obtained using a 
mixture of Me2AlCl and EtSH for cleaving 
the peptide from Wang and Pam resin to 
give the corresponding thioester.165  
Alternatively, the labile thioester can be 
introduced at the end of the synthesis. 
The backbone amide linker (BAL) 
strategy may be employed to achieve 
this.166 The C-terminal residue of the 
peptide, anchored to a solid support 
through its backbone nitrogen, is being 
activated and coupled to an amino acid 
thioester prior to final cleavage and 
deprotection. 
In this work the more general method 
using Kenner’s sulfonamide “safety-
catch” linker,143 used in a “native ligation” 
approach, a recently developed method 
for synthesis of larger peptides, was 
applied.167  
 
Scheme 19: Synthesis of peptides with  
                     thioester on the C-terminus. 
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The peptide was synthesized on the “safety catch” resin using Fmoc-chemistry. 
Then the linker was activated using iodoacetonitrile, and the peptide was cleaved 
with a nucleophiles, in this case N-acetyl cysteamine. Finally the peptide is 
deprotected and purified by reverse phase preparative HPLC (Scheme 19). 
Fmoc protected leucine is anchored on the “safety catch” resin using Ellman´s 
method.143 The maximal loading of amino acid on resin achieved by this method 
was about 0.7 mmol/g, and repeated reaction does not give better results. 
Racemization is not observed. The linear peptide (138) is synthesized using Fmoc 
chemistry only the N-terminal residue (D-Phe) is Boc protected. 
Activation of the resin can be achieved using iodoacetonitrile or diazomethane. 
Iodoacetonitrile was preferred in most experiments, although it is published168 that 
better results could be obtained with diazomethane if catalytic amounts of 
thiophenol are present in the reaction mixture during nucleophilic displacement in 
the next step of the synthesis. This is in good agreement with previous 
observations showing that diazomethane provides more efficient alkylation, while 
the product of alkylation with haloacetonitrile displays enhanced reactivity toward 
nucleophilic displacement.142c 
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Scheme 20: Synthesis of Tyrocidine A analog. 
 
The C-terminus of the peptide on the activated resin (139) is then reacted with 
N-acetylcysteamine as a nucleophile that is accompanied by cleavage of the 
peptide (140) from the resin. Better yields in this step are obtained if catalytic 
amounts of thiophenol or sodiumthiophenolate are added to the reaction 
mixture.168,169 The reason for this catalytic effect is that for both an aliphatic 
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sulfonamide and an aliphatic mercaptan the pKa in DMSO is 17, while for 
thiophenol the pKa in DMSO is 10.170 The strongly nucleophilic thiophenolate anion 
initially cleaves the peptide to give a phenyl-thioester, which exchanges in situ with 
the large excess of aliphatic thiol to produce a more stable aliphatic α-thioester. 
The rationale for this procedure is analogous to the use of thiol additives to 
improve the kinetics of native chemical ligation.167 
Composition of the cleavage mixture and reaction time should be fine-tuned on the 
specific peptide sequence. However, for these peptides reagent B is used and a 
cleavage time of 1-2 h is found to be optimal.  
 
 
 
 
 
Figure 31: HPLC chromatogram and mass spectra of peptidyl-SNAC (142) and  
   cyclic peptide (143) 
 
Using this methodology the peptide H-D-Phe-Pro-Phe-D-Phe-Asn-Gln-Tyr-Val- 
-Orn-Leu-S-CH2-CH2-NHCOCH3 (136) can be synthesized with an overall yield of 
63 % and in very high purity. An analogous peptide in which four amino acids are 
replaced by their corresponding β-homoamino acids, H-D-Phe-β-hPro-β-hPhe-D-β- 
-hPhe-β-hAsn-Gln-Tyr-Val-Orn-Leu-S-CH2-CH2-NHCOCH3 (142) is obtained with 
an overall yield of only 11 %. The major disadvantage of this methodology is that 
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there are no analytical methods for analyzing activation and nucleophilic 
displacement steps. Hence, there are no possibilities for selection and optimization 
of the problematic step.Cyclization of H-D-Phe-β-hPro-β-hPhe-D-β-hPhe-β-hAsn-
Gln-Tyr-Val-Orn-Leu-S-CH2-CH2-NHCOCH3 (142) with the isolated TycC TE 
domain was performed in the group of prof. A. Marahiel, Philipps-Universität 
Marburg. 
Preliminary results shows smooth cyclization to give a cyclic analog of Tyrocidine 
A (143), with a minor rate of hydrolysis (Figure 31). This experiment is performed 
under following conditions: 
2.5 µL peptidyl-SNAC (2.5 mM, final concentration 100 µM) 
0.5 µL TycC TE final concentration 1 µM 
47 µL puffer (50 mM Hepes, 0.1 M NaCl, pH 7.0) 
Temperature : 25 °C 
Reaction time: 10 min. 
 
 
4.6. RGD PEPTIDES 
 
The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site 
in extracellular matrix proteins, and peptides containing this sequence can mimic 
the activities of matrix proteins. They bind to integrins, the main cell surface 
receptors mediating cell adhesion to extracellular matrices.171 Peptides having little 
secondary structure bind to all integrins usually with low affinity, whereas 
conformational restriction of the RGD sequence in a peptide, combined with an 
appropriate choice of the amino acids that flank the RGD sequence, can yield 
more selective peptides. These conformationally restricted peptides can bind 
specifically to one integrin only or to a small group of closely related integrins.172 
Peptides that are specific for individual integrins are of considerable interest and 
medical significance. RGD peptides and peptidomimetics that block activity of the 
platelet integrin αIIbβ3 almost without interfering with other integrins are already in 
clinical use. The integrin αvβ3 receptor is present in a number of tumor cells, like 
osteosarcoma, neuroblastoma, prostate, breast, and lung cancer, and melanoma 
cells.173 RGD peptides that are selective antagonists of this integrin have 
numerous medical applications. They can be used as inhibitors of angiogenesis,174 
retinal angiogenesis,175 and osteoporosis.176 
RGD peptides selectively binding to αvβ3 are used for targeting anti-cancer drugs 
into tumor vasculature.177 Anticancer drugs coupled to the RGD peptide are less 
toxic and more active against human breast cancer tumors than unmodified drugs. 
RGD peptides are also used for selective targeting tumor cells (αvβ3 integrin) with 
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radiolabeled ligands, what may provide information about the receptor status and 
enable early discovery of cancer cells and specific therapeutic planning.178 
Moreover, RGD peptides grafted to surface proteins of adenoviruses change the 
infectivity pattern of the virus from all human cells to those expressing RGD-
directed integrins.179 Such viral vectors, if specific for αvβ3, could be particularly 
useful in gene therapy. 
For all of these applications, two properties of RGD peptides, affinity and 
selectivity are important. Both are achieved by bringing these three amino acid 
residues in an appropiate conformation. In conformational analysis of model 
peptides (chapter 4.2.2, P. 32) it is shown that β-homoproline, when incorporated 
in one cyclic pentapeptide, most likely will occupy the central position of a pseudo-
γ-turn. Consequently, β-amino acids can be used to force the rest of the cyclic 
peptide, which contains the active RGD sequence, to adopt a predefined 
conformation. 
The cyclic pentapeptide c-(Arg-Gly-Asp-D-Phe-β-hPro-) (146) was synthesized and 
cyclized on Wang resin, using previously described method (chapter 4.3.2, P. 51), 
with good yield and purity.  
A cyclopropyl (Cpr) analog of aspartic acid (148) (Figure 32) was incorporated in 
two other RGD peptides. Highly constrained β-aminocyclopropane carboxylic 
acids, recently recognized as conformationally rigid amino acids for the synthesis 
of peptides,180 exert strong conformational bias,181 and could be used to induce a 
pseudo-γ-turn in cyclic peptides. This cyclopropane rest 
(148) is introduced in the peptide chain as dipeptide 
because it is known that donor-acceptor-1,2-disubstituted 
cyclopropanes rapidly undergo ring opening.182 
 
Figure 32: Cyclopropyl analog of aspartic acid γ-methyl ester (148). 
 
The cyclopentapeptide c-(Arg-Gly-Asp-Phe-Cpr(OMe)-) (149) was synthesized and 
cyclized on Wang resin using the same method as described in chapter 4.3.2, P. 
51. The cyclopropyl ring is incorporated to the peptide as a dipeptide with Fmoc 
protected Phe residue at the N-terminus.183 After complete deprotection and 
cleavage from the resin, cyclopentapeptide (149) is obtained as a mixture of 
epimers, which could not be separated by reverse phase preparative HPLC, 
because the incorporated cyclpropyl rest was a diastereomeric mixture. 
For the synthesis of the cyclopentapeptide c-(Arg-Gly-Asp-Cpr(OMe)-Val-) (151) 
another method was used. First the linear peptide H-Asp(Ot-Bu)-Cpr(OMe)-Val- 
-Arg(Pbf)-Gly-OH (152) is synthesized on 2-ClTrt resin. As a C-terminal residue 
glycine is used to avoid racemization during the cyclization in the next step. The 
CO2MeO
OH
NH2
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cyclopropyl rest is incorporated, as a diastereomeric mixture, in to the peptide as a 
dipeptide with an Fmoc protected Asp residue at the N-terminus. After cleavage 
from the resin and purification, the linear peptide (152) is obtained in only 27 % 
yield. Several reasons for this low yield are possible: 
-Instability of the cyclopropane ring under the acidic cleavage conditions.  
-Instability of the cyclopropane rings under the basic conditions of the 
deprotection of the last Fmoc protective group.  
-Bad coupling efficiency of the dipeptide Fmoc-Phe-Cpr(OMe)-OH residue 
because of steric hindrance of the cyclopropyl ring or its instability. 
Nevertheless, this linear peptide (152) is cyclized, using method A (chapter 6.4.3.2, 
P. 116) for the cyclization in solution, and completely deprotected with good 
overall yield (55 %). 
A hydrophobic residue following the RGD sequence is very important for the 
inhibitory activity of the RGD peptides.184 For example, antithrombotic activity of 
the RGDX peptides increases in the series X= Phe>Val>Cys>Gln>Ser.185 The  
Arg-Gly-Asp-Xaa sequence is the essential pharmacophore for effective inhibition 
of the αIIbβ3-integrin, with Xaa being a hydrophobic residue.186 Similar results are 
obtained for the binding activity of the RGD peptides to the αvβ3 integrin.187  
For the further investigation of this hydrophobic effect on the binding activity of the 
RGD peptides, two cyclic tetrapeptides, c-(-Arg-Gly-Asp-D-1-Nal-) (154) and  
c-(-Arg-Gly-Asp-2-β-hNal-) (155) with D-1-Naphthylalanine and 2-β-homo- 
-naphthylalanine residues are synthesized. 
The linear precursors of these peptides, H-Asp(Ot-Bu)-D-1-Nal-Arg(Pbf)-Gly-OH 
(156) and H-Asp(Ot-Bu)-2-β-hNal-Arg(Pbf)-Gly-OH (158) are synthesized on 2-ClTrt 
resin. Gly is used as the C-terminal amino acid attached to the resin to avoid 
epimerization during cyclization, despite lower yields of linear peptides because of 
diketopiperazine formation on the resin-bound dipeptide stage. 
Peptides (156) and (158) are cyclized in solution using a method developed for the 
synthesis of cyclic analogs of the binding epitope of VCAM-1 (chapter 4.3.3, P. 
60). An excellent yield for the cyclization (94 %) of the linear tetrapeptide (156) is 
obtained. This is unusually high for cyclic tetrapeptides. Both of these cyclic 
peptides, (157) and (159), are not stable and hydrolyze very fast during purification 
by reverse phase preparative HPLC, what is the probable cause for the low yield 
(19 %) obtained on the cyclic tetrapeptide (159). The instability of peptides in acidic 
medium was also observed in the final deprotection and purification of these 
peptides. During the final purification of the cyclic tetrapeptide (154), by reverse 
phase preparative HPLC, two new, linear peptides with a mass difference of + 18 
compared to the cyclic peptide are observed. 
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Figure 33: Adhesion tests with wild type human ovarian carcinoma cells. 
 
Several adhesion tests with these peptides were performed by Dr. Ute Reuning, 
TU München. In the first assay the inhibitor affinity of these peptides toward the 
interaction between the wild type human OV-MZ-6 ovarial carcinoma cells and 
different extracellular matrix proteins (fibronectin, vitronectin and collagen type I) is 
tested. The cells were incubated with two different concentrations of a peptide. 
The number of the adhering cells on the plate was determined photometrically 
using the hexoaminidase activity. As a reference value c-(-Arg-Gly-Asp-D-Phe- 
-Val-) (24), which is a selective αVβ3 antagonist (see chapter 4.2, P. 27), is used. 
Results are presented in Figure 33. 
From these diagrams it is obvious that collagen type I is not a ligand for these type 
of cells. In both concentrations peptides (146), (149), (154) and (155) display no 
inhibition of the interaction of the cells with vitronectin and fibronectin.  
The cyclopeptide c-(Arg-Gly-Asp-Cpr(OMe)-Val-) (151) inhibits cell adhesion to 
vitronectin stronger than to fibronectin. When the peptide is present in higher 
concentration the interaction of the cells with fibronectin is surprisingly not 
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inhibited. Inhibition of cell adhesion to vitronectin by this peptide is not as strong as 
for the reference peptide.  
Because of solubility problems of two cyclotetrapeptides (154) and (155) the 
adhesion test for these peptides was repeated. Small quantities of DMSO are 
added to the peptide solutions. Peptide (155) has higher inhibitor capacity in 
vitronectin binding (Figure 34) than peptide (154), but slightly lower activity than the 
reference peptide.  
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Figure 34: Adhesion test for peptides (154) and (155). 
 
In the next assay cells overexpressing avß3 integrin (the concentration of the avß3 
integrin is 8-10 times higher than in wild type cells) were used with the same 
ligands and peptides. Different results compared to the wild type cells were 
obtained (Figure 35). This type of cells interacts also with collagen type I and this 
interaction is inhibited by all tested peptides except (146). This peptide has no 
inhibitor affinity on any of the ligands tested. Surprisingly all tested peptides have 
higher inhibitor activity in lower concentration. Interaction of fibronectin with this 
type of cells is inhibited slightly with cyclopeptide the c-(Arg-Gly-Asp-Cpr(OMe)- 
-Val-) (151). However, these experiments have to be repeated, because the cells 
display high adhesion to uncoated wells, too. Peptide (151) shows also the 
strongest inhibition of the cell interaction with vitronectin (in the same range like 
reference peptide c(RGDfV) (24), which IC50 is in nm scale188). This peptide is 
tested as a diastereomeric mixture and probably one of the diasteromers is a 
strong avß3 antagonist. The second peptide tested as a diasteromeric mixture,  
c-(Arg-Gly-Asp-Phe-Cpr(OMe)-) (149), also suppresses the interaction between the 
cells and vitronectin but this effect decreases with the concentration of the peptide. 
Very strong inhibition of the same interaction is also achieved with 
cyclotetrapeptides c-(-Arg-Gly-Asp-2-β-hNal-) (155) and c-(-Arg-Gly-Asp-D-1-Nal-) 
(154) in lower concentration.  
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Figure 35: Adhesion tests with αvβ3-overexpressing human ovarian carcinoma cells 
 
For the more insight in the selectivity and strength of the binding of these peptides 
to different integrins, more sophisticated tests are needed. Nevertheless, from 
these adhesion tests it is obvious that peptides c-(Arg-Gly-Asp-Cpr(OMe)-Val-) 
(151) and c-(-Arg-Gly-Asp-D-1-Nal-) (154) are good candidates for the development 
of strong and selective avß3 antagonists, but peptides c-(-Arg-Gly-Asp-2-β-hNal-) 
(155) and c-(Arg-Gly-Asp-Phe-Cpr(OMe)-) (149) should also be tested in different 
assays. 
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5. CONCLUSIONS 
 
Starting from protected α-amino acids the Arndt-Eistert approach via 
sonochemical Wolff rearrangement in the presence of Ag+ ions is a fast and 
efficient method for the synthesis of β-homoamino acids without racemization. 
Fourteen different β-homoamino acids were obtained using this method with good 
yields and purity. These β-homoamino acids have been incorporated into cyclic 
hexa-, penta-, and tetrapeptides, where they exert influence on the secondary 
structure. 
 
Different spectroscopic methods (FTIR, CD, NMR) have been used to study the 
conformational properties of cyclic hexa-, penta-, and tetrapeptides, with or without  
β-homoproline, and to examine the influence of this β-amino acid on the peptide 
conformation in different solvents. Combination of these three analytical 
techniques revealed that β-homoproline is an excellent inducer of secondary 
structure when inserted into a cyclic peptide. This residue stabilizes a pseudo-γ-
turn, or less frequently a pseudo-β-turn. Nevertheless, different conformations of 
peptides are found in different environments. Two-dimensional NMR experiments 
combined with molecular modeling techniques confirm observations obtained with 
CD and FTIR spectroscopy for the cyclic pentapeptide c-(-Ala-Val-β-hPro-Phe-Gly-
) (36). In dipolar aprotic solvents, like DMSO or ACN, this peptide is found to adopt 
two conformations. About 70 % of the population is found in one conformation 
consisting of one pseudo-γ-turn with the β-homoproline residue in central position 
of the turn and one βII-turn with glycine in i+1 position. Another conformation, 
adopted by 30 % of the population, consists of one pseudo-β-turn with  
β-homoproline in i+1 position and a γ-turn with alanine in the central position of the 
turn. In polar solvents, like H2O or TFE, this peptide is found in only one 
conformation very similar to the major conformation of this peptide described for 
DMSO solution, with the β-homoproline residue in the central position of a pseudo-
γ-turn. There are only few literature data about γ-turns, and no literature data about 
pseudo-γ-turn properties in CD and FTIR spectroscopy. These studies suggest 
that CD spectra of a pseudo-γ-turn are characterized by a positive band near 195 
nm and a broad and positive band between 230 and 240 nm. Hydrogen bonding 
within a pseudo-γ-turn shifts the amide I band to 1620-1630 cm-1 in FTIR spectra. 
CD and FTIR techniques allow a fast and simple screening of the peptides under 
different conditions. However, because of the complexity of these spectra more 
accurate conformational analysis currently is not possible. Low-resolution results 
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obtained by this way can be interpreted using much slower but accurate two-
dimensional NMR and molecular modeling techniques. These findings can 
generally be utilized in the de novo design of biologically active cyclopeptides, 
since the spatial orientation of side chains exposing potential pharmacophoric 
groups can be pre-defined by incorporation of tailor-made β-amino acids in 
appropriate sequential positions. 
 
CD spectroscopy was used in cation binding studies to investigate the influence of 
different cations (Al3+, Ca2+, Mg2+, Na+, Zn2+) in a different molar ratio on the 
conformation of all model peptides. Calcium ions have in the greatest influence on 
peptide conformation. The same change, a new positive broad band between 220 
and 230 nm, is observed in the CD spectra for all peptides regardless of the 
previous conformation upon titration with calcium ions.  
 
Twenty new cyclic peptides that mimic the VCAM-1 binding epitope 
(R36TQID40SPLN44) have been synthesized using Fmoc chemistry and cyclization 
in solution. D-amino acids, β-amino acids and proline are used as secondary 
structure inducers for the spatial screening of the pharmacophoric groups. These 
peptides, designed as α4β1 integrin antagonists, could have numerous medical 
applications and might be very useful in future studies of cell-cell and cell-
extracellular matrix interactions. 
A new method for cyclization in solution using two injection pumps for separate 
addition of peptide and coupling reagent solutions to the reaction mixture and a 
purification by precipitation extraction method was developed. Combination of 
these two methods allows any solvent to be used for peptide cyclization. HOAt as 
additive, a rational design of the linear peptide precursor and slow addition rate of 
the peptide solution to the reaction mixture suppresses dimerization and 
epimerization, the main side reactions of the cyclization. The best results have 
been obtained with proline at the C-terminus of the linear peptide. A β-homoamino 
acid in a central position of the linear precursor enhances the cyclization rate, and 
suppresses dimerization by bringing the peptide in a proper conformation. 
 
Invasin, a bacterial adhesion protein, is one of the most potent natural ligands of 
β1 integrins. Small compounds that mimic the invasin binding epitope might find 
pharmacological application. The crystal structure of the Y. Pseudotuberculosis 
invasin suggested the epitope -Ser910-Asp911-Met912-Ser913- to be critical for 
binding of invasin to integrins. Two additional residues important for binding were 
identified, Arg883 and Asp811. Mutations of these two residues affect the binding 
affinity to integrins but not so drastically as mutations of the Asp911 residue. 
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Two cyclic constrained peptide mimics of the invasin binding epitope  
c-(-Ser-Asp-Met-Ser-D-Gln-Gly-) (126) and c-(-Ser-Asp-Met-Ser-D-Ala-Gly-) (127) in 
which D-amino acids were designed to lock the peptide conformation in such a 
way that the critical Asp residue occurs in i+1 position of the β-turn were 
synthesized. The adhesion test shows that these peptides bind to α3β1 integrin 
with low affinity (mM range) and inhibit binding of laminin-5 to the integrin. Peptide 
(130) is a combination of a cyclic hexapeptide with the SDMS sequence with an 
arginine residue connected via a linker to mimic the synergistic activity of Arg883 
located 30 Å apart from the binding epitope. This peptide (130) completely 
suppresses the binding of laminin-5 to the α3β1 integrin and the IC50 value is in the 
µM range. Still better inhibitory activity could be achieved by optimization of the 
length and the flexibility of the peptide chain between Arg residue and the cyclic 
part of the peptide. Also incorporation of the third synergistic residue of invasin, 
Asp811 should improve the inhibitory affinity of this molecule. 
 
The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site 
in extracellular matrix proteins. Peptides containing this sequence can prevent 
binding of matrix proteins to integrins. RGD peptides that are specific for individual 
integrins are of considerable interest and medical significance. Small cyclic 
peptides containing this sequence are already in clinical trial. Affinity and 
selectivity are important for medical applications. Both could be achieved by 
locking the RGD amino acid sequence in an appropriate conformation. Three 
peptides, c-(Arg-Gly-Asp-D-Phe-β-hPro-) (146), c-(Arg-Gly-Asp-Phe-Cpr(OMe)-) 
(149) and c-(Arg-Gly-Asp-Cpr(OMe)-Val-) (151), all with one unnatural β-amino acid 
residue that exerts a strong conformational bias, were synthesized using both solid 
phase cyclization and cyclization in solution strategies. Hydrophobicity of the 
residue following the RGD triad is also very important for the binding affinity of the 
RGD peptides. For investigation of this influence, two cyclic tetrapeptides,  
c-(Arg-Gly-Asp-D-1-Nal-) (154) and c-(Arg-Gly-Asp-2-β-hNal-) (155) with  
D-1-naphtylalanine and β-homo-2-naphtylalanine, respectively, were synthesized 
by cyclization in solution. These peptides were tested as inhibitors of the 
interaction between OV-MZ-6 carcinoma cells with three different extracellular 
matrix proteins (vitronectin, fibronectin and collagen typ I). The cyclopentapeptide 
c-(Arg-Gly-Asp-Cpr(OMe)-Val-) (151), although present as a diastereomeric 
mixture, is a very strong inhibitor of the interaction of avß3 with vitronectin. 
Cyclotetrapeptide c-(Arg-Gly-Asp-D-1-Nal-) (154) shows also good inhibitor affinity. 
Both are very good starting points for developing even stronger and more selective 
avß3 antagonists. 
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Peptide synthetases are very large and complex multienzymes needed for 
nonribosomal peptide synthesis in bacteria and fungi. The mechanism of action of 
these enzymes is modular. Each module activates and modifies specific amino 
acid and forms the peptide bond. Modules are made up of distinct domains that 
catalyze different reactions. It was shown that a carboxy terminal thioesterase 
domain of peptide synthetase, that is involved in cyclization and product release 
can also catalyze macrocyclization, and elongation in the case of symmetric cyclic 
peptides, independently of upstream domains. Linear peptides with a C-terminal 
thioester are key intermediates for this enzymatic macrocyclization. These 
precursors were synthesized on Kenner’s sulfonamide “safety-catch” linker. N-
acetylcysteamine is used for nucleophilic displacement and cleavage of the 
peptides from the activated linker. Cyclizations of linear precursors (136) and (142) 
of the antibiotic tyrocidine A and its analogs proceed smoothly and with negligible 
rate of hydrolysis using isolated and purified TycC TE domain. 
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6. EXPERIMENTAL PART 
 
6.1. INSTRUMENTS AND MATERIALS 
6.1.1. Instruments 
 
Centrifuge: 
Eppendorf centrifuge 5810 R 
 
Circular Dichroism: 
Jobin-Yvon mark VI dichrograph 
 
Elemental Analysis: 
CHN-O-Rapid (Heraeus) 
Vario EL (Heraeus) 
CHNS-932 (Leco) 
 
Flash Chromatography: 
Silica Gel 60, 40-63 µm (Merck) 
Silica Gel 60, 15-40 µm (Merck) 
 
FTIR Spectroscopy: 
FT-IR-Spectrometer Genesis (Mattson) 
Bruker IFS-55 FTIR 
Jasco FT/IR-410 spectrometer 
 
HPLC (Preparative): 
Software: Chromquest 
Pump: Thermo Separation Products P 4000 
Controller: Thermo Separation Products SN 4000 
Detector: Thermo Separation Products UV 1000 
Columns: VydacTM 218 TP 1022 Efficiency, C18 250x220 mm,  
 VydacTM 300, C18, 10 µm, 250x220 mm 
Eluent A: 95 % H2O, 5 % ACN, 0.1 % TFA 
Eluent B: 95 % ACN, 5 % H2O, 0.1 % TFA 
 
 6. Experimental part 94 
Methods used for preparative HPLC: 
 
Method 1 (used for protected peptides): 
 
Table 23: Preparative method for fully protected peptides. 
 
Time (min) Eluent A (%) Eluent B (%) Flow (ml/min) UV (nm) 
0 92 8 
50 0 100 
60 0 100 
65 92 8 
10 220 or 245 
 
Method 2 (used for deprotected peptides): 
 
Table 24: Preparative method for cyclic deprotected peptides. 
 
Time (min) Eluent A (%) Eluent B (%) Flow (ml/min) UV (nm) 
0 92 8 
10 92 8 
25 50 50 
30 92 8 
25 220 
 
Method 3 (used for deprotected peptides): 
 
Table 25: Preparative method used for separation of epimeric mixtures. 
 
Time (min) Eluent A (%) Eluent B (%) Flow (ml/min) UV (nm) 
0 92 8 
20 68 32 
23 92 8 
25 220 
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HPLC (Analytical):  
Software: Chromquest 
Autosampler: Thermo Separation Products AS 100 
Pump: Thermo Separation Products P 4000 
Controller: Thermo Separation Products SN 4000 
Detector: Thermo Separation Products UV 6000 
Columns: VydacTM 300 C18 (218 TPB), 5 µm, 250x4 mm, 
Phenomenex, Jupiter C18, 5 µm, 250x 4.6 mm 
VydacTM 218TP54 efficiency C18, 5 µm, 250x4.6 mm 
Eluent A: H2O/ACN/TFA = 95 : 5 : 0.1 
Eluent B: ACN/H2O/TFA. = 95 : 5 : 0.1 
 
Methods used for analytical HPLC: 
 
Method 1: 
 
Table 26: The gradient for analytical method 1. 
 
Time (min) Eluent A (%) Eluent B (%) Flow (ml/min) UV (nm) 
0 100 0 
3 100 0 
40 0 100 
50 100 0 
1 220 and 245 
 
Method 2: 
 
Table 27: The gradient for analytical method 2. 
 
Time (min) Eluent A(%) Eluent B (%) Flow (ml/min) UV (nm) 
0 100 0 
5 100 0 
25 50 50 
40 0 100 
45 100 0 
1 220 and 245 
 
 
 6. Experimental part 96 
Method 3: 
 
Table 28: The gradient for analytical method 3. 
 
Time (min) Eluent A(%) Eluent B (%) Flow (ml/min) UV (nm) 
0 100 0 
5 100 0 
25 70 30 
30 100 0 
1 220 and 245 
 
Method 4: 
 
Table 29: The gradient for analytical method 4. 
 
Time (min) Eluent A (%) Eluent B (%) Flow (ml/min) UV (nm) 
0 100 0 
15 100 0 
35 0 100 
40 100 0 
1 220 and 245 
 
 
MALDI-ToF Mass Spectrometer: 
Voyager-DE BioSpectrometry Workstation (PerSeptive Biosystems) 
Laser:  Nitrogen Laser, α = 337 nm 
Delay-Time:  100 ns 
Accelerating Voltage: 20000 V 
Grid Voltage:  93.8 % 
Guide Wire Voltage: 0.05 % 
Scans:  up to 50 
Matrix:  2,5-dihydroxy benzoic acid or  
  α-cyano-4-hydroxycinnamic acid 
 
Melting Point Apparatus (uncorrected values): 
Tottoli Melting Point Apparatus (Büchi) 
Melting Point B-540 (Büchi) 
Electrothermal Melting Point Apparatus IA 6304 (Electrothermal) 
 
NMR-Spectroscopy: 
Gemini 200 (Varian): 1H: 199.975 MHz, 13C: 50.289 MHz 
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Gemini 2000 (Varian): 1H: 200.041 MHz, 13C: 50.305 MHz 
DRX 500 (Bruker): 1H: 500.130 MHz, 13C: 125.758 MHz 
AC 250-P (Bruker): 1H: 250.133 MHz, 13C: 62.896 MHz 
 
Optical Rotations: 
Digital Polarimeter DIP-360 (Jasco) 
Polatronic-D (Schmidt & Haensch), Sodium D-Line 
 
Sonification Baths: 
Sonorex RK 510 H (Bandelin) 
Sonorex TK 52 (Bandelin) 
T 480/H Digital (Elma) 
 
Peptide synthesizer: 
Advanced ChemTech 496 MOS 
Advanced ChemTech ACT 90. 
 
Shaker:  
IKA® KS 130 basic 
 
TLC: 
Silica Gel 60 F254 on aluminum sheets (Merck) 
 
Two-injection pump: 
Kd Scientific model 200 
 
 
6.1.2. Materials 
 
Commercially available amino acids, coupling reagents and resins were 
purchased from: Advanced ChemTech, Bachem, Fluka, and Novabiochem. 
Trifluoroethanol (TFE, n.m.r. grade, ≥99.5 %), NaClO4, Al(ClO4)3 × 9H2O, 
Ca(ClO4)2 × 4H2O and Mg(ClO4)2 were purchased from Aldrich. 
Fmoc-Phe-Cpr(OMe)-OH, and Fmoc-Asp(Ot-Bu)-Cpr(OMe)-OH were obtained 
from the group of Prof. Dr. O. Reiser, Institut für Organische Chemie, Universität 
Regensburg. 
DMF: Refluxed for 2 h over ninhydrine (100 mg/l) and then distilled 
under reduced pressure 
Chloroform: Distilled over calcium chloride and phosphorus pentoxide 
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Ethylacetate: Distilled from calcium chloride 
Diethylether: Distilled from calcium chloride and finally from sodium 
Petrolether: Distilled from calcium chloride and finally from sodium 
Methylenchloride: Distilled from calcium chloride and finally from calcium 
hydride 
THF: Distilled from calcium chloride and finally from sodium 
All mixtures of the solvents are given in the volume percents (v/v). 
 
HPLC solvents: 
 
Acetonitrile: Merck (gradient grade) 
Water: Purified Millipore water purification system 
TFA: Solvay Fluor and Derivate GMBH 
 
 
6.1.3. Biological Experiments 
 
Binding activity of laminin-5 on α3β1 integrin in the presence of cyclic inhibitors 
peptide inhibitors were performed by Dr. Johannes Eble, Institut für Physiologische 
Chemie und Pathobiochemie, Universität Münster, Germany. 
 
Cyclization of the linear precursors of Tyrocidine A analogs by the carboxy 
terminal thioesterase domain of peptide synthetase were performed in the group of 
Prof. Dr. A. Marahiel, Biochemie/Fachbereich Chemie, Philipps-Universität 
Marburg, Germany. 
 
Adhesions tests of human ovarian carcinoma cells on the extracellular matrix 
proteins in the presence of RGD cyclic peptide inhibitors were performed by Dr. 
Ute Reuning at the Frauenklinik der Technische Universität München, Germany. 
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6.2. SYNTHESIS OF β-HOMOAMINO ACIDS 
 
6.2.1. General Procedure  
 
The Fmoc protected α-amino acid derivative (5-15 mmol) is dissolved in dry THF 
(5 ml/mmol), triethylamine (1.0 equiv) and ethylchloroformate (1.0 equiv) are 
added subsequently at -15 °C. Stirring is continued for 15 min at the same 
temperature, then the solution is warmed up to 0 °C. A solution of diazomethane 
(3.0 equiv) in Et2O is added slowly at 0 °C. The solution is allowed to reach room 
temperature and stirred for further 3 h. Excess diazomethane is decomposed by 
dropwise addition of AcOH. The mixture is washed with satd. NaHCO3, satd. 
NH4Cl and brine. The organic layer is dried over Na2SO4 and evaporated in vacuo. 
The resulting diazo ketone is dissolved in dioxane/water (5 : 1; 50 ml/mmol). After 
addition of silver benzoate (0.1 equiv) the mixture is sonicated using an 
ultrasound-cleaning bath for ca. 30 min. The reaction progress is monitored by 
TLC (EtOAc/petroleum ether 1:1 or/and DCM/MeOH/AcOH 10:1:0.1). When the 
reaction has reached completion, the solution is acidified to pH 2 with 1M HCl and 
extracted with Et2O (1 x 100ml, 3 x 30 ml). The organic layers are pooled, dried 
over Na2SO4 and evaporated in vacuo. The resulting residue is crystallized from 
Et2O and/or PE. The resulting Fmoc protected β-amino acids are used in the 
peptide synthesis without further purification. 
For analysis small quantities of substances are purified by flash chromatography 
on silica gel with DCM/MeOH/AcOH = 10:0.5:0.1 as eluent.  
It is possible to purify the intermediate diazo ketone by chromatography on neutral 
aluminum oxide with PE/EtOAc = 4:1 as eluent. 
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6.2.2.Synthesized β-Homoamino Acids 
 
(3R)-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}butanoic acid (5) 
Fmoc-D-β3-hAla-OH  
 
C19H19NO4 (325.37 g/mol). 
Synthesized from 1.56 g (5.0 mmol) Fmoc-D-Ala-OH. 
Yield: 0.81 g (2.5 mmol), 50 %. 
Mp.: 164 °C (Lit. 165-166 °C).9a  
24][ Dα : -7.0 (c=1 in MeOH) (Lit. 20][ Dα : -7.4, c=1. in MeOH).9a  
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 326.14 [M+H]+, 348.12 [M+Na]+, 364.10 [M+K]+ 
Found: 348.14 [M+Na]+, 364.02 [M+K]+ 
IR (KBr), ν (cm-1): 3438m, 1712s, 1603s, 1510m, 1257m, 1008w. 
1H NMR (250 MHz, DMSO-d6), δ (ppm): 1.09 (d, 3J=6.5 Hz, 3H, Hγ), 2.27 (dd, 
2J=15.3 Hz, 3J=7.3 Hz, 1H, Hα), 2.45 (dd, 2J=15.3 Hz, 3J=6.5 Hz, 1H, Hα), 3.86 (m, 
1H, Hβ), 4.18-4.30 (m, 3H, Fmoc CH2, CH), 7.23 (d, 3J=7.7 Hz, 1H, NH), 7.33-7.88 
(m, 8H, Har), 12.10 (br, 1H, COOH). 
13C NMR (63 MHz, DMSO-d6), δ (ppm): 20.37 (Cγ), 40.77 (Cα), 43.71, 46.69 (CH), 
65.10 (Fmoc CH2), 119.99, 125.04, 126.95, 127.49 (CHar), 140.68, 143.90 (Car), 
155.17 (N-C=O), 172.28 (C=O). 
Element. Anal. (%): Calcd.: C 70.13, H 5.88, N 4.30 
Found: C 70.26, H 5.95, N 4.29. 
 
 
(3S)-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-5-oxo-5-(tritylamino)-
pentanoic acid (6) 
Fmoc-L-β3-hAsn(Trt)-OH  
 
C39H34N2O5 (610.72 g/mol). 
Synthesized from 5 g (8.4 mmol) Fmoc-L-Asn(Trt)-OH. 
Yield: 3.85 g (6.3 mmol), 75 %. 
Mp.: 187 °C. 
24][ Dα : -14.0 (c=0.25 in MeOH). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 611.25 [M+H]+, 633.24 [M+Na]+, 649.21 [M+K]+ 
Found: 633.39 [M+Na]+, 649.42 [M+K]+ 
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IR (KBr), ν (cm-1): 3316m, 2969w, 1713s, 1517s, 1256m, 1047m, 740m. 
1H NMR (500 MHz, CDCl3), δ (ppm): 2.61 (dd, 2J=15.4 Hz, 3J=7.2 Hz, 1H, Hα or 
Hγ), 2.55-2.68 (m, 2H, Hα, Hγ), 2.78 (dd, 2J=14.1 Hz, 3J=4.1 Hz, 1H, Hα or Hγ), 
4.09-4.31 (m, 4H, Hβ, Fmoc CH2, CH), 6.08 (d, 3J=7.5 Hz, NH), 7.08 (s, 1H, NH), 
7.16-7.76 (m, 23H, Har). 
13C NMR (125 MHz, CDCl3), δ (ppm): 37.83, 39.96 (CH2), 45.78, 47.03 (CH), 
67.00 (Fmoc CH2), 70.92 (Trt C), 119.94, 125.12, 127.15, 127.69, 127.70 128.00, 
128.57 (CHar), 141.21, 143.73, 144.13 (Car), 155.82 (N-C=O), 170.54, 174.63 
(C=O). 
Element. Anal. (%): Calcd.: C 76.69, H 5.61, N 4.58 
Found: C 76.65, H 5.81, N 4.33. 
 
 
(3R)-5-tert-butoxy-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-5-
oxopentanoic acid (7) 
Fmoc-L-β3-hAsp(Ot-Bu)-OH  
 
C24H27NO6 (425.49 g/mol). 
Synthesized from 2.05 g (5.0 mmol) Fmoc-L-Asp(Ot-Bu)-OH. 
Yield: 0.82 g (1.9 mmol), 39 %. 
Mp.: 90 °C (Lit. 88 °C).74 
24][ Dα : 0.4 (c=2 in MeOH) (Lit. 
28][ Dα : 0.3, c=1.9 MeOH).74 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 426.19 [M+H]+, 448.17 [M+Na]+, 464.15 [M+K]+ 
Found: 448.19 [M+Na]+, 464.27 [M+K]+ 
IR (KBr), ν (cm-1): 3347w, 2977w, 2927w, 1720s, 1531m, 1261m, 1153m, 740m. 
1H NMR (500 MHz, CDCl3), δ (ppm): 1.43 (s, 9H, t-Bu), 2.54-3.00 (m, 4H, Hα, Hγ), 
4.18-4.39 (m, 4H, Hβ, Fmoc CH2, CH), 5.65 (d, 3J=8.8 Hz, 1H, NH), 7.28-7.73 (m, 
8H, Har). 
13C NMR (125 MHz, CDCl3), δ (ppm): 28.04 (t-Bu, CH3), 37.82, 39.19 (CH2), 
44.90, 47.15 (CH), 66.90 (Fmoc CH2), 81.64 (t-Bu, C), 119.97, 125.08, 127.05, 
127.70 (CHar), 141.29, 143.82 (Car), 155.63 (N-C=O), 170.51, 175.66 (C=O). 
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(3S)-6-amino-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-6-oxohexanoic  
acid (8) 
Fmoc-L-β3-hGln-OH  
 
C21H22N2O5 (382.42 g/mol). 
Synthesized from 3.68 g (10.0 mmol) Fmoc-L-Gln-OH. 
Yield: 2.02 g (5.3 mmol), 53 %. 
Mp.: 206 °C. 
24][ Dα : 3.7 (c=1 in DMF). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 383.16 [M+H]+, 405.14 [M+Na]+, 421.12 [M+K]+ 
Found: 383.21 [M+H]+, 405.20 [M+Na]+, 421.15 [M+K]+ 
IR (KBr), ν (cm-1): 3397s, 3100m, 1695s, 1648s, 1535m, 1448m, 1267m. 
1H NMR (250 MHz, DMSO-d6), δ (ppm): 1.58-1.68 (m, 2H, Hγ), 2.01-2.06 (m, 2H, 
Hα), 2.34-2.37 (m, 2H, Hδ), 3.75 (m, 1H, Hβ), 4.19-4.26 (m, 3H, Fmoc CH2, CH), 
6.72 (br, 1H, NH), 7.24 (s, 1H, NH2), 7.26 (s, 1H, NH2), 7.32-7.87 (m, 8H, Har). 
13C NMR (63 MHz, DMSO-d6), δ (ppm): 29.69, 31.48, 39.75 (CH2), 46.79, 47.89 
(CH), 65.18 (Fmoc CH2), 120.83, 125.28, 127.15, 127.69 (CHar), 140.76, 143.94 
(Car), 155.65 (N-C=O), 172.48, 174.02 (C=O). 
Element. Anal. (%): Calcd.: C 65.95, H 5.80, N 7.33 
Found: C 65.81, H 6.16, N 7.22. 
 
 
(3R)-6-amino-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-6-oxohexanoic 
acid (9) 
Fmoc-D-β3-hGln-OH  
 
Synthesized from 1.84 g (5.0 mmol) Fmoc-D-Gln-OH. 
Yield: 0.80 g (2.1 mmol), 42 %. 
24][ Dα : -3.6 (c=1 in DMF). 
Element. Anal. (%): Calcd.: C 65.95, H 5.80, N 7.33 
Found: C 65.81, H 6.20, N 7.24. 
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Fmoc-L-Isoleucyldiazomethane (10) 
 
C22H23N3O3 (337.45 g/mol). 
Synthesized from 1.77g (5.0 mmol) Fmoc-L-Ile-OH. 
Yield: 1.28 g (3.8 mmol), 76 %. 
Mp.: 137-140 °C (Lit. 136-137 °C).77 
1H NMR (200 MHz, CDCl3), δ (ppm): 0.91-0.97 (m, 6H, 2xCH3), 1.10-1.46 (m, 2H, 
Hγ), 1.85 (m, 1H, Hβ), 4.18-4.25 (m, 2H, Hα, Fmoc CH), 4.37-4.45 (m, 2H, 2 Fmoc 
CH), 5.31 (s, 1H, CHN2), 5.41 (d, 3J=8.4 Hz, 1H, NH), 7.26-7.78 (m, 8H, Har). 
13C NMR (50 MHz, CDCl3), δ (ppm): 11.90, 16.04 (CH3), 25.00 (CH2), 38.05, 
47.72, 55.32, 62.73 (CH), 67.11 (Fmoc CH2), 120.50, 125.62, 127.62, 128.24 
(CHar); 141.90, 144.34, (Car), 156.78 (N-C=O), 193.92 (C=O). 
 
 
(3R,4S)-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-4-methylhexanoic  
acid (11) 
Fmoc-L-β3-hIle-OH  
 
C22H25NO4 (367.45 g/mol). 
Synthesized from 1.28 g (3.8 mmol) Fmoc-L-Isoleucyldiazomethane (10). 
Yield: 0.92 g (2.5 mmol), 66 %. 
Mp.: 133-135 °C (Lit. 138 °C).74 
24][ Dα : 3.6 (c=1 in MeOH) (Lit. 28][ Dα : 3.7, c=4.0. MeOH).74 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 368.19 [M+H]+, 390.17 [M+Na]+, 406.14 [M+K]+ 
Found: 390.18 [M+Na]+, 406.22 [M+K]+ 
IR (KBr), ν (cm-1): 3427br, 3327m, 2963m, 1700m, 1659m, 1544m, 1449m, 738m. 
1H NMR (200 MHz, CDCl3), δ (ppm): 0.77-0.91 (m, 6H, 2xCH3), 1.05-1.22 (m, 1H, 
Hδ), 1.46-1.50 (m, 2H, Hγ, Hδ), 2.54-2.57 (m, 2H, Hα), 3.88 (m, 1H, Hβ), 4.21 (t, 
3J=6.6 Hz, 1H, Fmoc CH), 4.39-4.23 (m, 2H, Fmoc CH2), 5.17 (d, 3J=10.0 Hz, 1H, 
NH), 7.26-7.75 (m, 8H, Har). 
13C NMR (50 MHz, CDCl3), δ (ppm): 11.82, 15.82 (CH3), 25.95, 36.77 (CH2), 
38.52, 47.79, 52.80 (CH), 67.11 (Fmoc CH2), 120.43, 125.52, 127.53, 128.14 
(CHar); 141.81, 144.34, (Car), 156.56 (N-C=O), 177.54 (C=O). 
Element. Anal. (%): Calcd.: C 71.91, H 6.85, N 3.81 
Found: C 72.04, H 6.67, N 3.60. 
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(3S)-4-(5,8-dihydro-2-naphthalenyl)-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]-
amino}butanoic acid (12) 
Fmoc-L-2-β3-hNal-OH  
 
C29H25NO4 (451.53 g/mol). 
Synthesized from 1.00 g (2.3 mmol) Fmoc-L-2-Nal-OH. 
Yield: 0.69 g (1.5 mmol), 67 %. 
Mp.: 144 °C. 
24][ Dα : -15.1 (c=0.21 in MeOH). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 452.19 [M+H]+, 474.17 [M+Na]+, 490.14 [M+K]+ 
Found: 452.08 [M+H]+, 474.14 [M+Na]+, 490.12 [M+K]+ 
IR (KBr), ν (cm-1): 3329m, 3049w,2922w, 1695s, 1536s, 1448m, 1271s, 738s. 
1H NMR (250 MHz, DMSO-d6), δ (ppm): 2.32-2.51 (m, 2H, Hα), 2.91-2.93 (m, 2H, 
Hγ), 3.31 (m, 1H, Hβ), 4.13-4.20 (m, 3H, Fmoc CH2, CH), 6.91 (br, 1H, NH), 7.21-
7.97 (m, 15H, Har), 12.26 (br, 1H, COOH). 
13C NMR (63 MHz, CDCl3), δ (ppm): 37.51, 40.40, (CH2), 47.24, 49.32 (CH), 66.82 
(Fmoc CH2), 119.97, 125.00, 125.68, 126.18, 127.44, 127.60, 127.66, 127.94, 
128.36, 128.49, 130.20, (CHar), 132.40, 133.51, 134.84, 141.33, 143.86 (Car), 
171.45 (N-C=O), 176.70 (C=O). 
Element. Anal. (%): Calcd.: C 77.14, H 5.58, N 3.10 
Found: C 76.80, H 5.89, N 2.82. 
 
 
Fmoc-L-phenylalanyldiazomethane (13) 
 
C25H21N3O3 (411.47 g/mol). 
Synthesized from 1.94 g (5.0 mmol) Fmoc-L-Phe-OH. 
Yield: 1.40 g (3.4 mmol), 68 %. 
Mp.: 128-130 °C (Lit. 136-137 °C).78 
1H NMR (200 MHz, acetone-d6), δ (ppm): 3.23 (dd, 2J =14.0 Hz, 3J=5.0 Hz, 1H, 
Hβ), 2.88 (dd, 2J=13.8 Hz, 3J=9.4 Hz, 1H, Hβ), 4.17 (m, 1H, Fmoc CH), 4.30-4.47 
(m, 3H, Fmoc CH2, Hα), 5.87 (s, 1H, CHN2), 6.86 (d, 3J=8.6 Hz, 1H, NH), 7.28-7.86 
(m, 13H, Har). 
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(3S)-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-4-phenylbutanoic acid (14) 
Fmoc-L-β3-hPhe-OH  
 
C25H23NO4 (401.47 g/mol). 
Synthesized from 1.40 g (3.4 mmol) Fmoc-L-phenylalanyldiazomethane (13). 
Yield: 1.20 g (3.0 mmol), 88 %. 
Mp.: 155 °C (Lit. 157 °C).74 
 26][ Dα : -23.6 (c=1 in MeOH) (Lit. 28][ Dα : -25.0, c=0.6 in MeOH).74 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 402.17 [M+H]+, 424.15 [M+Na]+, 440.13 [M+K]+ 
Found: 424.40 [M+Na]+, 440.32 [M+K]+ 
IR (KBr), ν (cm-1): 3330m, 3062w, 2921w, 1697s, 1532m, 1447m, 1261m, 738m.  
1H NMR (200 MHz, acetone-d6), δ (ppm): 2.55-2.59 (m, 2H, Hα), 2.90-2.94 (m, 2H, 
Hγ), 4.20-4.31 (m, 4H, Hβ, Fmoc CH2, CH), 6.52 (br. 1H, NH), 7.26-7.86 (m, 13H, 
Har). 
13C NMR (50 MHz, acetone-d6), δ (ppm): 38.46, 40.50 (CH2), 47.62, 50.52 (CH), 
66.27 (Fmoc CH2), 120.38, 125.74, 126.76, 127.53, 128.09, 128.77, 129.89 (CHar), 
139.17, 141.74, 144.78 (Car), 156.20 (N-C=O), 172.35 (C=O). 
 
 
(3R)-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-phenylpropanoic  
acid (15) 
Fmoc-L-β3-hPhg-OH  
 
C24H21NO4 (387.44 g/mol). 
Synthesized from 2.80 g (7.5 mmol) Fmoc-L-Phg-OH. 
Yield: 1.50 g (3.9 mmol), 52 %. 
Mp.: 178-184 °C (Lit. 184 °C).74 
24][ Dα : 19.6 (c=1 in DMF) (Lit. 25][ Dα : -22.0, c=1 in CHCl3).75 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 388.15 [M+H]+, 410.14 [M+Na]+, 426.11 [M+K]+ 
Found: 388.30 [M+H]+, 410.19 [M+Na]+, 426.13 [M+K]+ 
IR (KBr), ν (cm-1): 3363m, 1704s, 1531m, 1284m, 740m. 
1H NMR (250 MHz, acetone-d6), δ (ppm): 2.80 (m, 2H, Hα), 4.16-4.32 (m, 3H, 
Fmoc CH2, CH), 5.17 (dd, 3J=7.8 Hz, 3J=6.6 Hz, 1H, Hβ), 7.01 (br, 1H, NH), 7.20-
7.42 (m, 13H, Har). 
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13C NMR (63 MHz, acetone-d6), δ (ppm): 41.45 (CH2), 48.22, 53.08 (CH), 67.08 
(Fmoc CH2), 120.89, 126.19, 126.22, 127.51, 128.03, 128.04, 128.18, 128.59, 
129.40 (CHar), 142.03, 143.47, 144.98 (CHar), 156.31 (N-C=O), 172.00 (C=O). 
 
 
(3S)-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-phenylpropanoic  
acid (16) 
Fmoc-D-β3-hPhg-OH  
 
Synthesized from 1.90 g (5.0 mmol) Fmoc-D-Phg-OH. 
Yield: 1.10 g (3.9 mmol), 57 %. 
24][ Dα : -21.5 (c=1 in DMF) (Lit. 24][ Dα : -22.2, c=1 in DMF).74 
 
 
Fmoc-L-prolyldiazomethane (17) 
 
C21H19N3O3 (361.41 g/mol). 
Synthesized from 1.67 g (5.0 mmol) Fmoc-L-Pro-OH. 
Yield: 1.37 g (3.8 mmol), 76 %. 
Mp.: yellow oil (Lit. 136-138 °C).77 
1H NMR (200 MHz, CDCl3), δ (ppm): 1.80-2.10 (m, 4H, 2Hβ, 2Hγ), 3.45-3.48 (m, 
2H, 2Hδ), 4.10-4.53 (m, 4H, Hα, Fmoc CH2, CH), 5.30 (s, 1H, CHN2), 7.26-7.77 (m, 
8H, Har). 
 
 
{(2S)-1-[(9H-fluoren-9-ylmethoxy)carbonyl]pyrrolidinyl}acetic acid (18) 
Fmoc-L-β3-hPro-OH  
 
C21H21NO4 (351.41 g/mol). 
Synthesized from 1.37 g (3.8 mmol) Fmoc-L-prolyldiazomethane (17). 
Yield: 1.11 g (3.2 mmol), 84 %. 
Mp.: 171 °C (Lit. 191-192 °C).77 
24][ Dα : -37.6 (c=0.5 in MeOH) (Lit. 
20][ Dα : -33.6, c=0.9, in DMF).
77 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 352.15 [M+H]+, 374.14 [M+Na]+, 390.11 [M+K]+ 
Found: 352.28 [M+H]+, 374.35 [M+Na]+, 390.31 [M+K]+ 
IR (KBr), ν (cm-1): 3453s, 3065m, 2926w, 1689vs, 1623s, 1436m, 1336m, 739m. 
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1H NMR (200 MHz, CDCl3), δ (ppm): 1.67-2.14 (m, 4H, Hγ, Hδ), 2.39 (m, 1H, Hα), 
3.04 (m, 1H, Hα), 3.39-3.42 (m, 2H, Hε), 4.20-4.56 (m, 4H, Hβ, Fmoc CH2, CH), 
7.27-7.75 (m, 8H, Har), 9.40 (br, 1H, COOH). 
13C NMR (50 MHz, CDCl3), δ (ppm): 23.98, 31.39, 38.85, 47.02 (CH2), 47.75 (CH), 
54.79 (Fmoc CH), 67.61 (Fmoc CH2), 120.50, 125.59, 127.57, 128.21, (CHar), 
141.92, 144.54 (Car), 155.49 (N-C=O), 177.06 (C=O).  
Element. Anal. (%): Calcd.: C 71.77, H 6.02, N 3.99 
Found: C 71.63, H 6.29, N 3.85. 
 
 
(3S)-4-tert-butoxy-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}butanoic 
acid (19) 
Fmoc-L-β3-hSer(t-Bu)-OH  
 
C23H27NO5 (397.48 g/mol). 
Synthesized from 3.83 g (10.0 mmol) Fmoc-L-Ser(t-Bu)-OH. 
Yield: 3.16 g (8.0 mmol), 80 %. 
Mp.: 96-98 °C (Lit. 96-98°C).9a 
24][ Dα : 20.8 (c=1, MeOH) (Lit. 20][ Dα : 15.7, c=1, CHCl3)9a. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 397.19 [M+H]+, 420.18 [M+Na]+, 436.15 [M+K]+ 
Found: 420.24 [M+Na]+, 436.21 [M+K]+ 
IR (KBr), ν (cm-1): 3353m, 2974m, 1697s, 1528m, 1449m, 1193m, 1061m, 739m. 
1H NMR (500 MHz, CDCl3), δ (ppm): 1.17 (s, 9H, t-Bu), 2.68-2.69 (m, 2H, Hα), 
3.42-3.52 (m, 2H, Hγ), 4.17 (m, 1H, Hβ), 4.23 (t, 3J=7.2 Hz, 1H, Fmoc CH), 4.34-
4.42 (m, 2H, Fmoc CH2), 5.43 (d, 3J=8.8 Hz, 1H, NH), 7.31-7.76 (m, 8H, Har). 
13C NMR (125 MHz, CDCl3), δ (ppm): 27.34 (t-Bu, CH3), 36.02 (CH2), 47.18, 47.89 
(CH), 62.52, 66.83 (CH2), 73.42 (t-Bu, C), 119.97, 125.06, 127.04, 127.69 (CHar), 
14.29, 143.85 (Car), 155.89 (N-C=O), 176.48 (C=O). 
Element. Anal. (%): Calcd.: C 69.50, H 6.84, N 3.52  
Found: C 69.48, H 6.64, N 3.41. 
 
 
Fmoc-L-valyldiazomethane (20) 
 
C21H21N3O3 (315.41 g/mol). 
Synthesized from 1.70 g (5.0 mmol) Fmoc-L-Val-OH. 
Yield: 1.50 g (4.8 mmol), 95 %. 
Mp.: 129-130 °C (Lit. 123-125 °C).78 
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1H NMR (200 MHz, CDCl3), δ (ppm): 0.90 (d, 3J= 6.8 Hz, 3H, Hγ), 1.15 (d, 3J= 6.8 
Hz, 3H, Hγ), 2.08 (m, 1H, Hβ), 4.12 (m, 1H, Hα), 4.22 (t, 3J=6.8 Hz, 1H, Fmoc CH), 
4.41-4.46 (m, 2H, Fmoc CH2), 5.31 (s, 1H, CHN2), 5.41 (d, 3J=8.8 Hz, 1H, NH), 
7.26-7.77 (m, 8H, Har). 
13C NMR (50 MHz, CDCl3), δ (ppm): 17.79, 19.79 (CH3), 31.45, 47.70, 54.50 (CH), 
67.30 (Fmoc CH2), 120.49, 125.53, 127.61, 128.23 (CHar), 141.89, 144.33 (Car), 
156.70 (N-C=O), 193.77 (C=O). 
 
 
(3S)-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-4-methylpentanoic  
acid (21) 
Fmoc-L-β3-hVal-OH  
 
C21H23NO4 (353.42 g/mol). 
Synthesized from 1.50 g (4.8 mmol) Fmoc-L-valyldiazomethane (20). 
Yield: 1.10 g (3.1 mmol), 65 %. 
Mp.: 155-156 °C (Lit. 157 °C).74 
24][ Dα : -19.0 (c=1.0 in CHCl3) (Lit. 27][ Dα : -17.9, c=0.6 in CHCl3).74 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 354.17 [M+H]+, 376.15 [M+Na]+, 392.13 [M+K]+ 
Found: 354.30 [M+H]+, 376.31 [M+Na]+, 392.31 [M+K]+ 
IR (KBr), ν (cm-1): 3460br, 2924s, 1658s, 1512m, 1413m, 1306m, 1150m, 740m. 
1H NMR (200 MHz, CDCl3), δ (ppm): 0.83 (d, 3J= 6.2 Hz, 3H, Hδ), 0.93 (d, 3J=6.2 
Hz, 3H, Hδ), 1.85 (m, 1H, Hγ), 2.38-2.59 (m, 2H, Hα), 3.82 (m, 1H, Hβ), 4.21 (t, 
3J=6.6 Hz, 1H, Fmoc CH), 4.38-4.43 (m, 2H, Fmoc CH2), 5.15 (d, 3J=9.6 Hz, 1H, 
NH), 7.26-7.75 (m, 8H, Har), 8.80 (br, 1H, COOH). 
13C NMR (50 MHz, CDCl3), δ (ppm): 19.01, 21.12 (CH3), 32.03 (CH), 37.22 (CH2), 
47.73 (CH), 53.97 (Fmoc CH), 67.10 (Fmoc CH2), 120.46, 125.55, 127.56, 128.18 
(CHar), 141.86, 144.41 (Car), 156.70 (N-C=O), 177.67 (C=O). 
Element. Anal. (%): Calcd.: C 71.36, H 6.55, N 3.96 
Found: C 71.29, H 6.56, N 3.94. 
 
 
(3R)-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-4-methylpentanoic acid 
(22) 
Fmoc-D-β3-hVal-OH  
 
C21H23NO4 (353.42 g/mol). 
Synthesized from 1.70 g (5.0 mmol) Fmoc-D-Val-OH. 
6. Experimental part 109 
Yield: 1.10 g (3.1 mmol), 62 %. 
24][ Dα : 19.9 (c=1.0 in CHCl3). 
Element. Anal. (%): Calcd.: C 71.36, H 6.55, N 3.96 
Found: C 71.27, H 6.42, N 3.86. 
 
 
6.3. SYNTHESIS OF α-DMB PROTECTED AMINO ACIDS 
 
General Procedure for the Synthesis of Anhydrides 
 
1.0 equiv NMM is added at room temperature to the suspension of Fmoc protected 
amino acid (59) or (60) in 10 ml DCM. The mixture is cooled to –20 °C and 1.0 
equiv of ethylchloroformate is added dropwise. The mixture is allowed to reach 
room temperature and stirred at the same temperature for 20 min. Charcoal is 
added and the solution is filtered. DCM is evaporated under reduced pressure and 
the residue is crystallized from PE/DCM (anhydrides are used in the next step 
without further purification). 
 
9H-fluoren-9-ylmethyl (3S)-2,5-dioxotetrahydro-3-furanylcarbamate (61) 
Fmoc-L-Asp-Oanh  
Synthesized from 6.00 g (17.0 mmol) Fmoc-L-Asp-OH (59) 
Yield: 5.00 g (14.8 mmol), 87 % white crystals, mp 220 °C (Lit. 224-225 °C).123 
 
9H-fluoren-9-ylmethyl (3S)-2,6-dioxotetrahydro-2H-pyran-3-ylcarbamate (62) 
Fmoc-L-Glu-Oanh  
Synthesized from 6.30 g (18.0 mmol) Fmoc-L-Glu-OH (60) 
Yield: 5.80 g (17.0 mmol), 94 %, mp. 132-135 °C (Lit. 134-136 °C).123 
 
 
(3S)-4-[(2,4-dimethoxybenzyl)oxy]-3-{[(9H-fluoren-9-ylmethoxy)carbonyl]-
amino}-4-oxobutanoic acid (64) 
Fmoc-L-Asp-ODmb  
 
C28H27NO8 (505.53 g/mol). 
Procedure: 
A solution of 1.0 equiv of 2,4-dimethoxybenzylalcohol (63) (2.47 g, 14.7 mmol) and 
1.3 equiv dicyclohexylamine (3.50 g, 19.1 mmol) in 10 ml dry DCM is slowly added 
to a suspension of Fmoc protected anhydride (61) (5.20 g, 14.7 mmol) in dry THF 
(10 ml). 300 ml Dry Et2O is added and the suspension is stirred at room 
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temperature overnight. Crystals are filtered, washed with Et2O and recrystallized 
from 450 ml 96 % EtOH. 
Yield: Fmoc-Asp-ODmb dicyclohexylamine salt 5.50 g (8.2 mmol), 55 % white 
crystals, mp 156 °C. 
Crystals are suspended in 20 ml EtOAc. 20 ml 10 % citric acid is added, and 
mixture is stirred at room temperature for 30 min. The layers are separated and 
the organic layer is washed 3 times with water, dried over sodium sulfate and 
evaporated. The product is purified by flash chromatography on silica gel with 
DCM/i-PrOH = 10:1. 
Yield: 3.03 g (4.00 mmol), 33.3 %. 
Mp.: 79 °C. 
25][ Dα : 15.4 (c=1 in CHCl3). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 506.18 [M+H]+, 528.16 [M+Na]+, 544.14 [M+K]+ 
Found: 528.39 [M+Na]+, 544.37 [M+K]+ 
IR (KBr), ν (cm-1): 3347m, 2967w, 1725s, 1700s, 1617m, 1268m, 1209m, 1157m. 
1H NMR (500 MHz, CDCl3), δ (ppm): 2.93 (dd, 2J=17.6 Hz, 3J=4.3 Hz, 1H, Hβ), 
3.06 (dd, 2J=17.3 Hz, 3J=4.6 Hz, 1H, Hβ), 3.75 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 
4.19 (dd, 3J=7.2 Hz, 3J=7.2 Hz, 1H, Fmoc CH), 4.32 (dd, 2J=10.4 Hz, 3J=7.2 Hz, 
1H, Fmoc CH2), 4.42 (dd, 2J=10.7 Hz, 3J=6.9 Hz, 1H, Fmoc CH2), 4.65 (m, 1H, 
Hα), 5.18 (s, 2H, Dmb CH2), 5.84 (d, 3J=8.8 Hz, 1H, NH), 6.36-6.43 (m, 2H, 
DmbHar), 7.20-7.75 (m, 9H, Har). 
13C NMR (50 MHz, CDCl3), δ (ppm): 36.37 (CH2), 47.05, 50.30 (CH), 55.34 (CH3), 
63.46, 67.31 (CH2O), 98.48, 103.87, 119.95, 125.15, 127.08, 127.70, 131.58 
(CHar), 115.78, 141.25, 143.66, 156.05, 159.03 (Car), 161.45 (N-C=O), 170.57, 
175.52 (C=O). 
 
 
(4S)-5-[(2,4-dimethoxybenzyl)oxy]-4-{[(9H-fluoren-9-ylmethoxy)carbonyl]-
amino}-5-oxopentanoic acid (66) 
Fmoc-L-Glu-ODmb  
 
C29H29NO8 (519.53 g/mol). 
Procedure: 
1.6 ml (14.0 mmol) N-methylmorpholine are added to a suspension of 2.55 g (6.9 
mmol) Fmoc-L-Glu-OH (24) and 1.20 g (7.0 mmol) of 2,4-dimethoxybenzyl alcohol 
(31) in 100 ml dry DCM. The mixture is stirred at room temperature until the  
Fmoc-Glu-OH (24) is dissolved. The solution is cooled to -20 °C and 3.55 ml (7.1 
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mmol) of a 20 % solution of phosgene in toluene is added dropwise. The mixture is 
allowed to reach room temperature and stirred overnight. 
DCM is evaporated under reduced pressure, and the product is purified by flash 
chromatography on silica gel with DCM/i-PrOH = 10:1 as eluent. Two isomers are 
isolated with ratio α/γ=35. 
Yield: 2.80 g (5.4 mmol), 78 %. 
Mp.: 98 °C. 
24][ Dα : -7.4 (c=0.5 in MeOH). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 520.20 [M+H]+, 542.18 [M+Na]+, 558.15 [M+K]+ 
Found: 542.45 [M+Na]+, 558.48 [M+K]+ 
IR (KBr), ν (cm-1): 3332m, 2961m, 1748s, 1692s, 1614m, 1535m, 1211m, 1158m. 
1H NMR (250 MHz, DMSO-d6), δ (ppm): 1.84-2.18 (m, 2H, Hβ), 2.34-2.44 (m, 2H, 
Hγ), 3.79 (s, 6H, OCH3), 4.18 (m, 1H, Fmoc CH), 4.36-4-46 (m, 3H, Fmoc CH2, 
Hα), 5.09 (d, 2J=11.8 Hz, 1H, Dmb CH2), 5.19 (d, 2J =11.8 Hz, 1H, Dmb CH2), 5.52 
(d, 3J=7.9 Hz, 1H, NH), 6.41-6.43 (m, 2H, DmbHar), 7.19-7.73 (m, 9H, Har). 
13C NMR (50 MHz, DMSO-d6), δ (ppm): 27.68, 29.71 (CH2), 47.20, 53.36 (CH), 
55.39, 55.41 (CH3O), 63.28, 67.12 (CH2O), 98.62, 104.10, 119.99, 125.08, 127.11, 
127.73, 131.72 (CHar), 98.62, 141.32, 143.75, 155.98, 159.14 (Car), 161.67 (N-
C=O), 171.77, 177.40 (C=O). 
 
 
2-(9H-Fluoren-9-ylmehtoxycarbonylamino)-pentanedioic acid 5-(2,4-
dimethoxy-benzyl) ester (67) 
Fmoc-L-Glu(ODmb)-OH  
 
C29H29NO8 (519.53 g/mol). 
Yield: For the analysis small quantity (~80 mg, 0.15 mmol, 2 %) in above reaction 
is isolated as by-product. 
Mp.: 90 °C. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 520.20 [M+H]+, 542.18 [M+Na]+, 558.15 [M+K]+ 
Found: 542.34 [M+Na]+, 558.40 [M+K]+ 
IR (KBr), ν (cm-1): 3383m, 3319m, 2923m, 1722s, 1656m, 1591m, 1511m, 1293m. 
1H NMR (200 MHz, DMSO-d6), δ (ppm): 1.79-2.04 (m, 2H, Hβ), 2.35-2.41(m, 2H, 
Hγ), 3.74 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.97 (m, 1H, Fmoc CH), 4.06-4.41 (m, 
3H, Fmoc CH2, Hα), 4.99 (s, 2H, CH2O), 6.48-6.56 (m, 2H, DmbHar), 7.20-7.87 (m, 
9H, Har). 
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13C NMR (50 MHz, DMSO-d6), δ (ppm): 26.46, 30.16 (CH2), 46.65, 53.29 (CH), 
55.16, 55.46 (OCH3), 60.91, 65.51 (CH2O), 99.35, 104.52, 120.02, 125.16, 126.99, 
127.55, 130.90 (CHar), 115.99, 140.63, 143.74, 155.93, 158.46 (Car), 160.87  
(N-C=O), 172.25, 173.62 (C=O). 
 
 
6.4. PEPTIDE SYNTHESIS 
 
6.4.1. Attachment of the First Amino Acid on the Resin 
6.4.1.1. PROTOCOL 1: Attachment of the First Amino Acid on Wang Resin 
 
In a round-bottom flask Wang resin is covered with DMF and allowed to swell for 
30 min. 
In another round-bottom flask 1.0 – 10.0 equiv (1.5 equiv for cyclization on resin) 
of amino acid (relative to resin capacity) is dissolved in dry DCM under argon 
atmosphere. A small amount of DMF may be needed to achieve complete 
dissolution. This solution is cooled to 0 °C and 5.0 equiv of DIC (relative to resin 
capacity) are slowly added. The mixture is stirred for 20 min at the same 
temperature and DCM is evaporated. The residue is dissolved in a minimum of 
DMF and added to the resin suspension followed by 0.1 equiv of DMAP (relative to 
resin capacity). The suspension is shaken at room temperature for 1 h. In order to 
determine the resin loading, a small quantity of resin is removed and washed with 
DMF, DCM, MeOH. Loading should be 0.4 – 0.8 mmol/g resin for synthesis of the 
cyclic peptides with cyclization on resin. For capping the rest of the free hydroxyl 
groups, 2.0 equiv of acetic anhydride (relative to resin capacity) and 2.0 equiv of 
pyridine (relative to resin capacity) are added to the reaction mixture. The mixture 
is shaken at room temperature for additional 30 min. Resin is filtered, washed with 
DMF (3x), DCM (3x), MeOH (3x) and dried.  
 
 
6.4.1.2. PROTOCOL 2: Attachment of the First Amino Acid on “Safety Catch” 
Resin 
 
In a round-bottom flask the resin is covered with CHCl3 (1 ml/100 mg resin) that 
was previously filtered through a plug of basic alumina. 5.0 Equiv of DIPEA 
(relative to resin capacity) and 3.0 equiv of an amino acid (relative to resin 
capacity) are added to this mixture. The reaction mixture is stirred for 10 min at 
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room temperature followed by cooling to –20 °C. After mixing for 20 min at -20 °C, 
3.0 equiv of PyBOP (relative to resin capacity) are added to the reaction mixture, 
as a solid, and the reaction mixture is stirred for 8 h at the same temperature, 
filtered, washed with CHCl3 (3x), DMF (3x), DCM (3x), MeOH (3x) and dried under 
vacuum. 
 
 
6.4.1.3. PROTOCOL 3: Attachment of the First Amino Acid on 2-Chlorotrityl 
chloride Resin 
 
2.0 Equiv of an amino acid (relative to resin capacity) are dissolved in DCM 
(approximately 10 ml per gram of resin). A small amount of DMF may be needed 
to achieve complete dissolution. This solution is added to the resin followed by 2.0 
equiv (relative to resin capacity) of DIPEA. The mixture is agitated at room 
temperature for 5 min. 3.0 Equiv (relative to resin capacity) of DIPEA are added 
and mixture is agitated at room temperature for additional 1 h. 
Methanol (1 ml/g resin) is added to the mixture and shaking is continued for 15 
min at room temperature. The resin is drained, washed with DCM (3x), DMF (3x), 
DCM (3x), MeOH (3x), and dried in vacuum. After the determination of the resin 
loading, the Fmoc protective group is removed for long term storage. 
 
Removal of the Fmoc protective group: 
The resin is swollen in DMF for 20 min and drained. A solution of 2 % DBU and 2 
% piperidine in DMF (5 ml/g resin) is added. The mixture is shaken for 5 min at 
room temperature and drained. An additional portion of the solution of 2 % DBU 
and 2 % piperidine in DMF (5 ml/g resin) is added. The mixture is shaken at room 
temperature for 20 min, drained, washed with DMF (3x), DCM (3x), MeOH (3x), 
and dried in vacuum.  
 
 
6.4.1.4. PROTOCOL 4: Attachment of the First Amino Acid on Rink Amide Resin 
 
The resin is swollen in DMF and a solution of 20 % piperidine in DMF is added to 
cleave the resin-bound Fmoc groups. The reaction mixture is shaken for 20 min at 
room temperature. The resin is drained and washed with DMF (5x). Alternatively, 
the previously described protocol for Fmoc cleavage can be used. 
A solution of 3.0 equiv of amino acid (relative to resin capacity) in DMF is added to 
the resin. The reaction mixture is shaken at room temperature for 5 min. A solution 
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of 3.0 equiv TBTU (relative to resin capacity) in DMF (total volume of DMF is about 
15 ml/g resin) is added to the reaction mixture, followed by 6.0 equiv of DIPEA 
(relative to resin capacity). The reaction mixture is shaken for 45 min at room 
temperature. 
The resin is drained and washed with DMF (3x), DCM (3x), MeOH (3x). Small 
quantities of resin are tested for unreacted amine with Kaiser test.189 If the test is 
positive, the coupling reaction (with 3.0 equiv amino acid, 3.0 equiv TBTU, 3.0 
equiv DIPEA) is repeated. 
 
 
6.4.1.5. PROTOCOL 5: Estimation of Level of First Residue Attachment 
 
The cuvetee of the UV spectrophotometer is filled with 3 ml of a 20 % solution of 
piperidine in DMF and placed in a spectrophotometer. Absorbance at 290 nm is 
adjusted to zero. 1 - 2 mg of resin are added. The resin is shaken for 5 min and 
allowed to settle on the bottom of the cell. The cell is placed in the 
spectrophotometer and absorbance at 290 nm is read. 
 
Fmoc loading: mmol amino acid/g resin = Abssample/(1.65 x mg of resin) 
 
 
6.4.2. Solid Phase Peptide Synthesis  
 
Table 30: Protocol for peptide automated solid phase synthesis 
 
Step Operation Reagent 
Volume/ 
ml 
Repeats 
Time/min 
1a Swelling DMF 5 2 x 10 
2b Deprotection 
2 % DBU, 2 % piperidine in 
DMFc 
5 
1 x 5 
1 x 20 
3b Washing DMF 5 7 x 7 
4 Coupling 
3.0 equiv Xaa 
3.0 equiv TBTU 
6.0 equiv DIPEA in DMF 
3 1 x 45 
5 Washing DMF 5 5 x 7 
a Only for the first amino acid 
b On the end of the synthesis both steps are repeated to obtain the deprotected 
peptides 
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c To the solution for deprotection, HOBt (0.1 M) can be added to suppress side 
reactions like aspartimide formation. 
The protocol is used for the manual and automated peptide synthesis on 200–300 
mg of different resins (Wang, 2-ClTrt, Safety Catch, Rink amide resin). All steps 
are carried out at room temperature. The peptides synthesized by this protocol 
were fully protected (Fmoc on the N- terminus, resin at the C-terminus). For the 
cyclization peptides should be deprotected at the N-terminus, for that purpose on 
the end of the syntheses step 2 and 3 can be employed.  
 
 
6.4.3. Cyclization of the Peptides 
 
6.4.3.1. PROTOCOL 6: Cyclization on Wang and Rink Amide Resin 
 
The N-terminus of the fully protected peptide is deprotected by the protocol 
previously described (chapter 6.4.1.3, P. 113). 
The peptidyl resin is washed with DMF (7 x) and DCM (5 x). 
 
Deprotection of the C-terminal carboxy group: 
A solution of 1 % TFA in DCM (2 ml/100 mg resin) is added to the resin. The 
reaction mixture is shaken for 5 min at room temperature and filtered. This is 
repeated 20 times. The resin-bound peptide is washed with DCM (5 x) and DMF (5 
x). 
 
Cyclization: 
A solution of 1.0-3.0 equiv (relative to resin loading) of coupling reagent (HATU, 
PyAOP, DIC/HOAt) in 3 ml DMF followed by 6.0 equiv of DIPEA (relative to resin 
loading) is added to the resin. The reaction mixture is shaken for 45 min at room 
temperature and filtered. A small quantity of resin is washed with DMF (7 x) and 
DCM (5 x), and the peptide is cleaved from the resin, using protocol 10 (chapter 
6.4.4.2, P. 118). The progress of the cyclization is checked by MALDI-ToF MS 
or/and analytical HPLC. If the linear peptide is still detected, the coupling step is 
repeated. After the cyclization is complete, the resin is washed with DMF (7 x) and 
DCM (5 x). The cyclic peptide is cleaved from the resin and completely 
deprotected following protocol 10 (chapter 6.4.4.2, P. 118). 
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6.4.3.2. PROTOCOL 7: Cyclization in Solution 
 
By this method fully protected cyclic peptides are synthesized. 
 
6.4.3.2.1. Method A 
 
The protected linear peptide is dissolved in DMF, so that the final concentration is 
0.2 mmol/l for penta- and hexapeptides or 0.1 mmol/l for tetrapeptides. 1.1 Equiv 
of a coupling reagent (HATU, PyAOP, DIC/HOAt) and 3.0 equiv of DIPEA are 
added to this solution. The solution is stirred for 30 min at room temperature and 
cyclization is monitored by MALDI-ToF mass spectroscopy. If the linear peptide is 
still present in solution, an additional quantity of coupling reagent is added to the 
solution. After the cyclization is complete, DMF is evaporated under high vacuum 
(temperature of the bath must not exceed 30 °C) and peptide is purified by reverse 
phase preparative HPLC or by filtration through a C18 plug. 
 
 
6.4.3.2.2. Method B 
 
A solution of the linear peptide in DMF is added to a solution of 3.0-6.0 equiv of 
DIPEA and 1.0 equiv of HOAt in DMF using a syringe pump. Simultaneously, with 
a second syringe pump a solution of 1.0-3.0 equiv (relative to the peptide) of the 
coupling reagent HATU in DMF is added at the same rate. Then the solution is 
stirred for 10 min after the addition of the reagents is finished. DMF is evaporated 
under high vacuum. The temperature of the bath must not exceed 30 °C and the 
peptide is purified by reverse phase preparative HPLC. If DMSO or NMP are used 
instead of DMF as a solvent, solution is diluted with water after cyclization, filtered 
through a small reverse phase C18 plug and washed with water (3x) and Et2O (3x). 
The cyclic peptide is eluted from the plug with ACN or any other adequate solvent. 
The solvent is evaporated under reduced pressure and the cyclic peptide is 
purified by reverse phase preparative HPLC. 
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6.4.3.3. PROTOCOL 8: Cyclization on “Safety Catch” Resin 
 
By this method fully protected cyclic peptides are synthesized. Peptide chain 
elongation follows the usual Fmoc protocol. 
 
Protection of N-terminus with trityl protective group: 
After completion of the linear peptide synthesis and Fmoc deprotection of the  
N-terminus of the peptide the resin is washed with DCM (3x). Then, a solution of 
6.0 equiv of DIPEA (relative to resin loading) and 3.5 equiv of trityl chloride 
(relative to resin loading) in DCM (2 ml/100 mg resin) is added to the resin. The 
reaction mixture is shaken overnight at room temperature, drained and washed 
with DCM (3x), and NMP (3x). 
Alternatively, the N-terminal amino acid could be introduced as Nα-trityl protected 
amino acid during the synthesis of linear peptide. 
 
Activation of “Safety catch” resin: 
After the N-terminus of the peptide has been protected with a trityl group and 
washed with DCM and NMP, NMP (1 ml/100 mg resin), 10.0 equiv DIPEA (relative 
to resin loading) and 25.0 equiv (relative to resin loading) of iodoacetonitrile 
(previously filtered through a plug of basic alumina) are added to the resin. The 
reaction mixture is protected from light and shaken for 24 h at room temperature. 
The resin is drained and washed with NMP (5x) and DCM (5x). 
 
N-terminal deprotection: 
To the activated and washed resin a solution of 3 % TFA and 5 % TIS in DCM is 
added and shaken at the room temperature for 2 h. The resin is drained and 
washed 3 times with DCM and 3 times with dry THF. 
 
Cyclization and cleavage: 
Dry THF (2 ml/100 mg resin) and 3.0 equiv of DIPEA (relative to resin loading) are 
added to the activated, deprotected and washed resin. The reaction mixture is 
shaken overnight at room temperature. The solution is collected and the resin is 
washed with THF (3x) and DCM (3x). The combined washings are evaporated 
under reduced pressure and the peptide is purified by reverse phase preparative 
HPLC. 
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6.4.4. Cleavage from the Resin and Deprotection of the Peptides  
 
6.4.4.1. PROTOCOL 9: Cleavage of the Peptides from the 2-ClTrt Resin and 
Sasrin 
 
Before peptide cleavage the resin is washed with DCM (3x). 1 % TFA in DCM 
(2ml/100 mg resin) is added to the washed resin and the reaction mixture is 
shaken for 5 min at room temperature. The solution is filtered into a round bottom 
flask, and immediately neutralized with pyridine. This procedure is repeated until 
no more peptide is present in the filtered solution (test with MALDI-ToF MS and/or 
analytical HPLC); usually 6 – 10 times. All filtrates are collected and evaporated 
under reduced pressure. 10 ml water is added and the suspension is filtered 
through a small column filled with reverse phase C18 material (the material should 
be washed with methanol and water before use). Column and flask are washed 
with water (3x) and Et2O (3x). The cyclic peptide is eluted from the plug with ACN 
or any other adequate solvent. The solvent is evaporated under reduced pressure 
and the peptide is lyophilized. 
 
 
6.4.4.2. PROTOCOL 10: Cleavage of the Peptides from Wang and Rink amide 
Resins 
 
Before peptide cleavage the resin is washed with DCM (3x). One of the following 
cleavage cocktails (3 ml/100 mg of resin) is added to the washed resin: 
95 % TFA, 2.5 % H2O, 2.5 % TIS; 
82.5 TFA, 5 % Phenol, 5 % H2O, 5 % Thioanisol, 2.5 % EDT (Reagent K); 
88 % TFA, 5 % Phenol, 2 % TIS, 5 % H2O (reagent B). 
The resin is shaken at room temperature for 2-20 h, the solvent is evaporated and 
cold diethyl ether is added to the residue. Diethyl ether is decanted, centrifuged for 
1 h at 0 ºC with 4000 rpm, and again decanted. The residue (after both 
decantations) is dissolved in a minimum of solvent and purified by reverse phase 
preparative HPLC. Alternatively for preliminary purification before preparative 
HPLC and instead of precipitation with diethyl ether, the filtration method over a 
small C18 column described in protocol 9 could be used. 
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6.4.4.3. PROTOCOL 11: Cleavage of the Peptides from the “Safety Catch” Resin 
with Formation of a Thioester Bond at the C-terminus 
 
Activation of “Safety catch” resin: 
After the synthesis of the linear peptide (the N-terminus should be trityl or Boc 
protected) the resin is washed with DCM (3x) and NMP (3x). The NMP (1 ml/100 
mg resin), 10.0 equiv (relative to resin loading) of DIPEA and 25.0 equiv (relative 
to resin loading) of iodoacetonitrile (previously filtered through a plug of basic 
alumina) are then added to the resin. The reaction mixture is protected from light 
and shaken for 24 h at room temperature. The resin is drained and washed with 
NMP (5x) and DCM (5x). 
 
Cleavage of the peptide: 
A solution of 50.0 equiv (relative to resin loading) ethyl-3-mercaptopropionate in 
DCM (1 ml/100 g resin), and 0.5 equiv (relative to resin loading) Na-thiophenolate 
dissolved in a minimum of DMF is added to the activated and washed resin. The 
mixture is shaken for 24 h at room temperature. The solvent is filtered and the 
resin washed with DCM. The combined filtrates are evaporated under reduced 
pressure and the peptide is purified by reverse phase preparative HPLC. 
 
 
6.4.4.4. PROTOCOL 12: Cleavage of the Aloc Protective Group in Solution 
 
24.0 Equiv of PhSiH3 and a solution of 0.1 equiv [Pd(PPh3)4] in DCM are added to 
the solution of the peptide in a minimum quantity of dry DCM (if the peptide is not 
soluble small amounts of DMF can be added) under argon. The mixture is stirred 
at room temperature for 10 min and the progress of the reaction is monitored by 
MALDI-ToF MS and/or analytical HPLC. After completion of reaction, DCM is 
evaporated and the product is purified by reverse phase preparative HPLC. 
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6.4.4.5. PROTOCOL 13: Complete Deprotection of the Cyclic Peptides 
 
One of the following cleavage cocktails is added to the cyclic protected peptide: 
95 % TFA, 2.5 % H2O, 2.5 % TIS; 
82.5 TFA, 5 % Phenol, 5 % H2O, 5 % Thioanisol, 2.5 % EDT (Reagent K); 
88 % TFA, 5 % Phenol, 2 % TIS, 5 % H2O (reagent B). 
The solution is shaken at room temperature for 2-20 h (depending on the peptide 
and protective groups), the solvent is evaporated and cold diethyl ether is added to 
the residue. Diethyl ether is decanted, centrifuged for 1 h on 0 ºC with 4000 rpm, 
and again decanted. The residue (after both decantations) is dissolved in a 
minimum of solvent and purified by reverse phase preparative HPLC. Alternatively 
for preliminary purification before preparative HPLC and instead of precipitation 
with diethyl ether, the filtration method over a small C18 column described in 
protocol 9 could be used. 
 
 
6.4.5. Synthesis of Model Peptides 
 
 
c-(-Leu-Ala-Val-Pro-Phe-Gly-) (33) 
 
C30H44N6O6 (584.72 g/mol). 
The linear peptide H-Leu-Ala-Val-Pro-Phe-Gly-OH (27) is synthesized on 150 mg 
(104 µmol) Fmoc-Gly-Sasrin (loading 0.69 mmol/g), cleaved from the resin with 1 
% TFA in DCM (protocol 9), and purified by reverse phase preparative HPLC. 
Yield (Linear peptide (27)): 50 mg, 83 µmol, 80 %. 
HPLC (anal. method 3): tR=16.5 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 603.35 [M+H]+, 625.33 [M+Na]+, 641.31 [M+K]+ 
Found: 603.69 [M+H]+, 625.66 [M+Na]+, 641.59 [M+K]+ 
The linear peptide (27) (50 mg, 83 µmol) is dissolved in 500 ml DMF and cyclized 
following protocol 7, method A: 
1.1 equiv HATU (91 µmol, 34 mg). 
3.0 equiv DIPEA (250 µmol, 32 mg, 42 µl). 
After evaporation of DMF, the cyclic peptide (33) is purified by reverse phase 
preparative HPLC. 
Yield (cyclic peptide (33)): 20 mg, 34 µmol, 41 %. 
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HPLC (anal. method 3): tR=19.2 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 585.34 [M+H]+, 607.32 [M+Na]+, 623.30 [M+K]+ 
Found: 585.52 [M+H]+, 607.49 [M+Na]+, 623.48 [M+K]+ 
1H NMR (500 MHz, CDCl3), δ (ppm): 0.90 (m, 1H, Hγ (Pro)), 0.94 (d, 3J= 6.3 Hz, 
3H, Hδ (Leu)), 0.95 (d, 3J= 6.3 Hz, 3H, Hδ (Leu)), 0.99 (d, 3J= 6.3 Hz, 3H, Hγ (Val)), 
1.12 (d, 3J= 6.3 Hz, 3H, Hγ (Val)), 1.38 (d, 3J=6.9 Hz, 3H, Hβ (Ala)), 1.50-1.77 (m, 
4H, 2Hβ (Leu), Hγ (Leu), Hγ (Pro)), 1.89-2.06 (m, 2H, Hβ (Val), Hβ (Pro)), 2.22 (m, 
1H, Hβ (Pro)), 3.13 (dd, 2J =14.1 Hz, 3J=6.0 Hz, 1H, Hβ (Phe)), 3.26 (dd, 2J=14.1 
Hz, 3J=10.4 Hz, 1H, Hβ (Phe)), 3.40 (dd, 2J=14.1 Hz, 3J=6.6 Hz, 1H, Hα (Gly)), 
3.42-3.53 (m, 2H, 2Hδ (Pro)), 3.58 (d, 3J=8.8 Hz, 1H, Hα (Val)), 3.77 (dd, 2J=14.1 
Hz, 3J =5.3 Hz, 1H, Hα (Gly)), 4.07 (ddd, 3J =10.4 Hz, 3J =5.0 Hz, 3J =5.0 Hz, 1H, 
Hα (Leu)), 4.44 (d, 3J =8.8, 1H, Hα (Pro)), 4.59 (ddd, 3J =10.5 Hz, 3J=8.6 Hz, 3J=5.8 
Hz, 1H, Hα (Phe)), 4.69 (qd, 3J =9.1, 3J =7.2, 1H, Hα (Ala)), 6.20 (d, 3J =5.0 Hz, 1H, 
HN (Leu)), 6.82 (s, 1H, HN (Val)), 6.92 (d, 3J=9.4 Hz, 1H, HN (Ala)), 7.20-7.32 (m, 
5H, Har), 7.66 (dd, 3J=6.3 Hz, 3J=5.7 Hz, 1H, HN (Gly)), 9.03 (d, 3J=8.2 Hz, 1H, HN 
(Phe)). 
 
 
c-(-Leu-Ala-Val-β-hPro-Phe-Gly-) (34) 
 
C31H46N6O6 (598.75 g/mol). 
The linear peptide H-Leu-Ala-Val-β-hPro-Phe-Gly-OH (28) is synthesized on 200 
mg (152 µmol) Wang resin previously loaded with Fmoc-Gly-OH (loading 0.76 
mmol/g), cleaved with reagent B during 2 h (protocol 10), and purified by 
preparative HPLC. 
Yield (linear peptide (28)): 65 mg, 89 µmol, 59 %. 
HPLC (anal. method 3): tR=17.2 min, 84 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 617.37 [M+H]+, 639.35 [M+Na]+, 655.32 [M+K]+ 
Found: 617.65 [M+H]+, 639.59 [M+Na]+, 655.54 [M+K]+ 
The linear peptide (28) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (28) (65 mg, 89 µmol) in 10 ml DMF. 
Second syringe: Solution of HATU (1.5 equiv, 133 µmol, 51mg) in 10 ml DMF. 
Addition rate for both syringes: 0.05 ml/min. 
Flask: Solution of DIPEA (3.0 equiv, 267 µmol, 34 mg, 46 µl) in 20 ml DMF. 
The cyclicpeptide (34) is purified by reverse phase preparative HPLC after 
evaporation of DMF. 
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Yield (cyclic peptide (34)): 45mg, 75 µmol, 76 %. 
HPLC (anal. method 3): tR=19.6 min, 90 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 599.36 [M+H]+, 621.34 [M+Na]+, 637.31 [M+K]+ 
Found: 599.77 [M+H]+, 621.73 [M+Na]+, 635.75 [M+K]+ 
1H NMR (500 MHz, CDCl3), δ (ppm): 0.83 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 0.86 (d, 
3J=6.3 Hz, 3H, Hδ (Leu)), 0.91 (d, 3J=6.3 Hz, 3H, Hγ (Val)), 0.96 (d, 3J=6.3 Hz, 3H, 
Hγ (Val)), 1.47 (d, 3J=7.5 Hz, 3H, Hβ (Ala)), 1.53-1.69 (m, 2H, Hγ (β-hPro)), 1.75-
1.85 (m, 2H, Hγ (Leu), Hβ (Val)), 1.86-2.00 (m, 3H, 2Hβ (Leu), Hδ (β-hPro)), 2.10-
2.27 (m, 3H, 2Hα (β-hPro), Hδ (β-hPro)), 3.10 (dd, 2J=14.4 Hz, 3J =5.0 Hz, 1H, Hβ 
(Phe)), 3.28 (dd, 2J=14.4 Hz, 3J =5.0 Hz, 1H, Hβ (Phe)), 3.42 (dd, 2J=17.6 Hz, 
3J=8.2 Hz, 1H, Hε (β-hPro)), 3.69-3.86 (m, 2H, Hα (Gly), Hε (β-hPro)), 3.96 (m, 1H, 
Hα (Leu)), 4.05 (m, 1H, Hα (Ala)), 4.24 (m, 1H, Hβ (β-hPro)), 4.41 (m, 1H, Hα (Val)), 
4.48 (dd, 2J=17.3 Hz, 3J=7.9 Hz, Hα (Gly)), 4.65 (m, 1H, Hα (Phe)), 5.60 (br, 1H, HN 
(Phe)), 7.07-7.40 (m, 8H, 5Har, HN (Ala), HN (Leu), HN (Val)), 8.23 (br, 1H, HN (Gly)). 
 
 
c-(-Ala-Val-Pro-Phe-Gly-) (35) 
 
C24H33N5O5 (471.56 g/mol). 
The linear peptide H-Ala-Val-Pro-Phe-Gly-OH (29) is synthesized on 300 mg (0.21 
mmol) Fmoc-Gly-Sasrin (loading 0.69 mmol/g), cleaved from the resin with 1 % 
TFA in DCM (protocol 9), and purified by reverse phase preparative HPLC. 
Yield (linear peptide (29)): 60 mg, 0.12 mmol, 59 %. 
HPLC (anal. method 3): tR=15.0 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 490.27 [M+H]+, 512.25 [M+Na]+, 528.22 [M+K]+ 
Found: 512.27 [M+Na]+, 528.29 [M+K]+ 
The linear peptide (29) (60 mg, 0.12 mmol) is dissolved in 1000 ml DMF and 
cyclized following protocol 7, method A: 
1.1 equiv HATU (0.14 mmol, 51 mg). 
3.0 equiv DIPEA (0.37 mmol, 48 mg, 63 µl). 
After evaporation of the solvent the cyclic peptide (35) is purified by reverse phase 
preparative HPLC. 
Yield (cyclic peptide (35)): 25 mg, 53 µmol, 43 %. 
HPLC (anal. method 3): tR=18.1 min, 100 area %. 
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MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 472.26 [M+H]+, 494.24 [M+Na]+, 510.21 [M+K]+ 
Found: 472.51 [M+H]+, 494.46 [M+Na]+, 510.46 [M+K]+ 
1H NMR (500 MHz, CDCl3), δ (ppm): 0.87 (d, 3J=6.9 Hz, 3H, Hγ (Val)), 0.90 (d, 
3J=6.9 Hz, 3H, Hγ (Val)), 1.38 (m, 1H, Hβ (Pro)), 1.48 (d, 3J=6.9 Hz, 3H, Hβ (Ala)), 
1.58 (m, 1H, Hγ (Pro)), 1.72 (m, 1H, Hγ (Pro)), 1.99 (m, 1H, Hβ (Val)), 2.21 (m, 1H, 
Hβ (Pro)), 2.93 (dd, 2J=14.1 Hz, 3J=9.7 Hz, 1H, Hβ (Phe)), 3.00 (d, 2J=14.4 Hz, 1H, 
Hα (Gly)), 3.18 (dd, 2J=13.8 Hz, 3J=5.0 Hz, 1H, Hβ (Phe)), 3.48 (ddd, 2J=11.6 Hz, 
3J=6.9 Hz, 3J=6.9 Hz, 1H, Hδ (Pro)), 3.72 (ddd, 2J=11.3 Hz, 3J=6.9 Hz, 3J=6.9 Hz, 
1H, Hδ (Pro)), 4.00 (qd, 3J=6.9 Hz, 3J=11.0 Hz, 1H, Hα (Ala)), 4.55-4.62 (m, 2H, Hα 
(Val), Hα (Pro)), 4.92 (dd, 2J=14.4 Hz, 3J=10.6 Hz, 1H, Hα (Gly) ), 5.23 (ddd, 3J=9.9 
Hz, 3J=9.9 Hz, 3J=5.2 Hz, 1H, Hα (Phe)), 7.04 (d, 3J=10.5 Hz, 1H, HN (Phe)), 7.12 
(d, 3J=6.9 Hz, 1H, HN (Val)), 7.15-7.30 (m, 5H, Har), 7.9 (d, 3J=10.1 Hz, 1H, HN 
(Gly)), 8.56 (d, 3J=10.7 Hz, 1H, HN (Ala)). 
 
 
c-(-Ala-Val-β-hPro-Phe-Gly-) (36) 
 
C25H35N5O5 (485.59 g/mol). 
The linear peptide H-Ala-Val-β-hPro-Phe-Gly-OH (30) is synthesized on 300 mg 
(0.21 mmol) Fmoc-Gly-Sasrin (loading 0.69 mmol/g), cleaved from the resin with 1 
% TFA in DCM (protocol 9), and purified by reverse phase preparative HPLC. 
Yield (linear peptide (30)): 68 mg, 0.14 mmol, 68 %. 
HPLC (anal. method 3): tR=16.0 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 504.28 [M+H]+, 526.26 [M+Na]+, 542.24 [M+K]+ 
Found: 504.28 [M+H]+, 526.11 [M+Na]+, 542.06 [M+K]+ 
The linear peptide (30) (68 mg, 0.14 mmol) is dissolved in 700 ml DMF and 
cyclized following protocol 7, method A: 
1.1 equiv HATU (0.15 mmol, 56 mg). 
3 equiv DIPEA (0.41 mmol, 52 mg, 69 µl). 
After evaporation of DMF the cyclic peptide (36) is purified by reverse phase 
preparative HPLC. 
Yield (cyclic peptide): 18 mg, 37 µmol, 28 %. 
HPLC (anal. method 3): tR=18.2 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 486.27 [M+H]+, 508.25 [M+Na]+, 524.23 [M+K]+ 
Found: 486.48 [M+H]+, 508.47 [M+Na]+, 524.40 [M+K]+ 
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1H NMR (500 MHz, DMSO-d6), δ (ppm):  0.82 (d, 3J=6.9, 3H, Hγ (Val)), 0.87 (d, 
3J=6.8, 3H, Hγ (Val)), 1.33 (d, 3J=7.2 Hz, H, 3Hβ (Ala)), 1.46 (dddd, 2J=12.1 Hz, 
3J=11.9 Hz, 3J=11.9 Hz, 3J=6.4 Hz, 1H, Hγ (β-hPro)), 1.69 (m, 1H, Hδ (β-hPro)), 
1.82 (m, 1H, Hδ (β-hPro)), 1.94-2.04 (m, 2H, Hα (β-hPro), Hγ (β-hPro)), 2.16 (m, 1H, 
Hβ (Val)), 2.29 (dd, 2J=15.1 Hz, 3J=7.5 Hz, 1H, Hα (β-hPro)), 2.68 (dd, 2J=14.3 Hz, 
3J= 11.7 Hz, 1H, Hβ (Phe)), 3.32 (dd, 2J=14.3 Hz, 3J= 2.7 Hz, 1H, Hβ (Phe)), 3.39 
(ddd, 2J=10.4 Hz, 3J= 10.4 Hz, 3J= 6.4 Hz, 1H, Hε (β-hPro)), 3.57-3.65 (m, 2H, Hα 
(Gly), Hε (β-hPro)), 3.82 (dd, 2J= 13.5 Hz, 3J= 5.3 Hz, 1H, Hα (Gly)), 3.90-3.98 (m, 
2H, Hβ (β-hPro), Hα (Ala)), 4.35 (dd, 3J=9.3 Hz, 3J=3.3 Hz, 1H, Hα (Val)), 4.54 (ddd, 
3J=11.1 Hz, 3J=8.7 Hz, 3J=2.8 Hz, 1H, Hα (Phe)), 6.99 (d, J3=9.4 Hz, 1H, HN (Val)), 
7.16-7.30 (m, 5H, Har), 7.86 (d, 3J= 8.8 Hz, 1H, HN (Phe)), 8.41 (dd, 3J=5.4 Hz, 
3J=2.1 Hz, 1H, HN (Gly)), 8.90 (d, 3J=7.0 Hz, 1H, HN (Ala)). 
 
 
c-(-Ala-Pro-Phe-Gly-) (37) 
 
C19H24N4O4 (372.43 g/mol). 
The linear peptide H-Ala-Pro-Phe-Gly-OH (31) is synthesized on 290 mg (0.2 
mmol) Fmoc-Gly-Sasrin (loading 0.69 mmol/g), cleaved with 1 % TFA in DCM 
(protocol 9), and purified by preparative HPLC. 
Yield (linear peptide (31)): 47 mg, 0.12 mmol, 59 %. 
HPLC (anal. method 2): tR=12.0 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 391.20 [M+H]+, 413.18 [M+Na]+, 429.15 [M+K]+ 
Found: 391.17 [M+H]+, 413.13 [M+Na]+, 429.14 [M+K]+ 
The linear peptide (31) (47 mg, 120 µmol) is dissolved in 1.5 l DMF and cyclized 
following protocol 7, method A.  
1.1 equiv HATU (130 µmol, 50mg). 
3 equiv DIPEA (270 µmol, 34 mg, 46 µl). 
The cyclic peptide (37) is purified by reverse phase preparative HPLC after 
evaporation of the solvent. 
Yield (cyclic peptide (37)): 1 mg, 2 µmol, 2 %. 
HPLC (anal. method 2): tR=16.4 min, 90 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 373.19 [M+H]+, 395.17 [M+Na]+, 411.14 [M+K]+ 
Found: 373.53 [M+H]+, 395.51 [M+Na]+, 411.50 [M+K]+ 
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c-(-Ala-β-hPro-Phe-Gly-) (38) 
 
C20H26N4O4 (386.46 g/mol). 
The linear peptide H-Ala-β-hPro-Phe-Gly-OH (32) is synthesized on 200 mg (150 
µmol) Wang resin previously loaded with Fmoc-Gly-OH (loading 0.76 mmol/g), 
cleaved with reagent B during 2 h (protocol 10) and purified by preparative HPLC. 
Yield (linear peptide (32)): 36 mg, 89 µmol, 59 %. 
HPLC (anal. method 1): tR=13.40 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 405.21 [M+H]+, 427.20 [M+Na]+, 443.17 [M+K]+ 
Found: 405.48 [M+H]+, 427.44 [M+Na]+, 443.43 [M+K]+ 
The linear peptide (32) is cyclized following protocol 7, method B:  
First syringe: Solution of linear peptide (32) (36 mg, 89 µmol) in 15 ml DMF. 
Second syringe: Solution of HATU (1.5 equiv, 133 µmol, 51mg) in 15 ml DMF. 
Addition rate for both syringes: 0.66 ml/min. 
Flask: Solution of DIPEA (3.0 equiv, 267 µmol, 34 mg, 46 µl) in 20 ml DMF. 
The cyclic peptide (38) is purified by reverse phase preparative HPLC after 
evaporation of the solvent. 
Yield (cyclic peptide (38)): 15 mg, 37 µmol, 41 %. 
HPLC (anal. method 1): tR=19.5 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 387.20 [M+H]+, 409.19 [M+Na]+, 425.16 [M+K]+ 
Found: 387.47 [M+H]+, 409.41 [M+Na]+, 425.28 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 1.30 (d, 3J=6.9 Hz, 3H, Hβ (Ala)), 1.63 (m, 
1H, Hγ (β-hPro)), 1.80-1.90 (m, 3H, 2Hδ (β-hPro), Hγ (β-hPro)), 2.07 (dd, 2J=13.5 
Hz, 3J=7.2 Hz, 1H, Hα (β-hPro)), 2.45 (dd, 2J=13.5 Hz, 3J=1.6 Hz, 1H, Hα (β-hPro)), 
2.82 (dd, 2J=13.8 Hz, 3J=8.2 Hz, 1H, Hβ (Phe)), 2.93 (dd, 2J=14.1 Hz, 3J=7.9 Hz, 
1H, Hβ (Phe)), 3.03 (dd, 2J=14.7 Hz, 3J=5.3 Hz, 1H, Hα (Gly)), 3.24 (m, 1H, Hε (β-
hPro)), 3.56 (m, 1H, Hε (β-hPro)), 3.86 (dd, 2J=14.4 Hz, 3J=8.2 Hz,1H, Hα (Gly)), 
4.20-4.40 (m, 2H, Hα (Ala), Hα (Phe)), 4.57 (m, 1H, Hβ (β-hPro)), 6.91 (br, 1H, HN 
(Ala)), 7.15-7.30 (m, 5H, Har), 8.56 (d, 3J=5.7, 1H, HN (Phe)), 8.66 (br, 1H, HN 
(Gly)). 
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6.4.5.1. CD and FTIR Measurements 
 
Circular dichroism: 
 
Circular dichroism spectra are recorded in a 0.02 cm cell at room temperature,  
c~0.5-1 mg/cm3 of peptide. Spectra are smoothed by the Savitzky-Golay algorithm.  
  
 
Fourier transform infrared spectroscopy (FTIR): 
 
Infrared spectroscopic measurements (at a resolution of 2 cm-1) are performed at 
room temperature using 0.020-0.025 cm liquid cells with CaF2 windows. The 
contribution of the H-O-H deformation band to the amide I region which appears at 
about 1633 cm-1 in TFE due to traces of water is removed on the basis of the 
combination band of the O-H stretching and H-O-H deformation. The amide I 
region of the spectra is decomposed into individual bands by the Levenberg-
Marquardt nonlinear curve-fitting method using weighted sums of Lorentz and 
Gauss functions. The choice of the starting parameters is assisted by Fourier self-
deconvolution (FSD). Both curve fitting and FSD procedures are part of the 
instrument's software package (OPUS, version 2.2). 
 
 
Description of cation binding experiments: 
 
In general, the CD spectra show a continuous change up to peptide : Ca2+ ration 
of 1:2 in TFE. No significant spectral shifts are recorded in aqueous solution. 
Comparative CD and FTIR measurements were performed in TFE, c≅1mM at  
peptide : Ca2+ ration of 1:1 and 1:2 on all the model peptides. 
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6.4.6. Synthesis of Cyclic Analogs of the Binding Epitope of VCAM-1 
 
c-(-Ile-Asp-Ser-Pro-Leu-Asn-) (39) 
 
C28H45N7O10 (639.72 g/mol). 
Cyclization on resin: 
The linear peptides H-Ser(t-Bu)-Pro-Leu-Asn(Trt)-Ile-Asp(Wang)-ODmb (71) and  
H-Ile-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Leu-Asn(Rink amide)-ODmb are synthesized 
using standard protocol (Table 30, P. 114) and cyclized following protocol 6 using 
different coupling reagents (Table 31). After deprotection and cleavage from the 
resin with different cleavage reagents (Table 31), cyclic peptide (39) is purified by 
reverse phase preparative HPLC. 
 
Table 31: On resin synthesis of c-(-Ile-Asp-Ser-Pro-Leu-Asn-) (39) 
 
Resin 
n/ 
mmol 
Coupling reagent 
t/ 
min 
Cleavage 
reagent 
t/ 
h 
Yield 
HPLC/ 
% 
Wang 
135 mg 0.10 
1.1 equiv PyBOP  
3.0 equiv DIPEA  
2x45 
 
Reagent B 0.5 
4 mg 
4 µmol 
4 % 
 
56a 
 
Wang 
135 mg 0.10 
2.0 equiv PyAOP  
3.0 equiv DIPEA  
45 Reagent B 2 
4 mg 
7 µmol 
7 % 
 
100a 
 
Rink 
amide 
100 mg 
0.06 
3.0 equiv HATU  
6.0 equiv DIPEA  
45 Reagent K 0.5 0 0 
Wang 
400mg 
0.20 
3.0 equiv HATU  
6.0 equiv DIPEA  
45 
TFA 48 % 
DCM 48 % 
TIS 4 % 
2 
8 mg 
9 µmol 
4 % 
70a 
 
a The same HPLC analytical method and the retention time as for the cyclization in 
solution.  
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Cyclization in solution: 
a) The linear peptide H-Asn(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Leu-OH (72) is 
synthesized on 139 mg (100 µmol) Fmoc-Leu-Sasrin (loading 0.72 mmol/g) and 
cleaved with 1 % TFA in DCM (protocol 9).  
Yield (linear protected peptide (72)): 95 mg, 65 µmol, 65 %. 
HPLC (anal. method 1): tR=31.3 min, 68 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1012.58 [M+H]+, 1034.56 [M+Na]+, 1050.53 [M+K]+ 
Found: 1012.97 [M+H]+, 1034.63 [M+Na]+, 1050.78 [M+K]+ 
The linear peptide (72) is dissolved in 1 l DMF and cyclized following protocol 7, 
method A with different coupling reagents (Table 32). The cyclic protected peptide 
(73) is purified by reverse phase preparative HPLC. 
 
Table 32: Cyclization of H-Asn(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Leu-OH (72) 
 
Linear peptide Yield 
mg µmol 
Coupling 
reagents 
Time/ 
h mg µmol % 
68 47 
1.1 equiv PyAOP 
3.0 equiv DIPEA 
2x1 18 18 38 
27 19 2.0 equiv DIC 1.0 equiv HOAt 24 - - - 
27 19 1.1 equiv HATU 
3.0 equiv DIPEA 
0.5 5 5 26 
 
HPLC (anal. method 1): tR=37.0 min. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 994.57 [M+H]+, 1016.55 [M+Na]+, 1032.52 [M+K]+ 
Found: 1016.86 [M+Na]+, 1032.87 [M+K]+ 
The combined quantities of cyclic protected peptide (73) are completely 
deprotected with the mixture TFA/H2O/TIS = 95 : 2.5 :2.5 for 3 h (protocol 13) and 
finally purified by preparative HPLC. 
Yield (cyclic deprotected peptide (39)): 10 mg, 17 µmol, 74 %. 
HPLC (anal. method 2): tR=17.3 min, 100 area %. No isomers detected. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 640.33 [M+H]+, 662.31 [M+Na]+, 678.29 [M+K]+ 
Found: 640.45 [M+H]+, 650.63 [M+Na]+, 678.44 [M+K]+ 
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b) The linear peptide H-Asn(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Leu-OH (72) is 
synthesized on 2-ClTrt resin (295 mg, 200 µmol) previously loaded with Fmoc- 
-Leu-OH (loading 0.68 mmol/g) and cleaved with 1 % TFA in DCM (protocol 9).  
Yield (linear protected peptide (72)): 213 mg, 173 µmol, 86 %. 
HPLC (anal. method 1): tR=31.3 min, 82 area %. 
MALDI-ToF MSmonoisotopic, m/z: see above. 
The linear peptide (72) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (72) (213 mg, 173 µmol) in 20 ml DMF. 
Second syringe: Solution of HATU (1.2 equiv, 200 µmol, 76 mg) in 20 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (3.4 equiv, 585 µmol, 76 mg, 100 µl) and HOAt (1.2 
equiv, 200 µmol, 27 mg) in 10 ml DMF. 
The cyclic protected peptide (73) is purified by filtration through a C18 plug after 
evaporation of the solvent. 
Yield (cyclic protected peptide (73)): 205 mg, 126 µmol, 73 %. 
HPLC (anal. method 1): tR=37 min, 61 area %. 
MALDI-ToF MSmonoisotopic, m/z: see above 
The cyclic protected peptide (73) is completely deprotected with reagent K during 5 
h (protocol 13) and finally purified by preparative HPLC. 
Yield (cyclic deprotected peptide (39)): 30 mg, 46 µmol, 37 %. 
HPLC (anal. method 2): tR=17.3 min, 100 area %. No isomers detected. 
MALDI-ToF MSmonoisotopic, m/z: see above. 
1H NMR (500 MHz, DMSO-d6), δ (ppm): two set of signals (ratio 3 : 1). 
Major conformer: 0.77-0.86 (m, 12H, 3Hγ (Ile), 3Hδ (Ile), 6Hδ (Leu)), 1.18 (ddq, 
2J=13.6 Hz, 3J=7.1 Hz, 3J=7.1 Hz, 1H, Hγ (Ile)), 1.41-1.55 (m, 4H, Hγ (Ile), 2Hβ 
(Leu), Hγ (Leu)), 1.55-1.75 (m, 2H, Hβ (Ile) Hβ (Pro)), 1.82 (m, 1H, Hγ (Pro)), 1.93 
(m, 1H, Hγ (Pro)), 2.23 (m, 1H, Hβ (Pro)), 2.44 (dd, 2J=16.3 Hz, 3J=8.3 Hz 1H, Hβ 
(Asx)), 2.67 (dd, 2J=16.6 Hz, 3J=2.0 Hz, 1H, Hβ (Asx)), 2.78 (dd, 2J=16.6 Hz, 
3J=7.8 Hz 1H, Hβ (Asx)), 2.88 (dd, 2J=16.0 Hz, 3J=5.3 Hz 1H, Hβ (Asx)), 3.54 (br, 
1H, Hδ (Pro)), 3.65 (dd, 2J=15.1 Hz, 3J=3.1 Hz, 1H, Hβ (Ser)), 3.79 (m, 1H, Hδ 
(Pro)), 3.84 (dd, 3J=11.9 Hz, 3J=5.0 Hz 1H, Hα (Ile)), 3.88 (dd, 2J=14.8 Hz, 3J=7.2 
Hz 1H, Hβ (Ser)), 4.12 (m, 1H, Hα (Leu)), 4.16 (dd, 3J=9.7 Hz, 3J=7.9 Hz, 1H, Hα 
(Pro)), 4.34 (ddd, 3J=7.5 Hz, 3J=6.6 Hz, 3J=1.9 Hz, 1H, Hα (Asx)), 4.54 (ddd, 3J=8.0 
Hz, 3J=8.0 Hz, 3J=4.6 Hz, 1H, Hα (Asx)), 4.68 (m, 1H, Hα (Ser)), 7.40 (s, 1H, HN 
(Asn)), 7.54 (d, 3J=6.3 Hz, 1H, HN (Asx)), 7.61 (d, 3J=6.9 Hz, 1H, HN (Ser)), 7.69 (d, 
3J=8.8 Hz, 1H, HN (Leu)), 7.81 (s, 1H, HN (Asn)), 8.31 (br 1H, HN (Asx)), 8.73 (d, 
3J=5.0 Hz, 1H, HN (Ile)), 12.3 (br, 1H, Hcoo (Asp)). 
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Minor conformer 0.77-0.86 (m, 9H, 3Hγ (Ile), 3Hδ (Ile), 3Hδ (Leu)), 0.93 (d, 3J=6.3 
Hz, 3H, Hδ (Leu)), 1.07 (ddq, 2J=13.6 Hz, 3J=7.2 Hz, 3J=2.1 Hz, 1H, Hγ (Ile)),1.31 
(ddq, 2J=13.3 Hz, 3J=6.4 Hz, 3J=3.7 Hz, 1H, Hγ (Ile)), 1.41-1.55 (m, 2H, Hγ (Leu), Hγ 
(Pro)), 1.64 (m, 1H, Hβ (Leu)), 1.76-1.87 (m, 3H, Hβ (Leu), Hβ (Pro), Hγ (Pro)), 1.88-
1.99 (m, 2H, Hβ (Ile), Hβ (Pro)), 2.37 (dd, 2J=16.0 Hz, 3J=7.2 Hz, 1H, Hβ (Asx)), 2.42 
(dd, 2J=16.3 Hz, 3J=3.8 Hz, 1H, Hβ (Asx)), 2.58-2.75 (m, 2H, Hβ (Asx)), 3.39 (dt, 
2J=11.1 Hz, 3J=5.7 Hz, 1H, Hδ (Pro)), 3.44-3.63 (br, 3H, Hδ (Pro), 2Hβ (Ser)), 3.88 
(m, 1H, Hα (Ile)), 4.06 (ddd, 3J=11.6 Hz, 3J=10.1 Hz, 3J=2.5 Hz, 1H, Hα (Leu)), 4.31 
(m, 1H, Hα (Ser)), 4.41 (ddd, 3J=6.9 Hz, 3J=6.9 Hz, 3J=6.9 Hz, 1H, Hα (Asx)), 4.48 
(ddd, 3J=6.9 Hz, 3J=6.9 Hz, 3J=6.9 Hz, 1H, Hα (Asx)), 4.67 (m, 1H, Hα (Pro)), 7.07 
(s, 1H, HN (Asn)), 7.12 (d, 3J=6.3 Hz, 1H, HN (Asx)), 7.35 (d, 3J=8.2 Hz, 1H, HN 
(Ile)), 7.47 (s, 1H, HN (Asn)), 8.19 (d, 3J=3.8 Hz, 1H, HN (Asx)), 8.53 (d, 3J=10.1 Hz, 
1H, HN (Leu)), 8.57 (br, 1H, HN (Ser)), 12.3 (br, 1H, HCOO (Asp)). 
 
 
c-(-Ile-Asp-Ser-β-hPro-Leu-Asn-) (40) 
 
C29H47N7O10 (653.74 g/mol). 
Cyclization on resin: 
Linear peptides H-Ser(t-Bu)-β-hPro-Leu-Asn(Trt)-Ile-Asp(Wang)-ODmb (74) and  
H-Ile-Asp(Ot-Bu)-Ser(t-Bu)-β-hPro-Leu-Asn(Rink amide)-ODmb are synthesized 
following the standard protocol (Table 30, P. 114) and cyclized on resin following 
protocol 6.  
 
Table 33: On resin synthesis of c-(-Ile-Asp-Ser-β-hPro-Leu-Asn-) (40) 
 
Resin 
n/ 
mmol 
Coupling reagent 
Cleavage 
reagent 
Time/ 
h 
Yield 
HPLC/ 
% 
Wang 
(300 mg) 
0.20 
3.0 equiv HATU 
6.0 equiv DIPEA 
TFA/H2O/TIS 
95 : 2.5 : 2.5 
2 
1 mg 
2 µmol 
1 % 
 
100a  
Rink 
amide 
(170 mg) 
0.10 3.0 equiv HATU 
6.0 equiv DIPEA 
Reagent B 1 0 0 
a The same HPLC analytical method and the retention time as for the cyclization in 
solution. 
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After deprotection and cleavage from the resin with different cleavage reagents 
(Table 33) the cyclic peptide (40) is purified by reverse phase preparative HPLC: 
 
Cyclization in solution: 
The linear peptide H-Asn(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-β-hPro-Leu-OH (75) is 
synthesized on 280 mg (0.20 mmol) Fmoc–Leu-Sasrin (loading 0.72 mmol/g) and 
cleaved with 1 % TFA in DCM (protocol 9). 
Yield (linear protected peptide (75)): 134 mg, 0.12 mmol, 60 %. 
HPLC (anal. method 1): tR=29.8 min, 90 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1026.59 [M+H]+, 1048.57 [M+Na]+, 1064.55 [M+K]+ 
Found: 1026.94 [M+H]+, 1048.87 [M+Na]+, 1065.91 [M+K]+ 
The linear peptide (75) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (75) (180 mg, 0.12 mmol) in 10 ml DMF. 
Second syringe: Solution of HATU (3.0 equiv, 0.36 mmol, 137 mg) in 10 ml DMF. 
Addition rate for both syringes: 0.04 ml/min. 
Flask: Solution of DIPEA (6.0 equiv, 0.72 mmol, 93 mg, 123 µl) and HATU (0.1 
equiv, 12 µmol, 5 mg) in 10 ml DMF. 
The cyclic protected peptide (76) is purified by reverse phase preparative HPLC 
after evaporation of the solvent. 
Yield (cyclic protected peptide (76)): 72 mg, 72 µmol, 60 %. 
HPLC (anal. method 1): tR=35.8 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1008.58 [M+H]+, 1030.56 [M+Na]+, 1046.54 [M+K]+ 
Found: 1030.42 [M+Na]+, 1046.72 [M+K]+ 
The cyclic protected peptide (76) is completely deprotected with reagent K during 4 
h (protocol 13) and finally purified by preparative HPLC. 
Yield (cyclic deprotected peptide (40)): 47 mg, 71 µmol, 99 %. 
HPLC (anal. method 2): tR=16.7 min, 100 area %. No isomers detected. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 654.35 [M+H]+, 676.33 [M+Na]+, 692.30 [M+K]+ 
Found: 654.52 [M+H]+, 676.56 [M+Na]+, 692.50 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two set of signals (ratio 7 : 1). 
0.80 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 0.82 (dd, 3J=7.2 Hz, 3J=7.2 Hz, 3H, Hδ (Ile)), 0.84 
(d, 3J=6.3 Hz, 3H, Hγ (Ile)), 0.86 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 1.19 (ddq, 2J=15.5 
Hz, 3J=7.1 Hz, 3J=7.2 Hz, 1H, Hγ (Ile)), 1.37-1.48 (m, 2H, Hγ (Ile), Hβ (Leu)), 1.54-
1.64 (m, 2H, Hγ (Leu), Hγ (β-hPro)), 1.69-1.87 (m, 4H, Hβ (Ile), Hβ (Leu), 2Hδ  
(β-hPro)), 2.06 (dddd, 2J=11.9 Hz, 3J=6.4 Hz, 3J=6.4 Hz, 3J=5.4 Hz, 1H, Hγ  
(β-hPro)), 2.16 (dd, 2J=14.4 Hz, 3J=1.9 Hz, 1H, Hα (β-hPro)), 2.50-2.56 (m, 2H, Hβ 
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(Asx), Hα (β-hPro)), 2.67-2.73 (m, 2H, 2Hβ (Asx)), 2.83 (dd, 2J=15.4 Hz, 3J=4.1 Hz, 
1H, Hβ (Asx)), 3.43 (dd, 2J=10.4 Hz, 3J=8.5 Hz, 1H, Hβ (Ser)), 3.51 (dd, 2J=10.4 Hz, 
3J=4.7 Hz, 1H, Hβ (Ser)), 3.52 (m, 1H, Hε (β-hPro)), 3.59 (ddd, 2J=10.1 Hz, 3J=7.9 
Hz, 3J=7.9 Hz, 1H, Hε (β-hPro)), 3.69 (dd, 3J=5.0 Hz, 3J=3.6 Hz, 1H, Hα (Ile)), 4.11 
(dddd, 3J=7.5 Hz, 3J=7.5 Hz, 3J=6.3 Hz, 3J=1.9 Hz, 1H, Hβ (β-hPro)), 4.25 (ddd, 
3J=8.6 Hz, 3J=6.4 Hz, 3J=3.0 Hz, 1H, Hα (Leu)), 4.53-4.56 (m, 2H, Hα (Asx), Hα  
(Ser)), 4.72 (ddd, 3J=8.2 Hz, 3J=4.7 Hz, 3J=4.7 Hz, 1H, Hα (Asx)), 7.1 (d, 3J=7.5 
Hz, 1H, HN (Ser)), 7.19 (s, 1H, HN (Asx)), 7.62 (s, 1H, HN (Asx)), 7.79 (d, 3J=8.8 Hz, 
1H, HN (Leu)), 8.14 (d, 3J=9.4 Hz, 1H, HN (Asx)), 8.17 (d, 3J=3.2 Hz, 1H, HN (Ile)), 
8.48 (d, 3J=8.2 Hz, 1H, HN (Asx)).  
 
 
c-(-Ile-Asp-β-hSer-Pro-Leu-β-hAsn-) (41) 
 
C30H49N7O10 (667.77 g/mol). 
Cyclization on resin: 
The linear peptide H-β-hSer-Pro-Leu-β-hAsn(Trt)-Ile-Asp(Wang)-ODmb (77) is 
synthesized on Wang resin (170 mg, 90 µmol), and cyclized following protocol 6 
(HATU as coupling reagent). After complete deprotection and cleavage from the 
resin with the cleavage cocktail, TFA/DCM/TIS = 48 : 48 : 4 during 2 h, (protocol 
10), the cyclic peptide (41) is purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (41)): 3 mg, 4 µmol, 4 %. 
HPLC (anal. method 2): tR=14.5 min, 85 area %. 
 
Cyclization in solution: 
The linear peptide H-β-hAsn(Trt)-Ile-Asp(Ot-Bu)-β-hSer(t-Bu)-Pro-Leu-OH (78) is 
synthesized on 280 mg (0.20 mmol) Fmoc–Leu-Sasrin (loading 0.72 mmol/g) and 
cleaved with 1 % TFA in DCM (protocol 9). 
Yield (linear protected peptide (78)): 180 mg, 0.14 mmol, 70 %. 
HPLC (anal. method 1): tR=29.2 min, 80 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1040.61 [M+H]+, 1062.59 [M+Na]+, 1078.56 [M+K]+ 
Found: 1040.79 [M+H]+, 1062.73 [M+Na]+, 1078.75 [M+K]+ 
The linear peptide (78) is cyclized following protocol 7, method B. 
First syringe: Solution of linear peptide (78) (180 mg, 0.14 mmol) in 15 ml DMF. 
Second syringe: Solution of HATU (1.1 equiv, 0.15 mmol, 59 mg) in 15 ml DMF. 
Addition rate for both syringes: 0.02 ml/min. 
Flask: Solution of DIPEA (3.0 equiv, 0.42 mmol, 54 mg, 72 µl) and HATU (0.5 
equiv, 70 µmol, 27 mg) in 20 ml DMF. 
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The cyclic protected peptide (79) is purified by reverse phase preparative HPLC 
after evaporation of the solvent. 
Yield (cyclic protected peptide (79)): 78 mg, 76 µmol, 54 %. 
HPLC (anal. method 1): tR=34.5 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1022.60 [M+H]+, 1044.58 [M+Na]+, 1060.55 [M+K]+ 
Found: 1044.67 [M+Na]+, 1060.88 [M+K]+ 
The cyclic protected peptide (79) is completely deprotected with the cleavage 
mixture TFA/H2O/TIS = 95 : 2.5 : 2.5 during 1 h (protocol 13) and finally purified by 
reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (41)): 33 mg, 49 µmol, 65 %. 
HPLC (anal. method 2): tR=14.5 min, 100 area %. No isomers detected. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 668.36 [M+H]+, 690.34 [M+Na]+, 706.32 [M+K]+ 
Found: 668.64 [M+H]+, 690.62 [M+Na]+, 706.58 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two set of signals (ratio 6 : 1) 
0.76 (d, 2J=6.9 Hz, 3H, Hδ (Leu)), 0.82 (dd, 3J=7.5 Hz, 3J=7.5 Hz, 3H, Hδ (Ile)), 0.86 
(d, 3J=6.9 Hz, 3H, Hγ (Ile)), 0.87 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 1.23 (m, 1H, Hγ (Ile)), 
1.33-1.63 (m, 5H, Hγ (Ile), 2Hβ (Leu), Hγ (Leu), Hγ (Pro)), 1.73 (m, 1H, Hβ (Ile)), 1.83 
(m, 1H, Hγ (Pro)), 2.00-2.11 (m, 2H, Hβ (Pro)), 2.22-2.31 (m, 2H, Hα (β-hAsn), Hγ  
(β-hAsn)), 2.33-2.40 (m, 2H, Hγ (β-hAsn), Hβ (Asp)), 2.57 (dd, 2J=16.9 Hz, 3J=10.7 
Hz, 1H, Hα (β-hSer)), 2.63 (dd, 2J=15.7 Hz, 3J=5.7 Hz, 1H, Hα (β-hAsn)), 2.75 (dd, 
2J =16.6 Hz, 3J =2.8 Hz, 1H, Hα (β-hSer)), 2.86 (dd, 2J=16.0 Hz, 3J=11.6 Hz, 1H, 
Hβ (Asp)), 3.30 (ddd, 2J=11.3 Hz, 3J=9.7 Hz, 3J=9.4 Hz, 1H, Hδ (Pro)), 3.34 (dd, 
2J=11 Hz, 3J=3.4 Hz, 1H, Hγ (β-hSer)), 3.42 (ddd, 2J=11.2 Hz, 3J= 11.2 Hz, 3J= 7.1 
Hz, 1H, Hδ (Pro)), 3.67 (dd, 2J=10.7 Hz, 3J=3.8 Hz, 1H, Hγ (β-hSer)), 3.74 (dd, 
3J=3.8 Hz, 3J=3.8 Hz, 1H, Hα (Ile)), 4.04 (m, 1H, Hα (Asp)), 4.12 (ddd, 2J=4.2 Hz, 
2J=7.1 Hz, 2J= 11.2 Hz, 1H, Hα (Leu)), 4.25 (m, 1H, Hβ (β-hAsn)), 4.40-4.49 (m, 2H, 
Hβ (β-hSer), Hα (Pro)), 7.19 (s, 1H, HN (β-hAsn)), 7.45 (d, 3J=7.5 Hz, 1H, HN (Asp)), 
7.63 (d, 3J=8.8 Hz, 1H, HN (β-hAsn)), 7.66 (m, 2H, HN (β-hAsn), HN (Leu)), 8.34 (d, 
3J=3.8 Hz, 1H, HN (Ile)), 8.40 (d, J=7.5 Hz, 1H, HN (β-hSer)). 
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c-(-Val-Asp-Ser-Pro-Leu-Asn-) (42) 
 
C27H43N7O10 (625.69 g/mol). 
Cyclization in solution: 
The linear peptide H-Asn(Trt)-Val-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Leu-OH (80) is 
synthesized on 2-ClTrt resin (300 mg, 0.20 mmol) previously loaded with Fmoc- 
-Leu-OH (loading 0.67 mmol/g), cleaved with 1 % TFA in DCM (protocol 9), and 
purified by preparative HPLC. 
Yield (linear protected peptide (80)): 90 mg, 72 µmol, 36 %. 
HPLC (anal. method 1): tR=29.1 min, 80 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 998.56 [M+H]+, 1020.54 [M+Na]+, 1036.52 [M+K]+ 
Found: 998.66 [M+H]+, 1020.56 [M+Na]+, 1036.58 [M+K]+ 
The linear peptide (80) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (80) (90 mg, 72 µmol) in 10 ml DMSO. 
Second syringe: Solution of HATU (1.0 equiv, 72 µmol, 27mg) in 10 ml DMSO. 
Addition rate for both syringes: 0.02 ml/min. 
Flask: Solution of DIPEA (3.0 equiv, 216 µmol, 28 mg, 37 µl) and HOAt (0.1 equiv, 
7 µmol 10 mg) in 10 ml DMSO. 
After cyclization, the cyclic protected peptide (81) is precipitated with 200 ml H2O 
and filtered through a C18 plug. The peptide is washed with water (3x) and Et2O 
(3x) and eluted from the plug with DCM. 
Yield (cyclic protected peptide (81)): 75 mg, 61 µmol, 85 %. 
HPLC (anal. method 1): tR=34.5 min, 34.8 min, 80 area % sum of epimers. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 980.55 [M+H]+, 1002.53 [M+Na]+, 1018.51 [M+K]+ 
Found: 1002.30 [M+Na]+, 1018.59 [M+K]+ 
The cyclic protected peptide (81) is completely deprotected with reagent K during 5 
h (protocol 13) and finally purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (42)): 29 mg, 47 µmol, 77 %. 
HPLC (anal. method 2): tR=16.0 min, 16.6 min, 100 area %, epimers ratio 65:35. 
For the biological tests and the NMR analysis the epimers were separated by 
reverse phase preparative HPLC (preparative method 3). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 626.31 [M+H]+, 648.30 [M+Na]+, 664.27 [M+K]+ 
Found: 626.56 [M+H]+, 648.54 [M+Na]+, 664.52 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 0.79 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 0.85-
0.90 (m, 6H, 3Hδ (Leu), 3Hγ (Val)), 0.92 (d, 3J=6.9 Hz, 3H, Hγ (Val)), 1.49 (m, 1H, 
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Hβ (Leu)), 1.60-1.69 (m, 2H, Hβ (Leu), Hγ (Leu)), 1.71-1.86 (m, 2H, Hβ (Pro), Hγ 
(Pro)), 1.89-2.07 (m, 3H, Hβ (Pro), Hγ (Pro), Hβ (Val)), 2.30 (dd, 2J=16.0 Hz, 3J=2.8 
Hz, 1H, Hβ (Asx)), 2.45 (dd, 2J=15.4 Hz, 3J=8.8 Hz, 1H, Hβ (Asx)), 2.76 (dd, 
2J=15.4 Hz, 3J=5.3 Hz, 1H, Hβ (Asx)), 2.82 (dd, 2J=15.7 Hz, 3J=8.8 Hz, 1H, Hβ 
(Asx)), 3.48 (ddd, 2J=9.7 Hz, 3J=9.7 Hz, 3J=6.3 Hz, 1H, Hδ (Pro)), 3.53 (dd, 2J=11.3 
Hz, 3J=4.4 Hz, 1H, Hβ (Ser)), 3.61 (dd, 2J=11.3 Hz, 3J=4.4 Hz, 1H, Hβ (Ser)), 3.73 
(ddd, 2J=10.1 Hz, 3J=7.2 Hz, 3J=2.5 Hz, 1H, Hδ (Pro)), 3.77 (dd, 3J=7.5 Hz, 3J=5.7 
Hz, 1H, Hα (Val)), 4.04 (ddd, 3J=10.9 Hz, 3J=8.2 Hz, 3J=2.5 Hz, 1H, Hα (Leu)), 4.18 
(dd, 3J=8.5 Hz, 3J=7.2 Hz, 1H, Hα (Pro)), 4.45 (ddd, 3J=8.6 Hz, 3J=8.6 Hz, 3J=2.3 
Hz, 1H, Hα (Asx)), 4.52 (ddd, 3J=6.6 Hz, 3J=4.7 Hz, 3J=4.7 Hz, 1H, Hα (Ser)), 4.65 
(ddd, 3J=8.8 Hz, 3J=8.8 Hz, 3J=5.0 Hz, 1H, Hα (Asx)), 7.24 (s, 1H, HN (Asn)), 7.35 
(d, 3J=6.9 Hz, 1H, HN (Ser)), 7.65 (s, 1H, HN (Asn)), 8.10 (d, 3J=8.8 Hz, 1H, HN 
(Asx)), 8.43 (d, 3J=8.2 Hz, 1H, HN (Asx)), 8.74 (d, 3J=8.2 Hz, 1H, HN (Leu)), 9.07 
(d, 3J=5.7 Hz, 1H, HN (Val)), 12.32 (br, 1H, HCOO (Asp)). 
 
 
c-(-D-Val-Asp-Ser-Pro-Leu-Asn-) (43) 
 
C27H43N7O10 (625.69 g/mol). 
Cyclization on resin: 
The linear peptide H-Ser(t-Bu)-Pro-Leu-Asn(Trt)-D-Val-Asp(Wang)-ODmb (82) is 
synthesized on Wang resin (400 mg, 0.20 mmol) and cyclized following protocol 6 
(3.0 equiv HATU and 6.0 equiv DIPEA as the cleavage reagents). After complete 
deprotection and cleavage from the resin with the cleavage cocktail  
TFA/DCM/TIS = 48 : 48 : 4 during 2 h, (protocol 10) the cyclic peptide (43) is 
purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (43): 9 mg, 14 µmol, 7 %. 
HPLC (anal. method 2): tR=16.3 min, 100 area %. 
 
Cyclization in solution: 
The linear peptide H-Leu-Asn(Trt)-D-Val-Asp(Ot-Bu)-Ser(t-Bu)-Pro-OH (83) is 
synthesized on 2-ClTrt resin (260 mg 0.20 mmol) previously loaded with  
Fmoc-Pro-OH (loading 0.76 mmol/g), and cleaved with 1 % TFA in DCM (protocol 
9). 
Yield (linear protected peptide (83)): 133 mg, 99 µmol, 50 %. 
HPLC (anal. method 1): tR=31.5 min, 74 area %. 
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MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 998.56 [M+H]+, 1020.54 [M+Na]+, 1036.52 [M+K]+ 
Found: 998.74 [M+H]+, 1020.74 [M+Na]+, 1036.77 [M+K]+ 
The linear peptide (83) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (83) (133 mg, 99 µmol) in 15 ml DMF. 
Second syringe: Solution of HATU (2.0 equiv, 200 µmol, 76 mg) in 15 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (6.0 equiv, 600 µmol, 77 mg, 100 µl) and HOAt (3.0 
equiv, 200 µmol, 27 mg) in 20 ml DMF. 
The cyclic protected peptide (84) is purified by filtration through a C18 plug after 
removing the DMF. 
Yield (cyclic protected peptide (84)): 59 mg, 60 µmol, 61 %. 
HPLC (anal. method 1): tR=35.7 min, 77 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 980.55 [M+H]+, 1002.53 [M+Na]+, 1018.51 [M+K]+ 
Found: 1002.45 [M+Na]+, 1018.53 [M+K]+ 
The cyclic protected peptide is completely deprotected with reagent K during 5 h 
(protocol 13) and finally purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (43)): 32 mg, 51 µmol, 85 %. 
HPLC (anal. method 2): tR=16.3 min, 100 area %. No isomers detected. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 626.31 [M+H]+, 648.30 [M+Na]+, 664.27 [M+K]+ 
Found: 626.59 [M+H]+, 648.45 [M+Na]+, 664.48 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two sets of signals (ratio 6 : 1). 
0.78 (d, 3J=6.3 Hz, 3H, Hγ (D-Val)), 0.79 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 0.86 (d, 
3J=6.3 Hz, 3H, Hδ (Leu)), 0.91 (d, 3J=6.3 Hz, 3H, Hγ (D-Val)), 1.44-1.55 (m, 3H, 
2Hβ (Leu), Hγ (Leu)), 1.64 (m, 1H, Hβ (Pro)), 1.80-1.90 (m, 2H, Hγ (Pro), Hβ (D-Val)), 
1.94 (m, 1H, Hγ (Pro)), 2.18 (m, 1H, Hβ (Pro)), 2.23 (dd, 2J=15.1 Hz, 3J=3.8 Hz, 1H, 
Hβ (Asx)), 2.48 (br, 1H, Hβ (Asx)), 2.74 (dd, 2J=15.1 Hz, 3J=10.0 Hz, 1H, Hβ (Asx)), 
2.78 (dd, 2J=16.6 Hz, 3J=4.1 Hz, 1H, Hβ (Asx)), 3.55 (dd, 3J=9.7 Hz, 3J=5.3 Hz, 1H, 
Hα (D-Val)), 3.63-3.71 (br, 2H, Hδ (Pro)), 3.83 (dd, 2J=11.9 Hz, 3J=3.8 Hz, 1H, Hβ 
(Ser)), 3.93 (dd, 2J=11.6 Hz, 3J=6.6 Hz, 1H, Hβ (Ser)), 4.01 (dd, 3J=8.5 Hz, 3J=7.9 
Hz, 1H, Hα (Pro)), 4.08 (ddd, 3J=8.6 Hz, 3J=8.6 Hz, 3J=5.8 Hz, 1H, Hα (Leu)), 4.49 
(ddd, 3J=9.6 Hz, 3J=5.5 Hz, 3J=4.2 Hz, 1H, Hα (Asx)), 4.57 (ddd, 3J=10.2 Hz, 
3J=8.7 Hz, 3J=3.9 Hz, 1H, Hα (Asx)), 4.72 (ddd, 3J=9.6 Hz, 3J=6.1 Hz, 3J=3.6 Hz, 
1H, Hα (Ser)), 6.83 (s, 1H, HN (Asn)), 6.97 (d, 3J=5.7 Hz, 1H, HN (Asx)), 7.22 (s, 1H, 
HN (Asn)), 7.44 (d, 3J=8.8 Hz, 1H, HN (Leu)), 7.95 (d, 3J=9.4 Hz, 1H, HN (Ser)), 8.7 
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(d, 3J=8.2 Hz, 1H, HN (Asx)), 8.7 (d, 3J=5.7 Hz, 1H, HN (D-Val)), 12.30 (br, 1H, 
HCOO (Asp)). 
 
 
c-(-Val-Asp-Ser-β-hPro-Leu-Asn-) (44) 
 
C28H45N7O10 (639.72 g/mol). 
Cyclization on resin: 
The linear peptide H-Ser(t-Bu)-β-hPro-Leu-Asn(Trt)-Val-Asp(Wang)-ODmb (85) is 
synthesized and cyclized (protocol 6) on Wang resin. After complete deprotection 
and cleavage from the resin with different cleavage cocktails (Table 34, protocol 
10) the cyclic peptide (44) is purified by reverse phase preparative reverse phase 
HPLC: 
 
Table 34: On resin cyclization of H-Ser(t-Bu)-β-hPro-Leu-Asn(Trt)-Val-Asp(Wang)-ODmb 
 (85) 
 
Resin 
n/ 
mmol 
Coupling reagent 
t/ 
min 
Cleavage 
reagent 
t/ 
h 
Yield 
HPLC
/ 
% 
Wang 
280 mg 
0.20 
3.0 equiv HATU 
6.0 equiv DIPEA 
45 Reagent B 5 
8 mg 
6 µmol 
3 % 
50 
Wang 
400 mg 
0.20 
3.0 equiv HATU 
6.0 equiv DIPEA 
45 
TFA 48 
DCM 48 
TIS 4 
2 
10 mg 
16 µmol 
8 % 
100 
 
HPLC (anal. method 2): tR=17.0 min. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 640.33 [M+H]+, 662.31 [M+Na]+, 678.29 [M+K]+ 
Found: 640.42 [M+H]+, 662.55 [M+Na]+, 678.45 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): two sets of signals (ratio 8 : 1). 
0.79 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 0.86 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 0.88 (d, 3J=6.9 
Hz, 3H, Hγ (Val)), 0.90 (d, 3J=6.9 Hz, 3H, Hγ (Val)), 1.44 (ddd, 2J=13.5 Hz, 3J=11.9 
Hz, 3J=3.5 Hz, 1H, Hβ (Leu)), 1.53-1.62 (m, 2H, Hγ (Leu), Hγ (β-hPro)), 1.69-1.85 
(m, 3H, Hβ (Leu), 2Hδ (β-hPro)), 1.98-2.09 (m, 2H, Hγ (β-hPro), Hβ (Val)), 2.16 (dd, 
2J=14.4 Hz, 3J=1.9 Hz, 1H Hα (β-hPro)), 2.49 (br, 1H, Hα  (β-hPro)), 2.52 (dd, 
2J=16.3 Hz, 3J=10.0 Hz, 1H, Hβ (Asx)), 2.67 (dd, 2J=15.7 Hz, 3J=3.8 Hz, 1H, Hβ 
(Asx)), 2.69 (dd, 2J=15.1 Hz, 3J=5.7 Hz, 1H, Hβ (Asx)), 2.85 (dd, 2J=15.4 Hz, 
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3J=4.1 Hz, 1H, Hβ (Asx)), 3.42 (m, 1H, Hβ (Ser)), 3.47-3.54 (m, 2H, Hε  (β-hPro), Hβ 
(Ser)), 3.57 (m, 1H, Hε (β-hPro)), 3.61 (dd, 3J=4.1 Hz, 3J=4.7 Hz, 1H, Hα (Val)), 
4.10 (m, 1H, Hβ (β-hPro)), 4.24 (ddd, 3J=11.9 Hz, 3J=8.8 Hz, 3J=3.1 Hz, 1H, Hα 
(Leu)), 4.52-4.61 (m, 2H, Hα (Asx), Hα (Ser)), 4.73 (ddd, 3J=7.9 Hz, 3J=4.7 Hz, 
3J=4.7 Hz, 1H, Hα (Asx)), 4.87 (br, 1H, HO (Ser)), 7.11 (d, 3J=7.5 Hz, 1H, HN (Ser)), 
7.24 (s, 1H, HN (Asn)), 7.67 (s, 1H, HN (Asn)), 7.82 (d, 3J=8.8 Hz, 1H, HN (Leu)), 
8.16 (d, 3J=3.8 Hz, 1H, HN (Val)), 8.17 (d, 3J=10.1 Hz, 1H, HN (Asx)), 8.5 (d, 3J=8.2 
Hz, 1H, HN (Asx)), 12.33 (br, 1H, HCOO (Asp)). 
 
 
c-(-D-Val-Asp-Ser-β-hPro-Leu-Asn-) (45) 
 
C28H45N7O10 (639.72 g/mol). 
Cyclization on resin: 
The linear peptide H-Ser(t-Bu)-β-hPro-Leu-Asn(Trt)-D-Val-Asp(Wang)-ODmb (86) 
is synthesized and cyclized following protocol 6 (3.0 equiv HATU and 6.0 equiv 
DIPEA as the cleavage reagents) on Wang resin (330 mg, 0.20 mmol). After 
complete deprotection and cleavage from the resin with the cleavage cocktail 
TFA/DCM/TIS = 47 : 47 : 6 during 2 h, (protocol 10) the cyclic peptide (45) is 
purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (45)): 13 mg, 30 µmol, 15 %. 
HPLC (anal. method 2): tR=16.4 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 640.33 [M+H]+, 662.31 [M+Na]+, 678.29 [M+K]+ 
Found: 640.74 [M+H]+, 662.73 [M+Na]+, 678.69 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two sets of signals (ratio 6 : 1). 
0.77 (d, 3J=6.3 Hz, 3H, Hγ (D-Val)), 0.79 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 0.85 (d, 
3J=6.9 Hz, 3H, Hδ (Leu)), 0.92 (d, 3J=6.9 Hz, 3H, Hγ (D-Val)), 1.34 (ddd, 2J=13.7 
Hz, 3J=11.5 Hz, 3J=3.0 Hz, 1H Hβ (Leu)), 1.48-1.59 (m, 2H, Hγ (Leu), Hγ (β-hPro)), 
1.67 (ddd, 2J=13.7 Hz, 3J=10.2 Hz, 3J=3.3 Hz, 1H, Hβ (Leu)), 1.73-1.87 (m, 3H, 2Hδ 
(β-hPro), Hβ (D-Val)), 2.04 (dddd, 2J=12.1 Hz, 3J=6.1 Hz, 3J=6.1 Hz, 3J=6.1 Hz, 1H, 
Hγ (β-hPro)), 2.15 (d, 2J=14.5 Hz, 1H, Hα (β-hPro)), 2.25 (dd, 2J=15.1 Hz, 3J=7.5 
Hz, 1H, Hα (β-hPro)), 2.34-2.47 (m, 3H, Hβ (Asx)), 2.79 (dd, 2J=16.6 Hz, 3J=3.5 Hz, 
1H, Hβ (Asx)), 3.50 (dd, 3J=9.4 Hz, 3J=5.0 Hz, 1H, Hα (D-Val)), 3.55-3.62 (m, 2H, 
Hε (β-hPro), Hβ (Ser)), 3.70 (ddd, 2J=9.7 Hz, 3J=7.5 Hz, 3J=4.7 Hz, 1H, Hε (β-hPro)), 
3.83 (ddd, 2J=11.0 Hz, 3J=6.9 Hz, 3J=6.9 Hz, 1H, Hβ (Ser)), 4.06 (m, 1H, Hβ  
(β-hPro)), 4.25 (ddd, 3J=11.5 Hz, 3J=8.3 Hz, 3J=3.3 Hz, 1H, Hα (Leu)), 4.49 (ddd, 
3J=9.7 Hz, 3J=9.0 Hz, 3J=3.5 Hz, 1H, Hα (Asx)), 4.68 (ddd, 3J=9.1 Hz, 3J=7.2 Hz, 
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3J=7.2 Hz, 1H, Hα (Ser)), 4.74 (ddd, 3J=9.3 Hz, 3J=6.7 Hz, 3J=4.6 Hz, 1H, Hα 
(Asx)), 4.80 (dd, 3J=6.3 Hz, 3J=6.3 Hz, 1H, HO (Ser)), 6.84 (s, 1H, HN (Asn)), 7.23 
(s, 1H, HN (Asn)), 7.74 (d, 3J=6.3 Hz, 1H, HN (Asx)), 7.66 (d, 3J=8.2 Hz, 1H, HN 
(Leu)), 7.95 (d, 3J=8.8 Hz, 1H, HN (Ser)), 8.50 (d, 3J=5.0 Hz, 1H, HN (D-Val)), 8.60 
(d, 3J=8.8 Hz, 1H, HN (Asx)), 12.29 (br, 1H, HCOO (Asp)). 
 
 
c-(-Asp-Ser-Pro-Leu-Asn-) (46) 
 
C22H34N6O9 (526.55 g/mol). 
Cyclization on resin: 
The linear peptide H-Ser(t-Bu)-Pro-Leu-Asn(Trt)-Asp(Wang)-ODmb (87) is 
synthesized and cyclized following protocol 6 on Wang resin. After complete 
deprotection and cleavage from the resin (Table 35, protocol 10) cyclic peptide (46) 
is purified by reverse phase preparative HPLC. 
 
Table 35: On resin cyclization of H-Ser(t-Bu)-Pro-Leu-Asn(Trt)-Asp(Wang)-ODmb (87). 
 
Resin 
n/ 
mmol 
Coupling reagent 
t/ 
min 
Cleavage 
Reagent 
t/ 
h 
Yield 
HPLC/ 
% 
Wang 
135 mg 0.10 
1.1 equiv HATU 
3.0 equiv DIPEA 
45 
Reagent 
B 
5 
2 mg 
2 µmol 
2 % 
57a 
Wang 
130 mg 0.10 
3.0 equiv HATU 
6.0 equiv DIPEA 
2x45 
TFA 47 
DCM 47 
TIS 6 
2 
13mg 
22 µmol 
22 % 
90a 
a The same HPLC analytical method and the retention time as for the cyclization in 
solution. 
 
Cyclization in solution: 
The linear peptide H-Leu-Asn(Trt)-Asp(Ot-Bu)-Ser(t-Bu)-Pro-OH (88) is 
synthesized on 2-ClTrt resin (240 mg 0.20 mmol) previously loaded with Fmoc- 
-Pro-OH (loading 0.84 mmol/g), and cleaved with 1 % TFA in DCM (protocol 9). 
Yield (linear protected peptide (88)): 101 mg, 90 µmol, 45 %. 
HPLC (anal. method 1): tR=27.8 min, 80 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 899.49 [M+H]+, 921.47 [M+Na]+, 937.45 [M+K]+ 
Found: 921.51 [M+Na]+, 937.53 [M+K]+ 
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The linear peptide (88) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (88) (101 mg, 90 µmol) in 11 ml DMF. 
Second syringe: Solution of HATU (1.5 equiv, 135 µmol, 51 mg) in 11 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (3.0 equiv, 270 µmol, 35 mg, 46 µl) and HOAt (1.0 equiv, 
90 µmol, 12 mg) in 20 ml DMF. 
After evaporation of DMF the cyclic protected peptide (89) is purified by reverse 
phase preparative HPLC. 
Yield (cyclic protected peptide (89)): 90 mg, 60 µmol, 68 %. 
HPLC (anal. method 1): tR=31.3 min, 60 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 881.48 [M+H]+, 903.46 [M+Na]+, 919.44 [M+K]+ 
Found: 903.52 [M+Na]+, 919.55 [M+K]+ 
The cyclic protected peptide (89) is completely deprotected with reagent K during 5 
h (protocol 13) and finally purified by preparative HPLC. 
Yield (cyclic deprotected peptide (46)): 79 mg, 60 µmol, 100 %. 
HPLC (anal. method 2): tR=15.0 min, 40 area %. No isomers detected. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 527.25 [M+H]+, 549.23 [M+Na]+, 565.20 [M+K]+ 
Found: 549.49 [M+Na]+, 565.47 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 0.82 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 0.85 (d, 
3J=6.3 Hz, 3H, Hδ (Leu)), 1.28-1.43 (m, 3H, 2Hβ (Leu), Hγ (Leu)), 1.66 (m, 1H, Hγ 
(Pro)), 1.81-1.93 (m, 2H, Hβ (Pro), Hγ (Pro)), 2.10 (dd, 2J=15.7 Hz, 3J=4.4 Hz, 1H, 
Hβ (Asx)), 2.19 (m, 1H, Hβ (Pro)), 2.35 (m, 1H, Hβ (Asx)), 2.38 (dd, 2J=12.2 Hz, 
3J=9.7 Hz, 1H, Hβ (Asx)), 2.58 (dd, 2J=15.4 Hz, 3J=9.1 Hz, 1H, Hβ (Asx)), 3.40-3.50 
(m, 3H, Hδ (Pro), 2Hβ (Ser)), 3.55 (ddd, 2J=11.2 Hz, 3J=8.0 Hz, 3J=3.3 Hz, 1H, Hδ 
(Pro)), 4.12 (ddd, 3J=9.7 Hz, 3J=9.7 Hz, 3J=3.5 Hz, 1H, Hα (Asx)), 4.34 (ddd, 3J=9.1 
Hz, 3J=9.1 Hz, 3J=6.3 Hz, 1H, Hα (Leu)), 4.47 (ddd, 3J=8.6 Hz, 3J=4.9 Hz, 3J=3.9 
Hz, 1H, Hα (Ser)), 4.51 (dd, 3J=8.8 Hz, 3J=2.5 Hz, 1H, Hα (Pro)), 4.83 (ddd, 3J=9.1 
Hz, 3J=9.1 Hz, 3J=4.1Hz, 1H, Hα (Asx)), 4.95 (dd, 3J=6.3 Hz, 3J=5.0 Hz, 1H, HO 
(Ser)), 6.72 (s, 1H, HN (Asn)), 7.01 (d, 3J=8.8 Hz, 1H, HN (Ser)), 7.24 (s, 1H, HN 
(Asn)), 7.39 (d, 3J=9.4 Hz, 1H, HN (Leu)), 7.75 (d, 3J=10.0 Hz, 1H, HN (Asx)), 8.35 
(d, 3J=8.8 Hz, 1H, HN (Asx)), 12.5 (br, 1H, HCOO (Asp)). 
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c-(-Asp-Ser-Pro-Leu-β-hAsn-) (47) 
 
C23H36N6O9 (540.58 g/mol). 
Cyclization in solution: 
The linear peptide H-β-hAsn(Trt)-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Leu-OH (90) is 
synthesized on 280 mg (0.20 mmol) Fmoc-Leu-Sasrin (loading 0.72 mmol/g) and 
cleaved with 1 % TFA in DCM (protocol 9). 
Yield (linear protected peptide (90)): 167 mg, 0.15 mmol, 75 %. 
HPLC (anal. method 2): tR=29.5 min, 82 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 913.51 [M+H]+, 935.49 [M+Na]+, 951.46 [M+K]+ 
Found: 913.33 [M+H]+, 935.45 [M+Na]+, 951.39 [M+K]+ 
The linear peptide (90) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (90) (180 mg, 0.14 mmol) in 9 ml DMF. 
Second syringe: Solution of HATU (1.5 equiv, 0.22 mmol, 84mg) in 9 ml DMF. 
Addition rate for both syringes: 0.02 ml/min. 
Flask: Solution of DIPEA (6.0 equiv, 0.90 mmol, 116 mg, 154 µl) and HATU (0.1 
equiv, 15 µmol, 6 mg) in 20 ml DMF. 
After evaporation of DMF the cyclic protected peptide (91) is purified by reverse 
phase preparative HPLC. 
Yield (cyclic protected peptide (91)): 94 mg, 0.11 mmol, 70. %. 
HPLC (anal. method 1): tR=31.8 min, 100 area % sum of epimers. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 895.50 [M+H]+, 917.48 [M+Na]+, 933.45 [M+K]+ 
Found: 917.57 [M+Na]+, 933.74 [M+K]+ 
The cyclic protected peptide (91) is completely deprotected with a cleavage 
cocktail TFA/H2O/TIS = 95 : 2.5 : 2.5 during 2 h (protocol 13) and finally purified by 
reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (47)): 25 mg, 46 µmol, 44 %. 
HPLC (anal. method 2): tR=13.0 min, 13.6 min, 100 area %, epimers ratio 40:60. 
For the biological tests and the NMR analysis the epimers were separated by 
reverse phase preparative HPLC (preparative method 3). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 541.26 [M+H]+, 563.24 [M+Na]+, 579.22 [M+K]+ 
Found: 541.27 [M+H]+, 563.28 [M+Na]+, 579.47 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 0.82 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 0.89 (d, 
3J=6.3 Hz, 3H, Hδ (Leu)), 1.37-1.63 (m, 4H, Hβ (Leu), Hγ (Leu), 2Hγ (Pro)), 1.86-1.98 
(m, 2H, Hβ (Leu), Hβ (Pro)), 2.15 (dd, 2J=13.2 Hz, 3J=3.1 Hz, 1H, Hγ  (β-hAsn)), 2.19 
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(m, 1H, Hβ (Pro)), 2.28 (dd, 2J=14.4 Hz, 3J=6.9 Hz, 1H, Hα (β-hAsn)), 2.35 (dd, 
2J=14.4 Hz, 3J=5.7 Hz, 1H, Hα (β-hAsn)), 2.42-2.46 (m, 2H, Hβ (Asp)), 2.59 (dd, 
2J=13.2 Hz, 3J=11.9 Hz 1H, Hγ (β-hAsn)), 3.31 (ddd, 2J=11.8 Hz, 3J=8.9 Hz, 3J=2.4 
Hz, 1H, Hδ (Pro)), 3.34-3.51 (m, 2H, Hδ (Pro), Hβ (Ser)), 3.62 (dd, 2J=10.1 Hz, 
3J=5.7 Hz, 1H, Hβ (Ser)), 4.09-4.19 (m, 2H, Hβ (β-hAsn), Hα (Ser)), 4.32 (ddd, 
3J=9.6 Hz, 3J=9.6 Hz, 3J=4.9 Hz, 1H, Hα (Leu)), 4.55 (ddd, 3J=8.9 Hz, 3J=7.7 Hz, 
3J=6.8 Hz, 1H, Hα (Asp)), 4.64 (dd, 3J=8.2 Hz, 3J=1.0 Hz, 1H, Hα (Pro)), 6.82 (s, 
1H, HN (β-hAsn)), 7.31 (s, 1H, HN (β-hAsn)), 7.52 (d, 3J=7.5 Hz, 1H, HN (β-hAsn)), 
7.96 (d, 3J=8.8 Hz, 1H, HN (Asp)), 8.04-8.09 (m, 2H, HN (Leu), HN (Ser)) 
 
 
c-(-β-hAsp-Pro-Leu-Asn-) (48) 
 
C20H31N5O7 (453.50 g/mol). 
Cyclization in solution: 
The linear peptide H-Asn(Trt)-β-hAsp(Ot-Bu)-Pro-Leu-OH (92) is synthesized on  
2-ClTrt resin (280 mg, 0.20 mmol) previously loaded with Fmoc-Leu-OH (loading 
0.72 mmol/g), and cleaved with 1 % TFA in DCM (protocol 9). 
Yield (linear protected peptide (92)): 129 mg, 0.14 mmol, 68 %. 
HPLC (anal. method 1): tR=26.5 min, 80 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 770.41 [M+H]+, 792.39 [M+Na]+, 808.37 [M+K]+ 
Found: 770.82 [M+Na]+, 792.81 [M+K]+ 
The linear peptide (92) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (92) (129 mg, 0.14 mmol) in 10 ml DMF. 
Second syringe: Solution of HATU (3.9 equiv, 0.53 mmol, 200 mg) in 10 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (8.5 equiv, 1.2 mmol, 151 mg, 200 µl) in 10 ml DMF. 
After evaporation of DMF cyclic protected peptide (93) is purified by reverse phase 
preparative HPLC. 
Yield (cyclic protected peptide (93)): 51 mg, 48 µmol, 35 %. 
HPLC (anal. method 1): tR=30.5 min, 70 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 752.40 [M+H]+, 774.38 [M+Na]+, 790.36 [M+K]+ 
Found: 774.38 [M+Na]+, 790.48 [M+K]+ 
The cyclic protected peptide (93) is completely deprotected with reagent K during 5 
h (protocol 13) and finally purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (48)): 16 mg, 28 µmol, 58 %. 
HPLC (anal. method 2): tR=16.5 min, 82 area %. No isomers detected. 
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MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 454.23 [M+H]+, 476.21 [M+Na]+, 492.19 [M+K]+ 
Found: 454.62 [M+H]+, 476.61 [M+Na]+, 492.57 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 0.85 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 0.88 (d, 
3J=6.9 Hz, 3H, Hδ (Leu)), 1.36-1.45 (m, 2H, Hβ (Leu), Hγ (Leu)), 1.49 (ddd, 2J=13.7 
Hz, 3J=6.4 Hz, 3J=6.4 Hz, 1H, Hβ (Leu)), 1.69 (dddd, 2J=12.7 Hz, 3J=6.3 Hz, 3J=6.3 
Hz, 3J=6.3 Hz, 1H, Hβ (Pro)), 1.85-1.92 (m, 2H, Hγ (Pro)), 2.17 (dddd, 2J=12.6 Hz, 
3J=8.8 Hz, 3J=7.1 Hz, 3J=7.1 Hz, 1H, Hβ (Pro)), 2.26 (dd, 2J=14.4 Hz, 3J=8.8 Hz, 
1H, Hβ (Asn)), 2.45 (dd, 2J=10.1 Hz, 3J=6.3 Hz, 1H, Hα(γ) (β-hAsp)), 2.47-2.52 (m, 
2H, Hβ (Asn), Hα(γ) (β-hAsp)), 2.56 (dd, 2J=16.0 Hz, 3J=3.5 Hz, 1H, Hα(γ) (β-hAsp)), 
2.81 (dd, 2J=15.7 Hz, 3J=12.6 Hz, 1H, Hα(γ) (β-hAsp)), 3.47 (ddd, 2J=9.4 Hz, 3J=6.9 
Hz, 3J=6.9 Hz, 1H, Hδ (Pro)), 3.77 (ddd, 2J=9.7 Hz, 3J=6.6 Hz, 3J=6.6 Hz, 1H, Hδ 
(Pro)), 4.09 (dd, 3J=8.8 Hz, 3J=5.8 Hz 1H, Hα (Pro)), 4.14 (m, 1H, Hβ (β-hAsp)), 
4.36 (ddd, 3J=10.1 Hz, 3J=9.7 Hz, 3J=6.9 Hz, 1H, Hα (Leu)), 4.44 (ddd, 3J=9.1 Hz, 
3J=9.1 Hz, 3J=5.7 Hz, 1H, Hα (Asn)), 6.95 (s, 1H, HN (Asn)), 7.11 (d, 3J=10.2 Hz, 
1H, HN (Leu)), 7.14 (d, 3J=6.9 Hz, 1H, HN (β-hAsp)), 7.49 (s, 1H, HN (Asn)), 7.66 (d, 
3J=10.1 Hz, 1H, HN (Asn)), 12.31 (br, 1H, Hcoo (β-hAsp)). 
 
 
c-(-Thr-Gln-Ile-Asp-Ser-Pro-) (49) 
 
C27H43N7O11 (641.69 g/mol). 
Cyclization on resin: 
The linear peptide H-Ser(t-Bu)-Pro-Thr(t-Bu)-Gln(Trt)-Ile-Asp(Wang)-ODmb (94) is 
synthesized and cyclized following protocol 6, using different coupling reagents 
(Table 36), on Wang resin. After complete deprotection and cleavage from the 
resin with different cleavage cocktails (Table 36) the cyclic peptide (49) is purified 
by reverse phase preparative HPLC. 
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Table 36: On resin cyclization of H-Ser(t-Bu)-Pro-Thr(t-Bu)-Gln(Trt)-Ile-Asp(Wang)-ODmb 
(94) 
 
Resin 
n/ 
mmol 
Coupling reagent 
t/ 
min 
Cleavage 
Reagent 
t/ 
h 
Yield 
HPLC
/% 
Wang 
300 mg 
0.20 
3.0 equiv HATU 
6.0 equiv DIPEA 
45 Reagent K 5 0 0 
Wang 
130 mg 0.10 
2.0 equiv PyBOP 
6.0 equiv DIPEA 
60 Reagent K 2 0 0 
Wang 
130 mg 0.1 
1.1 equiv PyAOP 
3.0 equiv DIPEA 
2x30 
TFA 95 % 
H2O 2.5 % 
TIS 2.5 % 
2 0 0 
Wang 
500 mg 
0.2 
3.0 equiv HATU 
6.0 equiv DIPEA 
45 
TFA 95 % 
H2O 2.5 % 
TIS 2.5 % 
2 
12 mg 
15 µmol 
8 % 
80a 
a The same HPLC analytical method and the retention time as for the cyclization in 
solution. 
 
Cyclization in solution: 
The linear peptide H-lle-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Thr(t-Bu)-Gln(Trt)-OH (95) is 
synthesized on 2-ClTrt resin (300 mg, 0.20 mmol) previously loaded with  
Fmoc-Gln(Trt)-OH (loading 0.67 mmol/g), and cleaved with 1 % TFA in DCM 
(protocol 9). 
Yield (linear protected peptide (95)): 209 mg, 0.12 mmol, 58 %. 
HPLC (anal. method 1): tR=29.5 min, 60 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1070.62 [M+H]+, 1092.60 [M+Na]+, 1108.57 [M+K]+ 
Found: 1092.82 [M+Na]+, 1108.76 [M+K]+ 
The linear peptide (95) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (95) (209 mg, 0.12 mmol) in 10 ml DMF. 
Second syringe: Solution of HATU (4.5 equiv, 0.53 mmol, 200 mg) in 10 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (10.0 equiv, 1.17 mmol, 151 mg, 200 µl) in 20 ml DMF. 
After cyclization, DMF is evaporated and the protected cyclic peptide (96) is 
purified by filtration through a C18 plug. 
6. Experimental part 145 
Yield (cyclic protected peptide (96)): 37 mg, 35 µmol, 30 %. 
HPLC (anal. method 1): tR=35.5 min, 35.9 min, 100 area % sum of epimers. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1052.61 [M+H]+, 1074.59 [M+Na]+, 1090.56 [M+K]+ 
Found: 1074.56 [M+Na]+, 1090.81 [M+K]+ 
A similar procedure is used for the synthesis of the same cyclic peptide (96) from 
different linear precursors (97)-(99). Results are shown in Table 15, P. 68. 
The cyclic protected peptide (96) is complete deprotected with reagent K during 2 h 
(protocol 13) and finally purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (49)): 11 mg, 17 µmol, 49 %. 
HPLC (anal. method 2): tR=12.0 min, 13.3 min, 100 area %, epimers ratio 37:63. 
For the biological tests and the NMR analysis the epimers were separated by 
reverse phase preparative HPLC (preparative method 3). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 642.31 [M+H]+, 664.29 [M+Na]+, 680.27 [M+K]+ 
Found: 642.57 [M+H]+, 664.68 [M+Na]+, 680.58 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two sets of signals (ratio 2 : 1). 
Major conformer 0.79 (d, 3J=6.9 Hz, 3H, Hγ (Ile)), 0.80 (dd, 3J=7.5 Hz, 3J=7.5 Hz, 
3H, Hδ (Ile)), 1.06 (m, 1H, Hγ (Ile)), 1.15 (d, 3J=5.7 Hz, 3H, Hγ (Thr)), 1.32 (m, 1H, 
Hγ (Ile)), 1.54 (m, 1H, Hγ (Pro)), 1.70-1.83 (m, 2H, Hβ (Ile), Hβ (Pro)), 1.83-1.91 (m, 
2H, Hγ (Pro), Hβ (Gln)), 2.06-2.12 (m, 2H, Hβ (Gln), Hγ (Gln)), 2.17 (m, 1H, Hγ (Gln)), 
2.25 (m, 1H, Hβ (Pro)), 2.36 (dd, 2J=16.0 Hz, 3J=7.9 Hz, 1H, Hβ (Asp)), 2.54 (dd, 
2J=15.9 Hz, 3J=5.7 Hz, 1H, Hβ (Asp)), 3.40 (br, 1H, Hδ (Pro)), 3.45 (ddd, 2J=11.3 
Hz, 3J=11.3 Hz, 3J=6.6 Hz, 1H, Hδ (Pro)), 3.54 (m, 1H, Hβ (Ser)), 3.66 (dd, 2J=10.1 
Hz, 3J=5.7 Hz, 1H, Hβ (Ser)), 3.81 (dd, 3J=7.5 Hz, 3J=4.4 Hz, 1H, Hα (Ile)), 4.16 
(dd, 3J=10.1 Hz, 3J=2.5 Hz, 1H, Hα (Pro)), 4.28-4.38 (m, 2H, Hα (Gln), Hα (Ser)), 
4.48-4.58 (m, 3H, Hα (Asp), Hα (Thr), Hβ (Thr)), 5.04 (br, 1H, HO), 5.38 (br, 1H, HO), 
6.77 (d, 3J=6.3 Hz, 1H, HN (Asp)), 6.87 (s, 1H, HN (Gln)), 7.25 (m, 1H, HN (Ser)), 
7.37 (s, 1H, HN (Gln)), 8.47 (d, 3J=4.4 Hz, 1H, HN (Ile)), 8.74 (d, 3J=10.1 Hz, 1H, HN 
(Thr)), 8.84 (br, 1H, HN (Gln)), 12.32 (br, 1H, HCOO (Asp)). 
 
Minor conformer 0.83 (d, 3J=6.9 Hz, 3H, Hγ (Ile)), 0.85 (dd, 3J=7.5 Hz, 3J=7.5 Hz, 
3H, Hδ (Ile)), 0.97 (d, 3J=6.3 Hz, 3H, Hγ (Thr)), 1.06 (m, 1H, Hγ (Ile)), 1.32 (m, 1H, 
Hγ (Ile)), 1.76 (m, 1H, Hβ (Ile)), 1.82-1.91 (m, 3H, 2Hβ (Gln), Hγ (Pro)), 1.90-2.03 (m, 
3H, 2Hβ (Pro), Hγ (Pro)), 2.22-2.31 (m, 2H, Hγ (Gln)), 2.65 (dd, 2J=16.3 Hz, 3J=8.2 
Hz, 1H, Hβ (Asp)), 2.92 (dd, 2J=16.3 Hz, 3J=5.0 Hz, 1H, Hβ (Asp)), 3.54 (m, 1H, Hβ 
(Ser)), 3.61 (ddd, 2J=10.7 Hz, 3J=9.7 Hz, 3J=3.1 Hz, 1H, Hδ (Pro)), 3.77-3.84 (m, 
2H, Hα (Gln), Hδ (Pro)), 3.97 (dd, 3J=8.8 Hz, 3J=8.2 Hz, 1H, Hα (Ile)), 3.91 (m, 1H, 
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Hβ (Ser)), 4.18-4.25 (m, 2H, Hα (Thr), Hβ (Thr)), 4.33 (m, 1H, Hα (Asp)), 4.69-4.76 
(m, 2H, Hα (Pro), Hα (Ser)), 4.93 (br, 1H, HO), 5.38 (br, 1H, HO), 6.88 (s, 1H, HN 
(Gln)), 7.21-7.30 (m, 2H, HN (Gln), HN (Ile)), 7.49 (d, 3J=8.8 Hz, 1H, HN (Thr)), 7.77 
(d, 3J=6.9 Hz, 1H, HN (Ser)), 8.19 (d, 3J=5.0 Hz, 1H, HN (Gln)), 8.59 (br, 1H, HN 
(Asp)), 12.32 (br, 1H, HCOO (Asp)). 
 
 
c-(-Thr-Gln-Ile-Asp-Ser-β-hPro-) (50) 
 
C28H45N7O11 (655.71 g/mol). 
Cyclization on resin:  
The linear peptide H-Ser(t-Bu)-β-hPro-Thr(t-Bu)-Gln(Trt)-Ile-Asp(Wang)-ODmb 
(100) is synthesized and cyclized (3 equiv HATU and 6 equiv DIPEA as coupling 
reagents), on Wang resin (400 mg, 0.20 mmol) following protocol 6. After cleavage 
from the resin and deprotection (protocol 10), the cyclic peptide (50) is purified by 
reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (50)): 6 mg, 8 µmol, 4 %. 
HPLC (anal. method 2): tR=13.4 min, 90 area %. 
 
Cyclization in solution: 
The linear peptide H-lle-Asp(Ot-Bu)-Ser(t-Bu)-β-hPro-Thr(t-Bu)-Gln(Trt)-OH (101) is 
synthesized on 2-ClTrt resin (300 mg, 0.20 mmol) previously loaded with  
Fmoc-Gln(Trt)-OH (loading 0.67 mmol/g), and cleaved with 1 % TFA in DCM 
(protocol 9). 
Yield (linear protected peptide (101)): 190 mg, 0.15 mmol, 74 %. 
HPLC (anal. method 1): tR=29.2 min, 84 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1084.63 [M+H]+, 1106.62 [M+Na]+, 1122.59 [M+K]+ 
Found: 1084.82 [M+H]+, 1106.83 [M+Na]+, 1122.69 [M+K]+ 
The linear peptide (101) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (101) (190 mg, 0.15 mmol) in 15 ml DMF. 
Second syringe: Solution of HATU (1.8 equiv, 0.26 mmol, 100 mg) in 15 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (6.0 equiv, 0.88 mmol, 113 mg, 150 µl) and HOAt (1.0 
equiv, 0.15 mmol, 20 mg) in 20 ml DMF. 
After evaporation of DMF the cyclic protected peptide (102) is purified by reverse 
phase preparative HPLC. 
Yield (cyclic protected peptide (102)): 114 mg, 0.11 mmol, 73 %. 
HPLC (anal. method 1): tR=35.8 min, 36.4 min, 100 area % sum of epimers. 
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MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1066.62 [M+H]+, 1088.60 [M+Na]+, 1104.58 [M+K]+ 
Found: 1088.52 [M+Na]+, 1104.88 [M+K]+ 
The cyclic protected peptide (102) is completely deprotected with reagent K during 
5 h (protocol 13) and finally purified by preparative HPLC. 
Yield (cyclic deprotected peptide (50)): 36 mg, 55 µmol, 51 %. 
HPLC (anal. method 2): tR=12.4 min, 13.7 min, 100 area %, epimers ratio 43:57. 
For the biological tests and the NMR analysis the epimers were separated by 
reverse phase preparative HPLC (preparative method 3). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 656.32 [M+H]+, 678.31 [M+Na]+, 694.28 [M+K]+ 
Found: 656.37 [M+H]+, 678.38 [M+Na]+, 694.29 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two sets of signals (ratio 2 : 1). 
Major conformer 0.80 (dd, 3J=7.2 Hz, 3J=7.2 Hz, 3H, Hγ (Ile)), 0.82 (d, 3J=6.3 Hz, 
3H, Hδ (Ile)), 0.99 (d, 3J=6.3 Hz, 3H, Hγ (Thr)), 1.18 (m, 1H, Hγ (Ile)), 1.30 (m, 1H, 
Hγ (Ile)), 1.67-2.15 (m, 8H, 2Hβ (Gln), Hγ (Gln), Hβ (Ile), 2Hγ (β-hPro), 2Hδ (β-hPro)), 
2.43-2.53 (br, 2H, Hγ (Gln), Hα (β-hPro)), 2.61 (dd, 2J=17.3 Hz, 3J=9.1 Hz, 1H, Hβ 
(Asp)), 2.73 (dd, 2J=17.3 Hz, 3J=3.5 Hz, 1H, Hβ (Asp)), 2.93 (m, 1H, Hα (β-hPro)), 
3.26 (ddd, 2J=11.3 Hz, 3J=8.2 Hz, 3J=3.5 Hz, 1H, Hε (β-hPro)), 3.20-3.45 (br, 2H, 
Hε (β-hPro), Hβ (Ser)), 3.56 (dd, 2J=10.1 Hz, 3J=8.1 Hz, 1H, Hβ (Ser)), 3.85 (m, 1H, 
Hβ (Thr)), 4.08 (dd, 3J=8.8 Hz, 3J=4.4 Hz, 1H, Hα (Ile)), 4.26 (ddd, 3J=6.8 Hz, 
3J=6.8 Hz, 3J=6.8 Hz, 1H, Hα (Gln)), 4.31 (dd, 3J=7.9 Hz, 3J=4.7 Hz, 1H, Hα (Thr)), 
4.39 (m, 1H, Hβ (β-hPro)), 4.55 (ddd, 3J=7.9 Hz, 3J=7.2 Hz, 3J=6.6 Hz, 1H, Hα 
(Ser)), 4.74 (ddd, 3J=9.3 Hz, 3J=9.3 Hz, 3J=3.3 Hz, 1H, Hα (Asp)), 6.74 (s, 1H, HN 
(Gln)), 7.28 (s, 1H, HN (Gln)), 7.42 (d, 3J=8.2 Hz, 1H, HN (Thr)), 7.50 (d, 3J=9.4 Hz, 
1H, HN (Asp)), 8.1 (d, 3J=8.8 Hz, 1H, HN (Ile)), 8.35 (d, 3J=6.9 Hz, 1H, HN (Ser)), 
8.46 (d, 3J=6.9 Hz, 1H, HN (Gln)), 12.30 (br, 1H, HCOO (Asp)). 
 
Minor conformer 0.78 (dd, 3J=6.9 Hz, 3J=6.9 Hz, 3H, Hγ (Ile)), 0.82 (d, 3J=6.3 Hz, 
3H, Hδ (Ile)), 1.02 (d, 3J=6.3 Hz, 3H, Hγ (Thr)), 1.05 (m, 1H, Hγ (Ile)), 1.39 (m, 1H, 
Hγ (Ile)), 1.67-2.15 (m, 8H, 2Hβ (Gln), Hγ (Gln), Hβ (Ile), 2Hγ (β-hPro), 2Hδ (β-hPro)), 
2.25 (dd, 2J=14.1 Hz, 3J=1.0 Hz, 1H, Hα (β-hPro)), 2.43-2.53 (br, 3H, Hβ (Asp), Hγ 
(Gln), Hα (β-hPro)), 2.93 (dd, 2J=16.3 Hz, 3J=5.7 Hz, 1H, Hβ (Asp)), 3.20-3.45 (br, 
3H, 2Hε (β-hPro), Hβ (Ser)), 3.49 (m, 1H, Hβ (Ser)), 3.90 (dd, 3J=9.7 Hz, 3J=8.5 Hz, 
1H, Hα (Ile)), 3.95 (m, 1H, Hβ (Thr)), 4.08 (m, 1H, Hα (Asp)), 4.15 (dd, 3J=7.5 Hz, 
3J=3.8 Hz, 1H, Hα (Thr)), 4.39 (m, 1H, Hβ (β-hPro)), 4.44 (ddd, 3J= 8.6 Hz, 3J=4.6 
Hz, 3J=4.6 Hz, 1H, Hα (Gln)), 4.61 (ddd, 3J= 8.5 Hz, 3J=6.3 Hz, 3J=6.3 Hz, 1H, Hα 
(Ser)), 6.71 (s, 1H, HN (Gln)), 6.73 (d, 3J=8.8 Hz, 1H, HN (Ser)), 7.14 (s, 1H, HN 
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(Gln)), 7.29 (d, 3J=7.5 Hz, 1H, HN (Thr)), 7.98 (d, 3J=8.8 Hz, 1H, HN (Gln)), 8.12 (d, 
3J=8.2 Hz, 1H, HN (Ile)), 8.80 (d, 3J=7.5 Hz, 1H, HN (Asp)), 12.30 (br, 1H, HCOO 
(Asp)). 
 
 
c-(-Thr-β-hGln-Ile-Asp-β-hSer-Pro-) (51) 
 
C29H47N7O11 (669.74 g/mol). 
Cyclization on resin: 
The linear peptide H-β-hSer(t-Bu)-Pro-Thr(t-Bu)- β-hGln-Ile-Asp(Wang)-ODmb 
(103) is synthesized and cyclized following protocol 6 (3.0 equiv HATU and 6.0 
equiv DIPEA as coupling reagents), on Wang resin (200 mg, 92 µmol). After 
complete deprotection and cleavage from the resin with the cleavage cocktail  
TFA/DCM/TIS = 47 : 47: 6 during 2 h (protocol 10) the cyclic peptide (51) is purified 
by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (51)): 3 mg, 5 µmol, 5 %. 
HPLC (anal. method 2): tR=15.3 min, 100 area %. 
 
Cyclization in solution: 
a) The linear peptide H-β-hGln-Ile-Asp(Ot-Bu)-β-hSer(t-Bu)-Pro-Thr(t-Bu)-OH (104) 
is synthesized on 2-ClTrt resin (125 mg, 0.10 mmol) previously loaded with  
Fmoc-Thr(t-Bu)-OH (loading 0.80 mmol/g), and cleaved with 1 % TFA in DCM 
(protocol 9). The linear protected peptide (104) is not purified.  
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 856.54 [M+H]+, 878.52 [M+Na]+, 894.50 [M+K]+ 
Found: 856.74 [M+H]+, 878.55 [M+Na]+, 894.62 [M+K]+ 
The linear peptide (104), is cyclized following protocol 7, method B:  
First syringe: Solution of linear peptide (104) in 7 ml DMF. 
Second syringe: Solution of HATU (110 µmol, 42 mg) in 7 ml DMF. 
Addition rate for both syringes: 0.005 ml/min. 
Flask: Solution of DIPEA (300 µmol, 39 mg, 51 µl) and HATU (50 µmol, 19 mg) in 
10 ml DMF.  
After evaporation of the solvent the cyclic protected peptide (105) is purified by 
reverse phase preparative HPLC. 
Yield (cyclic protected peptide (105)): 15 mg, 18 µmol, 18 % (Calculated on resin 
loading). 
HPLC (anal. method 1): tR=23.7 min, 100 area % sum of epimers. 
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MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 838.53 [M+H]+, 860.51 [M+Na]+, 876.48 [M+K]+ 
Found: 860.83 [M+Na]+, 876.83 [M+K]+ 
The cyclic protected peptide (105) is completely deprotected with the cleavage 
mixture TFA/H2O/TIS = 95 : 2.5 : 2.5 during 2 h (protocol 13) and finally purified by 
reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (51)): 4 mg, 5.5 µmol, 31 %. 
HPLC (anal. method 2): tR=13.6 min, 14.1 min, 92 area %, epimers ratio 1:1. 
 
b) The linear peptide H-Thr(t-Bu)-β-hGln-Ile-Asp(Ot-Bu)-β-hSer(t-Bu)-Pro-OH (106) 
is synthesized on 2-ClTrt resin (265 mg, 0.20 mmol) previously loaded with  
Fmoc-Pro-OH (loading 0.76 mmol/g), and cleaved with 1 % TFA in DCM (protocol 
9). The linear protected peptide (106) is purified by filtration through a C18 plug.  
Yield (linear protected peptide (106): 180 mg, 174 µmol, 87 %. 
HPLC (anal. method 1): tR=22.6 min, 83 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 856.54 [M+H]+, 878.52 [M+Na]+, 894.50 [M+K]+ 
Found: 856.78 [M+H]+, 878.59 [M+Na]+, 894.60 [M+K]+ 
The linear peptide (106), is cyclized following protocol 7, method B:  
First syringe: Solution of linear peptide (106) (180 mg, 174 µmol) in 20 ml DMF. 
Second syringe: Solution of HATU (2.3 equiv, 0.4 mmol, 152 mg) in 20 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (4.5 equiv, 0.8 mmol, 103 mg, 136 µl) and HOAt (2.3 
equiv, 0.4 mmol, 54 mg) in 20 ml DMF.  
After evaporation of the solvent the cyclic protected peptide (105) is purified by 
filtration through C18 plug. 
Yield (cyclic protected peptide (105)): 92 mg, 66 µmol, 38 %. 
HPLC (anal. method 1): tR=23.7 min, 60 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 838.53 [M+H]+, 860.51 [M+Na]+, 876.48 [M+K]+ 
Found: 860.81 [M+Na]+, 876.83 [M+K]+ 
The cyclic protected peptide (105) is completely deprotected with reagent K during  
5 h, (protocol 13) and finally purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (51)): 14 mg, 21 µmol, 32 %. 
HPLC (anal. method 2): tR=15.3 min, 100 area %. No isomers detected. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 670.34 [M+H]+, 692.32 [M+Na]+, 708.30 [M+K]+ 
Found: 670.43 [M+H]+, 692.45 [M+Na]+, 708.39 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): two sets of signals (ratio 3 :1). 
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Major conformer 0.84 (dd, 3J=6.9 Hz, 3J=6.9 Hz, 3H, Hδ (Ile)), 0.86 (d, 3J=6.3 Hz, 
3H, Hγ (Ile)), 1.00 (d, 3J=6.3 Hz, 3H, Hγ (Thr)), 1.22 (ddq, 2J=13.0 Hz, 3J=8.2 Hz, 
3J=6.9 Hz, 1H, Hγ (Ile)), 1.42 (ddq, 2J=13.3 Hz, 3J=6.7 Hz, 3J=6.3 Hz, 1H, Hγ (Ile)), 
1.56-1.78 (m, 4H, 2Hγ (β-hGln), Hβ (Ile), Hγ (Pro)), 1.83 (m, 1H, Hγ (Pro)), 2.00-2.10 
(m, 4H, 2Hδ (β-hGln), 2Hβ (Pro)), 2.32 (dd, 2J=15.1 Hz, 3J=3.1 Hz, 1H, Hα (β-hGln)), 
2.37 (dd, 2J=16.9 Hz, 3J=3.8 Hz, 1H, Hα (β-hSer)), 2.58 (dd, 2J=15.1 Hz, 3J=6.9 Hz, 
1H, Hα (β-hGln)), 2.64 (dd, 2J=16.6 Hz, 3J=9.7 Hz, 1H, Hβ (Asp)), 2.77 (dd, 2J=17.0 
Hz, 3J=3.5 Hz, 1H, Hβ (Asp)), 2.80 (dd, 2J=16.6 Hz, 3J=11.6 Hz, 1H, Hα (β-hSer)), 
3.18-3.66 (br, 4H, 2Hδ (Pro), 2Hγ (β-hSer)), 3.69 (dd, 3J=4.4 Hz, 3J=4.4 Hz, 1H, Hα 
(Ile)), 3.82 (m, 1H, Hβ (β-hGln), 3.94 (dd, 3J=7.9 Hz, 3J=4.1 Hz, 1H, Hα (Thr)), 4.07-
4.15 (m, 2H, Hβ (β-hSer), Hβ (Thr)), 4.38 (ddd, 3J=10.2 Hz, 3J=7.1 Hz, 3J=3.3 Hz, 
1H, Hα (Asp)), 4.44 (dd, 3J=5.0 Hz, 3J=5.0 Hz, 1H, Hα (Pro)), 4.89-5.16 (br, 2H, HO 
(β-hSer), HO (Thr)), 6.85 (s, 1H, HN (β-hGln)), 7.30 (d, 3J=9.4 Hz, 1H, HN (β-hSer)), 
7.31 (s, 1H, HN (β-hGln)), 7.44 (d, 3J=7.5 Hz, 1H, HN (Thr)), 7.69 (d, 3J=8.8 Hz, 1H, 
HN (β-hGln)), 8.06 (d, 3J=6.9 Hz, 1H, HN (Asp)), 8.22 (d, 3J=3.8 Hz, 1H, HN (Ile)), 
12.33 (br, 1H HCOO Asp). 
 
Minor conformer 0.78-0.88 (m, 6H, 3Hγ (Ile), 3Hδ (Ile), 1.03 (d, 3J=6.3 Hz, 3H, Hγ 
(Thr)), 1.10 (m, 1H, Hγ (Ile)), 1.39 (m, 1H, Hγ (Ile)), 1.74 (m, 1H, Hβ (Ile)), 1.58-1.71 
(m, 2H, Hγ (Pro)), 1.81-1.91 (m, 3H, 2Hγ (β-hGln), Hβ (Pro)), 2.12 (m, 1H, Hβ (Pro)), 
2.45 (m, 1H, Hα (β-hSer)), 2.47-2.53 (br, 2H, Hβ (Asp)), 2.61-2.67 (m, 2H, Hδ  
(β-hGln)), 2.72-2.81 (m, 2H, Hα (β-hGln)), 2.93 (dd, 2J=16.0 Hz, 3J=7.2 Hz, 1H, Hα 
(β-hSer)), 3.00 (m, 1H, Hδ (Pro)), 3.18-3.66 (br, 3H, 2Hγ (β-hSer), Hδ (Pro)), 3.73-
3.85 (m, 2H, Hβ (β-hGln), Hβ (β-hSer)), 3.94 (m 1H, Hα (Ile)), 4.03 (dd, 3J=8.6 Hz, 
3J=2.5 Hz, 1H, Hα (Thr)), 4.20-4.28 (m, 2H, Hα (Pro), Hβ (Thr)), 4.42 (m, 1H, Hα 
(Asp)), 4.89-5.16 (br, 2H, HO (β-hSer), HO (Thr)), 6.78 (s, 1H, HN (β-hGln)), 7.08 (d, 
3J=8.2 Hz, 1H, HN (Thr), 7.18 (s, 1H, HN (β-hGln)), 7.55-7.59 (m, 2H, HN (Asp), HN 
(β-hGln)), 7.77 (d, 3J=6.9 Hz, 1H, HN (Ile)), 7.89 (d 3J=6.9 Hz, 1H, HN (β-hSer)), 
12.33 (br, 1H HCOO Asp).  
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c-(-Thr-Gln-Val-Asp-Ser-Pro-) (52) 
 
C26H41N7O11 (627.66 g/mol). 
Cyclization on resin: 
The linear peptide H-Ser-Pro-Thr(t-Bu)-Gln(Trt)-Val-Asp(Wang)-ODmb (107) is 
synthesized and cyclized following protocol 6 (3.0 equiv HATU and 6.0 equiv 
DIPEA as coupling reagents), on Wang resin (330 mg, 0.2 mmol). After complete 
deprotection and cleavage from the resin with the cleavage cocktail TFA/DCM/TIS 
= 48 : 48: 4 during 2 h (protocol 10), the cyclic peptide (52) is purified by reverse 
phase preparative HPLC. 
Yield (cyclic deprotected peptide (52)): 6 mg, 10 µmol, 5 %. 
HPLC (anal. method 2): tR=13.07 min, 100 area %. 
Cyclization in solution: 
The linear peptide H-Gln(Trt)-Val-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Thr(t-Bu)-OH (108) is 
synthesized on 2-ClTrt resin (250 mg, 0.2 mmol) previously loaded with  
Fmoc-Thr(t-Bu)-OH (loading 0.80 mmol/g), and cleaved with 1 % TFA in DCM 
(protocol 9). The linear protected peptide (108) is neither purified by reverse phase 
preparative HPLC nor with filtration through C18 plug. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1056.60 [M+H]+, 1078.58 [M+Na]+, 1094.56 [M+K]+ 
Found: 1078.69 [M+Na]+, 1094.67 [M+K]+ 
The linear peptide (108) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (108) in 7 ml DMF. 
Second syringe: Solution of HATU (0.22 mmol, 84 mg,) in 7 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (0.66 mmol, 85 mg, 113 µl) and HATU (0.10 mmol, 37 
mg) in 10 ml DMF. 
After evaporation of the solvent the protected cyclic peptide (109) is purified by 
reverse phase preparative HPLC. 
Yield (cyclic protected peptide (109)): 16 mg, 15 µmol, 8 % (calculated on resin 
loading). 
HPLC (anal. method 1): tR=32.0 min, 100 area % sum of epimers. 
Also 164 mg, 0.16 mmol of the linear peptide (108) is isolated by reverse phase 
preparative HPLC. 
Repeated cyclization following protocol 7, method B: 
First syringe: Solution of linear peptide (108) (164 mg, 0.16 mmol ) in 7 ml DMF. 
Second syringe: Solution of HATU (2.0 equiv, 0.32 mmol, 117 mg,) in 7 ml DMF. 
Addition rate for both syringes: 0.02 ml/min. 
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Flask: solution: DIPEA (6.0 equiv, 0.93 mmol, 120 mg, 159 µl) and HATU (1.0 
equiv, 0.16 mmol, 59 mg) in 10 ml DMF. 
After evaporation of the solvent the cyclic protected peptide (109) is purified by 
reverse phase preparative HPLC. 
Yield (cyclic protected peptide (109)): 35 mg, 34 µmol, 22 %. 
HPLC (anal. method 1): tR=32.0 min, 100 area % sum of epimers. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1038.59 [M+H]+, 1060.57 [M+Na]+, 1076.55 [M+K]+ 
Found: 1060.70 [M+Na]+, 1076.85 [M+K]+ 
In the reaction mixture linear protected peptide is again detected with MALDI-ToF 
MS. 
The combined cyclic protected peptide (109) (51 mg, 49 µmol) is completely 
deprotected with the cleavage mixture TFA/H2O/TIS = 95 : 2.5 : 2.5 during 2 h 
(protocol 13) and finally purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (52)): 19 mg, 30 µmol, 61 %. 
HPLC (anal. method 2): tR=13.1 min, 100 area %, sum of epimers. 
For the biological tests and the NMR analysis the epimers were separated by 
reverse phase preparative HPLC (preparative method 3). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 628.29 [M+H]+, 650.28 [M+Na]+, 666.25 [M+K]+ 
Found: 650.19 [M+Na]+, 666.26 [M+K]+ 
1H NMR (500 MHz, DMSO-d6),  δ (ppm): Two sets of signals (ratio 1.5 : 1). 
Major conformer 0.78 (d, 3J=6.3 Hz, 3H, Hγ (Val)), 0.82 (d, 3J=6.9 Hz, 3H, Hγ (Val)), 
1.14 (d, 3J=6.3 Hz, 3H, Hγ (Thr)), 1.56 (m, 1H, Hγ (Pro)), 1.80-1.90 (m, 4H, 2Hβ 
(Gln), Hβ (Pro), Hγ (Pro)), 1.90-2.02 (m, 2H, Hβ (Pro), Hβ (Val)), 2.06-2.31 (m, 2H, Hγ 
(Gln)), 2.36 (dd, 2J=15.7 Hz, 3J=8.2 Hz, 1H, Hβ (Asp)), 2.55 (dd, 2J=15.7 Hz, 3J=5.7 
Hz, 1H, Hβ (Asp)), 3.32-3.38 (m, 2H, 2Hδ (Pro)), 3.52 (br, 1H, Hβ (Ser)), 3.65 (dd, 
2J=10.4 Hz, 3J=5.3 Hz, 1H, Hβ (Ser)), 3.80 (ddd, 3J=6.4 Hz, 3J=6.4 Hz, 3J=3.8 Hz, 
1H, Hα (Gln)), 3.90 (m, 1H, Hα (Val)), 4.33 (m, 1H, Hα (Ser)), 4.47 (ddd, 3J=7.9 Hz, 
3J=7.2 Hz, 3J=5.9 Hz, 1H, Hα (Asp)), 4.50-4.56 (m, 2H, Hα (Thr), Hβ (Thr)), 4.69 (d, 
3J=8.8 Hz, 1H, Hα (Pro)), 4.90-5.10 (br, 2H, HO (Ser), HO (Thr)), 6.73 (d, 3J=6.9 Hz, 
1H, HN (Asp)), 6.85 (s, 1H, HN (Gln)), 7.20-7.26 (m, 2H, HN (Ser), HN (Val)), 7.45 (s, 
1H, HN (Gln)), 8.49 (d, 3J=3.8 Hz, 1H, HN (Gln)), 8.71 (d, 3J=8.8 Hz, 1H, HN (Thr)), 
12.31 (br, 1H, HCOO (Asp)).  
 
Minor conformer  0.86 (d, 3J=6.9 Hz, 3H, Hγ (Val)), 0.92 (d, 3J=6.9 Hz, 3H, Hγ 
(Val)), 0.96 (d, 3J=6.3 Hz, 3H, Hγ (Thr)), 1.74 (m, 1H, Hβ (Pro)), 1.80-1.90 (m, 2H, 
Hβ (Gln)), 1.90-2.02 (m, 3H, 2Hγ (Pro), Hβ (Val)), 2.06-2.31 (m, 3H, 2Hγ (Gln), Hβ 
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(Pro)), 2.91 (dd, 2J=16.3 Hz, 3J=5.0 Hz, 1H, Hβ (Asp)), 2.64 (dd, 2J=16.0 Hz, 3J=7.9 
Hz, 1H, Hβ (Asp)), 3.30-3.67 (br, 3H, 2Hδ (Pro), Hβ (Ser)), 3.69 (m, 1H, Hα (Val)), 
3.80 (ddd, 3J=6.4 Hz, 3J=6.4 Hz, 3J=3.8 Hz, 1H, Hα (Gln)), 3.90 (m, 1H, Hβ (Ser)), 
4.15 (dd, 3J=9.4 Hz, 3J=1.9 Hz, 1H, Hα (Pro)), 4.18-4.24 (m, 2H, Hα (Thr), Hβ (Thr)), 
4.30 (m, 1H, Hα (Asp)), 4.72 (ddd, 3J=6.8 Hz, 3J=3.3 Hz, 3J=3.3 Hz, 1H, Hα (Ser)), 
4.90-5.10 (br, 2H, HO (Ser), HO (Thr)), 6.88 (s, 1H, HN (Gln)), 7.24 (m, 1H, HN 
(Asp)), 7.45 (d, 3J=6.9 Hz, 1H, HN (Thr)), 7.78 (d, 3J=6.9 Hz, 1H, HN (Ser)), 8.22 (d, 
3J=5.0 Hz, 1H, HN (Val)), 8.45 (br, 1H, HN (Gln)), 8.83 (s, 1H, HN (Gln)), 12.31 (br, 
1H, HCOO (Asp)). 
 
 
c-(-Thr-Gln-Val-Asp-Ser-β-hPro-) (53) 
 
C27H43N7O11 (641.69 g/mol). 
Cyclization on resin: 
The linear peptide H-Ser(t-Bu)-β-hPro-Thr(t-Bu)-Gln(Trt)-Val-Asp(Wang)-ODmb 
(110) is synthesized and cyclized following protocol 6 (3.0 equiv HATU and 6.0 
equiv DIPEA as coupling reagents) on Wang resin (330 mg, 0.2 mmol). After 
complete deprotection and cleavage from the resin with the cleavage cocktail  
TFA/DCM/TIS = 48 : 48: 4 during 2 h (protocol 10), the cyclic peptide (53) is 
purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (53)): 10 mg, 16 µmol, 8 %. 
HPLC (anal. method 2): tR=13.0 min, 100 area %. 
 
Cyclization in solution: 
The linear peptide H-Gln(Trt)-Val-Asp(Ot-Bu)-Ser(t-Bu)-β-hPro-Thr(t-Bu)-OH (111) 
is synthesized on 2-ClTrt resin (250 mg, 0.20 mmol) previously loaded with  
Fmoc-Thr(t-Bu)-OH (loading 0.80 mmol/g), and cleaved with 1 % TFA in DCM 
(protocol 9). 
Yield (linear protected peptide (111)): 160 mg, 0.13 mmol, 67 %. 
HPLC (anal. method 1): tR=min, 90 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1070.62 [M+H]+, 1092.60 [M+Na]+, 1108.57 [M+K]+ 
Found: 1092.61 [M+Na]+ 
The linear peptide (111) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (111) (160 mg, 0.13 mmol) in 10 ml DMF. 
Second syringe: Solution of HATU (3.0 equiv, 0.4 mmol, 153 mg,) in 10 ml DMF. 
Addition rate for both syringes: 0.04 ml/min. 
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Flask: Solution of DIPEA (6.0 equiv, 0.80 mmol, 104 mg, 137 µl) and HATU (0.1 
equiv, 13 µmol, 5 mg) in 20 ml DMF. 
After evaporation of the solvent the cyclic protected peptide (112) is purified by 
reverse phase preparative HPLC. 
Yield (cyclic protected peptide (112)): 84 mg, 50 µmol, 37 %. 
HPLC (anal. method 1): tR=35.8 min, 62 area % sum of epimers. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1052.61 [M+H]+, 1074.59 [M+Na]+, 1090.56 [M+K]+ 
Found: 1074.72 [M+Na]+ 
The cyclic protected peptide (112) is completely deprotected with reagent K during 
2 h (protocol 13) and finally purified by preparative HPLC. 
Yield (cyclic deprotected peptide (53)): 27 mg, 42 µmol, 84 %. 
HPLC (anal. method 2): tR=11.4 min, 11.7 min, 100 area %, epimers ratio 1:1. 
For the biological tests and the NMR analysis the epimers were separated by 
reverse phase preparative HPLC (preparative method 3). 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 642.31 [M+H]+, 664.29 [M+Na]+, 680.27 [M+K]+ 
Found: 642.54 [M+H]+, 664.68 [M+Na]+, 680.58 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two sets of signals (ratio 3 : 1). 
Major conformer 0.87 (d, 3J=6.3 Hz, 3H, Hγ (Val)), 0.94 (d, 3J=6.3 Hz, 3H, Hγ (Val)), 
1.00 (d, 3J=6.9 Hz, 3H, Hγ (Thr)), 1.61 (dddd, 2J=12.4 Hz, 3J=7.9 Hz, 3J=7.9 Hz, 
3J=7.5 Hz, 1H, Hγ (β-hPro)), 1.72-1.88 (m, 4H, 2Hβ (Gln), 2Hδ (β-hPro)), 1.92 (m, 
1H, Hβ (Val)), 2.07 (dddd, 2J=12.2 Hz, 3J=6.2 Hz, 3J=6.2 Hz, 3J=6.2 Hz, 1H, Hγ (β-
hPro)), 2.11-2.18 (m, 2H, Hγ (Gln)), 2.21 (dd, 2J=14.8 Hz, 3J=1.6 Hz, 1H, Hα (β-
hPro)), 2.49 (br, 1H, Hβ (Asp)), 2.67-2.76 (m, 2H, Hβ (Asp), Hα (β-hPro)), 3.26-3.68 
(br, 5H, 2Hε (β-hPro), 2Hβ (Ser), Hα (Val)), 4.11 (m, 1H, Hβ (β-hPro)), 4.19 (dd, 
3J=9.4 Hz, 3J=1.3 Hz, 1H, Hα (Thr)), 4.36-4.47 (m, 2H, Hα (Asp), Hβ (Thr)), 4.55 
(ddd, 3J=7.2 Hz, 3J=7.2 Hz, 3J=5.0 Hz, 1H, Hα (Ser)), 4.63 (ddd, 3J=9.1 Hz, 
3J=10.1Hz, 3J=2.2 Hz, 1H, Hα (Gln)), 6.82 (s, 1H, HN (Gln)), 7.00 (d, 3J=6.9 Hz, 1H, 
HN (Ser)), 7.07 (s, 1H, HN (Gln)), 7.49 (d, 3J=10.0 Hz, 1H, HN (Thr)), 7.97 (d J=8.8 
Hz, 1H, HN (Asp)), 8.18 (d, 3J=8.8 Hz, 1H, HN (Gln)), 8.28 (d, 3J=3.1 Hz, 1H, HN 
(Val)), 12.33 (br, 1H, HCOO (Asp)). 
 
Minor conformer 0.77 (d, 3J=6.9 Hz, 3H, Hγ (Val)), 0.81 (d, 3J=6.9 Hz, 3H, Hγ (Val)), 
1.08 (d, 3J=6.3 Hz, 3H, Hγ (Thr)), 1.72-1.98 (m, 6H, 2Hγ (β-hPro), 2Hδ (β-hPro), 2Hβ 
(Gln)), 2.11-2.24 (m, 3H, 2Hγ (Gln), Hβ (Val)), 2.47-2.57 (br, 2H, Hβ (Asp)), 2.39 (dd, 
2J=14.4 Hz, 3J=8.2 Hz, 1H, Hα (β-hPro)), 2.99 (dd, 2J=14.1 Hz, 3J=2.2 Hz, 1H, Hα  
(β-hPro)), 3.17 (ddd, 2J=11.8 Hz, 3J=8.3 Hz, 3J=8.3 Hz, 1H, Hε (β-hPro)), 3.26-3.68 
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(br, 3H, Hε (β-hPro), 2Hβ (Ser)), 3.86 (dd, 3J=8.8 Hz, 3J=6.9 Hz, 1H, Hα (Val)), 3.97 
(ddd, 3J=7.9 Hz, 3J=5.7 Hz, 3J=5.7 Hz, 1H, Hα (Gln)), 4.29-4.35 (m, 2H Hα (Thr), Hβ 
(Thr)), 4.42 (m, 2H, Hα (Asp), Hβ (β-hPro)), 4.76 (ddd, 3J=8.5 Hz, 3J=6.3 Hz, 3J=6.3 
Hz, 1H, Hα (Ser)), 6.81 (s, 1H, HN (Gln)), 7.27 (d, 3J=6.9 Hz, 1H, HN (Asp)), 7.30 (s, 
1H, HN (Gln)), 7.46 (d, 3J=8.8 Hz, 1H, HN (Val)), 7.67 (d, 3J=9.4 Hz, 1H, HN (Thr)), 
8.25 (d, 3J=5.7 Hz, 1H, HN (Gln)), 8.43 (d, 3J=6.3 Hz, 1H, HN (Ser)), 12.33 (br, 1H, 
HCOO (Asp)). 
 
 
c-(-Thr-Gln-D-Val-Asp-Ser-Pro-) (54) 
 
C26H41N7O11 (627.66 g/mol). 
Cyclization on resin: 
The linear peptide H-Ser(t-Bu)-Pro-Thr(t-Bu)-Gln(Trt)-D-Val-Asp(Wang)-ODmb 
(113) is synthesized and cyclized following protocol 6 (HATU as coupling reagent) 
on Wang resin (400 mg, 0.20 mmol). The cyclic peptide (54) is completely 
deprotected, cleaved from the resin with the cleavage cocktail DCM/TFA/TIS = 48 
: 48 : 4 (protocol 10), and purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (54)): 10 mg 14 µmol, 7 %. 
HPLC (anal. method 2): tR=9.9 min, 90 area %. 
 
Cyclization in solution: 
The linear peptide H-D-Val-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Thr(t-Bu)-Gln(Trt)-OH (114) is 
synthesized on 2-ClTrt resin (400 mg, 0.20 mmol) previously loaded with  
Fmoc-Gln(Trt)-OH (loading 0.50 mmol/g), cleaved with 1 % TFA in DCM (protocol 
9), and purified by preparative HPLC. 
Yield (linear protected peptide (114)): 160 mg, 0.13 mmol, 65 %. 
HPLC (anal. method 1): tR=29.2 min, 85 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1056.60 [M+H]+, 1078.58 [M+Na]+, 1094.56 [M+K]+ 
Found: 1056.42 [M+H]+, 1078.31 [M+Na]+, 1094.45 [M+K]+ 
The linear peptide (114) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (114) (160 mg, 0.13 mmol) in 15 ml DMF. 
Second syringe: Solution of HATU (1.1 equiv, 53 mg, 0.14 mmol) in 15 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (3.0 equiv, 0.39 mmol, 50 mg, 67 µl) and HOAt (1.0 
equiv, 0.13 mmol, 17 mg) in 20 ml DMF. 
After evaporation of the solvent the epimers are separated by reverse phase 
preparative HPLC. 
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Yield (cyclic protected peptide (115)): 52 mg, 47 µmol, 36 %. 
HPLC (anal. method 1): tR=32.8 min, 93 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1038.59 [M+H]+, 1060.57 [M+Na]+, 1076.55 [M+K]+ 
Found: 1060.29 [M+Na]+, 1076.85 [M+K]+ 
The cyclic protected peptide (115) is completely deprotected with reagent K during 
5 h (protocol 13) and finally purified by preparative HPLC. 
Yield (cyclic deprotected peptide (54)): 27 mg, 43 µmol, 92 %. 
HPLC (anal. method 2): tR= 9.9 min, 100 area %. No isomers observed. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 628.29 [M+H]+, 650.28 [M+Na]+, 666.25 [M+K]+ 
Found: 628.27 [M+H]+, 650.32 [M+Na]+, 666.21 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two sets of signals (ratio 5 : 1). 
0.85 (d, 3J=6.3 Hz, 3H, Hγ (D-Val)), 0.97 (d, 3J=6.9 Hz, 3H, Hγ (D-Val)), 1.01 (d, 
3J=6.9 Hz, 3H, Hγ (Thr)), 1.68-1.81 (m, 2H, Hβ (Gln), Hβ (Pro)), 1.83-2.02 (m, 6H, 
2Hγ (Gln), Hβ (Gln), 2Hγ (Pro), Hβ (D-Val)), 2.24 (m, 1H, Hβ (Pro)), 2.45 (dd, 2J=16.8 
Hz, 3J=9.0 Hz, 1H, Hβ (Asp)), 2.83 (dd, 2J=16.6 Hz, 3J=4.7 Hz, 1H, Hβ (Asp)), 3.56 
(dd, 3J=10.1 Hz, 3J=5.0 Hz, 1H, Hα (D-Val)), 3.68 (ddd, 2J=9.7 Hz, 3J=9.7 Hz, 
3J=6.3 Hz, 1H, Hδ (Pro)), 3.76 (ddd, 2J=9.9 Hz, 3J=8.0 Hz, 3J=2.4 Hz, 1H, Hδ (Pro)), 
3.82 (dd, 2J=11.9 Hz, 3J=2.5 Hz, 1H, Hβ (Ser)), 3.95 (m, 1H, Hβ (Thr)), 4.00 (dd, 
2J=11.6 Hz, 3J=6.0 Hz, 1H, Hβ (Ser)), 4.04 (dd, 3J=9.4 Hz, 3J=3.8 Hz, 1H, Hα (Thr)), 
4.07 (dd, 3J=9.1 Hz, 3J=7.9 Hz, 1H, Hα (Pro)), 4.32 (ddd, 3J=7.7 Hz, 3J=5.2 Hz, 
3J=4.2 Hz, 1H, Hα (Gln)), 4.67 (ddd, 3J=9.0 Hz, 3J= 9.0 Hz, 3J= 4.6 Hz, 1H, Hα 
(Asp)), 4.74 (ddd, 3J=8.6 Hz, 3J=5.8 Hz, 3J=2.7 Hz, 1H, Hα (Ser)), 4.91 (br, 1H, HO 
(Thr)), 5.29 (br, 1H, HO (Ser)), 6.63 (br, 1H, HN (Gln)), 6.70 (d, 3J=5.0 Hz, 1H, HN 
(Gln)), 6.99 (d, 3J=9.4 Hz, HN (Thr)), 7.16 (br, 1H, HN (Gln)), 7.99 (d, 3J=8.2 Hz, 1H, 
HN (Ser)), 8.68 (d, 3J=8.8 Hz, HN (Asp)), 8.87 (d, 3J =5.0 Hz, HN (Val)), 12.84 (br, 
1H, HCOO (Asp)). 
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c-(-Gln-Ile-Asp-Ser-Pro-) (55) 
 
C23H36N6O9 (540.58 g/mol). 
Cyclization on resin: 
The linear peptide H-Ser(t-Bu)-Pro-Gln(Trt)-Ile-Asp(Wang)-ODmb (116) is 
synthesized and cyclized following protocol 6, with different coupling reagents 
(Table 37), on Wang resin. After complete deprotection and cleavage from the 
resin, with different cleavage cocktails (Table 37), the cyclic peptide (55) is purified 
by reverse phase preparative HPLC. 
 
Table 37: On resin cyclization of H-Ser(t-Bu)-Pro-Gln(Trt)-Ile-Asp(Wang)-ODmb (116) 
 
Resin 
n/ 
mmol 
Coupling reagent 
t/ 
min 
Cleavage 
Reagent 
t/ 
h 
Yield 
HPLC/ 
% 
Wang 
135 mg 0.10 
1.1 equiv HATU 
3.0 equiv DIPEA 
2.0 equiv HOAt 
45 Reagent B 5 
6 mg 
8 µmol 
8 %  
70a 
Wang 
130 mg 0.10 
3.0 equiv HATU 
6.0 equiv DIPEA 
40 
TFA 47 
DCM 47 
TIS 6 
2 
3 mg 
6 µmol 
6 % 
100a 
a The same HPLC analytical method and the retention time as for the cyclization in 
solution. 
 
Cyclization in solution: 
The linear peptide H-Ile-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Gln(Trt)-OH (117) is synthesized 
on 2-ClTrt resin (300 mg, 0.20 mmol) previously loaded with Fmoc-Gln(Trt)-OH 
(loading 0.66 mmol/g), and cleaved with 1 % TFA in DCM (protocol 9). 
Yield (linear protected peptide (117)): 150 mg, 89 µmol, 45 %. 
HPLC (anal. method 1): tR= 26.9 min, 54 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 913.51 [M+H]+, 935.49 [M+Na]+, 951.46 [M+K]+ 
Found: 913.33 [M+H]+, 935.28 [M+Na]+, 951.36 [M+K]+ 
The linear peptide (117) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (117) (150 mg, 89 µmol) in 10 ml DMF. 
Second syringe: Solution of HATU (6.0 equiv, 0.53 mmol, 200 mg) in 10 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (13.0 equiv, 1.17 mmol, 151 mg, 200 µl) in 20 ml DMF. 
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After evaporation of the solvent the epimers are separated by reverse phase 
preparative HPLC. 
Yield (cyclic protected peptide (118)): 29 mg, 26 µmol, 29 %. 
HPLC (anal. method 1): tR= 31.8 min, 81 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 895.50 [M+H]+, 917.48 [M+Na]+, 933.45 [M+K]+ 
Found: 917.28 [M+Na]+, 933.45 [M+K]+ 
The protected cyclic peptide (118) is completely deprotected with reagent K during 
5 h (protocol 13) and finally purified by preparative HPLC. 
Yield (cyclic deprotected peptide (55)): 15 mg, 24 µmol, 92 %. 
HPLC (anal. method 2): tR= 11.0 min, 85 area %. No isomers observed. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 541.26 [M+H]+, 563.24 [M+Na]+, 579.22 [M+K]+ 
Found: 541.49 [M+H]+, 563.69 [M+Na]+, 579.71 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two sets of signals (ratio 3 : 1). 
Major conformer: 0.81 (d, 3J=6.3 Hz, 3H, Hγ (Ile)), 0.82 (dd, 3J=7.5 Hz, 3J=7.5 Hz, 
3H, Hδ (Ile)), 0.98 (ddq, 2J=13.8 Hz, 3J=7.2 Hz, 3J=1.3 Hz, 1H, Hγ (Ile)), 1.38 (m, 
1H, Hγ (Ile)), 1.65-1.79 (m, 2H, Hβ (Gln), Hγ (Pro)), 1.79-1.92 (m, 3H, Hβ (Gln), Hβ 
(Ile), Hγ (Pro)), 1.92-2.09 (m, 3H, 2Hγ (Gln), Hβ (Pro)), 2.21 (dddd, 2J=10.4 Hz, 
3J=9.8 Hz, 3J=7.5 Hz, 3J=2.8 Hz, 1H, Hβ (Pro)), 2.33 (dd, 2J=16.9 Hz, 3J=11.3 Hz, 
1H, Hβ (Asp)), 2.71 (dd, 2J=16.6, 3J=2.2 Hz, 1H, Hβ (Asp)), 3.36 (dd, 2J=10.1 Hz, 
3J=5.0 Hz, 1H, Hβ (Ser)), 3.39-3.56 (br, 2H, Hδ (Pro), Hβ (Ser)), 3.60 (ddd, 2J=11.5 
Hz, 3J=7.7 Hz, 3J=3.6 Hz, 1H, Hδ (Pro)), 4.11 (ddd, 3J=10.8 Hz, 3J=10.8 Hz, 3J=2.6 
Hz, 1H, Hα (Asp)), 4.30 (ddd, 3J=9.9 Hz, 3J=9.9 Hz, 3J=5.5 Hz, 1H, Hα (Gln)), 4.40 
(ddd, 3J=8.6 Hz, 3J=8.6 Hz, 3J=5.2 Hz, 1H, Hα (Ser)), 4.47 (dd, 3J=9.1 Hz, 3J=9.1 
Hz, 1H, Hα (Ile)), 4.51 (dd, 3J=8.8 Hz, 3J=2.5 Hz, 1H, Hα (Pro)), 6.77 (s, 1H, HN 
(Gln)), 6.94 (d, 3J=8.2 Hz, 1H, HN (Ser)), 7.28 (s, 1H, HN (Gln)), 7.54 (d, 3J=10.0 
Hz, 1H, HN (Gln)), 7.84 (d, 3J=10.7 Hz, 1H, HN (Asp)), 8.35 (d, 3J=9.4 Hz, 1H, HN 
(Ile)), 12.51 (br, 1H, HCOO (Asp)). 
 
Minor conformer 0.78 (d, 3J=6.3 Hz, 3H, Hγ (Ile)), 0.79-0.83 (m, 3H, Hδ (Ile)), 1.04 
(m, 1H, Hγ (Ile)), 1.42 (m, 1H, Hγ (Ile)), 1.70 (m, 1H, Hγ (Pro)), 1.79-1.92 (m, 4H, 
2Hβ (Gln), Hβ (Ile), Hγ (Pro)), 1.92-2.09 (m, 4H, 2Hγ (Gln), 2Hβ (Pro)), 2.74 (dd, 
2J=16.0 Hz, 3J=6.0 Hz, 1H, Hβ (Asp)), 2.80 (dd, 2J=16.0 Hz, 3J=7.5 Hz, 1H, Hβ 
(Asp)), 3.39-3.56 (br, 3H, 2Hδ (Pro), Hβ (Ser)), 3.69 (dd, 2J=10.1 Hz, 3J=4.4 Hz, 1H, 
Hβ (Ser)), 3.75 (dd, 3J=8.7 Hz, 3J=8.5 Hz, 1H, Hα (Ile)), 4.10 (m, 1H, Hα (Ser)), 
4.19-4.27 (m, 2H, Hα (Asp), Hα (Gln)), 4.59 (dd, 3J=6.6 Hz, 3J=2.2 Hz, 1H, Hα 
(Pro)), 6.82 (s, 1H, HN (Gln)), 7.33 (s, 1H, HN (Gln)), 7.66 (d, 3J=3.8 Hz, 1H HN 
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(Ser)), 7.73 (d, 3J=8.8 Hz, 1H HN (Gln)), 7.94 (d, 3J=8.2 Hz, 1H HN (Ile)), 8.02 (d, 
3J=8.8 Hz, 1H HN (Asp)), 12.51 (br, 1H, HCOO (Asp)). 
 
 
c-(-Gln-Ile-Asp-Ser-β-hPro-) (56) 
 
C24H38N6O9 (554.61 g/mol). 
Cyclization on resin: 
The linear peptide H-Ser(t-Bu)-β-hPro-Gln(Trt)-Ile-Asp(Wang)-ODmb (119) is 
synthesized and cyclized following protocol 6 (HATU as coupling reagent), on 
Wang resin (125 mg, 50 µmol), After complete deprotection and cleavage from the 
resin with cocktail mixture TFA/DCM/TIS = 48 : 48 : 4 (protocol 10), the cyclic 
peptide (56) is purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (56)): 4 mg, 7.2 µmol, 14 %. 
HPLC (anal. method 2): tR= 13.1 min, 100 %. 
 
Cyclization in solution: 
The linear peptide H-β-hPro-Gln(Trt)-Ile-Asp(Ot-Bu)-Ser(t-Bu)-OH (120) is 
synthesized on 2-ClTrt resin (200 mg, 0.20 mmol) previously loaded with Fmoc- 
-Ser(t-Bu)-OH (loading 1.00 mmol/g), and cleaved with 1 % TFA in DCM (protocol 
9). 
Yield (protected linear peptide (120)): 74 mg, 72 µmol, 36 %. 
HPLC (anal. method 1): tR= 28.1 min, 90 %. 
MALDI-ToF MSmonoisotopic, m/z 
Calcd.: 927.52 [M+H]+, 949.51 [M+Na]+, 965.50 [M+K]+ 
Found: 927.49 [M+H]+ 
The linear peptide (120) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (120) (74 mg, 72 µmol) in 10 ml DMF. 
Second syringe: Solution of HATU (3.0 equiv, 0.22 mmol, 82 mg) in 10 ml DMF. 
Addition rate for both syringes: 0.05 ml/min. 
Flask: Solution of DIPEA (6.0 equiv, 0.43 mmol, 56 mg, 74 µl) and HATU (0.1 
equiv, 7 µmol 3 mg) in 10 ml DMF. 
After evaporation of the solvent the the epimers are separated by reverse phase 
preparative HPLC. 
Yield (cyclic protected peptide (121)): 40 mg, 26 µmol, 36 %. 
HPLC (anal. method 1): tR= 32.7 min, 60 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 909.51 [M+H]+, 931.49 [M+Na]+, 947.47 [M+K]+ 
Found: 931.54 [M+Na]+, 947.62 [M+K]+ 
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The cyclic protected peptide (121) is completely deprotected with reagent K during 
2 h (protocol 13) and finally purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (56)): 13 mg, 23 µmol, 89 %.  
HPLC (anal. method 2): tR= 13.1 min, 100 area %. No isomers observed. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 555.28 [M+H]+, 577.26 [M+Na]+, 593.23 [M+K]+ 
Found: 555.26 [M+H]+, 577.08 [M+Na]+, 593.00 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two sets of signals (ratio 2 : 1). 
Major conformation 0.73-0.88 (m, 6H, 3Hγ (Ile), 3Hδ (Ile)), 0.98 (ddq, 2J=14.4 Hz, 
3J=7.2 Hz, 3J=7.2 Hz, 1H, Hγ (Ile)), 1.35 (m, 1H; Hγ (Ile)), 1.62 (m, 1H, Hγ (Gln)), 
1.76-1.91 (m, 5H, Hβ (Ile), 2Hγ (β-hPro), 2Hδ (β-hPro)), 1.90-2.10 (m, 2H, Hβ (Gln), 
Hγ (Gln)), 2.17 (m, 1H, Hβ (Gln)), 2.34 (dd, 2J=17.3 Hz, 3J=6.6 Hz, 1H, Hα (β-hPro)), 
2.55 (dd, 2J=16.6 Hz, 3J=8.5 Hz, 1H, Hβ (Asp)), 2.60 (dd, 2J=17.6 Hz, 3J=2.5 Hz, 
1H, Hα (β-hPro)), 2.73 (dd, 2J=16.3 Hz, 3J=5.7 Hz, 1H, Hβ (Asp)), 3.27-3.55 (br, 2H, 
Hε (β-hPro)), 3.64 (dd, 2J=12.6 Hz, 3J=4.4 Hz, 1H, Hβ (Ser)), 3.82 (dd, 2J=12.6 Hz, 
3J=3.1 Hz, 1H, Hβ (Ser)), 3.87 (dd, 3J=9.7 Hz, 3J=9.7 Hz, 1H, Hα (Ile)), 4.06 (m, 1H, 
Hα (Gln)), 4.39 (m, 1H, Hα (Ser)), 4.50 (ddd, 3J=8.5 Hz, 3J=8.5 Hz, 6.3 Hz, 1H, Hα 
(Asp)), 4.60 (m, 1H, Hβ (β-hPro)), 6.72 (s, 1H, HN (Gln)), 7.22 (s, 1H, HN (Gln)), 
7.33 (br, 1H, HN (Gln)), 7.66 (d, 3J=9.4 Hz, 1H, HN (Ile)), 7.70 (d, 3J=8.8 Hz, 1H, HN 
(Asp)), 7.97 (d, 3J=6.9 Hz, 1H, HN (Ser)), 12.3 (br, 1H, HCOO (Asp)). 
 
Minor conformation 0.73-0.88 (m, 6H, 3Hγ (Ile), 3Hδ (Ile)), 0.98 (ddq, 2J=14.4 Hz, 
3J=7.2 Hz, 3J=7.2 Hz, 1H, Hγ (Ile)), 1.35 (m, 1H, Hγ (Ile)), 1.48 (m, 1H, Hδ (β-hPro)), 
1.59-1.76 (m, 2H, Hβ (Gln), Hγ (β-hPro)), 1.76-1.91 (m, 2H, Hβ(Gln), Hδ (β-hPro)), 
1.90-2.10 (m, 5H, 2Hγ (Gln), Hβ (Ile), Hα (β-hPro), Hγ (β-hPro)), 2.17 (m, 1H, Hα 
 (β-hPro)), 2.92 (m, 1H, Hε (β-hPro)), 2.89 (dd, 2J=16.3 Hz, 3J=8.8 Hz, 1H, 
Hβ (Asp)), 2.95 (dd, 2J=16.6 Hz, 3J=5.3 Hz, 1H, Hβ (Asp)), 3.27-3.55 (br, 2H, Hε (β-
hPro), Hβ (Ser)), 3.58 (dd, 2J=17.0 Hz, 3J=6.9 Hz, 1H, Hβ (Ser)), 3.93-4.01 (m, 2H, 
Hα (Asp), Hα (Ile)), 4.12 (ddd, 3J=9.1 Hz, 3J=9.1 Hz, 3J=5.0 Hz, 1H, Hα (Gln)), 4.31 
(m, 1H, Hβ (β-hPro)), 4.45 (m, 1H, Hα (Ser)), 6.81 (s, 1H, HN (Gln)), 7.33 (br, 1H, HN 
(Gln)), 7.66 (d 3J=8.2 Hz, 1H, HN (Ile)), 7.73 (d, 3J=9.3 Hz, 1H, HN (Gln)), 7.98 (d, 
3J=5.7 Hz, 1H, HN (Ser)), 9.21 (d, 3J=6.9 Hz, 1H, HN (Asp)), 12.3 (br, 1H, HCOO 
(Asp)). 
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c-(-Gln-Leu-Asp-Ser-Pro-) (57) 
 
C23H36N6O9 (540.58 g/mol). 
Cyclization in solution: 
The linear peptide H-Asp(Ot-Bu)-Ser(t-Bu)-Pro-Gln(Trt)-Leu-OH (122) is 
synthesized on 2-ClTrt resin (278 mg, 0.20 mmol) previously loaded with Fmoc- 
-Leu-OH (loading 0.72 mmol/g), cleaved with 1 % TFA in DCM (protocol 9) and 
purified by preparative HPLC. 
Yield (linear protected peptide (122)): 130 mg, 0.14 mmol, 71 %. 
HPLC (anal. method 1): tR= 27.4 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 913.51 [M+H]+, 935.49 [M+Na]+, 951.46 [M+K]+ 
Found: 935.93 [M+Na]+, 951.52 [M+K]+ 
The linear peptide (122) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (122) (130 mg, 0.14 mmol) in 20 ml DMF. 
Second syringe: Solution of HATU (1.1 equiv, 0.16 mmol, 59 mg) in 20 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (2.0 equiv, 0.28 mmol, 37 mg, 49 µl) and HOAt (1.0 
equiv, 0.14 mmol 19 mg) in 20 ml DMF. 
After evaporation of DMF the cyclic protected peptide (123) is purified by reverse 
phase preparative HPLC. 
Yield (cyclic protected peptide (123)): 120 mg, 0.10 mmol, 71 %. 
HPLC (anal. method 1): tR= 31.4 min, 75 area %.  
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 895.50 [M+H]+, 917.48 [M+Na]+, 933.45 [M+K]+ 
Found: 895.76 [M+H]+, 917.73 [M+Na]+, 933.70 [M+K]+ 
The cyclic protected peptide (123) is completely deprotected with reagent K during 
5 h (protocol 13) and finally purified by preparative HPLC. 
Yield (cyclic deprotected peptide (57)): 32 mg, 44 µmol, 44 %. 
HPLC (anal. method 2): tR= 11.9 min, 75 area %.  
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 541.26 [M+H]+, 563.24 [M+Na]+, 579.22 [M+K]+ 
Found: 541.27 [M+H]+, 563.43 [M+Na]+, 579.32 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two sets of signals (ratio 9 : 1). 
0.84 (d, 3J=6.9 Hz, 3H, Hδ (Leu)), 0.86 (d, 3J=6.3 Hz, 3H, Hδ (Leu)), 1.15 (ddd, 
2J=13.7 Hz, 3J=6.8 Hz, 3J=6.4 Hz, 1H, Hβ (Leu)), 1.47 (m, 1H, Hγ (Leu)), 1.62-1.76 
(m, 4H, 2Hβ (Gln), Hβ (Leu), Hγ (Pro)), 1.84 (m, 1H, Hγ (Pro)), 1.88-2.00 (m, 3H, 
2Hγ (Gln), Hβ (Pro)), 2.19 (dddd, 2J=16.3 Hz, 3J=9.3 Hz, 3J=6.8 Hz, 3J=6.8 Hz, 1H, 
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Hβ (Pro)), 2.36 (dd, 2J=16.9 Hz, 3J=2.1 Hz, 1H, Hβ (Asp)), 2.72 (dd, 2J=16.9 Hz, 
3J=11.0 Hz, 1H, Hβ (Asp)), 3.35 (dd, 2J=10.4 Hz, 3J=5.3 Hz, 1H, Hβ (Ser)), 3.41-
3.49 (m, 2H, Hδ (Pro), Hβ (Ser)), 3.60 (ddd, 2J=11.2 Hz, 3J=8.3 Hz, 3J=3.0 Hz, 1H, 
Hδ (Pro)), 4.12 (ddd, 3J=10.7 Hz, 3J=10.7 Hz, 3J=2.5 Hz, 1H, Hα (Asp)), 4.25 (ddd, 
3J=9.4 Hz, 3J=9.4 Hz, 3J=5.6 Hz, 1H, Hα (Gln)), 4.42 (ddd, 3J=8.6 Hz, 3J=8.6 Hz, 
3J=5.5 Hz, 1H, Hα (Ser)), 4.50 (dd, 3J=8.5 Hz, 3J=2.2 Hz, 1H, Hα (Pro)), 4.67 (ddd, 
3J=8.3 Hz, 3J=8.3 Hz, 3J=6.1 Hz, 1H Hα (Leu)), 6.78 (s, 1H, HN (Gln)), 7.00 (d, 
3J=8.2 Hz, 1H, HN (Ser)), 7.30 (s, 1H, HN (Gln)), 7.46 (d, 3J=9.4 Hz, 1H, HN (Gln)), 
7.83 (d, 3J=10.7 Hz, 1H, HN (Asp)), 8.4 (d, 3J=8.8 Hz, 1H, HN (Leu)), 12.54 (br, 1H, 
HCOO (Asp)). 
 
 
c-(-Ile-Asp-Ser-β-hPro-Leu-) (58) 
 
C25H41N5O8 (539.64 g/mol). 
Cyclization in solution: 
The linear peptide H-Ile-Asp(Ot-Bu)-Ser(t-Bu)-β-hPro-Leu-OH (124) is synthesized 
on 280 mg (0.20 mmol) Fmoc-Leu-Sasrin (loading 0.72 mmol/g), and cleaved with 
1 % TFA in DCM (protocol 9). 
Yield (linear protected peptide (124)): 98 mg, 0.13 mmol, 65 %. 
HPLC (anal. method 1): tR= 22.3 min, 88 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 670.44 [M+H]+, 692.42 [M+Na]+, 708.39 [M+K]+ 
Found: 670.66 [M+H]+, 692.56 [M+Na]+, 708.45 [M+K]+ 
The linear peptide (124) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (124) (98 mg, 0.13 mmol) in 10 ml DMF. 
Second syringe: Solution of HATU (3.0 equiv, 0.39 mmol, 148 mg) in 10 ml DMF. 
Addition rate for both syringes: 0.04 ml/min. 
Flask: Solution of DIPEA (6.0 equiv, 0.78 mmol, 101 mg, 133 µl) and HATU (0.1 
equiv, 13 µmol, 5 mg) in 10 ml DMF. 
After evaporation of the solvent the cyclic protected peptide (125) is purified by 
reverse phase preparative HPLC. 
Yield (cyclic protected peptide (125)): 8 mg, 10 µmol, 8 %. 
HPLC (anal. method 1): tR= 26.6 min, 87 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 652.43 [M+H]+, 674.41 [M+Na]+, 690.38 [M+K]+ 
Found: 674.80 [M+Na]+, 690.79 [M+K]+ 
The cyclic protected peptide (125) is completely deprotected with reagent K during 
2 h (protocol 13) and finally purified by preparative HPLC. 
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Yield (cyclic deprotected peptide (58)): 4 mg, 6 mmol, 62 %. 
HPLC (anal. method 2): tR= 21.54 min, 84 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 540.30 [M+H]+, 562.29 [M+Na]+, 578.26 [M+K]+ 
Found: 540.39 [M+H]+, 562.38 [M+Na]+, 578.25 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): Two sets of signals (ratio 8 : 1). 
0.74-0.91 (m, 12H, 3Hγ (Ile), 3Hδ (Ile), 6Hδ (Leu)), 0.98 (ddq, 2J=14.3 Hz, 3J=7.1 Hz, 
3J=7.1 Hz, 1H, Hγ (Ile)), 1.30-1.53 (m, 4H, Hγ (Ile), 2Hβ (Leu), Hγ (β-hPro)), 1.56 (m 
1H, Hγ (β-hPro)), 1.64 (m, 1H, Hδ (β-hPro)), 1.78-1.89 (m, 2H, Hγ (Leu), Hδ (β-
hPro)), 1.95 (m, 1H, Hβ (Ile)), 2.07 (m, 1H, Hα (β-hPro)), 2.17 (m, 1H, Hα (β-hPro)), 
2.49 (br, 1H, Hβ (Asp)), 2.71 (dd, 2J=15.7 Hz, 3J=5.6 Hz, 1H, Hβ (Asp)), 3.50 (m, 
1H, Hε (β-hPro)), 3.53-3.68 (m, 2H, Hε (β-hPro), Hβ (Ser)), 3.83 (dd, 3J=12.9 Hz, 
3J=10.4 Hz, 1H, Hβ (Ser)), 4.03-4.16 (m, 2H, Hα (Ile), Hβ (β-hPro)), 4.23 (ddd, 
3J=9.4 Hz, 3J=9.1 Hz, 3J=2.8 Hz, 1H, Hα (Leu)), 4.38 (m, 1H, Hα (Ser)), 4.48 (m, 
1H, Hα (Asp)), 7.25 (d, 3J=6.9 Hz, 1H, HN (Ile)), 7.66-7.74 (m, 2H, HN (Asp), HN 
(Leu)), 7.98 (d, 3J=6.9 Hz, 1H, HN (Ser)), 12.33 (br, 1H, HCOO (Asp)).  
 
 
6.4.7. Synthesis of Cyclic Analogs of the Binding Epitope of Invasin 
 
c-(-Ser-Asp-Met-Ser-D-Gln-Gly-) (126) 
 
C22H35N7O11S (605.63 g/mol). 
Cyclization on resin: 
The linear peptide H-Met-Ser(t-Bu)-D-Gln-Gly-Ser(t-Bu)-Asp(Wang)-ODmb (128) is 
synthesized and cyclized following protocol 6 (3.0 equiv HATU and 6.0 equiv 
DIPEA as coupling reagents) on Wang resin (250 mg, 0.10 mmol). After 
deprotection and cleavage from the resin with the cleavage cocktail TFA/DCM/TIS 
= 47 : 47 : 6 during 2 h (protocol 10) the cyclic peptide (126) is purified by reverse 
phase preparative HPLC. 
Yield: 5 mg, 7 µmol, 7 %. 
HPLC (anal. method 4): tR= 5.8 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 606.22 [M+H]+, 628.20 [M+Na]+, 644.18 [M+K]+ 
Found: 606.45 [M+H]+, 628.49 [M+Na]+, 644.47 [M+K]+ 
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c-(-Ser-Asp-Met-Ser-D-Ala-Gly-) (127) 
 
C20H32N6O10S (548.58 g/mol). 
Cyclization on resin: 
The linear peptide H-Met-Ser(t-Bu)-D-Ala-Gly-Ser(t-Bu)-Asp(Wang)-ODmb (129) is 
synthesized and cyclized following protocol 6 (3.0 equiv HATU and 6.0 equiv 
DIPEA as coupling reagents) on Wang resin (250 mg, 0.10 mmol). After complete 
deprotection and cleavage from the resin with the cleavage cocktail  
TFA/DCM/TIS = 47 : 47 : 6 during 2 h (protocol 10) the cyclic peptide (126) is 
purified by reverse phase preparative HPLC. 
Yield: 2 mg, 3 µmol, 3 %. 
HPLC (anal. method 4): tR= 6.1 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 549.20 [M+H]+, 571.18 [M+Na]+, 587.15 [M+K]+ 
Found: 549.30 [M+H]+, 571.32 [M+Na]+, 587.32 [M+K]+ 
 
 
c-(-Ser-Asp-Met-Ser-Lys(H-Arg-(β-Ala)5-)-Gly-) (130) 
 
C44H76N16O16S (1117.26 g/mol). 
Two segments of this peptide (131) and (132) are separately synthesized, 
selectively deprotected and condensed. 
 
 
Fmoc-Arg(Pbf)-β-Ala-β-Ala-β-Ala-β-Ala-β-Ala-OH (131) 
 
C49H65N9O12S (1004.19 g/mol). 
The peptide (131) is synthesized on 2-ClTrt resin (330 mg, 0.10 mmol) previously 
loaded with Fmoc-β-Ala-OH (loading 0.31 mmol/g), cleaved from the resin with 1 
% TFA in DCM (protocol 9) and purified by reverse phase preparative HPLC. 
Yield: 90 mg, 85 µmol, 85 %. 
HPLC (anal. method 1): tR= 26.7 min, 95 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1004.46 [M+H]+, 1026.44 [M+Na]+, 1042.41 [M+K]+ 
Found: 1004.64 [M+H]+, 1026.61 [M+Na]+, 1042.67 [M+K]+ 
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c-(-Ser(t-Bu)-Asp(Ot-Bu)-Met-Ser(t-Bu)-D-Lys-Gly-) (132) 
 
C35H63N7O10S (774.00 g/mol). 
The linear peptide H-Ser(t-Bu)-Asp(Ot-Bu)-Met-Ser(t-Bu)-D-Lys(Aloc)-Gly-OH (133) 
is synthesized on the 2-Cl-trityl resin (285 mg, 0.20 mmol) previously loaded with 
Fmoc-Gly-OH (loading 0.70 mmol/g), cleaved from the resin with 1 % TFA in DCM 
(protocol 9) and purified by reverse phase preparative HPLC. 
Yield: 160 mg, 0.13 mmol, 64 %. 
HPLC (anal. method 1): tR= 22.0 min, 70 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 876.48 [M+H]+, 898.46 [M+Na]+, 914.43 [M+K]+ 
Found: 876.64 [M+H]+, 898.71 [M+Na]+, 914.72 [M+K]+ 
The linear peptide (133) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (133) (160 mg, 0.13 mmol) in 17 ml DMF. 
Second syringe: Solution of HATU (1.5 equiv, 0.20 mmol, 76 mg) in 17 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (4.7equiv, 0.60 mmol, 77 mg, 102 µl) and HOAt (1.5 
equiv, 0.20 mmol, 27 mg) in 20 ml DMF. 
After evaporation of the solvent the cyclic protected peptide (134) is purified by 
reverse phase preparative HPLC. 
Yield (cyclic protected peptide (134)): 47 mg, 53 µmol, 41 %. 
HPLC (anal. method 1): tR= 25.9 min, 95 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 858.46 [M+H]+, 880.44 [M+Na]+, 896.42 [M+K]+ 
Found: 880.55 [M+Na]+, 896.59 [M+K]+ 
 
 
Aloc-cleavage: 
 
The Aloc protective group from the c-(-Ser(t-Bu)-Asp(Ot-Bu)-Met-Ser(t-Bu)-D- 
-Lys(Aloc)-Gly-), (134) (47 mg, 53 µmol) is cleaved with 0.2 equiv [Pd(PPh3)4] (10 
µmol, 12 mg) and 24.0 equiv (1.2 mmol, 130 mg, 0.15 ml) phenylsilane in 2 ml 
DCM (protocol 12). After evaporation of the solvent, the product (132) is used for 
the next reaction without further purification. 
HPLC (anal. method 1): tR= 23.1 min. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 774.44 [M+H]+, 796.43 [M+Na]+, 812.40 [M+K]+ 
Found: 774.64 [M+H]+, 796.61 [M+Na]+, 812.59 [M+K]+ 
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Segment condensation reaction: 
 
HATU (60 µmol, 23 mg) and DIPEA (150 µmol, 19 mg 25 µl) are added to the 
solution of Fmoc-Arg(Pbf)-β-Ala-β-Ala-β-Ala-β-Ala-β-Ala-OH (131) (90 mg, 85 µmol) 
in 3 ml DMF. The reaction mixture is stirred for 5 min at room temperature and 
added to the solution of c-(-Ser(t-Bu)-Asp(Ot-Bu)-Met-Ser(t-Bu)-D-Lys-Gly-) (132) 
in DCM. After 30 min stirring additional HATU (60 µmol, 23 mg) and DIPEA (150 
µmol, 19 mg 25 µl) are added to the reaction mixture. The mixture is stirred 
overnight at room temperature, DMF is evaporated and the fully protected peptide 
(135) is purified by reverse phase preparative HPLC. 
Yield (Fully protected peptide (135)): 39 mg, 18 µmol, 34 %. 
HPLC (anal. method 1): tR= 29.7 min, 80 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1759.88 [M+H]+, 1781.86 [M+Na]+, 1797.84 [M+K]+ 
Found: 1759.59 [M+H]+, 1781.42 [M+Na]+, 1797.74 [M+K]+ 
 
 
Cleavage of the protective groups: 
 
To the fully protected peptide (135), obtained by segment condensation reaction, is 
added a solution of 2 % DBU and 2 % piperidine in DMF. Reaction mixture is 
shaken at room temperature for 30 min and DMF is evaporated under high 
vacuum (temperature of the bath must not exceed 30 °C). To the residue are 
added 150 ml dried diethylether. The ether is decanted, centrifuged 1 h on 0 ºC 
with 4000 rpm, and again decanted. The residue (after both decantation) is dried 
in vacuum. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1537.81 [M+H]+, 1559.79 [M+Na]+, 1575.77 [M+K]+ 
Found: 1559.80 [M+Na]+, 1575.90 [M+K]+ 
The residue is completely deprotected with reagent K during 3 h (protocol 13) and 
purified by reverse phase preparative HPLC. 
Yield (peptide (130)): 7 mg, 6.3 µmol, 35 %. 
HPLC (anal. method 2): tR= 12.5 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1117.54 [M+H]+, 1139.52 [M+Na]+, 1155.50 [M+K]+ 
Found: 1117.94 [M+H]+, 1139.55 [M+Na]+, 1155.74 [M+K]+ 
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6.4.8. Synthesis of Linear Precursors of Tyrocidine A Analogs 
 
H-D-Phe-Pro-Phe-D-Phe-Asn-Gln-Tyr-Val-Orn-Leu-S-CH2-CH2-NHCOCH3 (136) 
 
C70H96N14O14S (1389.70 g/mol). 
The peptide Boc-D-Phe-Pro-Phe-D-Phe-Asn(Trt)-Gln(Trt)-Tyr(t-Bu)-Val-Orn(Boc)- 
-Leu-S-CH2-CH2-NHCOCH3 (144) is synthesized on the “safety catch” resin (240 
mg, 0.10 mmol) previously loaded with Fmoc-Leu-OH (protocol 2) and cleaved 
from the resin with formation of thioester bond (protocol 11).  
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 2130.09 [M+H]+, 2152.07 [M+Na]+, 2168.05 [M+K]+ 
Found: 2152.05 [M+Na]+, 2168.29 [M+K]+ 
Without further purification the peptide (144) is completely deprotected (except the  
N-acetyl group) with reagent B during 1h (protocol 13). Finally the peptide (136) is 
purified by reverse phase preparative HPLC. 
Yield: 90 mg, 61 µmol, 62 %. 
HPLC (anal. method 1): tR= 22.0 min, 95 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1389.70 [M+H]+, 1411.68 [M+Na]+, 1427.66 [M+K]+ 
Found: 1389.64 [M+H]+ 
 
 
H-D-Phe-β-hPro-β-hPhe-D-β-hPhe-β-hAsn-Gln-Tyr-Val-Orn-Leu-S-CH2-CH2- 
-NHCOCH3 (142) 
 
C74H104N14O14S (1445.81 g/mol). 
The peptide Boc-D-Phe-β-hPro-β-hPhe-D-β-hPhe-β-hAsn(Trt)-Gln(Trt)-Tyr(t-Bu)- 
-Val-Orn(Boc)-Leu-S-CH2-CH2-NHCOCH3 (145) is synthesized on the “safety 
catch” resin (240 mg, 0.1 mmol) previously loaded with Fmoc-Leu-OH (protocol 2) 
and cleaved from the resin with formation of thioester bond (protocol 11).  
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 2186.15 [M+H]+, 2208.13 [M+Na]+, 2224.11 [M+K]+ 
Found: 2208.27 [M+Na]+, 2224.30 [M+K]+ 
Without further purification the peptide (145) is completely deprotected (except the 
N-acetyl group) with reagent B during 2h (protocol 13). Finally the peptide (142) is 
purified by reverse phase preparative HPLC. 
Yield: 18 mg, 1.1 µmol, 11 %. 
 6. Experimental part 168 
HPLC (anal. method 1): tR= 21.0 min, 90 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 1445.77 [M+H]+, 1467.75 [M+Na]+, 1483.72 [M+K]+ 
Found: 1445.72 [M+H]+, 1467.70 [M+Na]+ 
 
 
6.4.9. Synthesis of RGD Peptides 
 
c-(Arg-Gly-Asp-D-Phe-β-hPro-) (146) 
 
C27H38N8O7 (586.66). 
Cyclization on resin: 
The linear peptide H-D-Phe-β-hPro-Arg(Pbf)-Gly-Asp(Wang)-ODmb (147) is 
synthesized and cyclized following protocol 6 (3.0 equiv HATU and 6.0 equiv 
DIPEA as coupling reagents) on Wang resin (300 mg, 0.2 mmol), previously 
loaded with Fmoc-Asp-ODmb (0.68 mmol/g). After complete deprotection and 
cleavage from the resin with the cleavage cocktail TFA/H2O/TIS = 95 : 2.5 : 2.5 
during 2 h (protocol 10) the cyclic peptide (146) is purified by reverse phase 
preparative HPLC. 
Yield: 30 mg, 51 µmol, 26 %. 
HPLC (anal. method 2): tR= 18.2 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 587.29 [M+H]+, 609.28 [M+Na]+, 625.25 [M+K]+ 
Found: 587.57 [M+H]+, 609.53 [M+Na]+, 625.51 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ  (ppm): 1.36-1.59 (m, 5H, Hβ  (Arg), 2Hγ  (Arg),  
Hγ  (β-hPro), Hδ  (β-hPro)), 1.60-1.75 (m, 2H; Hβ  (Arg), Hγ  (β-hPro)), 1.81 (m, 1H, 
Hδ  (β-hPro)), 2.18 (dd, 2J=13.8 Hz, 3J=10.1 Hz, 1H, Hα  (β-hPro)), 2.62 (m, 1H, Hβ 
(Asp)), 2.62 (m, 1H, Hβ (Asp)), 2.65 (dd, 2J=13.8 Hz, 3J=3.8 Hz, 1H, Hα  (β-hPro)), 
2.94-3.13 (m, 6H, 2Hδ  (Arg), Hβ (Asp), 2Hβ (Phe), Hε  (β-hPro)), 3.46-3.52 (m, 2H, 
Hα (Asp), Hε  (β-hPro)), 3.72 (dd, 2J=17.0 Hz, 3J=5.0 Hz, 1H, Hα (Gly)), 3.76 (dd, 
2J=17.3 Hz, 3J=5.3 Hz, 1H, Hα (Gly)), 4.16 (m, 1H, Hβ (β-hPro)), 4.32 (ddd, 3J=6.9 
Hz, 3J=7.9 Hz, 3J=6.9 Hz, 1H, Hα  (Arg)), 4.40 (ddd, 3J=6.6 Hz, 3J=7.9 Hz, 3J=7.5 
Hz, 1H, Hα  (Phe)), 7.25-7.36 (m, 6H, HN (Asp), 5Har (Phe)), 7.57 (br, 1H, HεN (Arg)), 
7.85 (d, 3J=7.5 Hz, 1H, HN (Phe)), 8.09 (d, 3J=8.2 Hz, 1H, HN (Arg)), 8.32 (dd, 
3J=5.3 Hz, 3J=5.3 Hz, 1H, HN (Gly)), 12.60 (br, 1H, HCOO (Asp)). 
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c-(-Arg-Gly-Asp-Phe-Cpr(OMe)-) (149) 
 
C27H36N8O9, (616.64 g/mol). 
Cyclization on resin: 
The linear peptide H-Cpr-Phe-Arg(Pbf)-Gly-Asp(Wang)-ODmb (150) is synthesized 
and cyclized following protocol 6 (3.0 equiv HATU and 6.0 equiv DIPEA as 
coupling reagents) on Wang resin (160 mg, 64 µmol), previously loaded with  
Fmoc-Asp-ODmb (0.40 mmol/g). After complete deprotection and cleavage from 
the resin with the cleavage cocktail TFA/H2O/TIS = 95 : 2.5 : 2.5 during 2 h 
(protocol 10) the cyclic peptide (149) is purified by reverse phase preparative 
HPLC. 
Yield: 4 mg, 5.8 µmol, 9 %. 
HPLC (anal. method 2): tR= 17.0 min, 17.2 min, 90 area % sum of epimers. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 617.27 [M+H]+, 639.25 [M+Na]+, 655.22 [M+K]+ 
Found: 617.53 [M+H]+, 639.52 [M+Na]+, 655.48 [M+K]+ 
 
 
c-(-Arg-Gly-Asp-Cpr(OMe)-Val-) (151) 
 
C23H36N8O9, (568.59 g/mol). 
Cyclization in solution: 
The linear peptide H-Asp(Ot-Bu)-Cpr(OMe)-Val-Arg(Pbf)-Gly-OH (152) is 
synthesized on 2-ClTrt resin (100 mg, 0.06 mmol), previously loaded with Fmoc- 
-Gly-OH (0.60 mmol/g), cleaved from the resin with 1 % TFA in DCM (protocol 9) 
and purified by reverse phase preparative HPLC. 
Yield: 14.3 mg, 16 µmol, 26 %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 895.42 [M+H]+, 917.41 [M+Na]+, 933.38 [M+K]+ 
Found: 895.50 [M+H]+, 917.88 [M+Na]+, 933.54 [M+K]+ 
The linear peptide (152) (14.3 mg, 16 µmol) is dissolved in 600 ml DMF and 
cyclized following protocol 7, method A.  
1.1 equiv HATU (18 µmol, 7 mg). 
3.0 equiv DIPEA (50 µmol, 6 mg, 8.0 µl). 
After evaporation of DMF, the protected cyclic peptide (153) is purified by filtration 
through a C18 plug. 
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MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 877.41 [M+H]+, 899.39 [M+Na]+, 915.37 [M+K]+ 
Found: 899.13 [M+Na]+, 915.11 [M+K]+ 
The protected cyclic peptide (153) is completely deprotected with the cleavage 
cocktail TFA/H2O/TIS = 95 : 2.5 : 2.5 (protocol 13) and the cyclic peptide (151) is 
finally purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (151)): 5 mg, 8.8 µmol, 55 % (Calculated from 
linear protected peptide (152)). 
HPLC (anal. method 2): tR= 13.5 min, 13.6 min, 100 area % sum of epimers. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 569.27 [M+H]+, 591.25 [M+Na]+, 607.22 [M+K]+ 
Found: 569.73 [M+H]+, 591.56 [M+Na]+ 
 
 
c-(-Arg-Gly-Asp-D-1-Nal-) (154) 
 
C25H31N7O6, (525.61 g/mol). 
Cyclization in solution: 
The linear peptide H-Asp(Ot-Bu)-D-1-Nal-Arg(Pbf)-Gly-OH (156) is synthesized on 
2-ClTrt resin (225 mg, 0.20 mmol), previously loaded with Fmoc-Gly-OH (0.90 
mmol/g), and cleaved from the resin with 1 % TFA in DCM (protocol 9). 
Yield (linear protected peptide (156)): 184 mg, 80 µmol, 40 %. 
HPLC (anal. method 1): tR= 27.1 min, 37 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 852.40 [M+H]+, 874.38 [M+Na]+, 890.35 [M+K]+ 
Found: 852.82 [M+H]+, 874.78 [M+Na]+, 890.77 [M+K]+ 
The linear peptide (156) is cyclized following protocol 7, method B:  
First syringe: Solution of linear peptide (156) (184 mg, 80 µmol) in 20 ml DMF. 
Second syringe: Solution of HATU (2.0 equiv, 160 µmol, 60 mg) in 20 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (5.3 equiv, 420 µmol, 54 mg, 84 µl) and HOAt (2.0 equiv, 
160 µmol, 22 mg) in 20 ml DMF.  
After evaporation of the solvent the cyclic protected peptide (157) is purified by 
filtration through C18 plug. 
Yield (cyclic protected peptide (157)): 123 mg, 75 µmol, 94 %. 
HPLC (anal. method 1): tR= 31.6 min, 51 area %. 
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MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 834.39 [M+H]+, 856.37 [M+Na]+, 872.34 [M+K]+ 
Found: 834.79 [M+H]+, 856.71 [M+Na]+, 872.72 [M+K]+ 
The cyclic protected peptide (157) is completely deprotected with the cleavage 
cocktail TFA/H2O/TIS = 95 : 2.5 : 2.5 during 2 h (protocol 13) and finally purified by 
reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (154)): 18 mg, 34 µmol, 45 %. 
HPLC (anal. method 2): tR= 20.5 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 526.24 [M+H]+, 548.22 [M+Na]+, 564.20 [M+K]+ 
Found: 526.50 [M+H]+, 548.51 [M+Na]+ 564.48 [M+K]+ 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 1.31 (m, 2H, 2Hγ (Arg)), 1.40 (m, 1H, Hβ 
(Arg)), 1.60 (m, 1H, Hβ (Arg)), 2.39 (dd, 2J=16.6 Hz, 3J=5.3 Hz, 1H, Hβ (Asp)), 2.72 
(dd, 2J=17.0 Hz, 3J=9.4 Hz, 1H, Hβ (Asp)), 2.94-3.06 (m, 2H, Hδ (Arg)), 3.14-3.21 
(m, 2H, Hα (Gly), Hβ (D-Nal)), 3.54 (dd, 2J=14.4 Hz, 3J=8.2 Hz, 1H, Hβ (D-Nal)), 
4.05 (dd, 2J=13.2 Hz, 3J=8.8 Hz, 1H, Hα (Gly)), 4.24 (ddd, 3J=9.1 Hz, 3J=8.8 Hz, 
3J=7.5 Hz, 1H, Hα (Arg)), 4.57 (ddd, 3J=9.1 Hz, 3J=9.1 Hz, 3J=5.7 Hz, 1H, Hα 
(Asp)), 4.71 (ddd, 3J=8.5 Hz, 3J=8.5 Hz, 3J=7.2 Hz, 1H, Hα (D-Nal)), 7.31-7.40 (m, 
2H, Har (D-Nal)), 7.47 (t, 3J=5.7 Hz, 1H, HεN (Arg)), 7.51 (m, 1H, Har (D-Nal)), 7.57 
(m, 1H, Har (D-Nal)), 7.76 (d, 3J=9.4 Hz, 1H, HN (Asp)), 7.77 (m, 1H, Har (D-Nal)), 
7.84 (d, 3J=9.4 Hz, 1H, HN (Arg)), 7.89-7.93 (m, 2H, HN (Gly), Har (D-Nal)), 7.98 (d, 
3J=8.8 Hz, 1H, HN (D-Nal)), 8.06 (d, 3J=8.2 Hz, 1H, Har (D-Nal)), 12.31 (br, 1H, 
HCOO (Asp)). 
 
 
c-(-Arg-Gly-Asp-2-β-hNal-) (155) 
 
C26H33N7O6, (539.63 g/mol). 
Cyclization in solution: 
The linear peptide H-Asp(Ot-Bu)-2-β-hNal-Arg(Pbf)-Gly-OH (158) is synthesized on  
2-ClTrt resin (280 mg, 0.20 mmol), previously loaded with Fmoc-Gly-OH 
(0.72mmol/g,), and cleaved from the resin with 1 % TFA in DCM (protocol 9). 
Yield (linear protected peptide (158)): 128 mg, 114 µmol, 57 %. 
HPLC (anal. method 1): tR= 26.8 min, 77 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 866.41 [M+H]+, 888.39 [M+Na]+, 904.37 [M+K]+ 
Found: 866.37 [M+H]+, 888.50 [M+Na]+, 904.42 [M+K]+ 
The linear peptide (158) is cyclized following protocol 7, method B: 
First syringe: Solution of linear peptide (158) (128 mg, 114 µmol) in 20 ml DMF. 
 6. Experimental part 172 
Second syringe: Solution of HATU (1.3 equiv, 150 µmol, 57 mg), in 20 ml DMF. 
Addition rate for both syringes: 0.01 ml/min. 
Flask: Solution of DIPEA (3.9 equiv, 0.45 mmol, 58 mg, 77 µl) and HOAt (1.3 
equiv, 0.15 mmol, 20 mg ) in 20ml DMF. 
After evaporation of the solvent the cyclic protected peptide (159) is purified by 
reverse phase preparative HPLC. 
Yield (cyclic protected peptide (159)): 18 mg, 21 µmol, 18 %. 
HPLC (anal. method 1): tR= 30.7 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 848.40 [M+H]+, 870.38 [M+Na]+, 886.36 [M+K]+ 
Found: 848.75 [M+H]+, 870.66 [M+Na]+, 886.80 [M+K]+ 
The cyclic protected peptide (159) is completely deprotected with reagent K during 
5 h (protocol 13) and finally purified by reverse phase preparative HPLC. 
Yield (cyclic deprotected peptide (155)): 11 mg, 20 µmol, 97 %. 
HPLC (anal. method 2): tR= 20.5 min, 100 area %. 
MALDI-ToF MSmonoisotopic, m/z: 
Calcd.: 540.26 [M+H]+, 562.24 [M+Na]+, 578.21 [M+K]+ 
Found: 540.20 [M+H]+, 562.20 [M+Na]+ 578.10 [M+K]+. 
1H NMR (500 MHz, DMSO-d6), δ (ppm): 1.35-1.50 (m, 3H, Hβ (Arg), 2Hγ (Arg)), 
1.59 (m, 1H, Hβ (Arg)), 2.32 (dd, 2J=14.4 Hz, 3J=3.8 Hz, 1H, Hα (β-hNal)), 2.37 (dd, 
2J=14.1 Hz, 3J=12.2 Hz, 1H, Hα (β-hNal)), 2.47 (br, 1H, Hβ (Asp)), 2.75 (dd, 2J=16.3 
Hz, 3J=6.3 Hz, 1H, Hβ (Asp)), 2.97 (dd, 2J=13.2 Hz, 3J=6.3 Hz, 1H, Hγ (β-hNal)), 
3.02 (dd, 2J=13.2 Hz, 3J=4.4 Hz, 1H, Hγ (β-hNal)), 3.00-3.09 (m, 2H, 2H δ (Arg)), 
3.54 (dd, 2J=13.8 Hz, 3J=6.9 Hz, 1H, Hα (Gly)), 3.70 (dd, 2J=13.8 Hz, 3J=5.0 Hz, 
1H, Hα (Gly)), 4.01-4.13 (m, 2H, Hα (Arg), Hβ (β-hNal)), 4.41 (ddd, 3J=8.6 Hz, 
3J=8.6 Hz, 3J=6.4 Hz, 1H, Hα (Asp)), 6.80 (br, 1H, HϖN (Arg)), 7.26 (d, 3J=6.9 Hz, 
1H, HN (β-hNal)), 7.32 (m, 1H, Har (β-hNal)), 7.40 (d, 3J=8.8 Hz, 1H, HN (Asp)), 
7.44-7.54 (m, 3H, HεN (Arg), 2Har (β-hNal)), 7.63 (s, 1H, Har 1 (β-hNal)), 7.82-7.91 
(m, 4H, HN (Gly), 3Har (β-h Nal)), 8.03 (d, 3J=7.5 Hz, 1H, HN (Arg)), 12.51 (br, 1H, 
HCOO (Asp)). 
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